AiArthritis Blog

AiArthritis Advocacy Field Trip: 2026 BMS Policy Forum

Wed, 22 Apr 2026 14:03:18 GMT

Ai Arthritis Advocacy Field Trip: 2026 BMS Policy Forum

Ai Arthritis' Grassroots Advocacy Manager Vanessa Lathan recently attended Bristol Myers Squibb's (BMS) first policy forum of 2026, which brought together patient leaders, advocates, and policy experts to discuss major healthcare policy issues that affect patients' ability to access and afford care and medications.

Conversations focused on how healthcare policies can create real, lasting improvements for patients - not just changes that look good on paper. Read on to uncover the key takeaways from these conversations.

Where the Healthcare System is Missing the Mark

A central theme was that healthcare reform must lower overall costs and improve patient health outcomes to ensure that patients can access treatments, afford medications, and receive quality care when needed. Speakers emphasized investing in primary care and prevention, which can help people stay healthier while lowering long-term healthcare costs. Another major topic was price transparency, especially when it comes to Pharmacy Benefit Managers (PBMs) , drug rebate systems, and what patients ultimately pay out of pocket for medications.

Speakers cautioned that some healthcare policies that look promising on paper do not always yield real savings or improved patient access. That is why transparency, monitoring, and accountability are critical as policies are implemented. Programs like 340B , which support healthcare providers serving underserved communities, were also discussed as areas where transparency and oversight remain important.

The timeline for new medications (often 7–8 years to reach patients) can delay timely access to important treatments.

Speakers discussed biosimilars , medications similar to existing biologic drugs, as a way to help create competition and potentially lower costs, though manufacturing and policy challenges can delay their availability. Strengthening biosimilar manufacturing in the US was identified as an important step forward.

Future advocacy priorities may include:

Linking drug pricing policies to improvements in patient health outcomes
Supporting personalized care models to address individual patient needs
Expanding proven healthcare innovation programs
Addressing long-term care challenges as the population ages

Keeping Patients at the Center of Policy

A second discussion focused on the patient perspective and why patient-centered policymaking is essential. Polling shows that healthcare costs are now the number one financial concern for many Americans, even higher than food or other household expenses. In fact, a recent survey found that 77% of patients worry about financial hardship related to healthcare costs more than those who worry about disease symptoms or disease progression. Speakers emphasized that while policymakers often talk about saving money in the healthcare system, those savings do not always reach patients directly.

Other challenges discussed included:

Rising insurance premiums and out-of-pocket costs
Structural barriers that limit access to copay assistance programs
Patients struggling to afford or maintain health insurance
Access issues in mental health care, especially when patients cannot find in-network providers

These issues can make it difficult for patients to receive the care or medications they need. To better understand these challenges, check out the recent survey conducted by the Patient Inclusion Council, organized by Ai Arthritis, which explores medication access and affordability across health conditions.

Why Patient Advocacy Matters

Throughout the event, the message was clear: patient voices are essential to shaping healthcare policy. Advocates play a key role in helping policymakers understand real patient experiences.

Speakers encouraged advocates to engage policymakers earlier and to continue holding them accountable to ensure healthcare policies truly improve affordability and access.

Ultimately, healthcare reform sho uld improve quality of life for patients and ensure healthcare system savings translate into lower costs, better access, and improved care for the people who need it most.

Drive Change Through Advocacy

Make your voice count—explore how you can drive change in healthcare, research, and policy through patient-powered advocacy.

How to Describe Pain Caused by Autoimmune and Autoinflammatory Arthritis Diseases

Sat, 04 Apr 2026 14:20:24 GMT

How to Describe Pain Caused by Auto immune and Auto inflammatory Arthritis Diseases

Auto immune and auto inflammatory arthritis ( Ai Arthritis ) diseases, such as rheumatoid arthritis (RA) , psoriatic arthritis (PsA) , lupus , and axial spondyloarthritis , cause chronic pain that can vary in intensity, location, and sensation. Accurately describing pain is crucial for effective communication with healthcare providers, leading to better treatment and management strategies.

Potential Causes of Pain in Auto i mmune and Auto inflammatory Arthritis

Pain in these conditions is primarily driven b y immune system dysfunction , leading to inflammation and tissue damage. Some key causes include:

1. Inflammatory Response

The immune system mistakenly attacks healthy tissues, causing joint inflammation and swelling.
This leads to pain, stiffness, and reduced mobility.

2. Synovial Membrane Damage

In autoimmune arthritis, the synovial membrane (which lubricates joints) becomes inflamed.
Over time, this can result in cartilage and bone erosion, worsening pain.

3. Cytokine Imbalance

Cytokines are proteins that regulate immune responses, but in autoimmune diseases, they become overactive, triggering excessive inflammation.
This contributes to persistent joint pain and fatigue .

4. Nerve Involvement

I n some cases, nerve compression or damage occurs due to inflammation.
This can lead to burning, tingling, or radiating pain.

5. Muscle and Tendon Strain

Chronic inflammation can weaken muscles, tendons, and ligaments, making movement painful.
Overcompensation by other muscles can lead to secondary pain and stiffness.

6. Weather Sensitivity

Many individuals report worsening pain in cold, damp, or humid conditions.
Changes in barometric pressure may affect joint fluid and inflammation levels .

7. Medication Side Effects

Some treatments for autoimmune arthritis can cause muscle pain, headaches, or digestive discomfort.
Adjusting medications under medical supervision may help manage these effects.

Types of Pain in Auto immune and Auto inflammatory Arthritis

Pain can manifest in different ways, and understanding these variations can help in describing symptoms more precisely:

1. Sharp or Stabbing Pain

Sudden, intense pain that feels like being pricked or stabbed
Often occurs during movement or sudden flare-ups

2. Burning or Tingling Pain

A sensation of heat or pins-and-needles in affected joints
Common in conditions like lupus or neuropathic pain

3. Aching or Throbbing Pain

A deep, dull pain that persists over time
Often worsens with activity or prolonged periods of immobility

4. Stiffness and Pressure Pain

A feeling of tightness or heaviness in joints, especially in the morning
Common in rheumatoid arthritis and axial spondyloarthritis

5. Radiating Pain

Pain that spreads from one area to another, such as from the lower back to the legs
Often linked to spinal inflammation or nerve involvement

6. Fatigue-Related Pain

A deep, overwhelming ache that accompanies extreme tiredness
Often worsens with stress or lack of sleep

7. Weather-Related Pain

Increased joint pain during cold, damp, or humid conditions
Some individuals report worsening symptoms before storms

How to Describe Pain to a Doctor

Using clear and specific language can help healthcare providers assess the severity and cause of pain:

1. Use a Pain Scale

Rate pain from 0 to 10, with 0 being no pain and 10 being unbearable pain

2. Identify the Location

Specify which joints or areas are affected (e.g., "sharp pain in my knees")

3. Describe the Sensation

Use words like burning, stabbing, aching, throbbing, or tingling

4. Note the Duration and Triggers

Mention if pain is constant, intermittent, or worsens with movement

5. Explain the Impact on Daily Life

Describe how pain a ffects mobility, sleep, mood, and daily activities

Managing and Communicating Pain Effectively

Keep a Pain Journal – Track symptoms , triggers, and relief methods
Use Visual Pain Charts – Some doctors use diagrams to pinpoint pain areas
Advocate for Yourself – Be honest about pain levels to receive proper care

Understanding and articulating pain effectively can lead to better treatment options and improved quality of life.

Tune into the AiArthritis Voices 360 Talk Show , where patients, doctors, and advocates come together to discuss the latest in autoimmune and autoinflammatory arthritis.

Why Rheumatologists Must Prioritize Heart Health

Sat, 04 Apr 2026 14:04:19 GMT

Why Rheumatologists Must Prioritize Heart Health for Ai Arthritis Patients

Heart health doesn’t always get the attention it deserves in autoimmune and autoinflammatory arthritis ( Ai Arthritis) disease care. At day 3 of ACR 2025, one session made it clear that this needs to change. Tiffany Westrich Robertson, CEO and founder of Ai Arthritis and someone living with non-radiographic axial spondyloarthritis, shared updates from a session focused on what researchers are now calling cardiac immunology or cardiac rheumatology .

The message was direct and urgent. Chronic inflammatory diseases significantly increase cardiovascular risk and this risk must be taken just as seriously as joint damage or disease flares.

Ai Arthritis Diseases and the Heart Are Deeply Connected

Researchers emphasized that people living with Ai Arthritis diseases are at higher risk for heart disease and heart failure than the general population. In fact, updated cardiovascular guidelines have shown that chronic inflammatory diseases can pose a higher heart failure risk than even hypertension – a risk factor most people are familiar with.

This increased risk is not theoretical. It is tied directly to immune system activity. The heart contains a large number of immune cells called leukocytes – roughly twelve times more than are found in skeletal muscle. These immune cells play a role in inflammation patterns. When the immune system is overactive, as it is in autoimmune disease, the heart becomes more vulnerable to inflammatory damage.

Understanding Cardiac Inflammation

The session focused closely on conditions such as pericarditis (inflammation of the lining around the heart) and myocarditis (inflammation of the heart muscle itself). Both conditions can occur in people with Ai Arthritis diseases and may be overlooked if symptoms are subtle or attributed to other causes.

Because Ai Arthritis diseases are systemic, meaning they affect the whole body, inflammation does not stay confined to joints or skin. Even when symptoms feel manageable, ongoing disease activity can still affect organs such as the heart.

What Science Is Teaching Us About Treatment

Much of the discussion highlighted how immune-targeted therapies may help protect the heart. Researchers are studying interleukins, which are signaling molecules in the immune system and common targets of biologic medications.

Early and ongoing research suggests that certain interleukin pathways play a role in heart inflammation. Interleukin-10 has shown promise in regulating inflammation, while interleukin-1 has emerged as a particularly important target in cases of heart involvement.

This matters clinically. International recommendations published in 2014 now identify interleukin-1–targeting therapies as the preferred second-line option for patients with inflammatory heart involvement when standard treatments, including steroids, are not effective. Second-line means these therapies are used when first approaches fail to adequately control the condition.

Why This Should Change Everyday Care

One of the strongest takeaways from this session was a call to action for rheumatologists. Cardiovascular health should not be an afterthought or something left entirely to primary care or cardiology.

People with autoimmune and autoinflammatory arthritis often live with ongoing inflammation , even between flares. That inflammation alone increases cardiovascular risk. Monitoring heart health, recognizing warning signs, and treating systemic inflammation aggressively and appropriately are essential parts of comprehensive care.

For patients, this reinforces the importance of speaking up about symptoms such as chest pain, shortness of breath, unexplained fatigue , or palpitations. It also means understanding that managing disease activity is not only about reducing pain or stiffness, but also about protecting long-term organ health.

The Bigger Picture

This session reinforced something many in the patient community have been saying for years. Ai Arthritis diseases affect the entire body. The heart is not separate from the immune system, and inflammation anywhere can have consequences everywhere .

By prioritizing heart health as part of routine Ai Arthritis disease care, clinicians can help reduce long-term risk and improve outcomes. Education, early intervention, and targeted treatment all play a role.

At Ai Arthritis, the goal of sharing these updates is to help patients understand why comprehensive care matters and to give them the knowledge needed to advocate for it. Heart health is not optional. It is a vital part of living well with Ai Arthritis diseases.

Join Tiffany Westrich-Robertson, CEO and founder of Ai Arthritis, as she shares key highlights from Day 3 of ACR 2025 through the Go With Us! program. Tiffany attended a session on cardiac immunology — exploring how inflammation from autoimmune diseases can affect the heart and what new treatments are emerging to protect patients.

Join the Go With Us AiArthritis Conferences Program to gain insights into the latest research and advancements in autoimmune and autoinflammatory arthritis. This unique, patient-led initiative connects individuals to cutting-edge information, empowering them to improve their healthcare journeys and advocate for change

Brain Fog and Sleep in AiArthritis Diseases

Sat, 04 Apr 2026 13:46:23 GMT

Brain Fog and Sleep Issues in Ai Arthritis Diseases

Brain fog is one of those symptoms patients talk about all the time, yet it is still often misunderstood or minimized in clinical care. At the American College of Rheumatology convergence in 2025, several sessions finally put this experience front and center, starting with patient voices and moving into emerging science. The takeaway was clear. Brain fog is real, it is disruptive, and sleep plays a much bigger role than many people realize.

These conversations, shared through the video debrief “ What Research Reveals About Brain Fog & Sleep in AiArthritis ,” helped bridge the gap between lived experience and research.

This video debrief was created as part of AiArthritis’ “Go With Us!” to Conferences program.

What Brain Fog Actually Feels Like for Patients

The first session centered on the patient perspective, with a patient speaking directly to rheumatologists about how brain fog affects daily life. Brain fog is not just about forgetting a dose of medication or misplacing keys. It can shape the entire day.

Many patients notice that cognitive function worsens as the day goes on. Tasks that feel manageable in the morning become overwhelming later, especially after pain, fatigue, or stress accumulate. Concentration drops, word recall becomes harder, and decision-making can feel exhausting. This cumulative effect is something patients experience every day, yet it is rarely captured in a clinic visit.

What Cognitive Testing Is Showing in Fibromyalgia

Researchers then shared data from fibromyalgia studies, where brain fog has been more formally studied. Cognitive testing showed that as the day progresses, people with fibromyalgia often perform worse on memory and response tasks.

The audience was asked to try some of these tests themselves, such as remembering images flashed on a screen or quickly ordering animals by size. Even without chronic illness, these tasks were challenging. After a long day or during a flare, they become even more difficult.

Researchers made an important acknowledgment that testing cognitive function only in a clinic setting may miss the full picture. Cognitive clarity can vary hour by hour depending on pain, fatigue, stress, and sleep. To address this, researchers are now using apps and text-based check-ins to collect data throughout the day. This allows them to track exactly when patients feel clear, when fog sets in, and possible triggers.

The Gap in Rheumatoid Arthritis Research

One surprising finding was how little research exists on brain fog in rheumatoid arthritis (RA). Despite how common it is for RA patients to report cognitive issues, formal studies have been scarce.

When researchers did look at available data, many standard cognitive tests showed results similar to those for people that are not living with RA. On paper, everything looked normal. But patients consistently reported feeling cognitively impaired. This highlighted a critical gap between perceived cognitive function and what traditional tests measure. In other words, patients feel brain fog, but current tools are not capturing it well.

When researchers dug deeper using alternative methods, patterns began to emerge. Memory, particularly verbal and short-term memory, appeared to be affected. Higher disease activity, moderate to high disease severity, oral steroid use, and rheumatoid factor positivity were all associated with greater cognitive dysfunction.

These findings suggest that something real is happening, even if standard tests are not yet sensitive enough to detect it. Researchers are now planning further studies to better understand and measure brain fog in RA.

Sleep Is a Common Thread Across Conditions

One theme echoed across nearly every session at ACR: sleep matters more than we think. Poor sleep is linked to faster aging, worse cognitive function, increased pain sensitivity, and impaired metabolism and digestion. When sleep is disrupted, brain fog becomes more severe, fatigue worsens, and the body has fewer resources to cope with inflammation.

For people living with rheumatoid arthritis in particular, researchers noted higher rates of sleep apnea than in the general population. This is important because untreated sleep apnea can significantly worsen fatigue, cognitive issues, and cardiovascular risk.

What This Means for Patients

The biggest validation from these sessions was hearing researchers say out loud what patients have long known. Brain fog is not imagined. It is not just stress or distraction. It is a real symptom that fluctuates throughout the day and is influenced by disease activity, medication use, and sleep quality.

If brain fog is affecting daily life, it may help to talk with your care team about patterns you notice. When does it get worse? Is it tied to poor sleep, flares, or medication changes? Asking about sleep quality and screening for conditions like sleep apnea may be an important step, especially if fatigue and cognitive issues feel overwhelming.

Looking Ahead

Research on brain fog is still catching up to patient experience, but momentum is building. Better measurement tools, real-time data collection, and greater attention to sleep are opening the door for more effective ways of addressing cognitive symptoms in autoimmune and autoinflammatory arthritis diseases.

For now, the message is both validating and practical. Brain fog is real. Sleep is foundational. And paying attention to how symptoms change throughout the day can help guide more meaningful conversations and better care.

Join Brittany Murray, a person living with psoriatic arthritis, as she shares highlights from Day 3 of ACR 2025 through Ai Arthritis ’ Go With Us! program.Brittany attended a session that focused on brain fog, cognition, and sleep—topics many patients experience but that are often overlooked in rheumatology. She explains what the latest research shows and how doctors are beginning to better understand this frustrating symptom.

Understanding Enthesitis: Why Tendon and Ligament Pain Matters in Spondyloarthritis

Wed, 25 Mar 2026 12:11:10 GMT

Understanding Enthesitis: Why Tendon and Ligament Pain Matters in Spondyloarthritis

At EULAR 2025, Tiffany attended a session on “ What’s Really Causing Enthesitis – and Why it Matters .” Enthesitis is a major source of pain and disability for people living with spondyloarthritis conditions like axial spondyloarthritis and psoriatic arthritis. While joints often get most of the attention, many patients know that the pain they feel most intensely does not always come from the joint itself. Instead, it comes from the places where tendons and ligaments attach to bone. These attachment points are called entheses, and when they become inflamed, the condition is known as enthesitis.

This session explored what may trigger enthesitis, how it spreads inflammation through the body, and why understanding these pathways could lead to better diagnosis and more targeted treatment.

In this Go With Us! video from EULAR 2025, Tiffany Westrich-Robertson—person living with axial spondyloarthritis and CEO of AiArthritis—shares important updates about enthesitis, a common and painful symptom in spondyloarthritis and psoriatic arthritis.

What exactly is enthesitis?

Enthesitis is inflammation at the point where tendons or ligaments connect to bone. These areas are under constant mechanical stress, which makes them especially vulnerable in inflammatory diseases. For people with spondyloarthritis , enthesitis can cause deep, persistent pain that is often mistaken for muscle strain or overuse injuries.

What makes enthesitis especially important is its location. Entheses sit right next to synovial tissue and bone. When inflammation starts here, it does not always stay localized. Over time, it can spread.

How enthesitis can drive joint and bone damage

The session highlighted that enthesitis may play a central role in how damage develops in spondyloarthritis.

The inflammatory process can follow a cycle:

Inflammation begins at the entheses
That inflammation spreads into nearby synovial tissue
Synovial inflammation contributes to joint damage
Ongoing inflammation can also affect the bone itself

This helps explain why some people experience significant pain and structural changes even when joint swelling does not seem severe at first. It also shifts how researchers think about where disease activity truly begi ns.

The gut, the skin, and inflammation pathways

Researchers have long studied the gut as a possible starting point for inflammation in psoriatic arthritis . Around 60 percent of people with psoriatic arthritis have some level of gut inflammation, even if they do not have a formal gastrointestinal diagnosis. This gut inflammation may act as an environmental trigger that sets the immune system in motion.

The session also explored another important pathway: the skin.

About 80 percent of people with psoriatic arthritis experience psoriasis at some point. Immune cells, particularly T cells, are active within psoriasis skin lesions. Researchers are studying how inflammation in the skin may cross biological barriers and contribute to inflammation at the entheses.

This creates a possible chain reaction:

Immune activity in psoriasis skin lesions
Spread of inflammatory signals beyond the skin
Activation of inflammation at the entheses
Progression to synovial and bone involvement

Understanding this sequence could help explain why skin symptoms and tendon pain are so closely linked in psoriatic arthritis.

Why this matters for diagnosis and treatment

One of the most exciting implications of this research is the potential to improve both diagnosis and treatment matching.

Enthesitis can look very similar to mechanical injury or overuse. Differentiating inflammatory enthesitis from sports injuries or repetitive strain is critical. When enthesitis is clearly driven by disease rather than mechanics, and especially when it occurs alongside psoriasis, it may help clinicians recognize psoriatic arthritis earlier.

It may also guide treatment decisions. If certain inflammatory pathways are more active in a person’s disease, that information could help determine which medications are more likely to work for them, such as choosing one biologic class over another.

A growing focus in spondyloarthritis research

Enthesitis has become a major focus at rheumatology conferences in recent years, and this session reinforced why. By shifting attention to where inflammation starts and how it spreads, researchers are uncovering new ways to understand pain, prevent damage, and personalize care.

For patients, this growing focus is encouraging. It validates the real pain experienced outside of the joints and signals that research is moving closer to addressing the full picture of spondyloarthritis , not just what shows up on traditional imaging or lab tests.

As research continues, better tools for detecting enthesitis and understanding its drivers may lead to earlier diagnosis, more effective treatment strategies, and improved quality of life for people living with these complex diseases.

Discover innovation and collaboration at the Ai Arthritis Go With Us Conferences Program , where patients and experts share knowledge to advance healthcare journeys and advocacy.

Navigating the Emotional Rollercoaster of Being Undiagnosed

Mon, 23 Mar 2026 09:36:03 GMT

Navigating the Emotional Rollercoaster of Being Undiagnosed

Living with unexplained symptoms and no clear diagnosis can be frustrating, isolating, and emotionally draining . The uncertainty of not knowing what is wrong, combined with fear of being dismissed, misdiagnosed, or misunderstood, can take a significant toll on mental health. Many individuals with autoimmune and autoinflammatory diseases experience years of uncertainty before receiving a diagnosis, making coping strategies, self-care, and emotional support essential for navigating the ups and downs of this journey.

Understanding the Emotional Impact of Being Undiagnosed

Why the Diagnostic Process Is Emotionally Challenging

Uncertainty and fear – Not knowing the cause of symptoms can trigger persistent anxiety about your health and future.
Medical dismissal – Some healthcare providers may minimize or attribute symptoms to stress, fatigue, or mental health issues.
Social isolation – Friends, family, and coworkers may struggle to understand the invisible burden of undiagnosed illness.
Self-doubt – Patients may question whether their symptoms are real, exaggerated, or imagined, which can intensify feelings of frustration and hopelessness.

Common Emotional Responses

Frustration – Feeling unheard or dismissed by healthcare professionals.
Anxiety – Worrying about disease progression, complications, or long-term health.
Depression – Experiencing hopelessness or low mood due to prolonged uncertainty.
Anger – Resentment toward the healthcare system, providers, or the lack of answers.

Recognizing these emotions as valid is a critical first step toward managing them.

Coping Strategies for Managing Frustration and Fear

Building Emotional Resilience

Acknowledge your feelings – Accept that anxiety, fear, and frustration are normal responses to uncertainty.
Practice mindfulness – Techniques like meditation, deep breathing, or progressive muscle relaxation can reduce stress.
Seek professional support – Therapy or counseling provides tools to navigate difficult emotions and maintain perspective.

Managing Anxiety and Depression

Cognitive-behavioral therapy (CBT) – Helps reframe negative thoughts and develop healthier coping mechanisms.
Medication options – Antidepressants or anti-anxiety medications may be appropriate under a provider’s guidance.
Journaling – Writing about emotions and symptoms can help process feelings and identify patterns.

Finding Support and Connection

Join online or in-person communities – Connecting with others who are undiagnosed or have autoimmune conditions can reduce feelings of isolation.
Educate loved ones – Helping friends and family understand your experience improves emotional support and reduces misunderstandings.
Engage in hobbies – Creative outlets, reading, or light exercise can boost mood and provide a sense of accomplishment.

Self-Care Strategies for Navigating Uncertainty

Physical Self-Care

Prioritize sleep – Consistent rest improves energy, focus, and emotional regulation.
Eat a nutrient-rich, anti-inflammatory diet – Omega-3s, leafy greens, whole grains, and lean proteins support overall health.
Stay active – Gentle exercise, such as yoga, walking, or swimming, can improve mood, reduce stress, and maintain joint mobility.

Mental and Emotional Self-Care

Set boundaries – Limit exposure to negativity, judgment, or medical gaslighting.
Practice self-compassion – Remind yourself that your symptoms are real, valid, and deserving of care.
Celebrate small victories – Acknowledge progress in symptom management, knowledge gained, or self-advocacy.

Advocating for Yourself in Healthcare

How to Communicate with Doctors

Prepare questions in advance – Keep a list of symptoms, concerns, and priorities for each visit
Track symptoms and flare patterns – Objective data can help providers understand your condition.
Request additional tests if symptoms persist or worsen.
Seek second opinions if you feel dismissed, misdiagnosed, or unclear about your care plan.

Building a Comprehensive Care Plan

Integrate mental health care into regular medical visits to ensure emotional support is part of your treatment plan.
Explore complementary approaches – Practices like acupuncture, massage, or guided relaxation can reduce stress and improve well-being.
Advocate for workplace accommodations – Flexible schedules, remote work options, or ergonomic adjustments can help maintain stability during periods of uncertainty.

Being undiagnosed can feel like navigating a constant emotional rollercoaster, but the journey is manageable with support, self-care, and proactive advocacy. While uncertainty can be overwhelming, trusting your intuition, building resilience, and prioritizing mental health are critical tools.

Remember: your symptoms are real, your emotions are valid, and seeking the right care, both medical and emotional, is a form of empowerment.

Mystery Patient Guide by Ai Arthritis

If you’ve been dismissed or misdiagnosed, this guide helps you tell your full story and advocate effectively for the treatment you deserve.

Explore the Ai Arthritis Patient Journey, a resource designed to guide patients through every stage of life with auto immune and auto inflammatory arthritis. From diagnosis to daily management, discover tools and insights to empower your journey!

What’s New in Lupus and Lupus Nephritis: Key Updates Patients Should Know

Tue, 10 Mar 2026 11:28:03 GMT

What’s New in Lupus and Lupus Nephritis: Key Updates Patients Should Know

Lupus care is changing, and that’s good news for patients. One important EULAR 2025 sessions focused on “What’s New in Lupus Nephritis and Why Early Action Matters”. These updates matter because lupus nephritis remains one of the most serious and life-altering complications of lupus, and early education and communication can make a real difference.

Lupus nephritis affects up to 60 percent of people living with lupus , often within the first five years after diagnosis. Many patients first learn they have lupus because they experience kidney problems before other symptoms are fully recognized. That makes early conversations, monitoring, and shared decision making critical from the very beginning.

Why lupus nephritis education matters so much

One of the strongest messages from this session was that patients want and need clearer education about kidney involvement early – not after damage has already occurred. Lupus nephritis can progress quietly, and many people do not realize something is wrong until inflammation or injury is already advanced.

Patients consistently say they want their care teams to explain:

What lupus nephritis is and why it happens
What lab tests like creatinine, eGFR, and urine protein actually mean
How kidney involvement can affect lupus over time
When and why a kidney biopsy may be needed

Visual tools such as diagrams, simple handouts, or short videos can make a huge difference. Kidney disease is complex and hearing unfamiliar lab terms without context can feel overwhelming. Education helps patients feel informed rather than frightened.

Monitoring and prevention are ongoing, not one-time conversations

Another major theme was the importance of regular monitoring. Keeping inflammation under control, staying consistent with treatment, and checking lab tests on schedule can help detect kidney changes early. Routine urine tests for protein are especially important, since protein leakage is often one of the first indications of kidney injury.

Many patients say they were never clearly told how likely lupus nephritis is, or what signs to watch for. Normalizing these conversations early allows patients to partner in prevention rather than feeling blindsided later.

Shared decision making is essential in lupus nephritis care

Treatments for lupus nephritis can be intense and complex. This makes shared decision making especially important. Patients want to understand their medication options, possible side effects, and how different treatment paths might affect their daily lives.

Preferences matter. Some people may prefer daily oral medications, while others may feel more comfortable with periodic infusions. Taking patient preferences into account helps improve adherence and outcomes, and it reinforces trust between patients and providers.

When patients feel dismissed or rushed through decisions, it can increase anxiety and make treatment harder to follow. Feeling heard can be just as important as the medication itself.

Mental and emotional health cannot be separated from physical care

One of the most powerful takeaways was the recognition that mental and emotional health are often overlooked in lupus care. Depression and anxiety are not just common in lupus, they are symptoms of the disease for many patients.

Living with lupus nephritis can be frightening and emotionally exhausting. Yet mental health is rarely discussed in routine appointments. Patients want providers to ask about stress, fear, coping, and support systems, not just lab numbers.

Simple questions can open the door:

Do you have support outside of clinic visits?
Are you feeling overwhelmed or anxious about your health?
Would it help to talk with a therapist or support group?

Addressing emotional health alongside physical care supports better quality of life and, for many patients, better disease control.

Key takeaways for providers and patients

For healthcare providers, the session emphasized:

Explaining kidney risks early and clearly
Using patient-friendly language and visual tools
Inviting patients into treatment decisions
Recognizing the connection between emotional and physical health

For patients, empowerment starts with asking questions. It is okay to ask:

How at risk am I for lupus nephritis?
What do my lab trends mean over time?
Can you explain this test in a simpler way?
Are there educational resources I can review at home?

Bringing a friend, partner, or family member to appointments and writing down questions ahead of time can also help reduce stress and ensure important concerns are addressed.

Looking ahead with hope

Lupus nephritis can be scary, especially when you first learn about it. But there is real progress happening. Compared to just ten years ago, there are more treatment options, better understanding of disease mechanisms, and greater awareness of the need for patient-centered care.

With education, early monitoring, shared decision making, and attention to mental health, many people can manage lupus nephritis effectively and avoid the most severe outcomes. Awareness and communication remain some of the strongest tools patients and providers have, and conversations like these help move lupus care forward.

In this Go With Us! video from EULAR 2025, Leila shares important updates about lupus nephritis, a serious kidney problem that affects more than half of people with lupus. As someone living with lupus herself, Leila explains the research in simple terms—so you can better understand what to watch for and how to take action early.

Explore the AiArthritis Patient Journey , a resource designed to guide patients through every stage of life with autoimmune and autoinflammatory arthritis. From diagnosis to daily management, discover tools and insights to empower your journey!

What the Psoriatic Arthritis EULAR Abstracts Tell Us

Thu, 05 Mar 2026 14:17:54 GMT

What the Psoriatic Arthritis EULAR Abstracts Tell Us

Scientific conferences like EULAR can feel overwhelming, especially when much of the research is shared through abstracts. These are short summaries of studies presented as posters or brief talks, often packed with dense data. On day one of EULAR 2025, Tiffany Westrich-Robertson, CEO of Ai Arthritis and a person living with non-radiographic axial spondyloarthritis , focused on abstracts related to psoriatic arthritis and what they mean for real-world patient care. To learn more, watch Tiffany’s full debrief “ Psoriatic Arthritis Updates Every Patient Should Know .”

The main takeaway was that there is no one “right” treatment path, but that disease severity, symptoms, and timing matter more than ever when choosing therapy.

Join Tiffany Westrich-Robertson, CEO of AiArthritis and a patient living with axial spondyloarthritis, as she shares key research updates from EULAR 2025! In this short debrief, Tiffany breaks down the latest findings on psoriatic arthritis treatments

Early Psoriatic Arthritis and the Step-Up Question

Several abstracts revisited a long-standing question in psoriatic arthritis care: when someone is newly diagnosed, should they start with a biologic right away, or is it appropriate to begin with a conventional DMARD like methotrexate and step up if needed?

Earlier studies suggested that in early psoriatic arthritis, starting immediately with a biologic did not offer a major advantage over step-up therapy. Because of this, current recommendations often still support beginning with methotrexate or another DMARD and escalating treatment if targets are not met.

This approach fits within what is called treat-to-target care. Treat-to-target means working closely with your rheumatologist, checking in regularly, and adjusting treatment based on symptoms, exams, and lab results until you reach the best possible quality of life and disease control.

Why Disease Severity Changes the Picture

More recent data presented at EULAR added an important layer of nuance. Researchers pointed out that participants in some of the earlier studies may not have had severe psoriatic arthritis at the start.

Psoriatic arthritis is not one-size-fits-all. People can present with mild, moderate, or severe disease, and severity is not just about joint count. It can include:

High inflammatory markers
Swollen, hot joints
Significant skin psoriasis
Dactylitis, often called “sausage digits”
Enthesitis, inflammation where tendons and ligaments attach to bone

In newer studies that included patients with more severe features early on, results looked different. After 48 weeks, patients who started biologics earlier showed significantly better outcomes compared to those who did not. This suggests that for people with aggressive or high-risk disease at onset, early biologic therapy may offer meaningful benefits.

The key message is personalization. What works well for one patient may not be the right approach for another, even if both have the same diagnosis.

Focus on Enthesitis and Dactylitis

Several abstracts specifically examined how different biologics perform for enthesitis and dactylitis, two symptoms that often drive pain and disability in psoriatic arthritis.

Enthesitis affects tendons and ligaments and can show up in many areas of the body, including the feet, hips, shoulders, and even the chest wall. Chest involvement is sometimes experienced as costochondritis (inflammation of chest cartilage), which is also common across spondyloarthritis conditions.

It was enc ouraging to see multiple therapies being evaluated specifically for these manifestations, rather than focusing only on joint counts. This reflects a growing recognition that patients experience disease in different ways, and treatments need to target what actually causes the most impact.

Long-Term Effectiveness Still Matters

One abstract highlighted a biologic that has now been on the market long enough to assess longer-term outcomes. In this study, people with psoriatic arthritis maintained a 50 percent improvement, measured by the ACR50 response, even three years after starting treatment.

For patients, this kind of data matters. Many people worry not just about whether a medication will work, but how long it will keep working. Seeing sustained benefit over several years provides reassurance that some therapies can remain effective over time .

What Patients Can Take From This

These abstracts reinforced several important points for people living with psoriatic arthritis:

Early treatment decisions should consider how severe and active the disease is at diagnosis
Step-up therapy may be appropriate for some, while others may benefit from earlier biologic use
Treat-to-target care relies on regular communication and adjustment, not a “set it and forget it” plan
Symptoms like enthesitis and dactylitis are increasingly being studied and taken seriously
Long-term data on biologics is growing and shows encouraging durability for some treatments

Most importantly, these findings underline why conversations with your rheumatologist matter so much. Research is moving toward better matching the right treatment to the right patient, based not just on diagnosis, but on how the disease actually shows up in your body.

EULAR abstracts may be brief, but together they paint a cl ear picture: psoriatic arthritis care is becoming more individualized, more nuanced, and more responsive to what patients experience in real life.

Join the AiArthritis Go With Us Conferences Program to gain insights into the latest research and advancements in autoimmune and autoinflammatory arthritis. This unique, patient-led initiative connects individuals to cutting-edge information, empowering them to improve their healthcare journeys and advocate for change .

Nutrition, Exercise, and Stress: Holistic Management for Co-Existing Conditions with Autoimmune and Autoinflammatory Arthritis Diseases

Wed, 04 Mar 2026 16:02:32 GMT

Nutrition, Exercise, and Stress: Holistic Management for Co-Existing Conditions with Autoimmune and Autoinflammatory Arthritis Diseases

Managing autoimmune and autoinflammatory arthritis diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus arthritis, and axial spondyloarthritis, requires a comprehensive approach that addresses inflammation, energy levels, and mental well-being. While medications play a crucial role, lifestyle modifications can significantly enhance symptom management and overall health.

This guide explores practical strategies for incorporating nutrition, exercise, and stress reduction techniques into daily life to support long-term well-being.

Nutrition: Reducing Inflammation Through Diet

Anti-Inflammatory Foods

Omega-3-rich foods – Fatty fish (salmon, mackerel), flaxseeds, and walnuts help reduce inflammation
Leafy greens – Spinach, kale, and Swiss chard contain antioxidants that support immune health
Berries – Blueberries, strawberries, and raspberries provide anti-inflammatory compounds
Whole grains – Brown rice, quinoa, and oats help maintain stable blood sugar levels
Healthy fats – Olive oil, avocado, and nuts support joint health

Foods to Avoid

Processed foods – High in preservatives and inflammatory additives
Refined sugars – Can trigger inflammation and worsen symptoms
Excessive alcohol – May interfere with medications and increase inflammation
Red meat – Contains compounds that may contribute to joint pain

Hydration and Gut Health

Drink plenty of water to support joint lubrication and detoxification
Probiotic-rich foods (yogurt, kimchi, sauerkraut) help maintain gut health, which is linked to immune function

Exercise: Maintaining Mobility and Strength

Low-Impact Exercises

Walking – Improves circulation and joint flexibility
Swimming – Reduces strain while strengthening muscles
Yoga and Tai Chi – Enhances balance and relaxation
Cycling – Provides gentle movement for lower-body joints

Strength Training

Resistance bands – Improve muscle strength without excessive strain
Bodyweight exercises – Squats, lunges, and modified push-ups help maintain muscle tone
Physical therapy – Customized exercises to improve mobility and reduce stiffness

Stretching and Recovery

Daily stretching – Prevents stiffness and improves flexibility
Foam rolling – Helps relieve muscle tension and improve circulation
Hydrotherapy – Warm water exercises ease joint pain and stiffness

Stress Reduction: Supporting Mental and Emotional Well-Being

Mindfulness and Relaxation

Meditation – Helps reduce stress -related inflammation
Deep breathing exercises – Improve oxygen flow and relaxation
Guided imagery – Visualizing calm environments can ease pain perception

Sleep Optimization

Maintain a consistent sleep schedule to regulate immune function
Use supportive pillows and mattresses to reduce joint discomfort
Limit caffeine and screen time before bed to improve sleep quality

Emotional Well-Being

J oin support groups to connect with others facing similar challenges
Practice gratitude journaling to shift focus toward positive experiences
Engage in hobbies that bring joy and relaxation

A holistic approach to managing autoimmune and autoinflammatory arthritis involves nutrition, exercise, and stress reduction. By incorporating anti-inflammatory foods, joint-friendly movement, and mindfulness techniques, individuals can reduce inflammation, improve energy levels, and enhance mental well-being.

Explore the AiArthritis Patient Journey , a resource designed to guide patients through every stage of life with autoimmune and autoinflammatory arthritis. From diagnosis to daily management, discover tools and insights to empower your journey!

What’s New in Still’s Disease: Key Takeaways from EULAR 2025

Mon, 23 Feb 2026 14:15:03 GMT

What’s New in Still’s Disease: Key Takeaways from EULAR 2025

At EULAR 2025 in Barcelona, one of the most talked-about sessions focused on “Big News in Still’s Disease Research You Need to Know”. For many patients, Still’s can feel overlooked compared to other autoimmune and autoinflammatory conditions, so this session felt especially meaningful. It delivered important updates about how Still’s is understood today, how it is diagnosed, and where research is heading.

Juvenile and adult Still’s are now understood as the same disease

One of the most significant updates is that systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still’s disease (AOSD) are no longer being treated as separate conditions. While they differ by age of onset, current research shows they share the same underlying biology, immune pathways, and molecular signatures.

This is different from conditions like juvenile idiopathic arthritis and rheumatoid arthritis , which are now clearly defined as distinct diseases. In Still’s, the age of symptoms onset does not change the fundamental disease process. This shift matters because it allows research, treatments, and clinical trials to apply across age groups, helping patients of all ages benefit from the same scientific progress.

Tiffany and Eileen from AiArthritis report live from EULAR 2025 with exciting updates on Still’s disease—including new research, emerging terminology, and a surprise discovery announced for the first time during this session.

Still’s is increasingly seen as both autoinflammatory and autoimmune

Another major theme was how Still’s disease does not fit neatly into a single immune category. Researchers now describe it as a polygenic autoinflammatory disease, meaning multiple genes and immune pathways are involved.

Traditionally, autoinflammatory diseases affect the innate immune system, the part we are born with that responds quickly to threats like infection. Autoimmune diseases involve the adaptive immune system – which learns and adapts over time and is often influenced by environmental triggers.

Still’s appears to involve both sides of the immune system. This helps explain why it can look different from patient to patient and why it shares features with other autoimmune and autoinflammatory conditions. It also opens the door to new ways of thinking about treatment strategies.

IL-18 is emerging as a key biomarker

One of the most promising developments discussed was the role of interleukin-18, or IL-18. This inflammatory marke r appears to be particularly elevated in Still’s disease and may help distinguish it from other autoimmune conditions.

Researchers are studying IL-18 not only as a diagnostic clue but also as a way to identify patients who may be at higher risk for serious complications like macrophage activation syndrome. Many people with Still’s are misdiagnosed early on with infections or viral illnesses, especially since some patients do not initially develop arthritis. A reliable biomarker like IL-18 could help shorten the time to diagnosis and improve early treatment decisions.

A new area of concern: Still’s lung disease

One of the most unexpected and important announcements was the introduction of a newly described condition being referred to as Still’s lung disease. This is a very new concept, and researchers emphasized that it is still early in the investigation process.

What is known so far is that some patients with Still’s develop a distinct type of lung involvement that does not fit neatly into existing categories. There is ongoing debate about possible risk factors, including whether certain biologic medications might play a role in triggering lung symptoms in a small subset of patients.

Some early data raised concerns about severe drug reactions that can affect the lungs, but other studies showed lung involvement occurring even in patients who were not exposed to those treatments. At this point, there is no clear cause, no established diagnostic criteria, and no reason for patients to panic. The key message is awareness. Researchers are paying attention, and AiArthritis will continue sharing updates as the science evolves.

Why this session mattered so much

This Still’s disease session was held in one of the largest auditoriums at the conference, a space typically reserved for the most impactful and forward-looking research. That alone sent a powerful message that Still’s disease is finally receiving the attention it deserves.

The discussion reflected a broader shift happening across rheumatology toward personalized medicine. Rather than viewing patients as one large group, researchers are focusing on subgroups, biomarkers, and individual disease patterns. For people living with Still’s, this means more targeted research, better diagnostic tools , and greater hope for tailored treatments in the future.

The big picture for patients

While some of the science presented was complex, the takeaway for patients is encouraging. Researchers are refining how Still’s disease is defined, finding better ways to identify it earlier, and uncovering new aspects of the disease that could explain why symptoms vary so widely.

Most importantly, Still’s disease is no longer on the sidelines of research. It is firmly on the map, and the momentum seen at EULAR 2025 signals continued progress ahead.

As always, AiArthritis will keep translating these scientific advances into clear, practical information so patients and families can stay informed without feeling overwhelmed.

Ai Arthritis is the official host of Still’s Disease Awareness Day on September 7th. When the International Still’s Disease Foundation (ISDF) dissolved in 2017, they asked Ai Arthritis to house their remaining resources, which included becoming the host of Still’s Disease Awareness Day and managing the Still’s Disease Patient Support Group on Facebook. To learn more about Still’s Disease Awareness Day, visit this link .

Growing Up With AiArthritis: Supporting the Transition From Pediatric to Adult Care

Wed, 18 Feb 2026 11:45:31 GMT

Growing Up With Ai Arthritis: Supporting the Transition From Pediatric to Adult Care

One of the most meaningful sessions from Day Three of the “Go With Us!” to Conferences program at EULAR 2025 focused on a topic that affects many families but is often overlooked: the transition from pediatric to adult rheumatology care. This shift is not just about changing doctors. It is about helping young people build the skills, confidence, and support they need to manage a lifelong condition during one of the most complex stages of life.

Ai Arthritis Health Education Manager Leila P.L. Valete covered this session, sharing her own experience transitioning from pediatric to adult care to add a personal touch. As a result, “ Helping Teens Transition from Pediatric to Adult Autoimmune Care ” brings together the patient voice and clinical expertise to explore why this transition can be so challenging and what actually helps.

In this Go With Us! video from EULAR 2025, Ai Arthritis Health Education Manager Leila P.L. Valete reflects on a powerful session focused on the transition from pediatric to adult care—a time that can be confusing, scary, and even dangerous for teens living with autoimmune and autoinflammatory arthritis diseases.

Why the transition period is so vulnerable

Moving from pediatric to adult care often happens during adolescence or early adulthood, a time when life is already full of change. School transitions, new independence, social pressures, and identity development are all happening at once. Adding a chronic autoimmune or autoinflammatory arthritis disease into that mix can feel overwhelming.

In pediatric care , parents often manage appointments, medications, and decisions. In adult care, the expectation shifts overnight. Patients are suddenly responsible for scheduling visits, understanding insurance, tracking medications, and speaking up for themselves in medical settings. Without preparation, this change can lead to gaps in care and worsening health outcomes.

Adherence matters more than many people realize

A major focus of the session was adherence , which means following the full treatment plan as intended. This includes medications, lab work, imaging, physical or occupational therapy, and regular appointments.

Research shared at the session highlighted that nearly 40 percent of treatment outcomes are influenced by adherence. Even the most effective medication cannot work properly if it is not taken consistently or correctly.

Adolescence is a partic ularly high-risk period for non-adherence. Many young people skip doses, miss appointments, or stop treatments altogether. This often happens not because they don’t care, but because they want to feel normal, avoid side effects, or simply do not fully understand their treatment.

Knowledge builds confidence and autonomy

One of the most important takeaways was the need to gradually shift responsibility from parents to patients. This should be a process, not a sudden handoff.

Young people are more likely to adhere to treatment when they understand:

The names of their medications
Why they take each medication
What happens if they miss doses
How to monitor symptoms and side effects
When and how to ask for help

Teaching these skills early helps patients feel more confident and less overwhelmed when they reach adulthoo d.

Transition should be a journey, not a jump

Healthcare teams can also support a successful transition by planning well in advance with their patients. Conversations about adult care should start early, not at the final pediatric visit.

Healthcare teams can support this by:

Introducing transition planning years ahead of time
Encouraging teens to speak directly during appointments
Gradually involving patients in decision making
Checking in about mental health , school stress , and social challenge s

Honest conversations about preferences also matter. Some patients may do better with infusions rather than injections. Others may need help managing side effects or scheduling treatments around school or work. Personalizing care increases the likelihood that patients will stay engaged.

Psychosocial support is just as important as medical care

The session highlighted that quality of life issues are often missed during routine visits. Tools like HEADSS assessments and quality-of-life screenings can help identify challenges related to mental health, stress, relationships, and daily functioning.

Flexibility also matters. Offering virtual visits, evening appointments, or alternative scheduling options can make it easier for young adults to stay connected to care while managing school, jobs, or family responsibilities .

Community support fills critical gaps

Healthcare providers have limited time with each patient. This is where patient organizations play a vital role. Support groups, educational resources, peer connections, and advocacy organizations help young people feel less alone and more empowered.

Connecting with organizations focused on arthritis and chronic illness can provide practical advice, emotional support, and reassurance that others have navigated this transition successfully.

The big takeaway

Transitioning from pediatric to adult rheumatology care is not just a medical milestone. It is a life milestone. When done well, it helps young people build independence while staying supported. When rushed or ignored, it can lead to missed care and preventable flares.

The message from EULAR was clear and hopeful: with early planning, honest communication, personalized care, and strong community support, young people with autoimmune and autoinflammatory arthritis can move into adulthood with confidence and better long-term health.

You are not meant to do this alone, and the right support can make all the difference.

Ai Arthritis can help patients and caregivers navigate every part of the disease journey, including transitioning from pediatric to adult care. To get started, visit the AiArthritis Patient Journey webpage and access tools and resources for every stage of your journey.

The Importance of Documenting Symptoms in Autoimmune and Autoinflammatory Arthritis Diseases

Mon, 16 Feb 2026 13:41:39 GMT

The Importance of Documenting Symptoms in Autoi mmune and Auto inflammatory Arthritis Diseases

Autoimmune and autoinflammatory arthritis ( Ai Arthritis) diseases can be complex, unpredictable, and difficult to diagnose . Symptoms often fluctuate, making it challenging for doctors to pinpoint a clear diagnosis . Keeping detailed records of symptoms, flare patterns, and potential triggers is essential for helping healthcare providers uncover underlying conditions, track disease progression, and develop effective treatment plans.

Why Symptom Documentation Matters

Helps Identify Patterns

Ai Arthritis diseases often present with waxing and waning symptoms , meaning they may appear suddenly and then disappear.
Tracking symptoms over time can reveal flare triggers, such as stress, diet, weather changes, or infections.

Supports Diagnosis and Treatment

Many Ai Arthritis diseases take years to diagnose due to overlapping symptoms.
A well-documented symptom history can help doctors rule out other conditions and determine the best course of treatment.

Improves Communication with Doctors

Patients often struggle to describe symptoms accurately during short medical appointments.
A symptom log provides objective data, making it easier for doctors to assess disease activity.

What to Include in a Symptom Log

Basic Information

Date and time of symptom onset
Duration of symptoms (hours, days, weeks)
Severity (use a scale from 1-10)

Physical Symptoms

Pain levels (sharp, dull, burning, throbbing)
Joint stiffness and swelling
Fatigue and energy levels
Skin changes (rashes, discoloration, sensitivity)
Digestive issues (bloating, nausea, diarrhea, constipation)
Neurological symptoms (brain fog, headaches, dizziness)

Flare Patterns

Frequency of flares (daily, weekly, monthly)
Symptoms during flares (increased pain, fever, swelling)
Recovery time after a flare

Potential Triggers

D ietary changes (new foods, processed foods, alcohol)
Stress levels (emotional distress, work-related stress)
Weather conditions (cold, humidity, seasonal changes)
Physical activity (exercise, prolonged sitting or standing)
Medications (new prescriptions, dosage changes)

Additional Notes

Photos of visible symptoms (rashes, swelling)
Temperature readings (for fever-related conditions)
Sleep quality and disturbances

How to Keep an Effective Symptom Log

Use a Digital or Physical Journal

Mobile apps designed for symptom tracking can provide easy access to records.
Handwritten journals allow for detailed notes and reflections.

Be Consistent

Log symptoms daily or weekly to maintain accuracy.
Include even mild symptoms, as they may indicate early warning signs.

Share Logs with Your Doctor

Bring symptom records to medical appointments to discuss patterns.
Use logs to advocate for additional testing or treatment adjustments.

Real-Life Benefits of Symptom Documentation

Early Diagnosis: Patients who track symptoms often receive faster diagnoses, as doctors can see clear patterns.
Better Treatment Adjustments: Doctors can modify medications based on symptom trends.
Improved Quality of Life: Understanding flare triggers allows patients to make lifestyle changes that reduce symptom severity.

Keeping detailed records of symptoms, flare patterns, and triggers is a powerful tool for managing autoimmune and autoinflammatory diseases. By documenting symptoms consistently, patients can help doctors uncover potential diagnoses, track disease progression, and improve treatment outcomes.

Symptom Trackers By Ai Arthritis

Explore the AiArthritis JIA Communication Aid , a patient-inspired initiative designed to improve communication between families affected by Juvenile Idiopathic Arthritis (JIA) and healthcare providers.

IgG4-RD - This toolkit was created to facilitate the prompt detection, diagnosis, or re-evaluation of IgG4-RD.

Take a Breath - A Patient's Guide to Understanding the Risk of Lung Involvement for Ai Arthritis Patients.

Navigate every phase of life with auto immune and auto inflammatory arthritis through the Ai Arthritis Patient Journey ! From diagnosis to daily living, discover empowering tools, resources, and insights crafted to support you at every step.

National Caregiver Day: Why Caregivers Are Essential in Autoimmune and Autoinflammatory Arthritis

Sun, 15 Feb 2026 14:22:34 GMT

National Caregiver Day: Why Caregivers Are Essential in Autoimmune and Autoinflammatory Arthritis

National Caregiver Day is more than a feel-good social media moment. It’s a necessary pause. A reckoning. A reminder that behind almost every person living with autoimmune or autoinflammatory arthritis (AiArthritis diseases) there is someone quietly holding the scaffolding of daily life together.

Caregivers are the invisible infrastructure of chronic disease.

AiArthritis diseases such as Rheumatoid Arthritis , Ankylosing Spondylitis , Psoriatic Arthritis , Lupus , and Juvenile Idiopathic Arthritis are not “just joint pain.” They are systemic inflammatory diseases. That means fatigue that feels like gravity doubled overnight. Brain fog that steals words mid sentence. Flares that erupt without warning. Medications that suppress the immune system. Pain that doesn’t politely clock out at 5 p.m.

Caregivers live in that reality too.

So what is a caregiver?

A caregiver is anyone who provides unpaid or paid support to someone living with illness or disability. It can be a spouse, parent, child, sibling, friend, neighbour, or hired professional. Caregiving is not defined by a job title. It’s defined by action.

A caregiver might:

Drive to rheumatology appointments and infusion clinics
Track medications, biologics, lab work, and side effects
Advocate when a patient is too exhausted to speak
Help with bathing, dressing, cooking, or household tasks during flares
Provide childcare when disease activity spikes
Monitor blood pressure, infections, or wound healing
Sit through emergency rooms and hospital stays
Offer emotional support during grief, medication failures, and uncertainty

Sometimes caregiving looks dramatic. Often it looks mundane. Grabbing ice packs. Opening jars. Lifting laundry baskets. These are small acts that have a profound impact on us.

And here’s the uncomfortable truth: without caregivers, many people with AiArthritis diseases would lose stability faster. Chronic inflammation does not just attack joints, it disrupts employment, parenting, finances, mental health, and independence. Caregivers buffer those shocks

From a health systems perspective, caregivers reduce hospitalizations, improve medication adherence, and support functional independence. Patients with strong social support tend to have better health outcomes. The science of stress biology backs this up. Chronic stress worsens inflammation. Support lowers stress. Lower stress can improve disease coping. The mind and immune system are not strangers.

Caregiving for someone with an AiArthritis disease is uniquely challenging because the diseases are often invisible. A caregiver may defend their loved one against skepticism: “But they look fine.” They may need to explain fluctuating symptoms, why yesterday’s energy doesn’t predict today’s capacity. They must learn medical language quickly: DMARDs, biologics, CRP, MRI findings, axial involvement.

Caregivers become mini-experts in immune modulation and fatigue management whether they signed up for that role or not.

There are also different types of caregivers in the AiArthritis disease community:

Spousal or partner caregivers
These individuals often absorb financial shifts, household changes, and emotional load. They witness the grief of lost identity and help rebuild new routines.

Parent caregivers
Parents of children with Juvenile Idiopathic Arthritis navigate school accommodations, injections, sports limitations, and the psychological toll of seeing a child in pain.

Young caregivers
Sometimes children or teens help a parent with autoimmune disease. That role reversal can be heavy and deserves recognition.

Professional caregivers
Nurses, personal support workers, and home care aides provide essential daily living assistance, particularly during severe flares or advanced disease.

And then there is the emotional caregiver, the friend who checks in, the person who believes the pain without proof, the one who doesn’t minimize fatigue.

National Caregiver Day matters because caregiving has a cost.

Caregivers are at increased risk of burnout, depression, sleep disruption, financial strain, and chronic stress. They often neglect their own health appointments. They postpone rest. They normalize exhaustion. Both the patient and caregiver can become depleted.

Supporting caregivers is not optional. It is preventative care.

That means encouraging respite services. Providing mental health resources. Including caregivers in education sessions about disease management. Listening to them during appointments. Asking, “How are you coping?” instead of assuming resilience is infinite.

Caregivers are not saints. They are humans adapting to complex, unpredictable disease landscapes. They make mistakes. They get tired. They feel frustrated. That doesn’t diminish their value, it makes their commitment more real.

Explore the Ai Arthritis Patient Journey, a resource designed to guide patients through every stage of life with autoimmune and autoinflammatory arthritis. From diagnosis to daily management, discover tools and insights to empower your journey!

Cannabis and AiArthritis Diseases: What We Heard in a Medical Debate at EULAR 2025

Mon, 09 Feb 2026 14:34:14 GMT

Cannabis and Ai Arthritis Diseases: What We Heard in a Medical Debate at EULAR 2025

Cannabis comes up a lot in chronic illness conversations, especially when pain, sleep, and stress are part of everyday life. At EULAR 2025 in Barcelona, Eileen attended a debate session where two physicians debated, “Should Doctors Prescribe Cannabis for Autoimmune Diseases?”. One presented the “No” case and one presented the “Yes” case. Their job was not to share personal opinions, but to review the evidence and argue their assigned position.

The audience was made up of healthcare providers, and they voted before and after the debate on two questions:

Do you recommend or prescribe cannabis for patients?
Do you think cannabis should be legalized?

Before the debate, about 35.4% said they recommend cannabis and 64.86% said they do not. On legalization, about 68.97% supported keeping it legal and 31.03% did not. After the debate, support for prescribing rose to about 40% , while support for legalization dipped slightly to about 66.7% , with “no” rising to about 33.3% .

So even in a room of clinicians, the conversation was still complicated.

In this Go With Us! video from EULAR 2025, Eileen Davidson breaks down one of the most talked-about sessions of the conference—a debate on whether cannabis should be prescribed for rheumatic and autoimmune diseases like RA, fibromyalgia, and scleroderma.

The “No” side: concerns about harm, dosing, and long-term risks

The physician presenting the “No” argument started with a point many people agree on: cannabis has been used historically for a long time. The concern is what happens when use becomes more widespread, especially with modern high-THC products and earlier exposure.

A few major themes came up:

1) Adolescents and brain development

The presenter emphasized that early cannabis use in adolescence can affect brain development, particularly the frontal lobe. He linked this to concerns about thinking, decision-making, and potential negative impacts on IQ.

2) Mixed evidence for chronic pain relief

He highlighted systematic review data suggesting that cannabis does not significantly reduce pain when added to opioids. He argued that evidence is limited or inconsistent for chronic pain overall, and raised the possibility that long-term use might actually increase pain sensitivity for some people.

3) “CBD” products may contain more THC than expected

A practical point that many patients can relate to: some over-the-counter CBD products may contain higher levels of THC than people realize. That matters for anyone trying to avoid feeling intoxicated, anyone who is sensitive to THC, or anyone who must avoid THC for work or legal reasons.

4) Pregnancy risks

The “No” side also raised concerns about cannabis use during pregnancy, including risks like preeclampsia, maternal anemia, and neonatal complications.

5) Mental health risks

This was one of the strongest parts of the “No” argument. The speaker pointed to correlations between cannabis use and mental health conditions like bipolar disorder and schizophrenia, and noted that high-THC products may increase the risk of psychosis in vulnerable individuals. He also mentioned increased ER visits and concerns about heavy use in young adults.

6) Other health concerns

He referenced possible cardiovascular risks (including blood pressure effects and myocardial infarction risk) and raised questions about long-term cancer risk in frequent, long-term users. A consistent message was that we still lack strong long-term data.

In short, the “No” side focused on uncertainty, safety, and the reality that legalization has changed patterns of use.

The “Yes” side: potential symptom relief and a harm-reduction approach

The physician presenting the “Yes” side also began with history, noting that cannabis has been used for centuries across cultures. But his emphasis was on how cannabis is actually used today, and why some patients report meaningful benefits.

Multiple ways to use cannabis

This was an important clarification: cannabis is not only smoked. The presenter discussed different delivery methods, including:

Vaping or inhalation
Edibles
Topicals
Patches

For some patients, the method matters as much as the product, especially if they are trying to avoid smoke exposure or want more controlled dosing.

Potential benefits for inflammation, pain, and quality of life

The “Yes” side highlighted data suggesting cannabis may help with inflammation and pain management in some cases. He specifically mentioned rheumatic conditions and symptom clusters that are notoriously hard to treat, including:

Rheumatoid arthritis pain
Fibromyalgia symptoms
Scleroderma -related symptom burden

A key theme was not just pain reduction, but improved quality of life. For many patients, the goal is not to erase every symptom. It is to function, sleep, work, parent, and live with fewer daily barriers.

Acknowledging side effects, but comparing risk realistically

The “Yes” presenter did not ignore risks. He noted memory issues, psychosis risk, and addiction potential. But he also cited evidence suggesting addiction risk may be lower than substances like alcohol and opioids, and emphasized the importance of dosing and medical supervision.

His bottom line was familiar to many patients: every treatment has side effects. Cannabis should be discussed like other symptom-management tools, with careful monitoring and shared decision-making.

Why the votes shifted, and what that might mean

After the debate, more providers were willing to prescribe cannabis. This suggests that the “Yes” argument helped some clinicians see why patients use it and where it might fit as a supervised option.

At the same time, support for legalization dropped slightly, likely reflecting concerns raised about ER visits, motor vehicle accidents, and rare but serious events like cannabis-related psychosis. Eileen also pointed out an important media literacy issue: some of the “risk” examples were presented through news headlines, and headlines can be misleading without context like prior mental health history or other contributing factors.

Key takeaways for patients

If you are thinking about cannabis for rheumatic disease symptoms, here are the patient-friendly takeaways from this debate:

The evidence is mixed , especially for chronic musculoskeletal pain. Some studies do not show strong benefits, while many patients report real-world relief.
THC and CBD are not the same. Product labeling can be confusing, and some CBD products may include more THC than expected.
Mental health history matters. If you have a history of psychosis, bipolar disorder, schizophrenia, or strong family history, cannabis may carry higher risk.
Method and dose matter. Inhalation, edibles, and topicals can feel very different in the body. Supervision helps reduce harm.
Sleep and stress are part of the pain conversation. If something improves sleep, it may indirectly reduce pain and improve daytime function.
Shared decision-making is the goal. If you want to use cannabis, the safest path is an honest conversation with a provider who can help you weigh benefits, risks, and monitoring.

A gentle reminder

This information is educational, not medical advice. Cannabis laws and medical access vary by location, and individual risk can depend on age, pregnancy status, heart health, mental health history, and other medications.

If you are considering cannabis, a helpful next step is to bring a few specific questions to your clinician, like:

What symptoms am I trying to target: pain, sleep, anxiety, stiffness?
Should I avoid THC given my health history?
What side effects should I watch for? Are there any side effects that would indicate that I should stop?
How do we track whether it is helpin g?

Cannabis is not a simple yes-or-no topic, and this debate reflected that. What matters most is making sure patients have accurate information, realistic expectations, and support to make the safest decision for their body and their life.

Cannabis has come a long way since we last covered it in 2020. With more patients using CBD and medical cannabis to help manage chronic pain, inflammation, anxiety, and sleep issues, it is time for an important update. In this episode, AiArthritis Health Education Manager Leila P. L. Valete is joined by co-hosts and patient advocates Eileen Davidson and Bridget Seritt for a real conversation about what has changed, what we still need to learn, and what patients should know before trying cannabis for autoimmune and autoinflammatory arthritis.

Understanding Pain and What Can Actually Help

Wed, 04 Feb 2026 12:48:12 GMT

Understanding Pain and What Can Actually Help

Pain is one of the most common and most misunderstood parts of living with autoimmune and autoinflammatory arthritis. On the final day of EULAR, Deb attended sessions on chronic pain, outlined in her debrief video “Understanding Chronic Pain in Autoimmune Arthritis – What Really Helps?” These session focused primarily on pain, how it develops , how it affects daily life, and what patients and providers can realistically do about it. These sessions brought together patient voices, clinicians, and researchers, and reinforced something many of us already know: pain is complex, personal, and deserves more thoughtful care.

In this Go With Us! episode from EULAR 2025, patient advocate Deb Constien dives into one of the most talked-about topics at the conference: chronic pain. If you live with autoimmune or autoinflammatory arthritis, you know pain isn’t just a symptom—it can affect every part of your life.

What Chronic Pain Really Looks Like From a Patient Perspective

The day began with a powerful, patient focused session led by Nadia Malliou, President of Pain Alliance Europe , psychologist, and PhD student. She started by grounding the conversation in lived experience, which immediately resonated with many in the room.

One of the first clarifications she made was the difference between acute and chronic pain. Acute pain typically lasts up to three months. Chronic pain extends beyond that timeframe and often becomes a condition of its own.

Common symptoms of chronic pain go far beyond aching joints. Many patients experience:

Persistent pain that does not fully go away
Fatigue and stiffness
Sleep disturbances
Mood changes and social withdrawal
Sensitivity to touch
Appetite changes
Cognitive difficulties or brain fog

She also explained that chronic pain is not a single category. There are several overlapping types:

Chronic primary pain: which lasts longer than three months and is linked to emotional distress and functional limitations
Chronic secondary pain: which comes from an underlying condition like rheumatoid arthritis, osteoarthritis, or cancer
Nociplastic pain: such as fibromyalgia or widespread pain syndromes, where pain processing itself is altered
Neuropathic pain: caused by nerve injury or disease, like sciatica or spinal cord inj ury

Many patients live with more than one type at the same time, which helps explain why pain can feel unpredictable or hard to treat.

Coping Strategies That Support The Whole Person

Rather than focusing only on medications, this session highlighted tools patients can use alongside medical care. These recommendations included physical therapy, pacing daily activities , and asking simple questions like whether something truly needs to be done right now or can wait.

Psychosocial support was emphasized as essential, not optional. Cognitive behavioral therapy, mindfulness practices, peer support groups, and mentoring can all help patients manage pain more effectively. Adaptive tools and technology were also discussed as practical ways to support daily function.

A key takeaway was the role of healthcare professionals. Empathy, respect, and listening matter. Not every rheumatologist specializes in pain, and pain specialists can play a critical role when pain becomes overwhelming . Shared decision making and individualized care planning were repeatedly emphasized .

Preventing Acute Pain From Becoming Chronic

The second session focused on a difficult but important question: how do we prevent acute pain from turning into chronic pain?

An integrative physician led this discussion and began by guiding the audience through a short mindfulness exercise, reminding everyone how awareness and regulation are part of pain care.

Some sobering statistics were shared. About 67 percent of healthcare visits are related to pain. Chronic pain is widespread, costly, frustrating for both patients and providers, and often associated with fragmented care, confusing diagnoses, medication side effects, and loss of productivity .

One resource highlighted was the US Academy of Medicine report on relieving pain. This work supports coaching and self care education as part of routine care. Studies show that this approach can reduce the risk of chronic pain and substance misuse, improve long term outcomes, increase patient satisfaction, and lower healthcare costs.

Risk factors like poor sleep, chronic stress, repeated strain, inactivity, and nutrition all influence pain progression. Protective factors, including movement, stress management, and support, can help slow that progression. Walking was specifically mentioned as one of the most accessible and effective activities for many people.

Unfortunately, training patients in whole person self care is still often overlooked in standard medical care.

Medications, Mixed Pain, and Why Pain is Underestimated

The next session explored pharmacological treatment of chronic musculoskeletal pain. One important concept introduced was the idea of a biological clock. In people with rheumatic and musculoskeletal diseases, this clock may be accelerated, contributing to more severe and persistent pain over time.

Pain severity is often underestimated because it does not always show up clearly on imaging or blood tests. When providers cannot see pain, patients may be unintentionally stigmatized or dismissed. This reinforces the need to believe patient reports and understand pain as multidimensional.

The speaker emphasized that pain is rarely just one thing. Many patients experience a mix of nociceptive, neuropathic, and nociplastic pain, sometimes all in the same day. This mixed pain model helps explain why single treatment approaches often fall short.

Cannabinoids were also discussed. Current evidence is considered low quality, and at this time THC and CBD are not broadly recommended for chronic musculoskeletal pain. At the same time, the speaker acknowledged that many patients report subjective benefit, highlighting the gap between research and lived experience.

Emerging pain treatments were briefly reviewed, including therapies targeting specific receptors and pathways. These are still largely in development but reflect growing interest in more targeted pain care.

Non Medication Approaches That Actually Help

The final session focused on non pharmacological treatments and showed just how important these approaches can be. Chronic pain affects about 20 percent of adults, and up to half of those individuals also experience severe depressive symptoms. One third live with high impact chronic pain that significantly limits daily life.

Non-drug treatments discussed included:

Exercise therapy, which consistently improves pain and function
Cognitive behavioral therapy and other psychological approaches
Non-invasive brain stimulation
Patient education and lifestyle changes
Multidisciplinary care that addresses physical, emotional, and social health together

Acupuncture and multidisciplinary programs were shown to reduce pain and improve function. Psychological therapies were also found to be effective, reinforcing that pain is not just physical.

Non-invasive brain stimulation techniques were introduced, including repetitive transcranial magnetic stimulation (TMS), which is similar to Vagus Nerve Stimulation but doesn’t require surgery. TMS may help some patients with conditions like fibromyalgia.

The Big Picture Takeaway

Pain is not a failure of treatment or a sign of weakness. It is complex, deeply personal, and influenced by biology, emotions, environment, and experience. The strongest message from these sessions was that effective pain care must be personalized, integrated, and compassionate.

Medication can play a role, but it is rarely enough on its own. Supporting mental health , encouraging movement, addressing sleep and stress, and truly listening to patients are just as important.

As research continues to evolve, one thing is clear. People living with autoimmune and autoinflammatory arthritis deserve pain care that sees the whole person, not just a diagnosis.

Join the Ai Arthritis Go With Us Conferences Program to gain insights into the latest research and advancements in autoimmune and autoinflammatory arthritis. This unique, patient-led initiative connects individuals to cutting-edge information, empowering them to improve their healthcare journeys and advocate for change.

Connecting the Dots: Managing Multiple Specialists and Treatment Plans with Autoimmune and Autoinflammatory Arthritis Diseases

Tue, 03 Feb 2026 13:02:07 GMT

Connecting the Dots: Managing Multiple Specialists and Treatment Plans with Auto immune and Auto inflammatory Arthritis Diseases

Autoimmune and autoinflammatory arthritis diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus arthritis, and axial spondyloarthritis, often require care from multiple specialists. Patients may see rheumatologists, dermatologists, gastroenterologists, neurologists, and pain management experts, making coordination essential for effective treatment.

Managing multiple specialists and treatment plans can feel overwhelming, but integrated healthcare approaches, proactive communication, and organized tracking can help patients navigate their care with confidence

Understanding the Role of Multiple Specialists

Why Multiple Specialists Are Needed

Autoimmune diseases affect multiple systems, requiring expertise beyond rheumatology.
Different specialists focus on specific symptoms or comorbidities, such as skin, digestive, or neurological issues.
Comprehensive care ensures better symptom management and reduces complications.

Common Specialists for Autoimmune & Autoinflammatory Arthritis

Rheumatologist – Manages joint inflammation and disease progression.
Dermatologist – Treats skin-related symptoms, such as psoriasis or lupus rashes.
Gastroenterologist – Addresses digestive issues linked to autoimmune diseases.
Neurologist – Evaluates nerve pain, brain fog, and neurological complications.
Pain Management Specialist – Helps with chronic pain relief strategies.
Physical Therapist – Provides mobility exercises and rehabilitation techniques.

Coordinating Care Between Specialists

Tips for Effective Coordination

Keep a centralized medical record with test results, medications, and treatment history.
Request referrals and specialist recommendations from your primary doctor.
Ensure specialists communicate with each other to avoid conflicting treatments.
Schedule appointments strategically to prevent medical fatigue.

Using a Primary Care Physician as a Coordinator

A primary care doctor can help streamline referrals and oversee overall health.
They can track medication interactions and ensure treatments align.
Regular check-ins with a primary doctor prevent gaps in care.

Tracking Treatment Progress

How to Stay Organized

Maintain a symptom journal to track flare-ups, medication effects, and triggers.
Use a medical planner or app to log appointments, prescriptions, and test results.
Request copies of lab reports and imaging scans for personal records.
Note changes in symptoms to discuss with specialists.

Questions to Ask at Each Appointment

How is my condition progressing?
Are there new treatment options available?
How do my medications interact with each other?
Should I adjust my lifestyle or diet to support treatment?

Advocating for Integrated Healthcare Approaches

Integrative care is a team-based, whole-person approach to healthcare that treats more than just inflammation on a lab report. For people living with AiArthritis diseases, it matters because these conditions affect the entire body and daily life, not just joints.

Integrative care bring s together medical treatment with allied health supports like physiotherapy, occupational therapy, mental health care, pain education, nutrition, and self-management strategies. This approach recognizes that fatigue, pain, mental health, mobility, sleep, and social factors all influence disease outcomes. When care is integrated, patients are more likely to function better, avoid unnecessary suffering, and stay engaged in treatment over the long term, because managing AiArthritis diseases requires more than a prescription; it requires coordinated, comprehensive support.

Why Integrated Care Matters

Reduces miscommunication between specialists.
Ensures treatments complement each other rather than conflict.
Improves patient outcomes by addressing all aspects of the disease .

How to Advocate for Integrated Care

Request a multidisciplinary team approach where specialists collaborate.
Ask for shared medical records to improve coordination.
Communicate concerns about conflicting treatments to your doctors.
Seek second opinions if care feels disjointed or ineffective.

Managing multiple specialists and treatment plans for autoimmune and autoinflammatory arthritis requires organization, proactive communication, and advocacy. By coordinating care, tracking progress, and pushing for integrated healthcare, patients can ensure comprehensive and effective treatment for their condition.

Tune into the AiArthritis Voices 360 Talk Show , where patients, doctors, and advocates come together to discuss the latest in autoimmune and autoinflammatory arthritis.

AxSpA Imaging and Treatment Updates

Tue, 20 Jan 2026 14:12:52 GMT

AxSpA Imaging and Treatment Updates

New research shared at the 2025 American College for Rheumatology (ACR) convergence is changing how clinicians think about diagnosing and treating axial spondyloarthritis – often called AxSpA. A recent session focused on AxSpA imaging advances and treatment decisions , with especially important implications for children and adolescents living with this disease.

Here is what stood out and why it matters for patients and families.

Go With Us! to ACR 2025: AxSpA Imaging & Treatment Updates from ACR 2025

Join Brittany Murray, a person living with psoriatic arthritis, as she reports from Day 2 of ACR 2025 through the Go With Us! program by AiArthritis. Brittany attended a session on imaging and Axial Spondyloarthritis (AxSpA) — highlighting how new research is improving diagnosis and treatment, especially for children and young adults.

Pediatric AxSpA Still Lacks Clear Guidelines

One of the most striking takeaways was how limited pediatric-specific guidance still is for AxSpA. There are currently no strong, standalone diagnostic criteria or comprehensive treatment guidelines for children beyond TNF inhibitors.

Because of this, pediatric rheumatologists often have to rely on adult research and adapt it to younger patients. This creates a gap. Adults now have access to many biologic options, while children are often limited to fewer choices, even though the disease can be just as impactful early in life.

That said, change is beginning to happen. Clinicians are increasingly moving pediatric patients from TNF inhibitors directly to interleukin-17 inhibitors such as secukinumab when needed. Importantly, they are skipping methotrexate in many cases, recognizing that there is little evidence it helps AxSpA and that NSAIDs alone do not stop disease progression.

Even though treatment guidelines have not officially caught up yet, clinicians are already applying newer evidence in practice, which is encouraging for families navigating pediatric AxSpA.

Imaging Is Becoming a Tool for Understanding, Not Just Diagnosis

Another major shift discussed in the session was how imaging is being used. Clinicians are increasingly sharing imaging results directly with patients, helping them visualize what is happening inside their bodies.

AxSpA is often described as an invisible disease. Pain, stiffness, and fatigue can be severe even when lab tests look normal. Seeing inflammation on imaging can help patients feel validated and better understand why treatment is necessary.

This visual approach can also strengthen communication between patients and providers, making shared decision-making easier and more meaningful.

MRI Is Changing How AxSpA Is Diagnosed

MRI, or Magnetic Resonance Imaging, is emerging as one of the most valuable tools for diagnosing AxSpA earlier and more accurately. Unlike X-rays, which often only show damage after it has already occurred, MRI can detect active inflammation before structural changes become permanent.

Lesions seen on MRI can serve as early indicators of AxSpA and may even help predict progression to radiographic disease. This allows clinicians to diagnose sooner, start treatment earlier, and potentially slow long-term damage.

Earlier diagnosis is critical. The sooner inflammation is controlled, the better the chances of preserving mobility and quality of life.

Reading MRIs Is Complex and Context Matters

While MRI is powerful, it is not simple. Interpreting AxSpA imaging requires expertise and careful attention to the full clinical picture. In the session, clinicians emphasized that reading these scans often feels like detective work.

AxSpA can mimic other conditions on MRI and X-ray. For example, sacroiliac inflammation is a hallmark of AxSpA, but similar findings can occur during pregnancy. Without context, imaging alone could lead to misdiagnosis.

This reinforces the importance of combining imaging with symptoms, medical history, and physical exam rather than relying on one test alone.

Why These Updates Matter for Patients

The biggest takeaway from this session is that AxSpA care is becoming more precise and preventative . Instead of waiting for irreversible damage to appear on X-rays, clinicians are learning to identify inflammation sooner and act faster.

For pediatric patients especially, this shift is critical. Early treatment decisions can shape long-term outcomes. Avoiding unnecessary medications while targeting the disease more effectively can make a real difference.

While gaps in guidelines still exist, the direction is clear. Imaging is becoming more central, treatment pathways are evolving, and clinicians are actively working to improve how AxSpA is recognized and managed.

Education and updates like these, shared through programs such as “Go With Us!” to Conferences by Ai Arthritis , help patients and families stay informed and empowered as care continues to advance.

Join the Ai Arthritis Conferences Program to gain insights into the latest research and advancements in autoimmune and autoinflammatory arthritis. This unique, patient-led initiative connects individuals to cutting-edge information, empowering them to improve their healthcare journeys and advocate for change.

Cannabis and AiArthritis: What Patients Need to Know

Tue, 20 Jan 2026 12:04:47 GMT

Cannabis and Ai Arthritis: What Patients Need to Know

Cannabis use among people living with autoimmune and autoinflammatory arthritis (AiArthritis) has quietly shifted from a fringe conversation to a mainstream reality. Patients are using it for pain, sleep, nausea, anxiety, mood, and quality of life—often long before their doctors feel comfortable discussing it. Five years after AiArthritis last tackled this topic, it was time for an honest update.

In AiArthritis Voices 360 – Episode 115 , patient leaders and subject-matter experts came together to unpack what has changed, what hasn’t, and what patients truly need to know before adding cannabis to their care plan .

This conversation wasn’t about hype. It was about lived experience, evolving science, legal reality, and patient safety.

Ep 115: CBD and Cannabis in 2025: Where are We Now?

From CBD to the Whole Plant: What’s Changed?

In 2020, most conversations centered on CBD alone. Today, patients are increasingly using full-spectrum cannabis , meaning products that contain THC, CBD, and other cannabinoids and terpenes working together (often called the entourage effect ).

Patients report benefits that go beyond pain relief, including:

Improved sleep
Reduced nausea
Better mood regulation
Improved ability to cope with chronic illness
Enhanced overall quality of life

That said, evidence still leans heavily on patient-reported outcomes , not long-term randomized clinical trials. For many clinicians, that gap remains a major barrier to formal recommendation or prescribing.

Stigma Is Shifting—but Not Evenly

Social stigma around cannabis has decreased dramatically in places like Canada, California, Colorado, and parts of Europe. Government-regulated dispensaries, standardized testing, and clearer labeling have helped normalize its use.

Medical acceptance, however, remains uneven:

Some clinicians are open to discussion but won’t guide dosing
Others still avoid the topic entirely
Reactions vary widely—even within the same healthcare system

Patients often find themselves navigating cannabis alone, despite using it specifically to manage medically complex diseases .

Forms of Cannabis: Not One-Size-Fits-All

Cannabis is not a single product. Different forms behave very differently in the body:

Edibles

Longer-lasting effects
Stronger binding in the body
Higher risk of overdoing it
Not tolerated well by some patients with GI disease

Inhaled (smoked or vaporized)

Faster relief
Shorter duration
Raises lung-health concerns, especially for patients at risk of interstitial lung disease

Topicals

Localized pain relief
Minimal systemic effects
Often underestimated but surprisingly effective for joint and muscle pain

Each method carries different benefits and risks, and what works one day may not work the next—especially in bodies already affected by immune dysregulation.

Lung Health Matters—Especially in Rheumatic Disease

People with inflammatory arthritis already face increased lung risks. Any inhalation—smoking or vaporizing—introduces potential harm.

Key takeaways:

Vaporizing flower is generally considered less harmful than smoking, but not risk-free
Vape cartridges carry their own safety concerns
Lung involvement in diseases like RA , lupus , and Sjögren’s must be considered
Inhalation should never be assumed “safe” simply because cannabis is legal

Patients must weigh symptom relief against long-term pulmonary risk, ideally with informed medical input .

Cannabis, Medications, and Real Risks

One of the most critical—and often ignored—issues is drug interaction .

Cannabis (especially THC and CBD) interacts with liver enzymes responsible for metabolizing many medications, including:

Biologics
DMARDs
Seizure medications
Psychiatric medications

These interactions are not theoretical. Patients—especially children—have ended up hospitalized due to unrecognized cannabis-drug interactions.

In the U.S., federal Schedule I status severely restricts research and physician guidance, leaving patients to figure this out largely on their own .

What Happened at EULAR?

At EULAR, a formal debate asked whether rheumatologists should prescribe cannabis.

Key points raised:

Evidence shows modest short-term benefits for pain, sleep, and anxiety
Potential to reduce opioid reliance is significant
Concerns remain around cognition, dependency, cardiovascular effects, and lung health
Physicians acknowledged that all treatments carry risk , including standard rheumatology medications

The conclusion? Interest is growing, but evidence isn’t yet strong enough for widespread prescribing. Most experts emphasized regulation, education, and shared decision-making .

Go With Us! to EULAR 2025: Should Doctors Prescribe Cannabis for Autoimmune Disease?

Practical Advice from Patients and Experts

Across the discussion, consistent guidance emerged:

Start low and slow
Track symptoms carefully
Treat cannabis like any other medication
Avoid unregulated or gas-station products
Consider cost—quality cannabis is expensive
Never replace prescribed medications without medical guidance
Understand terpenes and cannabinoids affect people differently
What helps inflammation may worsen heart rate, anxiety, or tremors in others

For many patients, cannabis works best as a complement , not a replacement, to standard care

The Bottom Line

Cannabis is not a cure. It’s not harmless. And it’s not going away.

For many people living with AiArthritis, it has become another tool—sometimes a crucial one—in managing symptoms that conventional medicine still struggles to control.

What patients need most now is:

Better research
Honest medical conversations
Clear safety guidance
Legal frameworks that prioritize patient protection over politics

AiArthritis will continue to center patient voices in this evolving conversation—because patients are already using cannabis, whether the system is ready or not .

Tune into the AiArthritis Voices 360 Talk Show , where patients, doctors, and advocates come together to discuss the latest in autoimmune and autoinflammatory arthritis.

Protecting Patients, Not Programs: Why 340B Reform Matters for Autoimmune Care

Thu, 15 Jan 2026 18:49:15 GMT

Protecting Patients, Not Programs: Why 340B Reform Matters for Autoimmune Care

As anyone who has dealt with an autoimmune condition can attest, these lifelong and chronic conditions are difficult to diagnose and treat. Many in the autoimmune community rely on biologics and biosimilars (specialty medications that often come with a significant price tag). Affordable and reliable access to these medications is critical for the treatment and maintenance of autoimmune diseases.

While some of these medications can be administered by patients themselves at home, some must be administered by healthcare professionals. Hospitals buy these drugs and administer them to patients; they are then reimbursed for these costs by insurance providers. When the reimbursement rate is higher than the acquisition cost of the drug, hospitals derive profit for the medications they administer to their patients.

With any healthcare service, it’s important that the hospital act in the best interest of the patient to minimize costs while also providing the most appropriate care for that individual. Abuse can occur when a hospital is incentivized to provide care that might not be in the interest of the patient but provides the hospital with a financial benefit. A very simplified example might be when a patient arrives with a broken arm which could be diagnosed with an X-ray, but an MRI is used instead. Unfortunately, the patient would be left paying a higher hospital bill for an MRI, when an X-ray would have sufficed.

Under a federal program called the 340B Drug Pricing Program, certain hospitals are eligible to purchase medications at significant discounts. The intent of this program is that these hospitals would utilize these discounts to ensure patients have access to affordable medications and healthcare services. The spread between what hospitals must pay to acquire the drugs and the amount that they are reimbursed for them can result in substantial markups for hospitals. Unfortunately, hospitals that participate in the 340B program are not required to disclose how they use the profits generated by the program.

Hospitals have recently been required to start disclosing their reimbursement rates as part of new transparency laws. AiArthritis commissioned the global healthcare consulting firm Milliman to use this newly available data to examine reimbursement rates for autoimmune drugs at 340B and non-340B hospitals. The analysis included 10 autoimmune drugs and their biosimilars across 25 hospitals in the United States.

The report found:

340B hospitals generally had higher contracted reimbursement rates for autoimmune drugs compared to non-340B hospitals.
Aggregate margins between the estimated acquisition cost and reimbursement rate were higher at 340B hospitals than non-340B hospitals for 9 out of the 10 drugs analyzed.
Drug level margins were variable, but specific drugs showed significantly higher margins for 340B hospitals than non-340B hospitals:
Margins for drug N at non-340B hospitals is 248% compared to 108721% at 340B hospitals
Margins for drug L at non-340B hospitals is 241% compared to 3610% at 340B hospitals

The Milliman report notes , “[I]t is important to recognize that while some 340B hospitals may use these margins to fund patient support services or community programs, many autoimmune patients are covered by traditional group insurance (e.g., Medicare Advantage, employer-sponsored plans, exchange plans) and are subject to high deductibles and copays/coinsurance amounts. For these patients, higher reimbursement levels can directly translate to greater out-of-pocket cost, especially if these costs are calculated as coinsurance amounts. Our study did not assess the impact of increased reimbursement on out-of-pocket costs, and further research is needed in this area.”

What does this all mean for autoimmune patients? Well, the short answer is we don’t know, and that’s due to the lack of transparency and accountability in the 340B program. It’s clear that the discounts received by 340B hospitals can drive higher profit margins on autoimmune medications. If hospitals are incentivized to prescribe more of these medications or choose to give patients the medications with higher margins, then, like the X-ray example above, autoimmune patients might be paying higher medical bills as a result of these decisions.

Unfortunately, the 340B program does not currently have enough transparency or oversight requirements to ensure that discounts are being used appropriately and to improve patient care. These findings demonstrate why transparency and accountability in the 340B program are vital to ensuring patients are getting most affordable and appropriate care.

AiArthritis supports legislation to protect the 340B program while also ensuring it lives up to its intended goal of helping patients. We urge Congress to implement reforms to:

Require 340B covered entities report detailed information on program savings, policies, and patient benefits
Implement clear standards and oversight requirements for 340B entities
Establish clear charity care and patient support requirements for program participation

We urge Congress and the Trump Administration to make 340B reform a healthcare priority in 2026.

“Go With Us!” Patient-Led Debrief: Key Highlights from ACR and EULAR 2025

Thu, 15 Jan 2026 18:35:02 GMT

“Go With Us!” Patient-Led Debrief: Key Highlights from ACR and EULAR 2025

The “Go With Us!” Debrief marked the first annual end-of-year/beginning-of-year reflection on AiArthritis’ conference programming, bringing together patient leaders, advocates, and experts to unpack vital information from the two largest rheumatology conferences of the year - ACR - The American College of Rheumatology Convergence in Chicago IL, and EULAR - European Alliance of Associations for Rheumatology Congress in Barcelona, Spain. We highlight where rheumatology is heading— and how lessons learned can be applied to patient journeys - through the lens of lived experience, emerging science, and advocacy.

This debrief reinforced a central message: progress in AiArthritis disease care depends on early diagnosis, personalized treatment, whole-person care, and strong patient voices shaping research.

Panelists included:

Tiffany Westrich-Robertson, CEO and Founder of AiArthritis, who lives with non-radiographic axial spondyloarthritis
Leila P.L. Valete , Health Education Manager at AiArthritis, living with lupus and Sjögren’s disease
Eileen Davidson , Educational Media Assistant at AiArthritis, living with rheumatoid arthritis and non-radiographic axial spondyloarthritis
Vanessa Lathan , Grassroots Advocacy Manager at AiArthritis, living with Undifferentiated Connective Tissue Disease (UCTD)

Tiffany also acknowledged Deb Costen for her role in building and sustaining the “Go With Us” program.

Watch The Full Debrief Webinar

Non-Pharmaceutical and Integrative Care: Beyond Medication

Eileen Davidson highlighted the growing focus on non-pharmaceutical and integrative approaches discussed across conference sessions. These included lifestyle interventions that complement medical treatment rather than replace it.

Key themes included:

Mediterranean diet as a sustainable, evidence-supported approach linked to reduced inflammation
Physical activity and movement, emphasizing individualized plans that align with patient preferences, access, and ability
The role of exercise in improving medication effectiveness, managing comorbidities , and supporting mental health
The discussion underscored that lifestyle care should be practical, accessible, and personalized—not prescriptive or one-size-fits-al l.

Stress, Mental Health, and the Missing Piece of Ai Arthritis Disease Care

Stress and mental health emerged as critical—and still under-addressed—drivers of disease outcomes. Eileen discussed how chronic stress fuels inflammation and worsens symptoms, while Leila emphasized the benefits of therapy and structured mental health support.

Key takeaways included:

Mental health conditions such as anxiety, depression, and grief are under-diagnosed and under-treated in autoimmune and inflammatory arthritis
Stress management strategies —exercise, nutrition, mindfulness, and cognitive behavioral therapy—can meaningfully reduce disease burden
There is a need for rheumatology care teams to recognize mental health as part of routine disease management, not an afterthought
The panel also discussed the dual role of medications such as SSRIs and SNRIs in supporting both mood and pain management for some patients.

Cannabis, Pain, and Health Literacy

Cannabis use in AiArthritis disease care continues to rise, and Eileen addressed this topic with a focus on education and safety . She emphasized the importance of reputable sources, understanding dosing, and acknowledging risks such as dependency or overuse.

Highlights included:

Increasing patient interest in cannabis for pain and symptom management
The importance of health literacy when discussing THC, CBD, and combination products
The need for clinicians to engage in open, non-judgmental conversations with patients

Advocacy and Policy: Why Engagement Matters

Vanessa Lathan focused on the role of advocacy in improving access, affordability, and long-term outcomes for people living with arthritis.

Key advocacy themes included:

Policy decisions directly affect treatment access, insurance coverage, and the healthcare workforce
Issues such as Medicare Advantage barriers and student loan challenges for providers impact patient care
Advocacy is not limited to policymakers—patients, caregivers, and clinicians all play a role through small, collective actions

Vanessa emphasized the importance of inclusive, global advocacy that prioritizes health equity and addresses environmental and social determinants of health.

Discover the AiArthritis Knowledge = Empowerment Classroom , a patient-led initiative designed to educate and empower individuals affected by autoimmune and autoinflammatory arthritis. Learn about healthcare policies, treatment access, and advocacy opportunities to make a meaningful impact in your community!

Precision Medicine, Comorbidities, and the Future of Treatment

Tiffany Westrich-Robertson discussed advancements in precision medicine , disease-specific research, and the growing focus on comorbidities.

Key highlights included:

Progress in CAR T-cell therapy , including exploration of mass-produced donor cells to improve access and reduce cost
Continued focus on B-cell targeting approaches, particularly for refractory or difficult-to-treat disease and more biomarker studies that find targeted treatments
Disease-specific research advancements in lupus, psoriatic arthritis, axial spondyloarthritis, Still’s Disease (including the introduction of ‘ Still’s Lung ’, and one session on the impacts of enthesitis - largely associated with the spondyloarthritis diseases and different than joint pain, as it’s inflammation where the tendons and ligaments meet the bone
Increased attention to comorbid conditions such as lung disease and cardiovascular health

These developments point toward more targeted, individualized care—but also underscore the need for equitable access.

Discover more about these advancements:

Early Diagnosis and Personalized Care

Leila Valete closed the thematic discussions by emphasizing early diagnosis and disease-specific research . She highlighted the importance of recognizing symptoms before traditional biomarkers appear and tailoring treatment early to improve long-term outcomes.

Key points included:

Advances in Sjögren’s disease research, including biologics and AI-supported diagnostic tools
Progress in understanding and treating IgG4-related disease, including recent FDA approvals
The need for continued awareness, education, and personalized approaches across less-recognized condition s.

Looking Ahead: Feedback, Community, and What’s Next

The session concluded with a call to action. Participants were encouraged to complete the post-debrief survey , share feedback, and stay engaged with future “Go With Us” programming. Tiffany emphasized the importance of community input in shaping future topics and expressed excitement about potential in-person connections at EULAR 2026 in London .

AiArthritis also committed to sharing debrief videos, transcripts, and resources discussed during the session, and to supporting attendees interested in advocacy and policy engagement.

Final Thought

The “Go With Us!” Debrief made one thing clear: progress in arthritis care happens when science, lived experience, advocacy, and education move forward together. As AiArthritis continues this work, patient voices will remain central—not as an afterthought, but as a driving force for change.

Thank you to our sponsors, Bristol Myers Squibb and Amgen Rare, for their support in making the meeting possible.

Glossary of Terms and Acronyms for Newly Diagnosed Autoimmune and Autoinflammatory Arthritis Patients

Sun, 11 Jan 2026 15:26:22 GMT

Glossary of Terms and Acronyms for Newly Diagnosed Autoimmune and Autoinflammatory Arthritis Patients

Being diagnosed with an autoimmune or autoinflammatory arthritis disease can feel overwhelming, especially when faced with complex medical terminology. This glossary explains common terms, acronyms, and concepts to help you understand your condition, communicate with healthcare providers, and make informed decisions about treatment.

General Medical Terms

Autoimmune Disease – When the immune system mistakenly attacks healthy tissues, causing inflammation and potential damage.

Autoinflammatory Disease – A disorder where the immune system overreacts without an external trigger, resulting in excessive inflammation.

Chronic Illness – A long-term health condition requiring ongoing management over months or years.

Flare-Up (Flare) – A period of increased disease activity with worsening pain, swelling, fatigue, or other symptoms.

Inflammation – The body’s immune response to injury or infection, often causing redness, warmth, swelling, and pain.

Remission – A phase where symptoms improve or disappear , even though the disease remains present.

Fatigue – Extreme tiredness that does not improve with rest, common in autoimmune conditions.

Brain Fog – Cognitive difficulties including memory lapses, poor focus, and mental fatigue .

Joint Stiffness – Reduced flexibility or movement in joints, often worse in the morning or after inactivity.

Erosion – Damage to cartilage or bone caused by chronic inflammation.

Synovium – The thin lining of joints that produces fluid; often inflamed in autoimmune arthritis.

Cartilage – Flexible tissue that cushions joints and protects bones from friction and damage.

Autoantibody – A protein produced by the immune system that mistakenly targets the body’s own tissues.

Cytokines – Signaling proteins that regulate immune responses and inflammation.

Enthesitis – Inflammation where tendons or ligaments attach to bone, common in psoriatic arthritis and ankylosing spondylitis.

Sacroiliitis – Inflammation of the sacroiliac joints, often causing lower back pain in ankylosing spondylitis.

Tendonitis / Tenosynovitis – Inflammation of tendons or their sheaths, sometimes seen in autoimmune arthritis.

Comorbidity – The presence of one or more additional health conditions alongside a primary disease.

Systemic Involvement – When autoimmune disease affects organs or systems beyond the joints, such as skin, lungs, kidneys, or heart.

Common Acronyms and Abbreviations

DMARDs (Disease-Modifying Antirheumatic Drugs) – Medications that slow disease progression and reduce inflammation.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) – Medications like ibuprofen or naproxen that reduce pain and inflammation.

Biologics – A type of DMARD targeting specific immune pathways to control inflammation (e.g., adalimumab, etanercept).

JAK Inhibitors (Janus Kinase Inhibitors) – Medications that block inflammatory signals in autoimmune arthritis.

CRP (C-Reactive Protein) – Blood test measuring inflammation levels in the body.

ESR (Erythrocyte Sedimentation Rate) – Lab test detecting inflammation by measuring how quickly red blood cells settle.

ANA (Antinuclear Antibody Test) – Test for autoimmune antibodies, often used to diagnose lupus.

RF (Rheumatoid Factor) – Antibody test used to help diagnose rheumatoid arthritis.

TNF (Tumor Necrosis Factor) – A protein involved in inflammation, targeted by some biologics.

HLA-B27 – A genetic marke r linked to certain autoimmune diseases, especially ankylosing spondylitis.

MRI (Magnetic Resonance Imaging) – Imaging scan that detects joint inflammation and tissue damage.

X-ray – Imaging test that shows joint erosion and bone changes.

Treatment and Management Terms

Physical Therapy (PT) – Programs to improve mobility, strength, and joint function.

Occupational Therapy (OT) – Therapy that helps manage daily activities and introduces adaptive techniques.

Hydrotherapy – Water-based exercises that reduce joint stress and improve flexibility.

Corticosteroids / Steroids – Medications that quickly reduce inflammation but may have long-term side effects.

Immunosuppressants – Drugs that dampen immune system activity to prevent tissue damage.

Targeted Therapy – Medications, including biologics and JAK inhibitors, that block specific immune pathways.

Combination Therapy – Using multiple medications together to better control disease activity.

Tapering – Gradually reducing medication doses to avoid flares or withdrawal effects.

Anti-Inflammatory Diet – Eating foods like leafy greens, fatty fish, and whole grains to h elp manage inflammation.

Heat Therapy – Warm compresses or baths to relieve stiffness and improve circulation.

Cold Therapy – Ice packs to reduce swelling and numb pain.

Mindfulness and Stress Management – Techniques like meditation, breathing exercises, and relaxation therapy to manage pain, fatigue, and stress.

Range of Motion (ROM) – The extent to which a joint can move.

Assistive Devices – Tools like braces, canes, or ergonomic equipment to support mobility or daily tasks.

Fatigue Management – Strategies to conserve energy, including pacing and prioritizing activities.

Flare Diary / Symptom Tracker – Logs used to track symptoms, flares, and triggers.

Adaptive Techniques – Adjustments in daily activities or work environments to reduce joint stress.

Psychosocial and Advocacy Terms

Medical Gaslighting – When symptoms are dismissed or minimized by healthcare professionals.

Health Advocacy – Actively participating in your healthcare decisions and ensuring your needs are met.

Support Network – Friends, family, support groups, or online communities providing emotional or practical help.

Coping Strategies – Methods used to manage stress, pain, or uncertainty associated with chronic illness.

Diagnostic and Lab Terms

Complement System – Part of the immune system often overactive in autoimmune diseases, sometimes measured in lab tests.

Biopsy – Sampling tissue to assist in diagnosis, sometimes used in skin or synovial evaluations.

Imaging Modalities – Diagnostic tools like ultrasound, CT scans, or bone scans to detect joint inflammation or damage.

Autoimmune Flare Markers – Blood tests such as CRP or ESR used to monitor disease activity and predict flares.

Understanding medical terminology empowers patients to advocate for themselves, communicate clearly with doctors, and make informed treatment decisions. Familiarizing yourself with these terms is an important step toward managing your condition with confidence and clarity.

Tune into the AiArthritis Voices 360 Talk Show , where patients, doctors, and advocates come together to discuss the latest in autoimmune and autoinflammatory arthritis.

4 Patient-Care Centered Studies on IgG4-RD That You Need to Know About

Thu, 04 Dec 2025 19:34:21 GMT

4 Patient-Care Centered Studies on IgG4-RD That You Need to Know About

IgG4-Related Disease (IgG4-RD) is a rare immune-mediated condition that can impact nearly every organ in the body. As researchers are still studying how IgG4-RD works, many new studies have emerged that examine treatments, diagnostic journeys, and outcomes for people living with IgG4-Rd.

In this post, we break down four of the most impactful and recent IgG4-RD studies on patient-centered care that provide key insight into this condition and how healthcare providers and patients cand understand and manage the diagnosis journey.

Why is AiArthritis raising awareness about IgG4-RD? Although IgG4-RD is not officially part of the AiArthritis disease umbrella, AiArthritis is raising awareness because it may end up being classified as autoimmune or autoinflammatory in the future. Additionally, as IgG4-RD is often confused with other conditions, many people with IgG4-RD may be misdiagnosed with an AiArthritis disease or face challenges getting a diagnosis.

Study That Examines Which IgG4-RD Patients Can Safely Stop Treatment and Maintain Remission

Factors Associated With Long-Term Remission After Drug Discontinuation in IgG4-Related Disease: A 3-Year Rule

Summary

This study explored which patients with IgG4-related disease (IgG4-RD) can safely stop treatment and maintain long-term remission without relapse. Since both continuing and discontinuing glucocorticoid (GC) or immunosuppressant (IM) therapy carry risks, identifying predictors of durable remission is critical. Researchers from Peking Union Medical College found that patients without salivary gland involvement and those who used an immunosuppressant early in treatment were significantly less likely to relapse after stopping medication. Additionally, remaining relapse-free for three years strongly predicted long-term remission.

Questions Answered by this Poster

What factors predict relapse in IgG4-RD patients after treatment withdrawal?
Does early use of immunosuppressants (IM) improve long-term outcomes?
How long must patients remain relapse-free before remission is likely to last?
Which organ involvements are associated with a higher risk of relapse?

Methods

Study design: Retrospective cohort of IgG4-RD patients at Peking Union Medical College Hospital (China).
Participants:
808 screened; 80 achieved remission before stopping treatment.
Divided into: No-relapse group (n=37) and Relapse group (n=43) .
Criteria: All met 2019 ACR/EULAR classification standards for IgG4-RD.
Data collected:
Demographics, family history, organ involvement, lab markers, and treatment regimens.
Laboratory values (IgG4 levels, eosinophil counts) before and after medication withdrawal.
Statistical analyses:
Univariate Cox regression for relapse predictors (HR, CI, p-values).
Kaplan-Meier curve to estimate relapse-free survival over time.

Results

Relapse group:
More likely to have salivary gland involvement (submandibular and parotid).
Less likely to have received immunosuppressant (IM) therapy at baseline.
Higher baseline and pre-withdrawal IgG4 levels and eosinophil counts .
Protective factors (lower relapse risk):
Initial IM use → HR 0.41 (95% CI 0.20–0.84, p = 0.017 ).
No salivary gland involvement → HR 3.26 (95% CI 1.32–8.06, p = 0.012 ).
Time to relapse:
Biphasic pattern with most relapses in first 36 months post-withdrawal.
Patients relapse-free for 3 years had a 94.6% chance of long-term remission.

Conclusions

IgG4-RD patients without salivary gland involvement and those who begin treatment with immunosuppressants have a significantly lower risk of relapse after stopping therapy. The study suggests that three years of relapse-free status can serve as a practical clinical marker for durable remission, helping physicians tailor follow-up and maintenance strategies more effectively.

Key Data

Sample: 80 remission patients (37 no-relapse, 43 relapse).
Predictive markers:
No salivary gland involvement (HR 3.26; p = 0.012 ).
Initial IM therapy (HR 0.41; p = 0.017 ).
Main relapse sites: Submandibular and parotid glands.
Relapse-free 3 years = 94.6% probability of durable remission.

Authors

Yifei Wang, Yuxue Nie, Jingna Li, Jialei Zhang, Qinhuan Luo, Xinli Yang, Jialing Jiang, Nianyi Zhang, Linyi Peng, Yunyun Fei, Jiaxin Zhou, and Wen Zhang.

Affiliations: Peking Union Medical College and Peking Union Medical College Hospital, Beijing, China.

Read the published abstract in AC R Meeting Abstracts

Study Highlights the Importance of Early Diagnosis and Treatment for IgG4-RD

Assessment of Damage Using the IgG4-Related Disease Damage Index

Summary

This study evaluated how often and where permanent organ damage occurs in patients with IgG4-related disease (IgG4-RD) and how the IgG4-RD Damage Index (DI) performs in a non-Chinese population. Researchers from Mexico found that organ damage was common (80%), especially in the pancreas, lungs, kidneys, and retroperitoneum, and that damage patterns differed by disease phenotype. The study highlights the importance of early diagnosis and careful management to prevent irreversible organ complications.

Questions Answered by this Poster

How common is permanent organ damage in IgG4-RD?
Which organs are most often affected by irreversible damage?
Do certain disease types or phenotypes carry higher or lower damage risk?
Can the IgG4-RD Damage Index (DI) effectively measure and compare damage across patients?

Methods

Study design: Retrospective analysis at the Instituto Nacional de Ciencias Médicas y Nutrición (Mexico).
Participants: 70 patients meeting 2020 Revised Comprehensive Diagnostic Criteria and/or 2019 ACR/EULAR Classification Criteria for IgG4-RD.
Follow-up period: ≥1 year.
Damage definition: Irreversible organ dysfunction caused by IgG4-RD or by its diagnostic/treatment procedures, persisting ≥6 months.
Assessment: IgG4-RD Damage Index (DI) scored at last follow-up.
Analysis: Comparisons by phenotype, organ domain, and clinical characteristics (IgG levels, complement levels, remission/relapse status).

Results

Damage prevalence:
56 of 70 patients (80%) had organ damage.
Median DI score = 1 (IQR 0–3).
Among those with damage: DI median = 2 (range 1–9).
Most commonly damaged organs:
Pancreas (31.4%)
Lung (15.7%)
Kidney (11.4%)
Retroperitoneum/Mediastinum (8.6%)
Liver/Biliary tree (8.6%)
Key associations:
High IgG levels were linked to greater damage (60.9% vs. 31.3%; p = 0.04 ).
Head and neck-limited phenotype had the least damage (20.4% vs. 56.3%; p = 0.005 ).
Fibrotic subtype often showed retroperitoneal or thyroid damage, while proliferative subtype showed pancreatic damage.
Additional contributors to damage:
Organ resections (22.8%)
Disease- or treatment-related diabetes (15.7%)
Glucocorticoid toxicity and diagnostic procedures

Conclusions

Organ damage is frequent and varies by phenotype in IgG4-RD. The pancreas is the most affected organ, and patients with higher total IgG levels face a greater risk of irreversible damage. Conversely, those with head and neck-limited disease tend to experience less damage. These findings support using the IgG4-RD Damage Index (DI) to monitor disease progression and tailor treatment to minimize long-term harm.

Key Data

Patients with damage: 56/70 (80%)
Median DI score: 2 (range 1–9)
Most affected organs: Pancreas → 31.4%, Lung → 15.7%, Kidney → 11.4%
High IgG linked to damage: p = 0.04
Head/neck-limited phenotype protective: p = 0.005

Authors

Eduardo Martin-Nares and Gabriela Hernández-Molina ,

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Read the published abstract in ACR Meeting Abstracts

Study Exploring When IgG4-RD Patients Should Start Treatment

Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation Without Treatment Intervention: A Single-Center Study

Summary

This study explored when treatment is needed for people newly diagnosed with IgG4-related disease (IgG4-RD) and when it may be safe to observe the disease without starting medication immediately. Researchers reviewed 80 cases and found that about one-third of patients were monitored without treatment. Those patients were typically younger, had lower inflammation markers, and had milder disease—often limited to glands or lymph nodes. Over time, most remained stable, though some required treatment later when new organ involvement appeared.

Questions Answered by this Poster

Which IgG4-RD patients can be safely monitored without starting treatment?
What clinical or lab factors predict who might eventually need therapy?
How do organ involvement patterns differ between treated and observed patients?
How long can untreated patients remain stable before needing intervention?

Methods

Study period: 2005–2024
Setting: Kagawa University Hospital, Japan
Participants: 80 patients diagnosed using the 2020 Revised Comprehensive Diagnostic Criteria for IgG4-RD
Groups:
Treatment group: 54 patients (67.5%) started therapy at diagnosis
Observation group: 26 patients (32.5%) were monitored without treatment
Analysis: Compared demographics, labs, and organ involvement; tracked which observed patients later required treatment and why

Results

At diagnosis:
Observation group was younger and had lower IgG, CRP, sIL-2R, and IgG4-RD RI scores .
Glandular and lymph node-only disease was more common in the observation group.
Severe organ involvement (retroperitoneal, renal, pancreatic, pulmonary, or orbital) was more frequent in patients who began treatment.
During follow-up:
7 of 26 observed patients (27%) eventually required therapy.
New organ involvement, especially pancreatic disease , triggered treatment in 5 of these 7 patients.
Average time to treatment: 30 ± 25 months after diagnosis.
No significant baseline differences predicted who would later need treatment.
19 patients (73%) continued observation without needing medication, even with multiple organ involvement.

Conclusions

Many IgG4-RD patients—especially those with limited glandular or lymph node disease and low inflammation—can be safely monitored without immediate treatment. However, regular follow-up is essential, as some patients may develop new organ involvement that requires timely intervention.

Key Data

Total patients: 80
Treatment at diagnosis – 54 (67.5%)
Observation only – 26 (32.5%)
Observation group characteristics:
Younger (average age ~63 years vs. 69 years in treatment group)
Lower inflammation (CRP 0.1 vs. 1.4 mg/dL)
Lower IgG levels (1789 vs. 2772 mg/dL)
Lower disease activity (IgG4-RD RI 4.8 vs. 7.7)
Commonly affected organs:
Observation group – glands (lacrimal, salivary, lymph nodes)
Treatment group – kidneys, lungs, pancreas, retroperitoneum, orbits
Of the 26 observed:
7 required later treatment (27%)
19 remained stable without therapy (73%)

Authors

Kanako Chujo, Hiromi Shimada, Shusaku Nakashima, Taichi Miyagi, Koichi Sugihara, Yusuke Ushio, Mao Mizusaki, Naoto Manabe, Mayuko Wada, Risa Wakiya, Hiroki Ozaki, Hiroaki Dobashi

Affiliations: Kagawa University and Toho University School of Medicine, Japan

Read the published abstract in ACR Meeting Abstracts

Study Highlights the Challenges, Frequent Misdiagnoses, and Daily Impact that IgG4-RD Patients Face

Diagnostic Journey, Clinical Burden, and Quality of Life of Patients with IgG4-RD: Results of a Cross-Sectional Survey of Patients and Physicians in the United States

Summary

This study describes the real-world experiences of people living with IgG4-related disease (IgG4-RD) in the United States. It highlights how long it takes for patients to be diagnosed, which symptoms and organs are most commonly involved, what treatments are used, and how the disease affects quality of life. Overall, the findings show that IgG4-RD is often misdiagnosed at first, requires many tests and doctor visits, and has a meaningful impact on day-to-day function.

Questions Answered by this Poster

What does the average diagnostic journey look like for IgG4-RD?
Which symptoms and organs are most commonly affected?
Who typically manages IgG4-RD care?
What treatments are being used in real-world practice?
How does IgG4-RD impact fatigue, daily activities, and work?

Methods

Data came from the Adelphi IgG4-RD Disease Specific Programme™ , a U.S. survey conducted in 2023–2024.
Physicians submitted detailed information on 161 patients with IgG4-RD.
27 patients completed questionnaires on fatigue, quality of life, and work impact.
Information collected included:
Symptoms at first presentation
Organ involvement
Diagnostic tests and number of consultations
Treatments used and timing
Hospitalizations
Patient-reported outcomes (FACIT-Fatigue, EQ-5D-5L, WPAI)

Results

Participants: 161 physician-reported patients; 27 completed surveys. Average age 55; 62% male; 71% White.
Before diagnosis: Symptoms began around age 50. Diagnosis took ~11.5 months. Most common initial symptoms were fatigue (42%), joint pain (23%), and weight loss (22%).
Organ involvement: Pancreas (32%), parotid glands (22%), and retroperitoneal fibrosis (19%) were most affected.
Diagnostic journey: First evaluations were usually by primary care (47%), gastroenterology (20%), or rheumatology (11%). Patients saw ~3 providers and underwent ~13 tests. 90% were initially misdiagnosed (often pancreatitis, chronic fatigue syndrome, or vasculitis).
Treatment patterns: Treatment started ~9 months after diagnosis. Managed primarily by rheumatology (70%). Most common first therapies were prednisone (66%), rituximab (17%), and azathioprine (11%).
Hospitalizations & impact: 14% were hospitalized in the prior year, mostly through the emergency room. Patient-reported outcomes showed notable impacts on fatigue, daily functioning, and quality of life.

Conclusions

This real-world survey highlights how challenging and time-consuming the diagnostic journey can be for people with IgG4-RD. Many patients face long delays, multiple tests, and frequent misdiagnoses before receiving proper care. Symptoms often affect quality of life, and treatment is highly variable. These findings underline the need for greater awareness, faster diagnosis, and more effective long-term management to improve daily functioning and overall health for patients living with IgG4-RD.

Key Data:

161 patients reported; 27 completed patient surveys.
11.5 months average time to diagnosis.
90% initially misdiagnosed.
Most affected organs: pancreas (32%), parotid glands (22%), retroperitoneum (19%).
Most common first symptoms: fatigue (42%), joint pain (23%), weight loss (22%).
First-line treatments: prednisone (66%), rituximab (17%), azathioprine (11%).
14% hospitalized for IgG4-RD in prior year.
Significant impact shown across fatigue, daily functioning, and work productivity .

Authors

Yasmin Hernandez-Barco (Massachusetts General Hospital; Harvard Medical School), Jenny Y. Park (Amgen Inc., Thousand Oaks, CA), Rajvi Wani (Amgen Canada Inc., Mississauga, ON), Andrea Meyers (Amgen Canada Inc., Thousand Oaks, CA), Matthew Charles Baker (Stanford University, Menlo Park, CA), Leonard Calabrese (Cleveland Clinic, Cleveland, OH), Kristina Patterson (Amgen Inc., Thousand Oaks, CA), Hannah Connolly (Adelphi Real World, United Kingdom), Shiva Lauretta Birija (Adelphi Real World, United Kingdom), Emma Culver (John Radcliffe Hospital; University of Oxford).

Read the published abstract in ACR Meeting Abstracts

IgG4-RD Education by Ai Arthritis

Go With Us! To EULAR 2025: What is IgG4-Related Disease -- and Why Are So Many Patients Misdiagnosed?

In this Go With Us! video from EULAR 2025, Health Education Manager Leila P.L. Valete breaks down key insights from a session on IgG4-related disease (IgG4-RD)—a rare immune condition that’s often confused with other autoimmune diseases like lupus, Sjögren’s, or rheumatoid arthritis.

This video covers:

What IgG4-RD is and why it’s so tricky to diagnose
What “SACQ” means (and why high lab numbers don’t always mean symptoms)
How doctors use histology (tissue samples) to confirm diagnosis—and where that can go wrong
A look at current and emerging treatments like Inebilizumab (Uplizna) and Ruznilomab
Why understanding this disease is key for “mystery patients” who still don’t have answers

Thank you to Amgen for supporting our IgG4-RD content

More About IgG4-RD On Our Blog

4 Groundbreaking Scientific Discoveries for IgG4-RD That You Need to Know About

Thu, 04 Dec 2025 18:41:01 GMT

4 Groundbreaking IgG4-RD Scientific Discoveries That You Need to Know About

In this post, we break down four of the most impactful and recent IgG4-RD lab science studies that provide key insight into this condition and potential treatment methods for healthcare providers and patients.

Early Results from a Study Testing the Safety of Rilzabrutinib for IgG4-RD Patients

Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study

Summary

This table shows how often different side effects (also called adverse events) happened among people who took rilzabrutinib in a research study. Overall, the treatment was generally well tolerated, meaning most people could continue taking it without serious issues.

Most side effects were mild to moderate , such as stomach problems or mild infections. Only two people (7%) had serious side effects, and there was one death reported (3.7%), which was considered related to a treatment-emergent adverse event (TEAE).

These findings suggest that rilzabrutinib may be a promising therapy with an acceptable safety profile , though more research is needed to confirm its safety and effectiveness in larger studies.

Questions Answered by this Poster

What types of side effects occurred in people taking rilzabrutinib?
How many participants experienced side effects, and how severe were they?
Were any serious or life-threatening side effects seen?
Are the side effects tolerable enough for future studies to continue?

Methods

Participants were divided into two cohorts:
Cohort A: 13 participants
Cohort B: 14 participants
Total: 27 participants
Side effects were recorded and grouped by category, using international medical standards (MedDRA 27.1).
Researchers tracked any side effects that started after participants began rilzabrutinib.

Results

85% of participants had at least one side effect.
7% experienced a serious side effect.
19% had to stop the treatment due to side effects.
The most common side effects were:
Gastrointestinal problems (59%) – such as nausea or diarrhea
Infections (44%) – typically mild
Skin issues (41%) – like rashes or irritation
Nervous system symptoms (30%) – possibly headaches or fatigue

Conclusions

Most patients tolerated rilzabrutinib well, with few serious events and a manageable side effect profile. The study supports continuing research into rilzabrutinib as a potential therapy for autoimmune diseases such as IgG4-RD.

Key Data

59% reported gastrointestinal disorders
44% reported infections
41% reported skin disorders
30% reported nervous system disorders

Authors

A. Meysami (Amgen, AstraZeneca, GSK, Janssen, Zenas); M. Carruthers (AbbVie, Amgen, Janssen, Pfizer, Roche, Sanofi, UCB, Zenas); J. Stone (Acepodia, Amgen, argenx, Bristol-Myers Squibb, Novartis, Q32 Bio, Sanofi, Zenas); F. Martinez-Valle (Amgen); N. Schleinitz (Amgen); D. Ghetie (None); R. Spiera (AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Certa, Chemocentryx, Corbus, Cytori, Galderma, GSK, Horizon, Kadmon, Novartis, Principia, Regeneron, Roche-Genentech, Sanofi, Vera Therapeutic); J. Choi, L. Mannent, and O. Hagino (Sanofi).

Read the published abstract in AC R Meeting Abstracts

Major International Study (MITIGATE) Shows Promise as a Safe, Effective Long-Term Treatment

Assessment of Baseline IgG4-RD Disease Characteristics and Impact upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study

Summary

The MITIGATE trial is a major international study evaluating a potential new treatment — inebilizumab — for IgG4-related disease (IgG4-RD), a chronic condition where the immune system causes inflammation and scarring in multiple organs.

Patients living with IgG4-RD often face recurrent flares , unpredictable organ involvement, and the long-term side effects of repeated steroid use. This study found that inebilizumab , a targeted therapy that removes certain overactive immune B cells, can reduce flares, prolong remission, and help patients stay off corticosteroids — regardless of how long they’ve had the disease, how high their IgG4 levels are, or how many organs are affected.

Importantly, the benefits were consistent across all patient subgroups and the treatment was generally well tolerated .

Questions Answered by this Poster

Does inebilizumab work equally well in patients with different disease histories and lab profiles?
Can inebilizumab reduce IgG4-RD flares and maintain remission without steroids?
Is the treatment safe across all types of patients with IgG4-RD?

Methods

Design: Phase 3, international, randomized, double-blind, placebo-controlled trial (MITIGATE; NCT04540497).
Participants: 135 adults meeting ACR/EULAR classification criteria for IgG4-RD (score ≥20), all with multiorgan involvement and a recent flare requiring steroids.
Groups: Inebilizumab (INEB, n=68) vs placebo (PBO, n=67).
Primary Endpoint: Time to first adjudication committee (AC)-determined, investigator-treated IgG4-RD flare during the 52-week randomized controlled period (RCP).
Key Secondary Endpoints:
Flare-free, corticosteroid-free complete remission at Week 52.
Annualized flare rate.
Disease activity score (ACR/EULAR).
Safety and tolerability.
Subgroup Analysis: By disease duration (<2 vs ≥2 years), diagnosis type (new vs recurrent), serum IgG4 level, ACR/EULAR score, CD20 B-cell count, and prior maintenance therapy.

Results

Flare Prevention: Inebilizumab reduced flare risk by 80–93% across all subgroups (hazard ratio range: 0.07–0.20).
Remission: At 52 weeks, 60% of inebilizumab-treated patients achieved flare-free, corticosteroid-free remission , compared with 20% on placebo .
Consistency: Benefits were observed across all categories of disease duration, baseline IgG4, and activity score.
Safety: No new safety issues were reported; adverse events were comparable between groups.

Conclusions

Inebilizumab demonstrated consistent, meaningful benefits across all patient subgroups, effectively reducing flares and enabling many to achieve steroid-free remission. The therapy showed a favorable safety profile, positioning it as a strong potential treatment option for long-term disease management in IgG4-RD.

Key Data

Participants: 135 (INEB: 68 | PBO: 67)
Average disease duration: 2.6 years
Recurrent disease: 54%
Median IgG4 level: 653 mg/dL
Flare risk reduction: 80–93% (HR 0.07–0.20)
Steroid-free remission: 60% (INEB) vs 20% (PBO)
Safety: No major differences in adverse events between groups

Authors

Yoshiya Tanaka, Emma Culver, Arezou Khosroshahi, Wen Zhang, Kazuichi Okazaki, Matthias Löhr, Nicolas Schleinitz, Xinxin Dong, Melissa Rosen, Sue Cheng, Daniel Cimbora, and John Stone.

Affiliations: University of Occupational and Environmental Health (Japan); University of Oxford (UK); Emory University (USA); Peking Union Medical College Hospital (China); Kansai Medical University (Japan); Karolinska Institutet (Sweden); Aix Marseille University (France); Amgen, Thousand Oaks, CA; and Massachusetts General Hospital/Harvard Medical School (USA).

Read the published abstract in ACR Meeting Abstracts

MITIGATE Trial Also Demonstrates Efficacy & Prevents Flares Across All Types of Organ Involvement

2020: Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial

Summary

This analysis from the MITIGATE Phase 3 trial evaluated how inebilizumab (INEB)—a CD19-directed B-cell–depleting therapy—performed across different organ subgroups of IgG4-related disease (IgG4-RD). Since organ involvement varies widely in urgency, severity, and fibrotic behavior, understanding organ-specific responses helps guide clinical expectations. Across all subgroups—including common organs, urgent organs (pancreas, kidney, bile ducts, aorta, orbits), and fibrotic organs (retroperitoneum, mediastinum, mesentery, thyroid, meninges)—INEB consistently reduced flare risk, lowered glucocorticoid exposure, and increased the proportion of patients achieving flare-free, steroid-free remission. Safety remained comparable across groups, with no unexpected organ-specific concerns.

Questions Answered by this Poster

Does inebilizumab work equally well across different IgG4-RD organ phenotypes?
Are urgent or high-risk organ manifestations (e.g., pancreas, kidney) responsive to INEB?
Do fibrotic-dominant phenotypes still benefit from B-cell depletion?
Does INEB reduce steroid use across organ subgroups?
What is the organ-specific flare risk reduction compared to placebo?

Methods

Post-hoc subgroup analysis of MITIGATE (Phase 3, randomized, placebo-controlled trial).
Participants recently experienced an IgG4-RD flare requiring glucocorticoids.
Randomized 1:1 to INEB or placebo, dosed Day 1, Day 15, Week 26.
Subgroups defined by:
Common organs (≥20% of participants).
Urgent organs: pancreas, kidney, bile ducts, aorta/large vessels, orbits.
Fibrotic phenotype organs: retroperitoneum, mediastinum, mesentery, thyroid, meninges.
Outcomes evaluated:
Risk of flare during randomized controlled period (RCP).
Flare-free, steroid-free complete remission.
On-study glucocorticoid use.
Safety by subgroup.

Results

Participants: 135 randomized (INEB n=68, placebo n=67).
Organ involvement balanced between groups at baseline.
Flare Risk Reduction: INEB reduced flare risk across all organ subgroups; HRs similar to overall HR (0.13).
Largest effects:
Pancreas: HR 0.03
Bile ducts: HR 0.00
Kidney: HR 0.08
Remission: Higher rates of flare-free, steroid-free complete remission in all subgroups with adequate sample size.
Steroid Use: INEB markedly reduced the need for on-study glucocorticoids and lowered mean daily doses across all groups.
Fibrotic organs: Also showed clear benefit, even though fibrotic disease can be less responsive to immunotherapy.
Safety:
No new safety signals.
Similar safety profile across organ subgroup categories.

Conclusions

Inebilizumab demonstrated consistent efficacy and safety across all IgG4-RD organ subgroups, including patients with urgent or fibrotic manifestations. INEB reduced flare risk, glucocorticoid exposure, and improved remission rates regardless of organ phenotype.

Key Data

Overall flare-risk HR: ~0.13 vs placebo (consistent across organ groups).
Urgent organs:
Pancreatic involvement → HR 0.03
Biliary involvement → HR 0.00
Kidney involvement → HR 0.08
Steroid reduction:
Fewer patients required on-study glucocorticoids in INEB arms.
Lower mean daily GC dose across all subgroups.
Remission: Higher rates of flare-free, GC-free remission at Week 52 in all analyzable subgroups.
Fibrotic organs: Still responded well despite typical treatment challenges.

Authors

Arezou Khosroshahi (Emory University, Atlanta, GA), Emma Culver (John Radcliffe Hospital, University of Oxford, United Kingdom), Wen Zhang (Peking Union Medical College Hospital, Beijing, China), Kazuichi Okazaki (Kansai Medical University Kori Hospital, Osaka, Japan), Yoshiya Tanaka (University of Occupational and Environmental Health, Kitakyushu, Japan), Matthias Lohr (Karolinska Institutet, Stockholm, Sweden), Nicolas Schleinitz (Aix Marseille University, AP-HM, Marseille, France), Xinxin Dong, Sue Cheng, and Daniel Cimbora (Amgen, Thousand Oaks, CA), and John Stone (Massachusetts General Hospital, Harvard Medical School, Concord, MA).

Read the published abstract in ACR Meeting Abstracts

European Trial Shows What IgG4-RD Looks Like in Everyday Clinical Practice

Clinical Features of IgG4-Related Disease - A Single Centre Experience

Questions Answered by this Poster

What does IgG4-RD look like in a real-world European cohort?
Which organ systems are most commonly affected?
What are the typical patient demographics?
How often do patients meet the 2019 ACR/EULAR criteria?
What treatments are most frequently used?

Methods

Design: Retrospective chart review
Timeframe: January 2012 – December 2024
Population: 58 adult patients diagnosed with IgG4-RD
Data collected:
Demographics
Comorbidities
Symptom duration
Organ involvement
Histopathology
Fulfillment of 2019 ACR/EULAR criteria
Treatment regimens
Analysis: Descriptive statistics

Results

79% male, median age 63 years.
Comorbidities: diabetes (10), asthma (10), atopy (5)
Disease presentation:
Median symptom duration before diagnosis: 6 months
Average organs/regions involved: 2 (range: 1–7)
Phenotypes: 63.8% proliferative; 36.2% fibrotic
Phenotype categories:
Retroperitoneal fibrosis/aortitis: 43.1%
Mikulicz/systemic phenotype: 25.9%
Pancreato-hepato-biliary: 17.2%
Head/neck limited disease: 10.3%
Unclassifiable: 2 patients
Histopathology:
Biopsies performed: 47
Consistent with IgG4-RD: 36 (76.6%)
Suspicious for IgG4-RD: 4 (8.5%)
Classification criteria:
2019 ACR/EULAR criteria met by 69% (40/58)
Treatment:
75.9% received systemic therapy
Glucocorticoids: 41 patients
Immunomodulators: 25 patients
3 used as standalone therapy
22 combined with glucocorticoids
Surgical therapy: 9 patients
Observation only: 5 patients

Conclusions

The Slovenian IgG4-RD cohort was predominantly composed of middle-aged men, with retroperitoneal fibrosis and aortitis as the most common phenotype. Most patients received glucocorticoid-based systemic therapy, and nearly 70% met the 2019 ACR/EULAR classification criteria.

Key Data:

79% male, median age 63
Most common phenotype: retroperitoneal fibrosis/aortitis (43%)
Proliferative phenotype: 63.8%
ACR/EULAR 2019 criteria met: 69%
Systemic therapy used in 76%
Biopsy-confirmed IgG4-RD: 76.6%

Authors

Alojzija Hočevar, Aleš Grošelj, Gregor Hawlina, Matic Koželj, Andrej Skoberne, Jože Pizem, and Vesna Jurčič from University Medical Center Ljubljana and the Institute of Pathology at the University of Ljubljana, Slovenia.

Read the published abstract in ACR Meeting Abstracts

IgG4-RD Education by AiArthritis

Go With Us! To EULAR 2025: What is IgG4-Related Disease -- and Why Are So Many Patients Misdiagnosed?

This video covers:

What IgG4-RD is and why it’s so tricky to diagnose
What “SACQ” means (and why high lab numbers don’t always mean symptoms)
How doctors use histology (tissue samples) to confirm diagnosis—and where that can go wrong
A look at current and emerging treatments like Inebilizumab (Uplizna) and Ruznilomab
Why understanding this disease is key for “mystery patients” who still don’t have answers

Thank you to Amgen for supporting our IgG4-RD content

More About IgG4-RD On Our Blog

Recognizing a Flare in Autoimmune and Autoinflammatory Arthritis Diseases

Sat, 29 Nov 2025 14:05:41 GMT

Recognizing a Flare in Auto immune and Auto inflammatory Arthritis Diseases

Autoimmune and autoinflammatory arthritis conditions such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus (SLE), and axial spondyloarthritis (axSpA) are chronic disorders in which the immune system mistakenly attacks the body’s joints and tissues. These conditions often have periods of flare-ups , where symptoms suddenly worsen, causing increased pain, stiffness, fatigue, and sometimes organ-specific issues. Recognizing the early signs of a flare can help individuals take timely action to manage symptoms, reduce complications, and maintain quality of life.

Common Symptoms of a Flare in AiArthritis Diseases

Flare intensity and duration can vary widely from person to person. Common warning signs include:

Increased Joint Pain and Stiffness

Sudden or worsening pain in previously affected joints, sometimes spreading to new areas.
Stiffness, particularly in the morning or after long periods of inactivity.
Difficulty performing daily activities, such as dressing, cooking, or walking, due to inflammation.

Swelling and Redness

Noticeable swelling in one or more joints, often accompanied by warmth.
Redness around affected areas, signaling increased local inflammation.
Sometimes, joints may feel tender even with light touch.

Fatigue and Weakness

Persistent, extreme tiredness that does not improve with rest.
Muscle weakness, making even routine tasks feel more challenging.
Fatigue often worsens alongside pain and stiffness, creating a cycle that impacts daily function.

Fever and Flu-like Symptoms

Low-grade fever or mild temperature elevation can occur as part of the immune response.
Chills, body aches, or malaise may accompany joint symptoms, particularly in systemic flares.

Skin and Nail Changes

In psoriatic arthritis , flares may cause scaly skin patches or nail abnormalities such as pitting or discoloration.
Lupus may trigger rashes, often on the face or sun-exposed areas.
Skin symptoms can appear before, during, or after joint flares.

Digestive Issues

Autoimmune conditions like Inflammatory Bowel Disease (Crohn’s Disease) can cause abdominal pain, diarrhea, bloating, or nausea during flare periods.
Gut inflammation can exacerbate fatigue and systemic symptoms.

Eye Problems

Inflammation such as uveitis can cause eye redness, dryness, light sensitivity, or blurred vision.
Prompt recognition is essential, as untreated eye inflammation can lead to vision complications.

Mental and Emotional Impact

Pain, fatigue, and unpredictability of flares can increase anxiety, depression, or irritability.
Cognitive difficulties, often called “brain fog”, can affect memory, focus, and decision-making.

Common Triggers of Flares

Flares can be unpredictable, but several factors often contribute to increased disease activity:

Stress – Emotional or physical stress can worsen symptoms and trigger immune responses.
Infections – Viral or bacterial infections may provoke systemic immune activation.
Weather Changes – Cold, damp, or fluctuating weather can intensify joint pain and stiffness.
Dietary Factors – Certain foods, like processed sugars, high-fat meals, or gluten (in sensitive individuals), may increase inflammation.
Medication Changes – Missing doses, stopping treatment abruptly, or changing medications without guidance can lead to flare-ups.

Managing and Preventing Flares

While flares may not always be fully preventable, proactive strategies can help reduce their severity and frequency:

Medication Adherence – Taking medications exactly as prescribed is critical to maintaining disease control.
Healthy Nutrition – Consuming anti-inflammatory foods, such as leafy greens, fatty fish, nuts, and berries, can help reduce inflammation .
Regular Exercise – Gentle, low-impact movement (e.g., yoga, swimming, walking) improves joint mobility, strength, and overall well-being.
Stress Management – Mindfulness, meditation, breathing exercises, and relaxation techniques can reduce flare frequency.
Adequate Rest – Prioritizing quality sleep and avoiding overexertion allows the body to recover and regulate inflammation.

When to Seek Medical Help

Recognizing early flare signs and taking proactive steps can help maintain daily function and quality of life. However, persistent, severe, or rapidly worsening symptoms require prompt consultation with a healthcare provider. Early intervention may prevent joint damage, control systemic inflammation, and guide treatment adjustments.

Tune into the AiArthritis Voices 360 Talk Show , where patients, doctors, and advocates come together to discuss the latest in autoimmune and autoinflammatory arthritis.

Understanding Co-Existing Conditions in Autoimmune & Autoinflammatory Arthritis

Sat, 29 Nov 2025 13:14:32 GMT

Understanding Co-Existing Conditions in Autoimmune & Autoinflammatory Arthritis

Living with autoimmune or autoinflammatory arthritis diseases often means navigating more than one diagnosis at the same time. These conditions don’t just affect joints—they influence the entire immune system, which can trigger a chain reaction of symptoms, complications, and additional health challenges. As a result, many people experience overlapping conditions that require coordinated care and careful monitoring.

Why Multiple Diagnoses Are Common

Immune System Dysregulation

Autoimmune and autoinflammatory diseases involve a malfunctioning immune system that mistakenly attacks healthy tissues. When the immune system is already overactive or dysregulated, it becomes more vulnerable to developing additional autoimmune or inflammatory diseases.

This is why it’s not unusual for someone with rheumatoid arthritis, psoriatic arthritis, lupus, or ankylosing spondylitis to also develop conditions such as Sjögren’s Disease, thyroid disorders, or inflammatory bowel diseases .

Systemic Chronic Inflammation

These diseases involve ongoing inflammation that can extend far beyond the joints. Chronic inflammation affects tissues and organs throughout the body, including the heart, lungs, skin, digestive system, nervous system, and glands.

Genetic and Familial Predisposition

Genetics play a significant role in autoimmune disease. Many people carry genes that make their immune system more reactive or less able to regulate inflammatory responses.

If a person has one autoimmune condition, their genetic profile may make them more susceptible to additional immune-mediated diseases, especially those that share similar pathways— such as HLA-B27, HLA-DR, or other inherited immune markers.

Family history also increases risk: if autoimmune diseases run in the fa mily, overlapping conditions become even more common.

Diagnostic Overlap and Symptom Similarities

Many autoimmune conditions mimic each other. Symptoms like fatigue, joint pain, dry eyes, digestive issues, or neuropathy overlap across several diseases.

Because of this, patients may receive more than one diagnosis over time as:

symptoms evolve
new organ systems are affected
blood tests or imaging reveal additional findings

It’s common for diagnoses to build upon one another as a fuller picture of the immune system emerges.

Fibromyalgia

Fibromyalgia frequently occurs alongside autoimmune and autoinflammatory arthritis. It causes widespread musculoskeletal pain, extreme fatigue, sleep disturbances, cognitive difficulties (“fibro fog”) , and heightened sensitivity to touch. Because symptoms overlap with arthritis flares—especially pain and stiffness—it can be challenging to determine whether symptoms are due to inflammation or neurological factors. While it does not cause joint damage, it can significantly amplify pain and reduce overall quality of life.

Irritable Bowel Syndrome (IBS)

IBS is common in people with rheumatic diseases and involves abdominal pain, bloating, irregular bowel habits, and food sensitivities. Although IBS is not an autoimmune condition itself, it is strongly associated with gut dysregulation, chronic inflammation, and microbiome imbalance—all of which are frequent in autoimmune diseases. In some cases, IBS coexists with inflammatory bowel disease (IBD ) , highlighting the need for careful monitoring and evaluation.

Depression and Anxiety

Living with chronic pain, fatigue, and uncertainty can significantly impact emotional health. Inflammation itself may contribute, as systemic cytokines can affect mood regulation. Untreated mental health conditions can worsen pain perception, interfere with treatment adherence, and further diminish overall quality of life, making mental health support a critical part of care.

Cardiovascular Disease

People with autoimmune and autoinflammatory arthritis have a higher risk of heart attack, stroke, atherosclerosis, and hypertension due to chronic systemic inflammation. Inflammation can accelerate plaque buildup and damage blood vessels, while some medications—like long-term corticosteroids—may increase metabolic o r cardiovascular risk . Proactive prevention, including monitoring cholesterol, blood pressure, and lifestyle factors, is essential for heart health.

Sjögren’s Disease

Sjögren’s Disease is an autoimmune disorder that often occurs alongside rheumatoid arthritis, lupus, psoriatic arthritis, and other rheumatic diseases. It primarily affects moisture-producing glands, leading to severe dry eyes and dry mouth, but may also cause joint pain, fatigue, neuropathy, lung involvement, and digestive issues. Because symptoms overlap with other autoimmune conditions, it is frequently underdiagnosed or misattributed to medication side effects.

Osteoporosis

Chronic inflammation and long-term corticosteroid use can weaken bones, increasing the risk of fractures. Osteoporosis is particularly common in people with rheumatoid arthritis, lupus, and other inflammatory diseases. Preventative measures, including bone density monitoring, diet, and exercise, are critical for maintaining bone health.

Type 2 Diabetes or Insulin Resistance

Systemic inflammation and certain medications, especially corticosteroids, can impair blood sugar regulation. This increases the risk for cardiovascular complications and can complicate medication management. Regular monitoring and lifestyle adjustments are essential for maintaining healthy blood sugar levels.

Thyroid Disorders

Autoimmune thyroid conditions, such as Hashimoto’s thyroiditis and Graves’ disease, frequently co-occur with autoimmune arthritis. Symptoms—including fatigue, weight changes, and temperature sensitivity—often overlap with arthritis manifestations, making diagnosis more complex. Thyroid health monitoring is recommended for anyone with autoimmune disease.

Lung Disease

Inflammatory arthritis can contribute to lung complications such as interstitial lung disease , pleuritis, or pulmonary fibrosis. Risk is higher with smoking, environmental exposures, and systemic inflammation. Pulmonary function testing and regular monitoring help detect issues early and guide treatment.

Kidney Disease

Kidney involvement can arise from autoimmune disease itself, as in lupus nephritis, or as a side effect of medications. Reduced kidney function can affect overall health and complicate treatment plans. Regular lab tests and kidney monitoring are crucial in multi-condition management.

Neuropathy

Peripheral neuropathy or nerve compression may result from inflammation, autoimmune activity, or medication side effects. Symptoms include tingling, numbness, and pain, which can interfere with daily activities. Addressing neuropathy early helps prevent progression and improves quality of life.

Skin Conditions

Psoriasis, vasculitis, rashes, and other dermatologic issues often accompany autoimmune arthritis. These may indicate systemic inflammation or flare-ups and sometimes require adjustments to treatment. Skin monitoring is important for overall disease management.

Eye Conditions

Beyond Sjögren’s Disease, autoimmune arthritis can cause uveitis, scleritis, or conjunctivitis. These eye issues can be painful and may threaten vision if untreated. Routine eye exams are recommended for early detection and management.

Gastrointestinal Conditions

Autoimmune and autoinflammatory arthritis can coexist with inflammatory bowel diseases (Crohn’s disease, ulcerative colitis), gastritis, or celiac disease. Gut inflammation can worsen systemic symptoms, interfere with nutrient absorption, and affect medication efficacy. Gastrointestinal monitoring and dietary guidance are often necessary.

Sleep Disorders

Chronic pain, inflammation, and fatigue contribute to insomnia, sleep apnea, and restless leg syndrome. Poor sleep exacerbates pain, fatigue, and mental health symptoms, creating a cycle that can intensify autoimmune symptoms. Addressing sleep health is essential for overall well-being.

Obesity or Metabolic Syndrome

Inflammation, limited mobility due to pain, and certain medications can increase weight and contribute to metabolic syndrome. This combination raises cardiovascular risk and complicates management of autoimmune disease. Lifestyle interventions, including nutrition and low-impact activity, are key strategies to improve outcomes.

Prioritizing Care for Overlapping Conditions

How to Know Which Condition Needs Immediate Attention

When managing multiple diagnoses, understanding which issue needs attention first can prevent complications and improve daily functioning.

Evaluate symptom impact — Prioritize conditions causing the greatest disruption to mobility, energy, digestion, or mental well-being.
Monitor disease progression — Some conditions worsen faster or can cause long-term damage if untreated, such as inflammatory arthritis, heart issues, or severe gastrointestinal symptoms.
Consult the right specialists — Rheumatologists, gastroenterologists, cardiologists, mental health professionals, and other specialists can help determine which condition requires timely treatment or testing .

Balancing Treatments Across Multiple Condit ions

Managing overlapping conditions often means finding the right combination of therapies without overwhelming your body .

Coordinate medications to reduce the risk of interactions, duplicated therapies, or conflicting treatment goals.
Adopt supportive lifestyle habits , such as anti-inflammatory nutrition, gentle movement, sleep optimization, and stress-management techniques, to help stabilize multiple conditions at once.
Track symptoms consistently to identify flare triggers, medication effects, and patterns that can guide treatment adjustments.

Managing Medication Conflicts

Common Challenges When Using Multiple Medications

People with autoimmune and autoinflammatory diseases often take several medications, which can create complexities.

Drug interactions : Certain medications can weaken or intensify each other’s effects, reducing safety or effectiveness.
Increased side effects : The more prescriptions involved, the higher the risk of fatigue, stomach issues, mood changes, or other adverse reactions.
Immune suppression: Some treatments lower immune activity, making infections or delayed healing more likely.

Strategies for Safe Medication Management

Keep an updated medication list with dosages, schedules, and reasons for use.
Review potential conflicts with healthcare providers and pharmacists, especially when starting or stopping a medication.
Monitor and report side effects early to prevent complications or uncover medication intolerance.
Consider alternative therapies or dosage adjustments if certain medications consistently create problems.

Communicating Effectively With Healthcare Providers

Advocating for Coordinated, Comprehensive Care

Navigating multiple conditions requires strong communication across your medical team.
Request a multidisciplinary care approach so specialists can collaborate on a unified treatment plan.
Ensure medical records and test results are shared across providers to prevent conflicting advice.
Ask for clear explanations of treatment goals, medication purposes, and expected outcomes.
Seek second opinions if your care feels fragmented, rushed, or ineffective.

Staying Organized With Your Medical Information

Use a health journal or digital app to document symptoms, flares, medications, and questions for appointments.
Keep copies of test results, imaging, and specialist reports to reference or share at medical visits.
Schedule consistent follow-ups with a primary care physician who can help oversee your overall health and coordinate between specialists.

Managing multiple diagnoses alongside autoimmune or autoinflammatory arthritis can feel overwhelming, but wi th the right tools and support , it becomes more manageable. Prioritizing your care, staying organized, maintaining open communication with your healthcare team, and advocating for coordinated treatment can significantly improve your quality of life and long-term health outcomes.

Explore the AiArthritis Equation Project - AUTO + Inflammatory Arthritis = X OR YZ, a patient-led initiative dedicated to enhancing the early detection and diagnosis of autoimmune and autoinflammatory arthritis. By increasing awareness of critical symptoms and encouraging timely referrals, this project enables patients and healthcare professionals to collaborate for quicker, more precise diagnoses.

Balancing Activity and Rest: Finding the Right Rhythm for Your Body with AiArthritis Diseases

Wed, 19 Nov 2025 10:38:30 GMT

Balancing Activity and Rest: Finding the Right Rhythm for Your Body with Ai Arthritis Diseases

Living with autoimmune and autoinflammatory arthritis ( AiArthritis ) diseases requires a delicate balance between activity and rest. While movement is essential for maintaining mobility and reducing stiffness, overexertion can trigger flare-ups and worsen fatigue.

Finding the right rhythm for your body involves optimizing energy, structuring daily activities, and managing symptoms effectively.

Understanding the Importance of Balance

Activity keeps joints flexible and strengthens muscles that support mobility
Rest allows the body to recover and prevents excessive inflammation
Overexertion can lead to flare-ups, making symptom management more difficult
Listening to your body helps determine when to push forward and when to slow down

Structuring Your Day for Optimal Energy

Morning Routine

Start with gentle stretching to reduce stiffness
Eat a nutritious breakfast to fuel your body
Plan low-energy tasks first if mornings are difficult

Midday Energy Management

Take short breaks between activities to prevent fatigue
Alternate between physical and mental tasks to avoid burnout
Stay hydrated and nourished to maintain stamina

Evening Wind-Down

Engage in relaxing activities like reading or meditation
Use heat therapy to soothe sore joints
Prioritize quality sleep to support recovery

Managing Symptoms Through Activity and Rest

Low-Impact Exercises

Walking – Improves circulation and joint flexibility
Swimming – Reduces strain while strengthening muscles
Yoga and Tai Chi – Enhances balance and relaxation

Rest Strategies

Scheduled rest periods prevent exhaustion
Comfortable seating and ergonomic tools reduce strain
Mindfulness techniques help manage stress-related fatigue

Recognizing When to Adjust Your Routine

Increase rest during flare-ups to allow recovery
Modify activities based on pain levels and energy fluctuations
Seek medical guidance if symptoms worsen despite adjustments

Balancing activity and rest is essential for optimizing energy, productivity, and symptom management in AiArthritis diseases . By structuring daily routines, listening to your body, and making mindful adjustments, individuals can maintain mobility while preventing unnecessary fatigue.

Explore the AiArthritis Patient Journey , a resource designed to guide patients through every stage of life with autoimmune and autoinflammatory arthritis. From diagnosis to daily management, discover tools and insights to empower your journey!

Early Symptoms and Uncertainty in Autoimmune and Autoinflammatory Diseases

Fri, 14 Nov 2025 11:25:02 GMT

Early Symptoms and Uncertainty in Auto immune and Auto inflammatory Diseases

Autoimmune and autoinflammatory diseases can be difficult to diagnose, as their early symptoms often appear subtle, inconsistent, or easily mistaken for other conditions. Many individuals experience joint stiffness, fatigue, low-grade fevers, and unexplained discomfort, leaving them puzzled about their health. Because these diseases involve immune system dysfunction, symptoms can fluctuate, making it challenging to pinpoint a clear cause.

Understanding the early warning signs and the uncertainty surrounding diagnosis can help individuals seek medical attention sooner, potentially preventing long-term complications.

Why Early Symptoms Are Often Overlooked

Autoimmune and autoinflammatory diseases affect millions of people worldwide, yet many cases go undiagnosed for years. This delay occurs because:

Symptoms mimic common ailments like stress, aging, or minor infections.
Patients may experience periods of remission, leading them to dismiss symptoms.
Many doctors prioritize ruling out other conditions before considering autoimmunity.

Since these diseases can affect multiple organs and systems, symptoms vary widely, making early detection difficult.

Common Early Symptoms

Joint Stiffness and Pain

Often worse in the morning or after periods of inactivity.
May affect multiple joints symmetrically, such as both hands or knees.
Can be accompanied by swelling, redness, or warmth.

Persistent Fatigue

Unlike normal tiredness, autoimmune-related fatigue does not improve with rest.
Can interfere with daily activities, concentration, and motivation.
Often linked to chronic inflammation and immune system overactivity.

Low-Grade Fevers

Frequent but mild fevers without an obvious infection.
May indicate immune system activation or underlying inflammation.
Often accompanied by chills, body aches, or flu-like symptoms.

Skin Changes

Rashes, discoloration, or thickened skin may appear suddenly.
Conditions like psoriasis, lupus , and scleroderma often present with skin symptoms.
Some autoimmune diseases cause sensitivity to sunlight or unexplained bruising.

Digestive Issues

Abdominal pain, bloating, diarrhea, or constipation may signal autoimmune involvement.
Diseases like Crohn’s , celiac disease, and ulcerative colitis affect the gut.
Many autoimmune conditions are linked to gut inflammation and microbiome imbalances.

Brain Fog and Cognitive Changes

Difficulty concentrating, remembering details, or processing information.
Often described as feeling mentally sluggish or disconnected.
Can be worsened by fatigue, stress, or inflammation.

Hair Loss and Nail Changes

Thinning hair or sudden bald patches may indicate autoimmune activity.
Brittle nails, ridges, or discoloration can be early signs of systemic disease.
Conditions like alopecia areata and lupus often affect hair and nails.

The Uncertainty of Diagnosis

Why Diagnosis Takes Time

Autoimmune diseases often require multiple tests to confirm.
Symptoms may come and go , making it hard to establish a pattern.
Many doctors rule out infections, hormonal imbalances, and other conditions first.

Common Diagnostic Tests

Blood tests (ANA, CRP, ESR, RF) to detect inflammation and autoantibodies.
Imaging scans (X-rays, MRIs) to assess joint damage.
Biopsies for skin or organ involvement in certain diseases.

Seeking a Second Opinion

If symptoms persist but tests are inconclusive, consulting a specialist (rheumatologist, immunologist) may help.
Keeping a detailed symptom journal can provide valuable insights for doctors.

What to Do If You Suspect an Autoimmune or Autoinflammatory Disease

Steps to Take:

Track symptoms daily, noting severity and triggers.
Consult a doctor and request autoimmune-specific tests.
Advocate for yourself if symptoms are dismissed or overlooked.
Join support groups to connect with others experiencing similar challenges.

Early symptoms of autoimmune and autoinflammatory diseases can be confusing, subtle, and frustrating, often leaving patients uncertain about their health. Recognizing these signs and seeking medical attention early can lead to faster diagnosis, better treatment options, and improved quality of life.

The AiArthritis Equation Project simplifies the path to early detection of autoimmune arthritis, promoting timely referrals through patient and provider collaboration.

From Fatigue to Brain Fog: Managing Complex Symptoms with AiArthritis

Thu, 13 Nov 2025 12:36:00 GMT

From Fatigue to Brain Fog: Managing Complex Symptoms with Ai Arthritis

Understanding Fatigue and Brain Fog in Autoimmune & Autoinflammatory Arthritis

Autoimmune and autoinflammatory arthritis diseases ( AiArthritis ) often come with debilitating symptoms that affect both physical and mental well-being. Fatigue and brain fog are among the most challenging aspects of these conditions, impacting daily life, productivity, and emotional resilience.

This guide explores strategies for managing exhaustion and cognitive dysfunction while maintaining a balanced life.

Why Fatigue Occurs

Chronic inflammation disrupts energy production and increases exhaustion.
Immune system overactivity drains physical and mental stamina.
Medication side effects contribute to drowsiness and sluggishness.

Why Brain Fog Happens

Inflammation in the brain affects cognitive function.
Neurotransmitter imbalances lead to memory issues and difficulty concentrating.
Sleep disturbances worsen mental clarity and focus.

Strategies for Managing Fatigue

Energy Conservation Techniques

Prioritize tasks and focus on essential activities first.
Use the “spoon theory” approach to manage daily energy levels.
Take scheduled breaks to prevent exhaustion.

Lifestyle Adjustments

Follow an anti-inflammatory diet to support energy levels.
Stay hydrated to improve circulation and reduce fatigue.
Engage in gentle movement like yoga or walking to boost stamina.

Sleep Optimization

Maintain a consistent sleep schedule to regulate energy cycles.
Use supportive pillows and mattresses to reduce discomfort.
Limit caffeine and screen time before bed to improve sleep quality.

Strategies for Managing Brain Fog

Cognitive Support Techniques

Break tasks into smaller step s to improve focus.
Use memory aids like lists, alarms, and reminders.
Practice mindfulness to enhance mental clarity.

Diet and Nutrition for Brain Health

Eat omega-3-rich foods (salmon, walnuts) to support cognitive function.
Reduce processed foods and sugar to minimize brain fog triggers.
Stay hydrated to maintain brain function.

Mental Stimulation

Engage in puzzles, reading, or creative activities to strengthen cognitive skills.
Limit multitasking to reduce mental overload.
Practice relaxation techniques to lower stress-related brain fog.

Seeking Support and Maintaining Emotional Resilience

Building a Support System

Join online communities to connect with others facing similar challenges.
Educate family and friends about your condition to foster understanding.
Seek professional counseling if emotional distress becomes overwhelming.

Mindfulness and Stress Reduction

Practice meditation and deep breathing to manage stress-related symptoms.
Engage in hobbies that bring joy and relaxation.
Set boundaries to protect mental and emotional well-being.

Managing fatigue and brain fog takes patience, planning, and self-compassion. Through balanced lifestyle choices, cognitive support, and strong emotional connections, people living with autoimmune and autoinflammatory arthritis can reclaim energy, focus, and a sense of control over their daily lives.

Join the AiArthritis Volunteer Program and be part of the change! Your skills and passion can support advocacy and outreach in the autoimmune arthritis community.

What Are Clinical Trials?

Thu, 06 Nov 2025 13:33:53 GMT

What Are Clinical Trials?

Clinical trials are the backbone of medical progress. They provide the scientific evidence needed to determine whether new treatments, drugs, or medical devices are safe, effective, and improve quality of life.

Every therapy that becomes standard care — from vaccines to biologics to cutting-edge targeted therapies — was once tested through a clinical trial.

These studies not only help doctors and researchers discover better ways to treat disease but also give patients the opportunity to access innovative options before they’re widely available.

By participating in or supporting clinical research, we all contribute to the future of medicine and improved outcomes for generations to come.

What Clinical Trials Are

A clinical trial is a research study that involves human participants and evaluates medical, surgical, or behavioral interventions. These studies help determine whether new approaches to prevention, diagnosis, or treatment are effective and safe.

Depending on their focus, clinical trials may also be referred to as:

Clinical studies: Broadly include any research involving human participants.
Interventional studies : Participants receive a specific treatment or intervention under a structured protocol.
Therapeutic or treatment trials : Evaluate new therapies for diseases or conditions.
Randomized controlled trials (RCTs) : Participants are randomly assigned to a treatment or control group to compare outcomes.
Observational studies : Collect data without altering treatment; often used to understand real-world outcomes.

While these terms are sometimes used interchangeably, the distinctions help clarify a study’s design and purpose.

What is a Clinical Trial Video

Phases of Clinical Trials

Clinical trials typically progress through four main phases, each answering different research questions:

Phase I: Tests a new treatment in a small group (often healthy volunteers) to evaluate safety, dosage, and side effects.
Phase II: Expands testing to more participants with the target condition, assessing early evidence of effectiveness and continued safety.
Phase III: Compares the new treatment to standard therapies or placebo in a large population, gathering data needed for regulatory approval.
Phase IV: Conducted after regulatory approval to monitor long-term safety and effectiveness in broader, real-world use.

Discover More Of Our Resources

Types of Clinical Trials

Each type of trial addresses a specific goal within medical research:

Treatment trials: Test new drugs, biologics, or surgical procedures.
Prevention trials: Explore ways to prevent disease through lifestyle, medications, or vaccines.
Diagnostic trials: Improve methods for identifying diseases or conditions.
Screening trials: Focus on early detection, before symptoms appear.
Quality-of-life trials: Evaluate interventions that help patients manage symptoms and live better with chronic illness.

When Should I Consider Participating in a Clinical Trial?

Why Clinical Trials Matter

Clinical trials are essential for:

Advancing medical knowledge: They generate reliable data on new therapies and medical innovations.
Improving patient care: Findings from trials shape treatment guidelines and elevate standards of care.
Ensuring safety: Regulatory agencies such as the U.S. Food and Drug Administration (FDA) rely on clinical trial data to approve new therapies.
Offering access to innovation: Participants may gain early access to promising treatments and contribute to discoveries that benefit others.

Ethical Safeguards

Protecting participants is central to every clinical trial. Research must follow strict ethical and regulatory standards, including:

Informed consent: Participants must understand the study’s purpose, procedures, risks, and potential benefits before agreeing to join.
Confidentiality: Personal data is protected and used solely for research purposes.
Risk-benefit analysis: Researchers ensure that potential benefits outweigh the risks.
Independent oversight: Institutional Review Boards (IRBs) or ethics committees review all protocols to ensure participant safety and ethical conduct.

Clinical Trial Diversity

The Bigger Picture

Clinical trials are how medicine moves forward, step by step, study by study. They provide the scientific foundation for safer, more effective treatments and the evidence needed to transform care.

By understanding how clinical trials work, and the protections in place, patients and the public can make informed choices about participation and become partners in advancing medical science.

Are you navigating life with treatment-resistant rheumatoid arthritis?

If so, you may be eligible for this study which aims to assess a study drug for treatment-resistant rheumatoid arthritis (RA). Participating in this study may help researchers learn more about rheumatoid arthritis and whether the study drug is a safe and effective treatment option.

You may be eligible to participate in this study if you:

Are between the ages of 18 - 75 years old
Have a confirmed diagnosis of rheumatoid arthritis
Have been told by your doctor that your rheumatoid arthritis is refractory*

Learn More About Clinical Trials

3 Groundbreaking CAR-T Therapy Studies You Need to Know About

Wed, 08 Oct 2025 14:20:07 GMT

3 Groundbreaking CAR-T Therapy Studies You Need to Know About

Early Results from a Study Testing CAR-Treg Cell Therapy for Hard-to-Treat Rheumatoid Arthritis

REGULATE-RA: A Phase 1 Study of CAR-Treg Cells Targeting Citrulinated Proteins in Refractory Rheumatoid Arthritis: Interim Report of Patient Characteristics and Safety

This poster shares early findings from the first-in-human trial using CAR-T regulatory (CAR-Treg) cells for autoimmune disease, specifically rheumatoid arthritis (RA) . Unlike standard CAR-T cells that eliminate B cells, CAR-Treg cells are designed to calm down the immune system and stop it from attacking the body.

For patients, this is exciting because it shows a new approach—using CAR-Tregs to restore balance rather than destroy cells . The interim report shows the treatment was feasible and appeared safe so far , with participants tolerating therapy and no major safety concerns reported.

Questions Answered by this Poster

Can CAR-Treg therapy be used to treat refractory RA?
Is CAR-Treg treatment safe and tolerable for patients?
What makes CAR-Tregs different from standard CAR-T therapies?

Methods

Trial type: Phase 1, first-in-human safety study.
Participants: Patients with refractory RA (resistant to standard treatments).
Therapy: CAR-Tregs engineered to target citrullinated proteins , a hallmark of RA autoimmunity.
Focus: Interim report on patient characteristics and safety outcomes .

Results

Patients successfully enrolled and treated with CAR-Tregs.
Safety profile looked favorable in interim analysis.
Early results indicate no unexpected toxicities or major adverse events.

Conclusions

CAR-Treg therapy appears safe and feasible for refractory RA in early testing.

Represents a new therapeutic strategy : restoring immune tolerance rather than destroying immune cells.

More follow-up is needed to confirm long-term safety and potential clinical benefit.

Key Data

All treated patients tolerated infusion without major safety issues.

Interim analysis suggests encouraging safety profile .

Data still preliminary—effectiveness outcomes not yet fully available.

Authors

The poster was produced by a team affiliated with Sonoma Biotherapeutics.

Baxter SK, Bitton A, Dubovsky JA, Jensen M, Yuan V, Do J, Gordon G, Griffith M, Massarotti E, Moreland L, Sparks J, Charrow A, Pacha O, Jaleel T, Clauw A, Gabriel O, Gyurko R, Seifert J, Beilke J, Blake ML, Fox-Bosetti S, Fromhold M, Lebrec H, O'Bryan S, Pace A, van der Vuurst de Vries AR, Wang ML, Xiao Y, Arron J, Bluestone J

Read the published abstract in Annals of the Rheumatic Diseases

Initial Results of a New CD19 CAR-T Cell Therapy for Systemic Sclerosis Show Promising Safety and Effectiveness

Tolerability and efficacy of BMS-986353, a CD19-directed chimeric antigen receptor T cell therapy manufactured using a next-generation process for systemic sclerosis

This poster presents early findings on BMS-986353 , a CAR-T therapy specifically developed for systemic sclerosis , a severe autoimmune disease with limited treatment options. Using a next-generation manufacturing process, the therapy aims to be more efficient and potentially safer.

The results show that patients tolerated the therapy well, with manageable side effects , and experienced signs of clinical improvement in systemic sclerosis symptoms. For patients, this is important because it demonstrates that CAR-T therapy could become a viable new treatment for a disease that currently has very few effective options.

Questions Answered by this Poster

Is BMS-986353 safe and tolerable for people with systemic sclerosis?
How effective is CAR-T therapy in reducing symptoms of systemic sclerosis?
What advantages does the next-generation manufacturing process provide?
Could CAR-T therapy become a new option for systemic sclerosis patients who lack effective treatments?

Methods

Participants: Patients with systemic sclerosis receiving BMS-986353.
Therapy: CD19-directed CAR-T cells manufactured with a next-generation process.
Focus: Tolerability and early efficacy.
Measurements: Safety profile, clinical symptoms, and disease activity markers.

Results

Safety: Treatment was well tolerated , with side effects consistent with CAR-T therapy and manageable.
Efficacy: Patients showed clinical improvements , including reduced disease activity.
Manufacturing process: Designed to enhance product quality and consistency, potentially improving safety and outcomes.

Conclusions

BMS-986353 appears safe and effective in systemic sclerosis patients.
Next-generation process could represent an important step in improving CAR-T therapies for autoimmune diseases.
Findings support continued development and larger trials.

Key Data

Tolerability: No unexpected toxicities observed.
Clinical response: Patients experienced improvements in systemic sclerosis symptoms.
Process innovation: Next-generation manufacturing approach highlighted as a strength.

Authors

Developed by researchers from Bristol Myers Squibb (BMS) in collaboration with clinical trial investigators at University Hospital Erlangen , Friedrich-Alexander University Erlangen-Nürnberg (FAU) , and partner rheumatology centers.

Dinesh Khanna, Margrit Wiesendanger, Richard Nash, Philip Mease, Anca Askanase, Elana Bernstein, Neil Kramer, Vikas Majithia, Jacques Azzi, David Korman, Krish Patel, Matthew H. Schwede, Ran Reshef, Ernesto Ayala, Alisha Desai, Griff McTume, Sharmila Das, Jerill Thorpe, Ashley Koegel, Georg Schett

Read the published abstract in Annals of the Rheumatic Diseases

Study Looks at How a CD19 CAR-T Therapy Works in Bone Marrow of Autoimmune Disease Patients

Effect of KYV-101 Anti-CD19 CAR-T Cell Therapy in the Bone Marrow of Patients with Systemic Autoimmune Rheumatic Diseases

This study examined what happens in the bone marrow of patients with systemic autoimmune rheumatic diseases (such as lupus and related conditions) after receiving KYV-101, an anti-CD19 CAR-T therapy. The bone marrow is important because it produces the immune cells that drive autoimmune activity.

The researchers found that after CAR-T therapy, there were major changes in the bone marrow, including depletion of disease-causing B cells and early signs of immune “reset.” These findings suggest CAR-T therapy works not just in the blood but also at the source of immune cell production, which may explain why patients can enter long-lasting remission.

Questions Answered by this Poster

How does CAR-T therapy affect the bone marrow in autoimmune patients?
What happens to B cells and other immune cells in the marrow after treatment?
Does bone marrow rebalancing help explain remission after CAR-T therapy?
Can studying bone marrow responses improve understanding of long-term outcomes?

Methods

Patients: Individuals with systemic autoimmune rheumatic diseases receiving KYV-101 CAR-T therapy.
Samples: Bone marrow biopsies analyzed before and after treatment.
Focus: Looked at B cell presence, immune cell activity, and changes in marrow composition.

Results

Clear reduction in CD19+ B cells in the bone marrow after CAR-T therapy.
Signs of immune system reset , with healthier cell populations repopulating.
Evidence that CAR-T activity extends beyond circulation into bone marrow niches.

Conclusions

CAR-T therapy impacts the bone marrow directly, where many disease-driving immune cells originate.
This may be a key reason patients experience strong remission after treatment.
Supports the idea that CAR-T has systemic and long-lasting effects in autoimmunity.

Key Data

Marked depletion of B cells from the bone marrow following therapy.
Evidence of immune reconstitution (healthy cells returning).
Bone marrow findings paralleled clinical remission improvements.

Authors

The poster was produced by a team affiliated with Charité - Universitätsmedizin Berlin, Kyverna Therapeutics, Universitätsklinikum Erlangen, and University of Erlangen-Nuremberg.

loanna Minopoulo, Artur Wilhelm, Fredrik Albach, Arnd Kleyer, Edgar Wiebe, Anja Fleischmann, Mareike Frick, Frederik Damm, Dominic Borie, Vincent Casteleyn, Robert Biesen, Thomas Dörner, Tobias Alexander, Jan Zernickel, Lukas Hinkelmann, Elpida Phithak, Norman Drzeniek, Kamran Movassaghi, Marie Luise Hütter-Krönke, Eva Schrezenmeier, Adrian Schreiber, Udo Schneider, Georg Schett, Lars Bullinger, Gerhard Krönke, Olaf Penack, David Simon

CAR-T Cell Therapy Education by AiArthritis

Episode 113: What is CAR-T Therapy?

CAR-T Therapy is one of the most talked about advances in autoimmune research today, offering new hope for people living with AiArthritis diseases such as lupus, myositis, scleroderma, and Sjögren’s. In this episode, co-hosts Leila P.L. Valete, AiArthritis Health Education Manager, and Tiffany Westrich-Robertson, CEO and Original Founder of AiArthritis, explain what CAR-T is, how it works, and why it matters.

They walk through the treatment process step by step from collecting a person’s own immune cells, to reprogramming them in a lab and reintroducing them so the immune system can reset. This episode highlights promising results from early clinical trials including patients reaching remission and stopping other medications, while also addressing safety, access, and what is still unknown.

More About CAR-T Therapy On Our Blog

AiArthritis Launches #WTHellth?! to Support Patients Frustrated with the Health Care System and Amplify their Voices

Wed, 01 Oct 2025 12:47:16 GMT

Ai Arthritis Launches # WTH ellth ?! to Support Patients Frustrated with the Health Care System and Amplify their Voices

The name #WTHellth?! riffs on the widely used online abbreviation “WTH” to illustrate the “hellish” experiences people face when navigating our health care system. These rants are not limited to patients living with autoimmune or autoinflammatory arthritis. #WTHellth?! is a disease-agnostic campaign encouraging submissions from any person who has faced challenges within the health care system – whether it’s difficulties dealing with health insurers, hospitals, pharmacy benefit managers, or other barriers to accessing treatments.

#WTHellth?! contributors submit a variety of content – some use humor, memes, and trending soundbites to demonstrate what they went through, while others soulfully recount their plight from start to finish. One patient shared a story about how insurance initially denied her the rheumatology medication she needed, only to be eligible for it a year later. Once she was eligible, it drastically improved her life, but there never should have been a yearlong delay for her to find relief. ”

One of the most exhausting and frustrating things to do as a patient is self-advocacy, but it can also be incredibly empowering,” said Leila P.L. Valete, Health Education Manager at AiArthritis and #WTHellth?! contributor. “Venting through #WTHellth?! about the time I was automatically switched to a cheaper medication that did nothing for my lupus really helped me connect with people who were going through the same thing. Sharing your story can help you stand up for yourself and let others in the same situation know they’re not alone.”

Examples of #WTHellth?! videos, social media pages and detailed submission information can be found on the website .

Participating is easy: Either post your own video on any social media platform and add the tag #WTHellth?! Or simply visit the website and submit your story through the online form , where there is an option to remain anonymous.

About Ai Arthritis

The International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis) was founded in 2011 by people living with autoimmune and autoinflammatory arthritis diseases. Over the past decade, AiArthritis has emerged as a leader in education, public policy, and research, serving on advisory panels, participating as research liaisons, and using patient experience data to influence policy. Learn more via aiarthritis.org.

Discover The #WTHellth?! Video Library

Mental Health After Diagnosis of Autoimmune and Autoinflammatory Arthritis Diseases

Sat, 27 Sep 2025 13:39:33 GMT

Mental Health After Diagnosis of Auto immune and Auto inflammatory Arthritis Diseases

Being diagnosed with an autoimmune or autoinflammatory arthritis disease—such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus , or a nkylosing spondylitis , is life-changing. These conditions not only affect physical health but also have a profound impact on mental and emotional well-being. Many individuals experience stress, anxiety, depression, and emotional exhaustion as they navigate the complexities of chronic illness.

Understanding the psychological effects of AiArthritis Diseases and learning strategies to support mental health can help patients cope with the emotional challenges that come with their diagnosis.

The Emotional Impact of Diagnosis

Common Emotional Responses

Shock and denial – Many patients struggle to accept their diagnosis, especially if symptoms were previously dismissed or misdiagnosed.
Grief and loss – Adjusting to a new reality can feel like mourning the life they had before illness.
Anxiety about the future – Concerns about disease progression, treatment effectiveness, and lifestyle changes can cause significant stress.
Depression and isolation – Chronic pain and fatigue can lead to withdrawal from social activities and feelings of loneliness.

Why Mental Health Is Affected

Inflammation and brain function – Studies suggest that chronic inflammation may contribute to mood disorders.
Medication side effects – Some treatments, such as corticosteroids, can cause mood swings and emotional instability.
Social stigma – Invisible illnesses are often misunderstood, leading to frustration and lack of support.

Coping Strategies for Mental Health

Building Emotional Resilience

Acknowledge emotions – Accepting feelings of frustration, sadness, or anger is the first step toward healing.
Practice mindfulness – Meditation, deep breathing, and relaxation techniques can help manage stress.
Seek professional support – Therapy or counseling can provide coping strategies tailored to chronic illness.

Managing Anxiety and Depression

Cognitive-behavioral therapy (CBT) – Helps reframe negative thoughts and develop healthier coping mechanisms.
Medication options – Antidepressants or anti-anxiety medications may be recommended for some.
Journaling – Writing about emotions can help process feelings and track mental health patterns.

Social Support and Connection

Join support groups – Connecting with others who have similar conditions can reduce feelings of isolation.
Educate family and friends – Helping loved ones understand the disease can improve emotional support.
Engage in hobbies – Creative activities, reading, or light exercise can provide mental stimulation and joy.

Lifestyle Changes to Support Mental Health

Diet and Nutrition

Eat anti-inflammatory foods – Omega-3s, leafy greens, and whole grains can support brain health.
Limit processed foods and sugar – These can contribute to mood fluctuations and fatigue.
Stay hydrated – Proper hydration supports cognitive function and energy levels.

Exercise and Movement

Engage in low-impact activities – Yoga, swimming, and walking can improve mood and reduce stress.
Stretch regularly – Helps relieve tension and improve circulation.
Listen to your body – Rest when needed and avoid overexertion.

Sleep and Fatigue Management

Maintain a consistent sleep schedule – Helps regulate mood and energy levels.
Use supportive pillows and mattresses – Reduces discomfort and improves sleep quality.
Limit caffeine and screen time before bed – Promotes restful sleep.

Advocating for Mental Health in Healthcare

Communicating with Doctors

Discuss mental health openly – Many doctors focus on physical symptoms, so it’s important to bring up emotional concerns.
Request mental health screenings – Depression and anxiety are common in AiArthritis patients but often overlooked.
Seek referrals to specialists – Psychologists, psychiatrists, or counselors can provide additional support.

Building a Comprehensive Care Plan

Integrate mental health care into routine medical visits.
Explore holistic approaches – Acupuncture, massage therapy, and relaxation techniques may help.
Advocate for workplace accommodations – Flexible schedules and remote work options can reduce stress.

Mental health is an essential part of managing AiArthritis diseases. While the emotional challenges of chronic illness can be overwhelming, support, self-care, and proactive mental health strategies can help patients navigate their diagnosis with resilience.

Join A Community Team (ACT) II , where patients come together to co-create solutions for autoimmune and autoinflammatory arthritis. From advocacy to innovation, this initiative empowers individuals to take action and make a difference. Get involved at ACT II .

Common Co-Existing Conditions in AiArthritis: What to Watch For

Wed, 10 Sep 2025 14:33:41 GMT

Common Co-Existing Conditions in Ai Arthritis: What to Watch For

Autoimmune and autoinflammatory arthritis diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus arthritis , and ankylosing spondylitis , often come with co-existing conditions that complicate symptom management. These conditions may develop due to chronic inflammation, immune system dysfunction, over-stimulated central nervous system, or medication side effects, making it essential for patients to recognize overlapping symptoms and seek comprehensive care.

This guide explores frequently associated conditions, their impact, and how they overlap with autoimmune and autoinflammatory arthritis.

Fibromyalgia

What It Is A chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties. Often coexists with autoimmune arthritis, making it difficult to distinguish between the two conditions.

How It Overlaps

Pain amplification – Fibromyalgia causes heightened pain sensitivity, worsening arthritis-related discomfort.
Fatigue and brain fog – Shared symptoms with autoimmune diseases, complicating diagnosis.
Sleep disturbances – Poor sleep quality exacerbates inflammation and pain.

Management Strategies

Gentle exercise (yoga, swimming) to reduce stiffness.
Cognitive behavioral therapy (CBT) for pain perception and emotional well-being.
Medication adjustments to address nerve pain and inflammation.

Irritable Bowel Syndrome (IBS)

What It Is A gastrointestinal disorder causing abdominal pain, bloating, diarrhea, and constipation. Common in patients with autoimmune diseases due to gut inflammation and microbiome imbalances.

How It Overlaps

Inflammatory bowel conditions – Some autoimmune diseases, like Crohn’s and ulcerative colitis, share symptoms with IBS, however it is not to be confused with Irritable Bowel Disease (IBD) such as Crohn’s and Colitis.
Medication side effects – Certain arthritis treatments may trigger digestive issues.
Stress-related flares – Emotional distress can worsen both IBS and arthritis symptoms.

Management Strategies

Anti-inflammatory diet (fiber-rich foods, probiotics) to support gut health.
Stress reduction techniques (meditation, deep breathing) to minimize flare-ups.
Medication review to identify triggers and adjust treatment plans.

Depression and Anxiety

What It Is Mood disorders characterized by persistent sadness, worry, and emotional distress. Common in autoimmune patients due to chronic pain, fatigue, and social isolation.

How It Overlaps

Inflammation and brain function – Studies suggest chronic inflammation contributes to mood disorders.
Medication effects – Some arthritis treatments may cause mood swings or emotional instability.
Social stigma – Invisible illnesses lead to frustration and lack of support.

Management Strategies

Therapy and counseling to address emotional challenges.
Mindfulness and relaxation techniques to reduce stress-related inflammation.
Support groups to connect with others facing similar struggles.

Cardiovascular Disease

What It Is Increased risk of heart disease , high blood pressure, and stroke due to chronic inflammation. Patients with autoimmune arthritis are 1.5 to 2 times more likely to develop cardiovascular conditions.

How It Overlaps

Inflammation and blood vessel damage – Autoimmune diseases contribute to arterial stiffness.
Medication risks – Some arthritis treatments may affect heart health.
Limited mobility – Reduced physical activity increases cardiovascular risk.

Management Strategies

Heart-healthy diet (omega-3s, whole grains, lean proteins).
Regular exercise (walking, swimming) to maintain circulation.
Routine cardiovascular screenings to monitor heart health.

Sjögren’s Disease

What It Is Sjögren’s Disease is an autoimmune condition causing dry eyes, dry mouth, and systemic inflammation. Frequently coexists with RA and lupus, affecting mucous membranes and joints.

How It Overlaps

Joint pain and stiffness – Similar to arthritis symptoms, making diagnosis challenging.
Medication side effects – Some treatments may worsen dryness.
Fatigue and systemic inflammation – Shared symptoms with autoimmune arthritis.

Management Strategies

Artificial tears and saliva substitutes to relieve dryness.
Hydration and humidifiers to maintain moisture levels.
Medication adjustments to balance symptom relief.

Diabetes

What It Is A metabolic disorder affecting blood sugar regulation. Nearly half of adults with diabetes also have arthritis.

How It Overlaps

Inflammation – Chronic inflammation is a shared factor in both conditions.
Medication effects – Some arthritis treatments may impact blood sugar levels.
Obesity link – Excess weight increases the risk of both arthritis and diabetes.

Management Strategies

Blood sugar monitoring and anti-inflammatory diet.
Regular physical activity to improve insulin sensitivity.
Medication review to balance arthritis and diabetes treatments.

Obesity

What It Is Excess body weight that contributes to joint stress and inflammation. A major risk factor for autoimmune arthritis.

How It Overlaps

Joint strain – Increased weight exacerbates arthritis symptoms.
Inflammatory markers – Fat cells release inflammatory substances.
Reduced mobility – Pain and stiffness limit physical activity.

Management Strategies

Weight management through diet and exercise.
Anti-inflammatory foods to reduce systemic inflammation.
Physical therapy to improve mobility and joint function.

Osteoporosis

What It Is A condition characterized by weakened bones and increased fracture risk. Common in autoimmune arthritis patients, especially those on long-term steroids.

How It Overlaps

Bone loss – Chronic inflammation accelerates osteoporosis.
Steroid use – Medications for arthritis can weaken bones.
Limited mobility – Reduced activity affects bone density.

Management Strategies

Calcium and vitamin D supplementation.
Weight-bearing exercises to strengthen bones.
Medication review to minimize osteoporosis risk.

Recognizing co-existing conditions in autoimmune and autoinflammatory arthritis is essential for comprehensive symptom management. Many patients experience multiple autoimmune and autoinflammatory arthritis conditions simultaneously, making diagnosis and treatment more complex. By understanding how these conditions overlap, patients can advocate for proper care, adjust treatment plans, and improve overall well-being.

Discover the AiArthritis Precision Medicine Initiative , a patient-led effort advocating for tailored treatments based on individual biomarkers and disease profiles. Learn how precision medicine is transforming autoimmune and autoinflammatory arthritis care by promoting personalized therapies and improving outcomes.

The Long Road to Answers: Why Persistence Matters

Wed, 10 Sep 2025 14:07:22 GMT

The Long Road to Answers: Why Persistence Matters

For many individuals living with autoimmune and autoinflammatory arthritis, the journey to diagnosis is long, frustrating, and emotionally exhausting . Symptoms may be subtle, intermittent, or mimic other conditions, leading to misdiagnoses, medical dismissal, and years of uncertainty. However, persistence in seeking answers can make all the difference in receiving appropriate care, treatment, and support. Without a clear diagnosis, patients may struggle to access necessary medications, preventive measures, and accommodations to manage their condition effectively.

The Challenge of Getting Diagnosed

Why Diagnosis Takes So Long

Symptom Overlap – Autoimmune and autoinflammatory arthritis share symptoms with many other conditions, including fibromyalgia, osteoarthritis, and even viral infections, making accurate identification challenging.
Fluctuating Symptoms – Disease activity comes in waves, with some periods of remission where symptoms appear mild, causing delays in diagnosis and sometimes leading patients to question whether they are truly sick.
Medical Bias & Dismissal – Patients—especially women, minorities, and younger individuals—are often told their symptoms are due to stress, anxiety, or lifestyle factors rather than a physical illness, leading to years of unnecessary suffering.
Limited Awareness of Rare Autoimmune Diseases – While conditions like rheumatoid arthritis (RA) and lupus are relatively well-known, others—such as Still’s disease , autoinflammatory syndromes, and seronegative arthritis—are frequently misdiagnosed due to lack of familiarity among general practitioners.
Inconsistent Lab Results – Some autoimmune conditions may not show obvious markers in standard blood tests (such as rheumatoid factor or antinuclear antibodies), leading doctors to prematurely rule out certain diseases.

The Emotional Toll of Uncertainty

Self-Doubt – After repeated medical dismissals, patients may begin to question whether their symptoms are real or exaggerated.
Frustration – Multiple medical visits, inconclusive test results , and ever-changing symptoms can make the journey exhausting and discouraging.
Isolation – Friends, family, and even healthcare providers may struggle to understand the depth of pain and fatigue, leading patients to feel unsupported.
Fear – Untreated disease progression can cause permanent joint damage, organ complications, and disability, making the search for answers critical.

Despite these barriers, patients who persist are more likely to receive a proper diagnosis, leading to targeted treatments, symptom relief, and improved quality of life.

Why Persistence Matters in Diagnosis

Autoimmune and autoinflammatory arthritis are complex, and diagnosis often requires multiple consultations, advanced testing, and strong self-advocacy. Without persistence, misdiagnosis or delayed care can result in worsening symptoms, disease progression, and irreversible joint damage.

Patients who push for further evaluations, document their symptoms , and seek out specialists are more likely to receive a timely and accurate diagnosis. This can open the door to more effective treatments, lifestyle adjustments, and preventive care to slow disease progression.

Without persistence, many patients may be misdiagnosed with fibromyalgia, generalized anxiety disorder, chronic fatigue syndrome, or somatic symptom disorder, when in reality, their symptoms are caused by underlying autoimmune or autoinflammatory processes.

How to Get Answers: Practical Strategies

Seeking a Second Opinion

If you feel your concerns are being dismissed or your diagnosis does not fully explain your symptoms, seeking a second opinion can be crucial. Here’s how to approach it:

Find a specialist – Look for a rheumatologist, immunologist, or other expert with experience in diagnosing complex autoimmune and autoinflammatory diseases.
Research patient reviews – See if others have had success in finding answers with a specific doctor.
Request medical records – Bring copies of your test results, imaging, and previous doctor notes to ensure the new provider has full context.
Prepare specific questions – Ask about alternative diagnoses, additional testing options, and treatment plans.
Be honest about your experience – Let the new provider know why you're seeking another opinion, whether it's due to lack of answers, dismissal, or worsening symptoms.

Tracking Symptoms & Flare Patterns

Keep a journal documenting pain levels, stiffness, fatigue, digestive issues, and other symptoms daily.
Note patterns such as weather changes, stress levels , diet, sleep habits, and physical activity that affect symptoms.
Use a pain scale (0-10) and describe how symptoms affect daily activities (e.g., "I cannot grip objects due to morning stiffness" or "Fatigue prevents me from walking more than a few minutes").
Track medication effects —including relief, side effects, and worsening symptoms—to better understand treatment responses.

Communicating Effectively with Doctors

Prepare a list of questions before appointments to ensure concerns are addressed efficiently.
Use precise descriptions when explaining symptoms—rather than saying "I feel tired," specify "I experience extreme fatigue where I cannot complete simple tasks."
Request specific tests including autoimmune panels, inflammatory markers (CRP, ESR), imaging scans (X-rays, MRIs, ultrasounds), and specialty blood tests (such as HLA-B27 for ankylosing spondylitis).
Bring research and medical studies that align with your symptoms to help encourage further testing or referrals.
Ask for referrals to specialists , particularly rheumatologists, immunologists, and neurologists who understand complex autoimmune conditions.

Seeking the Right Medical Providers

Find a rheumatologist —a specialist in autoimmune and autoinflammatory arthritis—who has experience with complex cases.
Consider second or third opinions —if your symptoms are repeatedly dismissed, look for doctors who take a deeper investigative approach.
Ask about rare diseases —if common diagnoses are ruled out, consider asking about conditions like Still’s disease , mixed connective tissue disease , and Behcet's disease .

Building a Support Network

Join online communities and patient advocacy groups —they provide shared experiences, symptom tracking tips, and recommendations for specialists.
Educate family and friends —help them understand your condition and challenges to improve emotional support.
Seek mental health support —uncertainty and medical dismissal can take a significant toll, so therapists, counselors, and support groups can help manage the emotional burden.

The journey to diagnosis is often long and frustrating, but your persistence matters. By tracking symptoms, advocating for proper care, and seeking support, patients can overcome delays and find the answers they need. Seeking a second opinion when needed is a powerful tool in ensuring thorough evaluations and proper diagnosis. A diagnosis can open the door to better treatment options, lifestyle adaptations, and long-term management strategies, ensuring that autoimmune and autoinflammatory arthritis don’t define a person’s future.

At AiArthritis, the number one question we get is: "Why won't they diagnose me?" We've heard countless stories of patients waiting 3 months to over 15 years for proper diagnosis and treatment. We aim to find innovative ways to help bridge that gap and expedite detection and diagnosis and this is one of those ways. This is a living document, meaning your contribution will continue to help us to improve our guide.

Could CAR-T Cell Therapy Reset the Immune System? (EULAR 2025)

Thu, 04 Sep 2025 19:18:59 GMT

Could CAR-T Cell Therapy Reset the Immune System? (EULAR 2025)

What Is CAR-T Cell Therapy?

CAR-T stands for Chimeric Antigen Receptor T-cell therapy . It was first developed for cancer, where it showed remarkable success. Now, scientists are bringing it into the autoimmune world. Here's how it works:

Step 1: Remove immune cells (T cells) from your blood.
Step 2: Genetically engineer those cells in a lab to attack malfunctioning immune cells (like B cells).
Step 3: Use a chemotherapy drug to clear out existing B cells in your body (this temporarily weakens the immune system).
Step 4: Re-infuse your engineered T cells back into your body in a single treatment.
Step 5: Monitor recovery in the hospital (usually 2 weeks), and wait for your immune system to rebuild in a more balanced, less self-attacking way.

This approach is often referred to as “resetting the immune system.”

Why It Matters for Autoimmune Patients

Autoimmune diseases like lupus and systemic sclerosis (scleroderma) cause the immune system to mistakenly attack healthy tissues. Traditional treatments often involve ongoing immune suppression. But CAR-T therapy offers a whole new approach: retraining your immune system to behave properly again.

So far, most autoimmune trials have focused on:

Lupus
Systemic sclerosis/Scleroderma
Myositis (closely related but not under AiArthritis)

What’s New This Year?

Since last year’s updates at ACR, the research has exploded. Here’s what’s new:

1. “Off-the-Shelf” Cell Therapies Are Coming

Normally, CAR-T therapy requires creating cells from your own body—a lengthy and expensive process. Now, researchers are developing allogeneic (donor-based) or “off-the-shelf” CAR-T cells:

Made from healthy donor cells
Can be stored and used as needed
Less waiting time
Potentially more affordable and scalable

2. Drug-Free Remission Is Becoming Real

One patient with lupus has remained in drug-free remission for 4 years after a single CAR-T treatment. Another cancer patient was featured who has been in remission for 10+ years. While not yet considered a "cure," long-term remission is a huge breakthrough.

3. Safety Is Improving

While the process is intensive, most side effects are short-term and manageable:

Temporary use of steroids
Cytokine release syndrome (a type of immune reaction), usually mild
Local rashes or inflammation
Immune system recovery (especially B cells) happens quickly

Limitations You Should Know

Still Experimental : These therapies are currently only available through clinical trials.
Complex Process : Requires hospital stay, immune suppression, and careful monitoring.
Not a Cure : While remission is possible, it’s not guaranteed—and more data is needed.
Not Yet Widely Available : We're likely still a few years away from widespread access, though it’s progressing fast.

Discover More Of Our Resources

What Could This Mean for You?

Even if you’re not in one of the first clinical trial groups, this research gives us hope for the future. Here’s how it might impact your disease journey:

A single treatment instead of lifelong medications
More precise, personalized care
Fewer side effects from long-term immune suppression
Potential application to other AiArthritis diseases in the future

One exciting note: the team also mentioned ITP (immune thrombocytopenia) as a future target. I personally had ITP as a child, and it was a precursor to my lupus. It’s incredible to think that CAR-T might one day help people before full autoimmune disease develops.

Looking Ahead

We’re watching closely as this therapy expands beyond lupus and systemic sclerosis. The hope is that it can be adapted for more AiArthritis diseases—possibly within the next 5–10 years.

Thanks to Bristol Myers Squibb for sponsoring our “Go With Us” program so we can keep bringing you these updates. We’re proud to help you stay informed and empowered every step of your journey.

Go With Us Video Debrief

Debrief Video by: Leila P.L. Valete, Health Education Manager at AiArthritis

Lifestyle Modifications to Support Your Health Journey with AiArthritis Diseases

Sat, 19 Jul 2025 13:04:28 GMT

Lifestyle Modifications to Support Your Health Journey with Ai Arthritis Diseases

Autoimmune and autoinflammatory arthritis ( AiArthritis ) diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus , and axial spondyloarthritis , require a holistic approach to symptom management . While medications play a crucial role, lifestyle modifications can significantly improve overall well-being, reduce inflammation, and enhance mobility.

Understanding a holistic approach to treating AiArthritis Diseases

A holistic approach means looking at the bigger picture rather than focusing on just one aspect of a problem or condition. It considers the interconnectedness of physical, mental, emotional, and even social or environmental factors in achieving overall well-being. In healthcare, for example, a holistic approach means addressing not only symptoms but also lifestyle, nutrition, stress, and personal circumstances to create a more comprehensive and sustainable treatment plan. This perspective acknowledges that balance and wellness come from treating the whole person, not just isolated concerns.

This guide explores dietary changes, exercise routines, and stress reduction techniques tailored for those living with AiArthritis diseases.

Dietary Changes to Reduce Inflammation

Anti-Inflammatory Foods

Omega-3-rich foods – Fatty fish (salmon, mackerel), flaxseeds, and walnuts help reduce inflammation
Leafy greens – Spinach, kale, romaine lettuce and Swiss chard contain antioxidants that support immune health
Berries – Blueberries, strawberries, and raspberries provide anti-inflammatory compounds
Whole grains – Brown rice, quinoa, and oats help maintain stable blood sugar levels
Healthy fats – Olive oil, avocado, and nuts support joint health

Foods to Avoid

Processed foods – High in preservatives and inflammatory additives
Refined sugars – Can trigger inflammation and worsen symptoms
Excessive alcohol – May interfere with medications and increase inflammation
Red meat – Contains compounds that may contribute to joint pain

Hydration and Gut Health

Maintaining adequate hydration supports optimal joint lubrication and facilitates the body’s natural detoxification processes. Incorporating electrolytes enhances fluid absorption and ensures efficient muscular and neurological function.
Probiotic-rich foods (yogurt, kimchi, sauerkraut) help maintain gut health, which is linked to immune function

Who to see for help: A registered dietitian helps people with autoimmune and autoinflammatory arthritis by creating personalized nutrition plans to reduce inflammation, support joint health, and manage conditions like diabetes and obesity, which often coexist with arthritis.

Exercise Routines for Mobility and Strength

Low-Impact Exercises

Swimming – Reduces joint strain while improving flexibility
Yoga – Enhances mobility, balance, and relaxation
Walking – Helps maintain cardiovascular health without excessive joint stress
Cycling – Provides gentle movement for lower-body joints
Elliptical - Full body workout that reduces impact on the joints

Strength Training

Resistance bands – Improve muscle strength without excessive strain
Bodyweight exercises – Squats, lunges, and modified push-ups help maintain muscle tone
Physical therapy – Customized exercises to improve mobility and reduce stiffness

Stretching and Recovery

Daily stretching – Prevents stiffness and improves flexibility
Foam rolling – Helps relieve muscle tension and improve circulation
Hydrotherapy – Warm water exercises ease joint pain and stiffness

Who to see for help: A physical therapist guides patients through tailored exercises and movement strategies to improve mobility, reduce stiffness, and strengthen muscles, helping to prevent joint deterioration and maintain function.

Stress Reduction Techniques for Symptom Management

Mindfulness and Relaxation

Meditation – Helps reduce stress-related inflammation
Deep breathing exercises – Improve oxygen flow and relaxation
Guided imagery – Visualizing calm environments can ease pain perception

Sleep Optimization

Maintain a consistent sleep schedule to regulate immune function
Use supportive pillows and mattresses to reduce joint discomfort
Limit caffeine and screen time before bed to improve sleep quality

Emotional Well-Being

Join support groups to connect with others facing similar challenges
Practice gratitude journaling to shift focus toward positive experiences
Engage in hobbies that bring joy and relaxation

Who to see for help:

An occupational therapist works with patients to modify daily activities, recommend assistive devices, and develop strategies to maintain independence while managing pain and mobility limitations.
A social worker provides emotional and practical support, assisting patients in accessing healthcare resources, disability benefits, and coping strategies to navigate the challenges of chronic illness.
A psychiatrist addresses the mental health impact of arthritis, prescribing medications and offering therapeutic approaches for depression, anxiety, and other mood disorders linked to chronic pain and inflammation.
A psychologist helps patients process the emotional toll of living with arthritis through talk therapy, coping techniques, and behavioral strategies to improve mental well-being.
A counselor offers guidance and emotional support, helping patients develop resilience, manage stress, and improve communication in relationships affected by chronic illness.

Lifestyle modifications play a critical role in managing AiArthritis diseases. By incorporating anti-inflammatory nutrition, tailored exercise routines, and stress reduction techniques, individuals can enhance their quality of life and support long-term health.

Your path to managing autoimmune arthritis starts here. Explore the AiArthritis Patient Journey and access expert guidance, practical tools, and personalized resources for living your best life.

How to Support a Loved One with Autoimmune and Autoinflammatory Arthritis Diseases

Fri, 18 Jul 2025 22:30:23 GMT

How to Support a Loved One with Autoimmune and Autoinflammatory Arthritis Diseases

Autoimmune and autoinflammatory arthritis diseases ( AiArthritis Diseases ) can be physically and emotionally challenging for those affected. These conditions cause chronic pain, fatigue, mobility issues, and unpredictable flare-ups, making daily life difficult. As a friend, family member , or caregiver, your support can make a significant difference in their well-being.

Understanding Their Condition

Learn About Their Disease

Educate yourself on symptoms, treatments, and triggers to better understand their struggles.
Read reliable sources or ask their healthcare provider for guidance.
Understanding their condition helps you provide empathetic and informed support.

Recognize the Unpredictability

Symptoms can fluctuate daily, making it hard to plan ahead.
Be patient and flexible when making plans, as they may need to cancel last-minute.
Avoid frustration if they seem fine one day and struggle the next.

Validate Their Experience

Many AiArthritis diseases are invisible, meaning they may look fine but feel terrible.
Acknowledge their pain and fatigue without dismissing their concerns.
Saying “I believe you” can be incredibly powerful for someone who feels misunderstood.

Providing Emotional Support

Be a Good Listener

Let them express their frustrations without offering unsolicited advice.
Ask open-ended questions like, “ How are you feeling today? ”
Avoid minimizing their experience with phrases like “It could be worse” or “You don’t look sick”.

Offer Encouragement

Remind them that they are strong and resilient.
Celebrate small victories, like completing daily tasks despite pain or fatigue.
Send supportive messages or check in regularly to show you care.

Respect Their Boundaries

Some days, they may need rest and solitude rather than social interaction.
Avoid pressuring them into activities that may worsen their symptoms.
Understand that their energy levels may not match yours.

Helping with Daily Life

Assist with Physical Tasks

Offer help with grocery shopping, cooking, cleaning, or childcare .
Be mindful of their limitations and ask what they need rather than assuming.
Small gestures, like carrying heavy items or opening doors, can make a big difference.

Encourage Healthy Habits

Support t heir anti-inflammatory diet by cooking meals that align with their needs.
Join them in gentle exercises like yoga or swimming.
Help them stay hydrated and remind them to take breaks when needed.

Accommodate Their Needs in Social Settings

Choose accessible venues for gatherings.
Be understanding if they need to cancel plans due to a flare-up.
Offer alternatives, like virtual hangouts or quiet meetups, if large events are overwhelming.

Advocating for Their Health

Help with Medical Appointments

Offer to drive them to appointments or take notes during doctor visits.
Assist with medication reminders if needed.
Help them organize medical paperwork or insurance claims.

Support Their Treatment Choices

Respect their decisions regarding medications, therapies, and lifestyle changes.
Avoid pushing unproven remedies or dismissing their medical choices.
Encourage them to seek professional advice when needed.

Raise Awareness

Share information about their condition to help others understand.
Participate in fundraisers or advocacy efforts for autoimmune research.
Educate others about the challenges of living with an autoimmune disease.

Self-Care for Caregivers and Supporters

Supporting someone with a chronic illness can be emotionally demanding. Taking care of yourself ensures you can continue to provide meaningful support.

Set Boundaries

Offer help without overextending yourself.
Recognize when you need a break to recharge.

Seek Support

Join caregiver support groups or talk to others who understand.
Share your feelings with trusted friends or professionals.

Practice Self-Care

Engage in activities that bring you joy and relaxation.
Prioritize your own health and well-being.

Supporting a loved one with autoimmune or autoinflammatory arthritis require s patience, empathy, and adaptability . Small gestures—like listening, helping with daily tasks, and advocating for their needs—can make a profound impact on their quality of life.

Find patient-led programs, tools, and community support designed to help you navigate life with AiArthritis with confidence and connection. Download the Support Tool now.

Be part of the conversation with the AiArthritis Voices 360 Talk Show ! Explore diverse topics impacting autoimmune arthritis communities, featuring real patient stories and expert insights. Tune in to stay informed and inspired!

July 23: World Sjögren’s Day – Raising Awareness for a Complex Autoimmune Disease

Wed, 16 Jul 2025 13:20:26 GMT

July 23: World Sjögren’s Day – Raising Awareness for a Complex Autoimmune Disease

World Sjögren’s Day, observed annually on July 23, is dedicated to increasing awareness of Sjögren’s disease , an autoimmune condition that primarily affects moisture-producing glands, leading to dry eyes, dry mouth, joint pain, and systemic complications. The date was chosen to honor Dr. Henrik Sjögren, the Swedish ophthalmologist who first identified the disease.

The Sjögren’s Foundation created this awareness day to educate the public, advocate for better healthcare access, and support individuals living with Sjögren’s disease. April is Sjögren’s Awareness Month.

Learn more about The Sjögren’s Foundation and World Sjögren’s Day.

What Is Sjögren’s Disease?

Sjögren’s disease is a chronic autoimmune condition where the immune system mistakenly attacks the body’s moisture-producing glands, leading to dryness in the eyes, mouth, and other areas. It can also affect the thyroid, kidneys, liver, lungs, nerves, and joints, making it a systemic disease rather than just a localized condition.

Ai Arthritis Disease Symptoms

AiArthritis diseases share common features such as flares, where symptoms worsen for hours to months, and improvements with physical activity, while rest can make symptoms worse. Genetic predisposition or mutations can lead to these conditions running in families, and uncontrolled inflammation often results in comorbidities, affecting 70% of patients.

Key symptoms of AiArthritis diseases include:

Severe fatigue that persists despite rest or stimulants
Brain fog , making concentration difficult
Flu-like sensation s like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness , especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptl y

Common Symptoms of Sjögren’s Disease:

Dry eyes – Grittiness, irritation, and sensitivity to light.
Dry mouth and mouth sores – Difficulty swallowing, increased dental issues, and persistent thirst.
Swollen salivary glands – Can cause discomfort and difficulty eating.
Skin rashes and dryness – A result of immune system dysfunction.

Since symptoms vary widely, Sjögren’s disease is often misdiagnosed or overlooked , leading to delays in treatment.

How to Participate in World Sjögren’s Day

There are several ways to get involved in World Sjögren’s Day and support individuals living with this condition:

Spread Awareness

Share educational posts on social media using hashtags like #WorldSjögrensDay and #SjögrensAwareness and wear blue.
Talk to friends and family about Sjögren’s symptoms and challenges to foster understanding.
Encourage workplaces and schools to provide accommodations for individuals with Sjögren’s disease.

Share Your Story

If you or a loved one has Sjögren’s disease , talk about your journey to help others recognize symptoms and seek early diagnosis.
Write a blog post or create a video explaining how Sjögren’s impacts daily life.
Engage with patient advocacy groups to connect with others and share experiences.

World Sjögren’s Day on July 23 is an opportunity to educate, advocate, and support individuals living with this complex autoimmune disease. Sjögren’s disease is often misunderstood and misdiagnosed, making awareness and early intervention essential.

Dive into the AiArthritis Voices 360 Talk Show , where patient leaders, medical experts, and advocates join forces to discuss life with autoimmune and autoinflammatory arthritis. Don't miss these candid and empowering conversations!

Learn More About Sjögren’s Disease

July 10: Chronic Disease Awareness Day – Raising Awareness for Lifelong Conditions

Thu, 26 Jun 2025 11:37:00 GMT

July 10: Chronic Disease Awareness Day – Raising Awareness for Lifelong Conditions

Chronic Disease Awareness Day, observed annually on July 10, is dedicated to increasing public understanding of chronic illnesses, advocating for better healthcare access, and supporting those living with long-term health conditions. The date was chosen because 7 out of the top 10 leading causes of death in the United States are chronic diseases.

Autoimmune and autoinflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus , and axial spondyloarthritis , are chronic diseases that require lifelong management. This awareness day highlights the challenges faced by individuals with these conditions and encourages proactive healthcare measures.

What Are Chronic Diseases?

A chronic disease is a health condition that lasts one year or more, requires ongoing medical care, and may limit daily activities. Unlike acute illnesses, chronic diseases do not have a quick cure and often require long-term treatment and lifestyle adjustments.

Common chronic diseases include:

Autoimmune and autoinflammatory arthritis (RA, PsA, lupus, ankylosing spondylitis)
Diabetes
Heart disease
Cancer
Chronic respiratory diseases (asthma, COPD)
Neurological disorders (Alzheimer’s, Parkinson’s)

Chronic diseases can result from genetic factors, environmental influences, lifestyle choices, or immune system dysfunction. They often require multidisciplinary care, including medication, physical therapy, dietary changes, and mental health support. It's not uncommon for people with a chronic disease to have co-existing conditions.

Autoimmune and Autoinflammatory Arthritis as Chronic Diseases

Autoimmune and autoinflammatory arthritis are lifelong conditions where the immune system mistakenly attacks the body’s own tissues, leading to inflammation, joint damage, and systemic complications. With AiArthritis diseases there is potential organ involvement as some forms can affect the heart, lungs, and kidneys. Since these conditions do not have a cure, raising awareness on early diagnosis, treatment options, and patient support is crucial.

How to Participate in Chronic Disease Awareness Day

Chronic Disease Awareness Day is led by the national nonprofit advocacy organization Good Days , in partnership with more than two dozen national patient advocacy organizations. Their mission is to raise awareness, advocate for better healthcare access, and support individuals living with chronic illnesses through educational campaigns, policy forums, and community engagement.

Learn more about Chronic Disease Awareness Day

There are several ways to get involved in Chronic Disease Awareness Day and support individuals living with chronic illnesses:

Participate in the “I Stay Strong” Campaign

Write your reason for staying strong (e.g., “For my family” or “For my future”) on your palm.
Take a photo and post it on social media channels Facebook and Instagram using the official campaign hashtag #ChronicDiseaseDay
Tag three friends to encourage participation and raise awareness. You could be featured on ChronicDiseaseDay.org by doing this!

Spread Awareness

Share educational posts on social media using hashtags like #ChronicDiseaseDay and #AutoimmuneAwareness.
Talk to friends and family about chronic disease challenges to foster understanding.
Encourage workplaces and schools to provide accommodations for individuals with chronic illnesses.

Schedule a Wellness Checkup

Preventative healthcare is key in managing chronic diseases.
Book an annual checkup to monitor blood pressure, cholesterol, blood sugar levels, and inflammation markers.
Discuss early symptoms of autoimmune diseases with a doctor to ensure timely diagnosis.

Support Chronic Disease Advocacy Groups

Donate to organizations that fund research and patient support programs.
Volunteer for chronic disease awareness events in your community.
Sign petitions advocating for better healthcare policies and insurance coverage for chronic disease patient s.

Discover More Awareness Dates

Awareness Articles

Highlighting Schnitzler Syndrome: A Rare Autoinflammatory Disorder

Fri, 30 May 2025 11:20:05 GMT

Highlighting Schnitzler Syndrome : A Rare Autoinflammatory Disorder

Schnitzler Syndrome is a rare and underdiagnosed autoinflammatory disease first described by French dermatologist Liliane Schnitzler in 1972. It is characterized by a combination of chronic urticarial rash, monoclonal gammopathy (typically IgM), and systemic inflammation. This condition is considered a paradigm of acquired autoinflammatory diseases and poses significant challenges in diagnosis and management due to its rarity and complex presentation.

There are only about 300 or so known cases of Schnitzler in the world. Most of the reported cases of Schnitzler syndrome have been from Europe, particularly France, but cases from Australia, Japan and the United States have been reported too.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases )
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Clinical Features of Schnitzler Syndrome

Schnitzler Syndrome manifests with a range of symptoms, including:

Chronic Urticarial Rash: Persistent hives-like rash that does not respond to conventional antihistamines.
Monoclonal Gammopathy: Presence of monoclonal IgM (or occasionally IgG) in the blood, which is a hallmark of the disease.
Systemic Inflammation: Symptoms such as fever, joint pain, bone pain, muscle aches, and fatigue.
Enlarged Organs: Enlargement of lymph nodes, spleen, or liver may occur.
Laboratory Findings: Elevated inflammatory markers like ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), along with increased neutrophil counts.

Diagnosis

Diagnosing Schnitzler Syndrome requires a combination of clinical evaluation and laboratory tests. The Strasbourg Diagnostic Criteria are commonly used, which include:

Chronic urticarial rash.
Monoclonal IgM or IgG gammopathy.
At least two of the following: fever, bone pain, elevated ESR/CRP, neutrophilia, or abnormal bone imaging findings.

Due to its nonspecific symptoms, Schnitzler Syndrome is often misdiagnosed as other conditions like chronic urticaria or autoimmune diseases .

Treatment

The introduction of IL-1 receptor antagonists , such as anakinra, has revolutionized the treatment of Schnitzler Syndrome . Anakinra provides rapid relief from symptoms, often within hours of administration, and helps control systemic inflammation. However, continuous treatment is required, as symptoms typically recur upon discontinuation.

Other treatment options include:

Corticosteroids: May provide temporary relief but are less effective long-term.
Immunosuppressive Drugs: Often used in cases with severe systemic involvement.
Supportive Care: Management of complications like anemia or organ dysfunction.

Living with Schnitzler Syndrome

Patients with Schnitzler Syndrome face significant challenges in managing their condition. The chronic nature of the disease and its impact on quality of life necessitate a multidisciplinary approach, including:

Regular monitoring by specialists in dermatology, rheumatology, and hematology.
Psychological support to address the emotional toll of living with a rare disease.
Patient advocacy to raise awareness and improve access to effective treatments.

Research and Future Directions

Ongoing research into the pathophysiology of Schnitzler Syndrome focuses on the role of the NLRP3 inflammasome, a key component of the immune system involved in inflammation. Understanding this mechanism may lead to the development of targeted therapies and improved diagnostic tools.

Schnitzler Syndrome is a rare but impactful disease that requires early recognition and effective management to prevent complications and improve patient outcomes. Advances in treatment, particularly with IL-1 receptor antagonists, offer hope for those living with this challenging condition. Increased awareness among healthcare providers and patients is essential to ensure timely diagnosis and access to care.

Discover the AiArthritis Equation Project - AUTO + Inflammatory Arthritis = X OR YZ , a patient-led initiative aimed at improving early detection and diagnosis of autoimmune and autoinflammatory arthritis. By raising awareness of key symptoms and promoting timely referrals, this project empowers patients and healthcare providers to work together for faster, more accurate diagnoses.

Learn More About Schnitzler Syndrome

June 29: World Systemic Sclerosis (Scleroderma) Day

Wed, 21 May 2025 12:04:18 GMT

June 29: World Systemic Sclerosis (Scleroderma) Day

June is recognized as Scleroderma Awareness Month with a day to emphasize this AiArthritis Disease. Every year on June 29, the global community observes World Systemic Sclerosis (Scleroderma) Day, a day dedicated to raising awareness about this rare autoimmune disease and supporting those living with its challenges. The date honors the life of Swiss painter Paul Klee, who was diagnosed with scleroderma and passed away on June 29, 1940.

The sunflower is the international symbol of scleroderma because, just like sunflowers turn toward the sun for warmth and light, people living with scleroderma seek hope and resilience in their journey. It represents strength, perseverance, and the ability to find brightness even in difficult times.

TealTalk 2025 is set to be a powerful platform for advocacy, bringing the scleroderma community together for live conversations with special guests. Hosted by the National Scleroderma Foundation, this initiative aims to amplify voices, share personal stories, and drive awareness throughout Scleroderma Awareness Month. With a focus on education and advocacy, TealTalk will highlight the importance of recognition, research, and support for those affected by scleroderma.

Learn more about Teal Talk on the National Scleroderma Foundation webpage.

Artwork By Paul Kleen

Klee was diagnosed with scleroderma at 57 in 1936. His health declined, leading to his death in 1940. Despite decreased productivity after his diagnosis, he adapted his style and created over 1,000 works in his final years. His legacy not only inspires the art world but also reminds us of the resilience of individuals battling this condition.

What Is Systemic Sclerosis (Scleroderma)?

Systemic Sclerosis also known as Scleroderma , is a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues . Scleroderma, meaning “hard skin,” comes from the Greek words “sclero” (hard) and “derma” (skin), first named in the 18th century by Italian physician Carlo Curzio. The name refers to the thickening and hardening of the skin, the most visible feature of the disease. It was later discovered that this autoimmune disease can also affect internal organs through excessive collagen production.

Systemic Sclerosis can affect the skin, internal organs, blood vessels, and the immune system. While its exact cause remains unknown, it is linked to abnormal immune responses and overproduction of collagen, a protein that forms connective tissue.

There are two primary types of scleroderma:

Localized Scleroderma: Limited to the skin and sometimes underlying tissues; less severe but still impactful.
Systemic Scleroderma: Affects not only the skin but also vital organs such as the lungs, heart, kidneys, and digestive system, making it potentially life-threatening.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog , making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness , especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Systemic Sclerosis

Symptoms vary greatly among individuals but may include:

Hardening and tightening of the skin
Swelling and itchiness
Small red spots: (telangiectasia) on their hands and face
Calcium deposits: form under the skin, particularly at the fingertips, causing bumps that can be seen on X-rays
Raynaud's phenomenon: Fingers and toes that turn white or blue when exposed to cold or during stressful periods
Heartburn
Difficulty swallowing
Gastrointestinal symptoms: bloating, diarrhea, constipation, fecal incontinence
Shortness of breath
Decreased exercise tolerance
Dizziness
Pulmonary hypertension
Irregular heartbeat

Patient Perspective On Living With Systemic Sclerosis

World AiArthritis Day 2024 - Conversation with Scleroderma patient Demi Montgomery. Discover more of our Ai Arthritis 360 Talk Show here

The Significance of World Systemic Sclerosis (Scleroderma) Day

World Systemic Sclerosis (Scleroderma) Day serves several crucial purposes:

Awareness: Many people, including some healthcare professionals, may not fully understand the complexities of scleroderma. This day highlights the need for early diagnosis and comprehensive care.
Advocacy: Patients often face challenges related to access to affordable treatment and specialized care. The day encourages policy changes to support those with Systemic Sclerosis.
Support and Solidarity: The global community unites to show solidarity with patients, their families, and caregivers, letting them know they are not alone in their journey.
Research and Funding: The day underscores the need for ongoing research to uncover the underlying causes of Systemic Sclerosis and develop better treatments or a cure.

How to Participate in World Systemic Sclerosis (Scleroderma) Day

Raise Awareness: Share educational content on social media using hashtags like #WorldSclerodermaDay or #SclerodermaAwareness and #TealTalk
Attend or Host Events: Participate in virtual or in-person walks, seminars, or fundraisers to support scleroderma advocacy groups.
Support Patients: Reach out to someone living with scleroderma to offer encouragement or help in their daily life.
Donate: Contribute to organizations funding scleroderma research and providing resources for patients and caregivers.

The Path Forward

While Systemic Sclerosis remains an incurable disease, significant progress has been made in understanding its mechanisms and improving patient care. World Systemic Sclerosis (Scleroderma) Day is a reminder of the importance of continued advocacy, research, and support for those living with this condition. Working together, we can create a world where Systemic Sclerosis patients feel seen, supported, and hopeful for the future.

Volunteer Make a difference by joining the AiArthritis Volunteer Program . From advocacy to outreach, your skills and passion can help create positive change in the autoimmune arthritis community. Learn how to get involved at AiArthritis Volunteer.

Learn More About Systemic Sclerosis (Scleroderma)

Chronic Nonbacterial Osteomyelitis (CNO): A Rare Autoinflammatory Bone Disorder

Mon, 19 May 2025 11:57:21 GMT

Chronic Nonbacterial Osteomyelitis (CNO): A Rare Autoinflammatory Bone Disorder

Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO) are rare autoinflammatory diseases that cause bone inflammation without infection, leading to long-term pain and swelling. They primarily affect children and adolescents, though adults can also be diagnosed. CNO represents a spectrum of disease severity, with CRMO being the most severe form, involving recurrent and multifocal bone lesions. Thanks to advances in diagnostic techniques and growing awareness, these disorders are now more widely recognized.

First described in the 1970s, CNO and CRMO were identified when doctors observed recurring bone inflammation in children without bacterial infection. The term “osteomyelitis” refers to bone inflammation, while “nonbacterial” indicates no infection is involved. CRMO specifically highlights the recurring and multifocal nature of the disease, where symptoms flare and resolve over time. Over the years, CNO has become the broader term for nonbacterial bone inflammation, while CRMO describes its chronic, recurrent form.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog , making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Chronic Nonbacterial Osteomyelitis (CNO)

CNO/CRMO presents with a variety of symptoms, including:

Bone Pain: Persistent or recurrent pain in affected areas, often worsening at night.
Swelling and Tenderness: Localized swelling and tenderness over inflamed bones.
Fluid buildup around painful areas
Swollen, warm skin over painful bones
Thicker joint linings
Damage to cartilage
Sometimes linked with skin conditions like psoriasis or Crohn’s disease
Multifocal Lesions: In CRMO, inflammation may affect multiple bones simultaneously or sequentially, with common sites including the long bones, pelvis, spine, and clavicle.

Diagnosing Chronic Nonbacterial Osteomyelitis (CNO)

Diagnosing Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO) requires a combination of tests, as no single test can confirm these conditions. Rheumatologists use physical exams, blood tests (ESR, CRP), and imaging techniques, including X-rays, MRIs, CT scans, and nuclear bone scans. In some cases, bone biopsies help rule out infections or other causes. Family history of autoimmune or autoinflammatory disease is also considered to better assess risk factors.

Because CNO/CRMO symptoms overlap with infections, bone cancers, and other autoinflammatory disorders , diagnosis depends on excluding other conditions. While ACR and EULAR guidelines don’t offer specific criteria for CNO/CRMO, they emphasize the importance of thorough investigation to ensure accurate diagnosis and effective management.

Treatment of Chronic Nonbacterial Osteomyelitis (CNO)

Management of CNO/CRMO focuses on controlling inflammation, alleviating symptoms, and preventing long-term complications such as bone deformities. Treatment options include:

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Often the first-line therapy for reducing pain and inflammation.
Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate or sulfasalazine may be used in more severe cases.
Biologic Therapies: IL-1 inhibitors (e.g., anakinra) or TNF inhibitors (e.g., etanercept) are effective for patients with refractory disease.
Physical Therapy: Helps maintain mobility and prevent complications related to bone damage.

Living with CNO/CRMO

Patients with CNO/CRMO often face challenges related to chronic pain, reduced mobility, and emotional stress. A multidisciplinary approach involving rheumatologists, orthopedic specialists, and mental health professionals is essential for comprehensive care. Support groups and patient advocacy organizations can provide valuable resources and emotional support.

Research and Future Directions

Ongoing research aims to better understand the underlying mechanisms of CNO/CRMO and develop targeted therapies. Advances in genetic studies and cytokine signaling pathways offer hope for improved diagnostic tools and personalized treatment strategies.

CNO/CRMO is a complex and rare autoinflammatory disorder that requires early recognition and effective management to prevent complications and improve quality of life. Increased awareness among healthcare providers and patients is crucial for timely diagnosis and access to appropriate care. With continued research and advocacy, the outlook for individuals living with CNO/CRMO is steadily improving.

Check out AiArthritis RANT (Rheumatology Action Network Teams) , a platform where patients can raise their voices and advocate for change in the autoimmune and autoinflammatory arthritis community. Join the movement and turn passionate ideas into impactful action!

Learn More About Chronic Nonbacterial Osteomyelitis (CNO)

May 20: Behcet's Disease Awareness Day

Fri, 02 May 2025 18:23:22 GMT

May 20: Behcet's Awareness Day

Behcet's Disease Awareness Day: Highlighting a Rare but Life-Changing Condition

Every year on May 20th, Behcet's Disease Awareness Day serves as a vital platform to shed light on Behcet’s disease, a rare but serious autoinflammatory form of vasculitis. This day unites patients, caregivers, and advocates to educate others, promote understanding, and push for better care, treatment, and research efforts to improve the lives of those affected.

Learn more about Behcet’s Awareness Day

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

What Is Behcet’s Disease?

Behcet’s disease , also called Behcet’s syndrome, is a rare systemic condition that causes inflammation in blood vessels throughout the body. As a result, it can affect multiple organs and systems, with symptoms varying widely from person to person.

Common symptoms include:

Oral and genital ulcers: Painful, recurring sores are often among the earliest and most recognizable signs of Behcet’s disease.
Eye inflammation: Uveitis (inflammation of the eye) can lead to pain, blurred vision, redness, and potential vision loss if left untreated.
Skin lesions: These may include acne-like sores or tender red bumps.
Joint pain: Arthritis-like symptoms in knees, ankles, and other joints are common.
Gastrointestinal: In some cases, inflammation can affect the digestive tract
Neurological : Inflammation of the brain and spinal cord, with severe headaches, stiff neck, and fever in the brain, leading to more severe complications.
Lung involvement

Behcet’s disease is considered part of a group of rare autoimmune disorders known as vasculitis, in which the immune system attacks healthy blood vessels. Its exact cause remains unknown, though genetics and environmental factors are thought to play a role.

Who Is Affected by Behcet’s Disease?

Behcet’s disease is more prevalent in regions along the ancient “Silk Road,” such as the Middle East, Mediterranean, and Asia, but it can affect individuals worldwide. Most commonly diagnosed in young adults between ages 20 and 40, the condition impacts men and women, though its severity and manifestations may vary by gender.

Treatment and Management

While there is no cure for Behcet's disease, several treatment options can help control inflammation and manage symptoms:

Medications: These may include corticosteroids, immunosuppressants, and biologics to reduce inflammation and regulate immune activity.
Symptom-specific care: Topical treatments for ulcers, as well as eye drops for uveitis, can provide targeted relief.
Lifestyle changes: Stress management, a healthy diet, and avoiding known triggers may help reduce flare-ups.
Ongoing monitoring: Regular check-ups with specialists, such as rheumatologists or ophthalmologists, are crucial for comprehensive care.

The Importance of Behcet's Disease Awareness

Due to its rarity and the variability of symptoms, Behcet’s disease is often misdiagnosed or misunderstood. Many patients face years of uncertainty and improper treatment before receiving an accurate diagnosis.

Behcet's Disease Awareness Day emphasizes the importance of:

Increasing public and professional knowledge to shorten the time to diagnosis.
Encouraging early intervention , which can prevent or manage serious complications.
Educating patients and families about available treatments and resources.

Raising awareness also helps combat the isolation often felt by individuals with rare diseases, fostering a sense of connection and community.

Advocacy and Research

Behcet’s Disease Awareness Day also shines a spotlight on the need for:

Continued research funding to uncover the underlying causes of Behcet’s disease and develop new treatments.
Global collaboration among researchers, medical professionals, and patient organizations to improve care standards.
Support networks and advocacy groups to ensure those with Behcet’s disease feel empowered and understood.
The day encourages all stakeholders—patients, families, and allies—to speak up, share their experiences, and inspire action.

How You Can Get Involved

On May 20th, everyone has a role to play in supporting Behcet's Disease Awareness Day . Here’s how you can help:

Spread information on social media using hashtags like #BehcetsDiseaseAwareness and #BehcetsAwarenessDay.
Participate in events or campaigns organized by advocacy groups like the Vasculitis Foundation.
Contribute to research efforts by donating or volunteering with organizations dedicated to rare diseases.
Listen to and share stories of those living with Behcet’s disease to foster understanding and solidarity.

A Day to Amplify Voices

Behcet's Disease Awareness Day reminds us of the power of awareness, advocacy, and compassion. Together, we can work toward a future where this rare condition is better understood, diagnosed promptly, and treated effectively, giving hope to those who face its challenges.

Join the AiArthritis Conferences Program to gain insights into the latest research and advancements in autoimmune and autoinflammatory arthritis. This unique, patient-led initiative connects individuals to cutting-edge information, empowering them to improve their healthcare journeys and advocate for change.

Learn More About Behcet’s Disease

May 19: World IBD Day

Fri, 02 May 2025 17:58:38 GMT

May 19: World IBD Day

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Crohn’s Disease:

Persistent diarrhea
Abdominal pain and cramping
Blood in your stool
Mouth sores
Reduced appetite and weight loss
Urgent need to move bowels
Delayed growth and development in children
Eye complications: redness or pain in the eyes, or vision changes
Skin complications: bumps, sores, or rashes
Loss of normal menstrual cycle
Osteoporosis
Kidney stones

Learn More About Crohn's Disease

Joint Pain and Crohn’s Disease: An Overlooked Connection

Crohn’s disease is a chronic autoimmune condition that primarily affects the gastrointestinal (GI) tract, causing inflammation, abdominal pain, diarrhea, and fatigue. However, the inflammation isn’t confined to the GI system—it can extend to other parts of the body, including the joints. Up to 25% of people with Crohn’s disease experience joint pain, which may occur in one of two forms:

Peripheral Arthritis : Inflammation in joints like the knees, ankles, elbows, or wrists, often correlating with intestinal flare-ups. This type of arthritis tends to improve as Crohn’s disease comes under control.
Axial Spondyloarthritis : Chronic inflammation of the spine and sacroiliac joints (similar to ankylosing spondylitis), which may persist independently of GI symptoms. It can cause stiffness, pain, and reduced mobility .

Joint pain associated with Crohn’s can range from mild discomfort to debilitating inflammation, significantly impacting quality of life. It highlights the systemic nature of IBD and the importance of multidisciplinary care.

Challenges in Diagnosing and Managing Joint Pain

The relationship between Crohn’s disease and joint pain often complicates diagnosis and treatment:

Delayed recognition : Patients may not connect their joint symptoms to Crohn’s disease, and healthcare providers might focus exclusively on GI issues.
Overlapping conditions : Joint pain may stem from Crohn’s-related inflammation or separate conditions, such as osteoarthritis or fibromyalgia.
Impact on mobility : Persistent joint pain can make physical activity difficult, exacerbating fatigue and emotional distress.

Addressing joint pain requires coordinated care between gastroenterologists and rheumatologists to ensure comprehensive treatment.

Discover More Of Our Resources

Advocacy and Research for Crohn’s Disease and Joint Pain

World IBD Day emphasizes the need for:

Expanded research funding to explore the mechanisms linking Crohn’s disease to joint pain and develop targeted therapies.
Improved education for healthcare providers to recognize and treat extra-intestinal manifestations like joint pain.
Support networks that empower individuals with Crohn’s disease to advocate for better care and share their experiences.

Raising awareness about the systemic nature of Crohn’s disease fosters understanding and encourages multidisciplinary approaches to care.

How You Can Support World IBD Day

On May 19th, there are many ways to help spread awareness about Crohn’s disease and its joint-related complications:

Share information on social media, highlighting the link between IBD and joint pain using hashtags like #WorldIBDDay and #IBDawareness.
Participate in events organized by advocacy groups or local health organizations.
Donate to research initiatives focusing on innovative treatments for Crohn’s disease.
Wear purple to show solidarity with the IBD community.

A Call to Action

World IBD Day is a chance to amplify the voices of individuals living with Crohn’s disease and shed light on the lesser-known challenges, like joint pain. By fostering awareness, supporting research, and advocating for multidisciplinary care, we can work toward a future where IBD patients have access to better treatment options and the opportunity to live more comfortable lives.

Tune into the AiArthritis Voices 360 Talk Show , where patients, doctors, and advocates come together to discuss the latest in autoimmune and autoinflammatory arthritis. Join the conversation to learn, share, and make a difference in the world of arthritis care!

New Research on Vitamin D and T-Cells: How It Can Improve Patient Care in Autoimmune Diseases

Tue, 22 Apr 2025 13:03:53 GMT

New Research on Vitamin D and T-Cells: How It Can Improve Patient Care in Autoimmune Diseases

At the ACR 2024, new research has emerged that could significantly impact how we manage autoimmune diseases. From the essential role of vitamin D to groundbreaking findings on exhausted T-cells, this research is shedding light on ways to better understand, manage, and treat autoimmune conditions.

Here's a closer look at two sessions that could change the future of patient care.

Vitamin D: A Powerful Ally in Autoimmune Disease Management

In a session titled "Fun in the Sun: The Benefits of Vitamin D," several key findings about the role of vitamin D in autoimmune diseases were highlighted. Here’s how this research can improve patient care:

Vitamin D Deficiency and Autoimmune Disease:
Vitamin D deficiency is common in autoimmune diseases and is linked to more severe disease and worse outcomes. Regular monitoring of vitamin D levels can help adjust treatment plans accordingly.

Long-Term Benefits:
A study demonstrated that long-term use of 2,000 IUs of vitamin D per day can reduce the incidence of autoimmune diseases by 22% over five years. Although the benefits may dissipate after discontinuation, ongoing supplementation helps maintain vitamin D status and may contribute to better disease management.

Impact on Bone Health:
Vitamin D is vital for bone health, and it’s recommended for autoimmune disease patients to help prevent bone loss , even if the effect on disease activity is modest. As vitamin D also plays a role in immune regulation, ensuring adequate levels is essential for overall health.

Importance for Children:
Vitamin D is crucial in early life for immune system development. Deficiency in children can lead to lasting effects on immune function and increased susceptibility to infections, underscoring the importance of adequate vitamin D during prenatal development and early childhood.

Exhausted T-Cells: A New Biomarker for Personalized Treatment

Another exciting session focused on "Exhausted T-Cells and Their Role in Autoimmune Disease" introduced a breakthrough in personalized medicine. Here's what this could mean for patients:

What Are Exhausted T-Cells?
T-cells are essential white blood cells that play a crucial role in immune defense. However, prolonged activation can lead to "exhausted" T-cells, which lose their ability to function effectively. These exhausted cells are marked by specific markers, which could now be measured in patients.

T-Cells in Autoimmune Diseases:
Studies showed that Sjogren’s disease , rheumatoid arthritis (RA), and spondyloarthritis (SpA) patients exhibited higher levels of exhausted T-cells compared to healthy individuals. The higher the levels of these T-cells, the more likely it is that disease activity is present.

Predicting Response to Treatment:
Interestingly, patients with elevated exhausted T-cells responded better to anti-TNF therapies, a common treatment for RA and SpA. This discovery means that measuring these T-cells could help predict how well a patient will respond to specific therapies, enabling more tailored and effective treatment plans.

Improved Disease Monitoring:
The identification of exhausted T-cells as biomarkers could help in monitoring disease activity and adjusting treatments more accurately. This is particularly beneficial for conditions like Sjogren's, where disease progression is often slow and harder to track.

How This Research Can Improve Patient Care

These two studies represent significant steps forward in understanding and managing autoimmune diseases:

Personalized Medicine: By identifying biomarkers like exhausted T-cells, doctors can more accurately predict which treatments will work best for individual patients, reducing the trial-and-error approach often seen in autoimmune disease management.

Better Disease Management: With vitamin D playing a role in immune regulation and disease progression, ensuring adequate levels can help maintain better control over autoimmune symptoms and prevent complications like bone loss.

Empowering Patients: Armed with knowledge about vitamin D and T-cell biomarkers, patients can engage in more informed discussions with their healthcare providers, leading to more effective treatment plans.

What Patients Can Do

If you are living with an autoimmune disease, here’s how you can apply this research to improve your care:

Talk to Your Healthcare Provider About Vitamin D: Regularly check your vitamin D levels and ensure that you're taking an appropriate supplement if necessary. If you're experiencing symptoms related to vitamin D deficiency, discuss it with your doctor.

Explore Exhausted T-Cell Testing: Ask your rheumatologist about testing for exhausted T-cells to see how they might affect your disease activity and treatment response. This could lead to more personalized and effective therapies.

Looking Ahead

As we continue to advance our understanding of autoimmune diseases, these findings pave the way for better diagnostics, more personalized treatments, and improved patient outcomes. Patients, researchers, and healthcare providers are working together to ensure that these insights are applied in clinical settings, ultimately improving the lives of those affected by autoimmune conditions.

Go With Us Video Debrief

Leila, our Health Education Manager at AiArthritis, shares insights from her ACR 2024 debrief in this video. Key highlights include:

Vitamin D’s Role: Benefits for immune regulation and autoimmune disease outcomes.
T-Cell Exhaustion: Predicts responses to anti-TNF therapies for personalized medicine.

Leila provides actionable advice for patients on discussing vitamin D levels and exploring new biomarker tests. Stay informed and empowered!

Menopause and Rheumatic Diseases: Insights from ACR 2024 on Improving Patient Lives

Tue, 22 Apr 2025 12:48:54 GMT

Menopause and Rheumatic Diseases: Insights from ACR 2024 on Improving Patient Lives

Menopause can profoundly impact patients with rheumatic diseases, influencing symptoms, treatment outcomes, and overall quality of life. At ACR 2024, a session titled “ Transitioning Through Menopause: Implications for Patients with Rheumatic Diseases ” shed light on this critical topic.

Here’s how the latest research and insights can improve the lives of patients navigating menopause alongside rheumatic conditions.

Understanding Menopause in the Context of Rheumatic Diseases

Menopause is a natural biological transition, but for patients with rheumatic diseases, it often presents unique challenges. Key symptoms and their impact include:

Sleep Disturbances: A top concern for many, sleep issues exacerbate fatigue and can worsen disease management.
Mood Swings and Depression: Hormonal changes can amplify psychological distress, compounding the emotional toll of chronic illness.
Joint Pain: Frequently mistaken for flares, joint pain linked to menopause can complicate diagnosis and treatment.
Hot Flashes: These can significantly disrupt daily life, sometimes leading to chills due to excessive sweating.

Impact on Specific Rheumatic Diseases

Lupus (SLE):
Earlier Onset: Studies show that menopause may begin earlier in lupus patients, with an average age of 46.4 years.
Potential Symptom Improvement: Interestingly, lupus symptoms may improve post-menopause, providing hope for long-term relief.
Osteoporosis Risk: Increased bone fragility necessitates vigilant monitoring and preventative care.

Rheumatoid Arthritis (RA):
Bone Health: Accelerated bone loss and heightened osteoporosis risk are prevalent, requiring proactive management.
Inconclusive Data on Disease Activity: While menopause’s effect on RA severity varies, many patients report symptom exacerbation.

Managing Menopause-Related Challenges

The session highlighted a comprehensive approach to managing menopause in rheumatic diseases:

Lifestyle Adjustments:
Focus on nutrition, physical exercise , and reducing alcohol and tobacco use.
Engage in stress -reducing activities to support emotional well-being.
Hormone and Non-Hormone Therapies:
Short-term hormone replacement therapy (HRT) has shown promising results in reducing flares and improving quality of life in lupus and RA patients.
Non-hormonal options, such as low-dose paroxetine, gabapentin, and serotonin modulators, can alleviate symptoms like hot flashes and sleep disturbances.
Sexual Health:
Use lubricants, moisturizers, and even lidocaine to manage discomfort during intercourse.
Consider counseling to address the emotional and relational aspects of menopause.

Future Research Directions

One key takeaway is the need for more studies on menopause in AiArthritis Diseases. Understanding its impact can lead to tailored treatment options, such as:

Hormone therapies adjusted to individual risk factors like cardiovascular disease or breast cancer history.
Personalized care plans that address the unique needs of patients navigating both menopause and rheumatic conditions.

Empowering Patients Through Knowledge

Navigating menopause alongside AiArthritis Diseases can be daunting, but knowledge and proactive care can make a difference. Patients are encouraged to:

Communicate Symptoms: Share changes in mood, sleep, and joint pain with healthcare providers.
Explore Treatment Options: Discuss the benefits and risks of hormone and non-hormonal therapies.
Adopt Healthy Habits: Small lifestyle changes can mitigate the effects of menopause and support disease management.

Menopause is a significant, often under-discussed phase of life for patients with rheumatic diseases. The insights shared at ACR 2024 highlight the importance of comprehensive, patient-centered care. By addressing menopause-related challenges, we can empower patients to thrive through this transition, improving their overall health and quality of life

Go With Us Video Debrief

Dive into a vital topic for many: menopause in rheumatic diseases. From navigating hot flashes to managing joint pain and mood swings, I'll share everything I learned, including insights from leading experts like Dr. Sharon Parrish of Weill Cornell Medicine. Whether you're transitioning through menopause or supporting someone who is, this video breaks down the connections between menopause, lupus, RA, and more.

Discover innovation and collaboration at the AiArthritis Conferences Program , where patients and experts share knowledge to advance healthcare journeys and advocacy .

Exploring New Research: Transforming Lives Through Better Understanding and Treatment

Tue, 22 Apr 2025 12:20:05 GMT

Exploring New Research: Transforming Lives Through Better Understanding and Treatment

The ACR 2024 conference continues to shed light on groundbreaking research that has the potential to transform the way autoimmune diseases are understood and treated. Day two highlights focused on the relationship between obesity and autoimmune diseases, advancements in managing chronic pain, and individualized approaches to lupus nephritis care.

Here's how these findings can improve the lives of patients.

The Link Between Obesity and Autoimmune Diseases

One session delved into the prevalence of obesity in autoimmune diseases and its impact on inflammation. Highlights included:

Prevalence Rates:
14% of patients with lupus or rheumatoid arthritis (RA) are obese.
20% of those with psoriatic arthritis are obese, with obesity linked to a higher likelihood of developing this condition.
Actionable Insights:
Obesity exacerbates inflammation, making it a critical factor to address in autoimmune care.
Recommendations for managing obesity include discussing weight with providers, adopting a balanced diet, and incorporating exercise , though these can be challenging for those experiencing chronic symptoms like fatigue and pain.
A Call for Tailored Programs:
Current weight-loss strategies often fail to consider the unique challenges faced by autoimmune patients. Research highlights the need for specialized programs that accommodate these barriers, such as fatigue and physical limitations.

Managing Chronic Pain Through Self-Management

A presentation on the Stanford Chronic Pain Self-Management Program emphasized practical strategies to reduce pain-related disabilities, especially in older adults. Key takeaways included:

Personalized Pain Management:
The program equips patients with tools to track activities , manage rest, and schedule tasks around pain thresholds.
Patients were encouraged to prioritize time-oriented activities rather than pain-oriented responses, maintaining control over daily routines.
Real-Life Strategies:
Break tasks into smaller , manageable pieces.
Use timers to avoid overexertion.
Incorporate frequent changes in activities or body position to reduce strain.
Impact on Patients:
Participants reported significant reductions in pain-related disabilities, demonstrating that these self-management techniques can empower patients and improve their quality of life.

Personalized Care in Lupus Nephritis

The session on lupus nephritis explored how a tailored approach to treatment can make a difference in patient outcomes. Highlights included:

The Role of Kidney Biopsies:
Kidney biopsies remain the most reliable method for understanding the severity and progression of lupus nephritis, particularly when considering treatment changes.
While invasive, biopsies provide critical insights that help rheumatologists customize treatment plans.
Collaborative Decision-Making:
Patients are increasingly involved in choosing treatments based on personal preferences, including delivery methods (e.g., pills vs. infusions), family planning considerations, and tolerance to medications.
Future Alternatives:
Researchers are exploring non-invasive alternatives to kidney biopsies, which could revolutionize how lupus nephritis is monitored and treated.

How This Research Can Improve Lives

The advancements discussed at ACR 2024 highlight the potential for a more patient-centered approach to autoimmune care. By addressing obesity, providing tools for managing chronic pain, and personalizing treatments for lupus nephritis, this research paves the way for:

Improved Quality of Life:
Reducing inflammation and pain can enhance daily living for patients.
Better Health Outcomes:
Tailored care ensures treatments are more effective and aligned with patient needs.
Empowered Patients:
Providing tools and involving patients in decisions fosters autonomy and confidence in managing their health.

Looking Ahead

These insights underscore the importance of continued research and collaboration in autoimmune care. With a focus on tailored treatments and addressing often-overlooked aspects of health, such as obesity and chronic pain, we are on the path to better, more effective care for all.

Stay tuned for more updates from ACR 2024, and reach out with questions or comments about these findings. Together, we can support a brighter, healthier future for those living with autoimmune diseases.

Go With Us Video Debrief

Leila, Health Education Manager at AI Arthritis, shares highlights from Day 2 of the American College of Rheumatology (ACR) 2024 Conference. Learn about groundbreaking research on obesity's impact on autoimmune diseases, chronic pain management tips from Stanford's program, and insights into lupus nephritis care. Don't miss this in-depth look at how science is shaping the future for autoimmune patients.

May 10: World Lupus Day

Mon, 21 Apr 2025 16:11:42 GMT

May 10: World Lupus Day

On May 10th, people around the globe come together to observe World Lupus Day, a powerful initiative dedicated to raising awareness about S ystemic Lupus Erythematosus (SLE) , advocating for better care, and supporting ongoing research. This important day is an opportunity to educate the public, celebrate the resilience of those living with lupus, and push for advancements in treatment and understanding.

SLE, is also known as the “The Great Imitator” because the symptoms are often "imitating" other diseases.

Lupus derives from the Latin word for wolf because doctors described the rashes on the face as resembling a wolf’s bite. The full name, systemic lupus erythematosus, includes “erythematosus,” which means “reddened,” referring to the characteristic butterfly rash.

To learn more about World Lupus Day, visit the World Lupus Day website.

What Is Lupus?

Lupus, also known as Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition where the immune system mistakenly attacks the body’s healthy tissues and organs, leading to widespread inflammation. It can impact several areas of the body, including:

Skin: Common symptoms include rashes, especially the well-known “butterfly rash” across the cheeks.
Joints: Pain and swelling can resemble arthritis.
Kidneys: Lupus nephritis, a severe inflammation of the kidneys, can result in long-term complications.
Heart and Lungs: Inflammation can cause conditions like pericarditis (around the heart) or pleuritis (around the lungs).
Blood and Brain: Lupus may lead to anemia, clotting disorders, or neurological symptoms such as headaches, confusion, and memory challenges.

Other Symptoms of Lupus

While lupus symptoms can vary widely, common features include fatigue, joint pain, and sensitivity to sunlight. The unpredictable nature of the disease—marked by periods of flares and remission—makes it challenging for those affected.

Sensitivity to sunlight or fluorescent light, often causing rashes or lesions
Hair thinning or loss
Depression and anxiety
Raynaud’s phenomenon: Fingers and toes turning white or blue in response to cold or stress
Mouth sores

Lupus symptoms can vary widely, making early diagnosis and tailored management crucial for improving quality of life.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog , making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Who Does Lupus Affect?

An estimated 5 million people worldwide are living with lupus , and approximately 90% of those diagnosed are women. Lupus often develops between the ages of 15 and 45, though it can affect people of all ages, genders, and ethnicities. While its exact cause remains unknown, researchers believe it results from a combination of genetic predisposition, hormonal influences, and environmental triggers, such as infections or stress.

Why World Lupus Day Matters

Lupus is sometimes referred to as "the great imitator" because its symptoms often resemble those of other illnesses, leading to significant delays in diagnosis. On World Lupus Day , advocates strive to:

Raise awareness about the early signs and symptoms of lupus.
Improve access to care by advocating for patient-centered support and healthcare resources.
Break down stigma associated with invisible illnesses and chronic pain conditions.
Support research efforts to find better treatments and ultimately a cure.

For those living with lupus, the day is also a chance to amplify their voices and share personal stories to help others understand the challenges they face.

Advocacy and Progress

World Lupus Day is not only about raising awareness but also advocating for:

Increased funding for research to develop targeted therapies.
Collaboration among global health organizations to tackle disparities in lupus care.
Improved education for medical professionals to reduce diagnostic delays.

Additionally, community-focused initiatives foster hope and connection among those affected, reminding them that they are not alone.

How You Can Support World Lupus Day

There are many ways to make a difference on May 10th:

Share information : Use social media platforms to spread awareness using hashtags like #WorldLupusDay and #MakeLupusVisible
Participate in events : Join virtual webinars, fundraisers, or lupus awareness campaigns.
Donate to research organizations : Support foundations committed to finding better treatments and advancing understanding of lupus.
Wear purple : The color associated with lupus awareness, as a visible sign of solidarity.

World Lupus Day reminds us of the importance of coming together to support those living with lupus and advocate for meaningful change. By increasing understanding and driving progress, we can work toward a future where individuals with lupus have better tools to thrive and, ultimately, hope for a cure.

Learn More About Lupus

May 3: World Axial Spondylitis Day

Mon, 21 Apr 2025 15:25:21 GMT

May 3 : World Axial Spondylitis Day

Each year on the first Saturday of May (except when May 1st falls on that day), the global community unites to observe World Axial Spondylitis Day. This vital awareness day brings attention to axial spondylitis (AxSpA) , a chronic inflammatory condition that primarily affects the spine and sacroiliac joints, and seeks to empower patients, educate the public, and improve the quality of life for those living with the disease.

Learn more about Learn more about World Axial Spondylitis Day.

Understanding Axial Spondylitis

Axial spondylitis, also referred to as axial spondyloarthritis (AxSpA ), is a lifelong rheumatic disease that causes pain, stiffness, and inflammation in the spine and pelvis. It is classified into two forms:

Radiographic AxSpA (commonly known as ankylosing spondylitis): In this form, structural changes to the joints, visible via X-rays, are present.
Non-Radiographic AxSpA: In this type, there are no visible changes on imaging tests, though symptoms are just as debilitating.

What sets AxSpA apart is the gradual fusion of the spine in severe cases, leading to significant mobility limitations and an altered posture. Beyond the physical challenges, living with axial spondylitis often impacts emotional well-being, social life, and day-to-day activities.

Ai Arthritis Disease Symptoms

Symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog , making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms and Impact on Lives

Key symptoms include:

Lower back pain and stiffness in the hip joint
Enthesitis: inflammation of tendon or ligament
Uveitis: Inflammation inside the eye
Dactylitis: Inflammation in fingers and toes
Limited spinal flexibility

Axial spondylitis typically develops in young adults, often beginning in late teens or early twenties, and disproportionately affects men compared to women. Due to its subtle and progressive nature, it often goes undiagnosed for years, delaying treatment and exacerbating long-term complications.

The Importance of Early Diagnosis

One of the critical goals of World Axial Spondylitis Day is to promote early detection and diagnosis. A prompt diagnosis can make an enormous difference in managing the disease's progression and improving outcomes. Specialized imaging, such as MRI, along with inflammatory markers and clinical evaluation, can help confirm the presence of AxSpA.

The delay in diagnosis, which can average between 7 to 10 years, underscores the need for greater awareness—both among healthcare professionals and the public. Increased recognition of early signs can lead to earlier referrals to rheumatologists and appropriate interventions.

Treatment Options and Support

While there is currently no cure for axial spondylitis, various treatments can help manage symptoms and improve quality of life:

Medications: Nonsteroidal anti-inflammatory drugs (NSAIDs), biologics (such as TNF inhibitors and IL-17 inhibitors), and pain relievers help reduce inflammation and manage pain.
Physical therapy and exercise: Regular movement and tailored physiotherapy play a crucial role in maintaining flexibility and posture.
Lifestyle changes : Healthy eating, stress management, and quitting smoking can help alleviate symptoms and prevent complications.
Support groups: Connecting with others who understand the condition fosters a sense of community and emotional well-being.

Advocating for Change

World Axial Spondylitis Day also serves as a platform to advocate for better access to healthcare, advanced treatments, and patient-centered support systems. People living with axial spondylitis often face barriers with accessing specialist care, affordable treatment, and workplace accommodations. Advocates work tirelessly to reduce these challenges and improve outcomes globally.

Moreover, addressing misconceptions about axial spondylitis is vital. Many people misunderstand it as simply "back pain," when it is, in fact, a systemic disease that affects multiple aspects of life. Educational campaigns and storytelling by patients help shed light on the reality of AxSpA.

How to Get Involved

On May 3, there are numerous ways to participate in World Axial Spondylitis Day and help spread awareness:

Share educational materials on social media using hashtags like #WorldAxialSpondylitisDay and #AxSpA.
The Spondylitis Association of America is hosting their 7th Annual Global Spondyloarthritis Summit on May 2nd and 23rd. Learn more here
Support advocacy efforts by signing petitions, donating to research, or volunteering with patient organizations.
Talk to friends and family about axial spondylitis, helping dispel myths and encourage understanding.

A Call to Action

World Axial Spondylitis Day is more than a calendar date, it’s a powerful reminder to amplify the voices of patients, promote early diagnosis, and advocate for better care. This year, let’s stand together to make a difference for the millions worldwide who live with this challenging disease.

To learn more about World Axial Spondylitis Day, visit the Spondylitis Association of America’s website.

Learn more about Axial Spondyloarthritis

Mark your calendar and join us in raising awareness—discover key arthritis awareness days that unite patients, advocates, and allies.

Beyond Medications: The Impact of Occupational Therapy on My AiArthritis Management

Mon, 21 Apr 2025 14:22:01 GMT

Beyond Medications: The Impact of Occupational Therapy on My Ai Arthritis Management

AiArthritis diseases are so much more than joint pain. They require an integrative team to treat the many forms of arthritis effectively.

April is Occupational Therapy Month, a time to celebrate occupational therapists who empower people to overcome challenges and live independently. It’s also an opportunity to raise awareness about this essential healthcare field and its transformative impact.

Diagnosed with rheumatoid arthritis at the young age of 29, it's difficult to find an aspect of my life that hasn't been impacted by this disease. As a single mother , the unrelenting fatigue can make caring for myself and my child feel like a daily mountain to climb. Pain can turn simple tasks like washing my face or vacuuming into painful ordeals, and a shower can leave me needing a nap. Medications and inflammation can cause fogginess and forgetfulness. Every day I walk a fine line between doing too much or too little, both of which can aggravate my arthritis symptoms.

Rheumatologists can prescribe medications and explain our diseases, but they can't fully guide us on how to adapt and live well with arthritis outside of their medical scope. They are crucial in referring us to the right care providers we need beyond their expertise.

The daily struggles I face are incredibly common among arthritis patients. Before, I felt alone in how arthritis w as affecting me each day, but that is far from the truth. Occupational therapy helps us better perform daily activities, maintain independence, and achieve a better overall quality of life by protecting inflamed and painful joints and addressing other debilitating AiArthritis disease symptoms.

My Experience with Occupational Therapy

My journey with occupational therapy has evolved over the years. From being devastated to becoming a patient leader, eight years into my diagnosis, I am now a well-known rheumatoid arthritis patient advocate, writer, speaker, support group host, and patient partner in health research and steering committees. I owe much of my understanding, navigation, and thriving as an advocate, mother, and person living with arthritis to occupational therapy.

Occupational therapists play a critical role in self-management, a crucial part of living well with any chronic illness. While rheumatologists focus on medical treatments, OTs provide practical advice on making daily life easier with an AiArthritis disease. Physical therapists and occupational therapists have been invaluable in managing my AiArthritis disease.

Beyond Work-Related Assistance

Initially, I thought OTs were only for work-related advice, but I soon learned that "occupational" refers to all the activities we need, like, and want to do—from parenting to socializing, house chores, sex lives, and work- life balance. The role of an OT is endless, much like our journey with an AiArthritis disease.

The Accessibility Problem

Unfortunately, not everyone with arthritis has timely access to occupational therapy, especially those in rural areas or facing financial or language barriers. Some rheumatologists also fail to inform patients about OT referrals. It's crucial to refer newly diagnosed patients and those throughout their arthritis journey to an OT to provide customized support and care.

Small Changes, Big Impact

One of the simplest yet most effective pieces of advice from an OT was to place my most-used items within arm's reach to reduce joint pain and overuse. These joint protection strategies help avoid overusing joints, reduce fatigue triggers, and prevent further injury. Shelving my daily used items for easy access has significantly reduced my pain and cognitive dysfunction, simplifying my daily routine even when feeling foggy or forgetful.

Prioritizing, Pacing, Positioning, and Planning

OTs emphasize the importance of prioritizing, pacing, positioning, and planning to manage arthritis effectively. Prioritizing what truly matters, pacing activities to manage symptoms, maintaining proper ergonomics, and planning daily tasks around peak energy times are crucial strategies that have transformed my life.

Understanding Pain Mechanisms

Occupational therapy helps us understand pain mechanisms and provides tools, techniques, and exercises for pain alleviation. For example, I learned that applying too much heat to inflamed joints was more harmful than beneficial; instead, using ice and minimizing heat helped reduce inflammation.

Navigating Assistive Devices

Choosing the right assistive devices can be overwhelming. OTs guide us in selecting cost-effective, high-quality equipment that reduces joint stress and improves daily functioning. From electric can openers to jar openers, raised toilet seats, and more, OTs help identify the best tools for our needs.

A Critical Role in My Care Team

Occupational therapists provide unique care and expertise essential for managing AiArthritis disease . Their practical advice and easy-to-understand knowledge make them invaluable members of my healthcare team.

In conclusion, occupational therapists are unsung heroes in my AiArthritis disease care team. Their support and guidance have been instrumental in helping me navigate life with an AiArthritis disease, achieving a better quality of life, and thriving as an advocate and mother.

Discover Our Patient Journey Resources

Navigate every phase of life with autoimmune and autoinflammatory arthritis through the AiArthritis Patient Journey ! From diagnosis to daily living, discover empowering tools, resources, and insights crafted to support you at every step.

What Stress Does to My AiArthritis Disease and How I Deal With It

Mon, 21 Apr 2025 13:47:29 GMT

What Stress Does to My Ai Arthritis Disease and How I Deal With It

Living with a chronic illness like autoimmune and autoinflammatory arthritis, I try to avoid stress as much as possible. However, stress is not always avoidable. In fact, living with these conditions itself is quite stressful and all that stress significantly impacts my emotional and physical wellbeing. Stress has the ability to put me into a flare, and with autoimmune and autoinflammatory arthritis being progressive systemic diseases, that's a big deal to me.

Chronic illness itself brings a whole new level of stress that someone healthy wouldn’t fully understand. Juggling appointments, overcoming needle or medical test phobias, navigating self-management through debilitating symptoms, the impact chronic illness has on our social lives, and of course, the financial burden that comes with a chronic illness. It’s safe to say the average healthy person wouldn’t understand the unique stress that comes with living with chronic illness.

I am a single mom on disability living in one of the most expensive cities in North America. Not only is rent soaring high, but the cost of living is increasing all the time, while disability pay stays the same, which is below the poverty line. Finances are always my main stressor, next to how autoimmune and autoinflammatory arthritis impact the quality of my life. I say finances come first because if I had better finances, I would more than likely have the ability to live healthier with these diseases.

The Mental Impact of Stress on My Life

Stress often leaves me irritable, angry, impatient, overwhelmed, and anxious. I become uninterested in life, lose the ability to concentrate because my thoughts are racing in a million directions, have difficulty making decisions, my memory worsens, I find it hard to enjoy life and feel insecure. Stress causes me to eat too much or too little, clench my jaw, become restless, and not exercise as much as I need to. I often withdraw from friends, family, or any other engagements.

Stress is a constant presence in my life and if I don’t do something about it, it can consume me, leaving me trapped and paralyzed with intrusive thoughts. What’s even worse, stress can cause a lot of uncomfortable symptoms and make my arthritis worse.

What Stress with Chronic Pain Feels Like

Stress is a vicious cycle for our bodies, especially when living with a disease that causes widespread chronic pain. The fact that stress causes more pain is stressful itself.

Stress has the ability to impact our nervous system. When our nervous system is impacted by stress, it causes us to feel tense, which can lead to painful muscle spasms. This aggravates joints and causes higher fatigue. Let's not forget that stress also increases anxiety and depression, which worsen the perception of pain.

When I am stressed, I feel my breath quicken, my heart rate increase, and my muscles tense up. I can feel myself getting warm and my body stiffens. This can increase tension in our muscles and amplify our arthritis pain. If a stressful event happens one day, I will have a massive spike in fatigue within hours and it can impact my ability to function for a few days. I’m left groggy and fatigued. Stress can stop me in my tracks and leave me feeling paralyzed by it.

Stress has caused me many symptoms including hair loss, cold sores, cystic acne, muscle weakness and tension, headaches, increased pain, insomnia, and crushing depression or anxiety that consumes me. Stress even causes me to gain weight suddenly, either by a chemical imbalance or because stress often makes me crave unhealthy foods or coping mechanisms like cannabis, alcohol, or excessive shopping. A huge part of my financial stress as someone getting by on disability means I often can’t afford the healthiest groceries to combat my illness, which is not good for my overall well-being either.

Not just that, but stress also affects you on a mental level, making you less resilient and able to deal with the symptoms of your disease. The longer the stress, the worse the inflammation and impact on your immune system. I don’t need a doctor to tell me this, I’ve felt the physical response to stress and it can be debilitating with autoimmune and autoinflammatory arthritis.

This is because stress works on a physical level by increasing levels of the hormone cortisol in your body, which triggers the immune system hyperactivity that is the hallmark of inflammatory types of arthritis while also reducing your immune system’s ability to fight off harmful germs. After prolonged stress, I can find myself sick and have a difficult time recovering.

So yes, stress makes our arthritis worse. It makes everything worse. Stress sucks.

How I Deal With Stress

Ask for Help: I can’t control everything, however, I can control how I respond to things, to some degree. Being proactive, realistic, and productive helps me eliminate some stress. I definitely can’t completely get rid of stress, at least not until I win the lottery and they find a cure for this disease. Asking for help from people I know who are supportive and trustworthy is crucial. My support network is essential.

Say No: Learning to say no when I need to was a lesson for me. I am a people pleaser, I want to make everyone happy, but doing so can cause me a lot of stress. If I know it will overwhelm me, put me into a flare, or throw me off my self-care management, I may need to say no. It is okay to be highly protective of your time and energy.

Pace Yourself: Chronic illness is bumpy and I move at an arthritic speed. I make an attempt to remind myself that I am living with a debilitating illness and not to feel guilty about that if I need to ask for an extension or cannot be present at the moment because life is getting too overwhelming. I will tell my editors, researchers, clinicians, media companies, or whoever I am collaborating with when I need more time and that I may need reminders.

Stay Organized: I make a point to stay as organized as I can possibly be. I write everything down: my thoughts, my concerns, my to-do lists, and so on. This helps me remember them easier and create an action plan when needed.

Plan Ahead: After several years of living with these diseases and knowing how stress can impact me, I try my best to plan ahead to avoid any surprises. Not always possible, but certainly helpful.

Have a Good Cry and Swear: Sometimes things just get to be too much and you need to cry and swear your frustrations out. I am a big fan of swearing, and research has proven it does relieve stress. Again, stress sucks.

Let Go of Guilt: I remind myself that what I go through is not my fault. I do my best to try to remove as many emotions of guilt that come with living with a chronic illness. They do me no good. I’m not always successful at this, but I do make a point to try to rationalize my negative emotions.

Keep Moving and Take Time to Breathe: Even though stress paralyzes me in my tracks, I need to make sure to keep moving as it does help alleviate pain and how I handle stress. This is because our body releases feel-good chemicals called endorphins when we regularly exercise.

I don’t just exercise one way, I will hike, swim, use my treadmill, the elliptical at the gym, strength train, or do gardening. When stressed, I try to do the exercises I enjoy the most.

Yoga is a great movement when stressed because it also incorporates deep breathing. When I feel overwhelmed with stress, I make a point to sit quietly for a few minutes and focus on breathing deeply as this does help put my body into a calmer state, even if just mildly, it helps.

Eat Healthy: I do the best with what I have, of course, inflation is making this more and more difficult as prices increase. Avoiding sugar and processed foods when stressed can make a difference.

Get Out into Nature: Did you know that stress can be partially relieved when exposed to nature? Nature has the ability to reduce our stress, which is measured by muscle tension, blood pressure, and brain activity. This happens because nature spaces work by reducing that pesky inflammation-promoting hormone cortisol and instead boost endorphins and dopamine production.

Cuddle a Pet: I have four cats for this. The squishy chonks really hit the spot when I cuddle them.

See a Therapist and Your Doctor: If stress is consuming you, there is no shame in reaching out for help from a professional. You may benefit from Cognitive Behavioral Therapy, which aims to help you reframe the issues that are causing your worry and can help guide you to deal with them in a more positive light.

National Stress Awareness Month

April is recognized as National Stress Awareness Month, a time dedicated to raising awareness about the negative impact of stress and promoting effective stress management strategies. Since 1992, this month has been an opportunity for open conversations about the causes and cures for our modern-day stress epidemic. Stress Awareness Month encourages individuals to recognize the difference between good and bad stress and to find healthy ways to manage it.

During this month, various organizations and healthcare professionals provide resources and support to help people cope with stress. Activities such as meditation, exercise, and spending time in nature are promoted as effective ways to reduce stress levels. By becoming more aware of stress and learning to apply coping mechanisms, individuals can improve their overall well-being and lead healthier, more balanced lives

Got Something To Say?

Check out AiArthritis RANT (Rheumatology Action Network Teams) , a platform where patients can raise their voices and advocate for change in the autoimmune and autoinflammatory arthritis community. Join the movement and turn passionate ideas into impactful action!

Advancing Sjögren's Disease Research: A Hopeful Future for Patients

Sat, 12 Apr 2025 12:05:20 GMT

Advancing Sjögren's Disease Research: A Hopeful Future for Patients

Challenges in Sjögren's Disease Treatment

Dr. Alan Baer of Johns Hopkins University highlighted significant hurdles in advancing therapies for Sjogren’s disease, including:

Discrepancy in Disease Measurement:
Tools like the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and the EULAR Patient Reported Index (ESSPRI) often fail to align, complicating evaluations in clinical trials.
Slow Disease Progression:
The gradual nature of Sjögren's progression limits the ability to detect meaningful outcomes within typical clinical trial timelines.
Limited Inclusion in Trials:
Many trials exclude seronegative patients, reducing the applicability of findings to the broader patient population

Despite these challenges, the focus on patient-reported outcomes and systemic symptoms is a step forward, aiming to address both the immediate and long-term impacts of the disease.

Novel Imaging Techniques for Earlier Diagnosis

Dr. Josevar from Slovenia presented promising advancements in imaging technology:

Ultrasound of Salivary Glands:
This technique shows potential in diagnosing Sjögren's earlier and tracking disease progression.
However, it must be combined with other clinical and histological assessments for accuracy.
MRI and Sialendoscopy:
These methods are being explored to detect changes in salivary glands that are not visible with traditional techniques.

While imaging advancements are promising, they remain focused on glandular symptoms, underscoring the need for tools that also capture systemic manifestations of the disease.

Discover More Of Our Resources

Progress in Clinical Trials

Dr. George Bruin from the Netherlands reviewed two decades of clinical trials, highlighting both setbacks and progress:

Past Challenges:
Many trials failed to demonstrate significant improvements in symptoms or biological markers.
A robust placebo effect in studies further complicated the evaluation of drug efficacy.
Current Optimism:
Over 20 trials are now underway, with three reaching phase three—indicating promising results that warrant further study.
Pharmaceutical companies are prioritizing autoimmune diseases, suggesting increased resources for Sjögren's research.

One audience member insightfully noted that longer trials may be needed to capture the full therapeutic effects, particularly in a slowly progressing disease like Sjögren's.

What This Means for Patients

The renewed focus on Sjögren's disease brings hope to patients:

Earlier Diagnosis:
Imaging advancements could reduce diagnostic delays, enabling earlier intervention and better management of symptoms.
Better Understanding of Systemic Symptoms:
Tools that incorporate both glandular and systemic involvement may provide a more holistic picture of the disease.
Potential New Treatments:
The progress in clinical trials, particularly those reaching phase three, suggests that new therapies tailored to Sjogren’s unique challenges may soon be within reach.

Learn More About Sjögren's Disease

A Call for Cautious Optimism

While these advancements are exciting, researchers emphasize the need for measured expectations. As clinical trials evolve and diagnostic tools improve, patients should remain hopeful but understand that significant breakthroughs take time.

A Brighter Future for Sjögren's Research

The growing interest in Sjögren's, evidenced by packed sessions at ACR 2024, signals a shift in the attention given to this often-overlooked disease. With continued collaboration between researchers, clinicians, and patients, the path forward looks promising. Together, we can foster a future where those living with Sjogren’s receive the care, understanding, and support they deserve.

Go With Us Video Debrief

Advancing Care Through Research: How New Findings Are Improving Patient Lives

Thu, 10 Apr 2025 23:52:28 GMT

Advancing Care Through Research: How New Findings Are Improving Patient Lives

Precision Treatment for Lupus Through Biomarkers

A groundbreaking session titled "Genetic and Phenotypic Spectrum of SLE Across the Ages" showcased the potential of genetic and cellular markers in revolutionizing lupus care. Here’s how:

Biomarker-Based Clusters: Researchers are using mitochondrial DNA, red blood cells, kidney biopsies, and even stool samples to classify lupus patients into clusters. These clusters help predict disease severity, treatment response, and potential comorbidities, such as macrophage activation syndrome.
Reduced Trial and Error: With biomarker identification, treatments can be customized, reducing the frustration of ineffective medications and adverse reactions.
Hope for the Future: This shift toward precision medicine ensures that therapies are tailored to individual needs, offering a more efficient and targeted approach to managing lupus and related conditions.

Improved Collaboration for Managing Interstitial Lung Disease (ILD)

A session titled "Conversations in Autoimmune-Associated ILD: The Patient Journey and Physician Perspective" emphasized the importance of multidisciplinary collaboration in treating ILD, which frequently affects patients with autoimmune conditions like scleroderma, Sjogren’s disease, and rheumatoid arthritis.

Key Indicators of ILD: Symptoms such as fatigue, shortness of breath, dry cough, and lung crackles can signal the onset of ILD. However, not all cases present with these early signs, necessitating regular monitoring by rheumatologists.
Essential Diagnostic Tests: For suspected ILD, three primary tests were highlighted:
High-Resolution CT Scan
Pulmonary Function Test
Six-Minute Walk Test These tests provide critical information for pulmonologists to diagnose and develop treatment plans.
Collaboration Is Key: The session stressed the need for rheumatologists and pulmonologists to work closely. Rheumatologists must recognize the diseases linked to ILD and include regular screenings in patient care. Early detection and timely referrals ensure effective management of both ILD and the underlying autoimmune condition.

Discover More Of Our Resources

The Bigger Picture: How These Findings Transform Patient Lives

These advancements are more than scientific breakthroughs—they represent hope for patients. By leveraging biomarkers and fostering collaboration across specialties, healthcare providers can:

Deliver Personalized Care: Tailored treatments improve outcomes and minimize unnecessary side effects.
Enhance Early Detection: Proactive monitoring leads to quicker diagnoses and interventions.
Improve Quality of Life: With better tools and strategies, patients can enjoy more stability and less disruption in their health journeys.

A Patient-Centric Future

The progress seen at ACR 2024 is a testament to the power of research and collaboration. As we continue to explore the micro-level complexities of diseases like lupus and ILD, the vision of a future with more precise, accessible, and effective care is becoming a reality.

Patients can take comfort in knowing that these efforts aim to not just manage but truly enhance their quality of life. Stay tuned for more updates as research drives us toward a brighter, healthier future.

Go With Us Video Debrief

Cell Therapy: A Promising Horizon for Autoimmune Disease Treatment

Tue, 08 Apr 2025 13:19:44 GMT

Cell Therapy: A Promising Horizon for Autoimmune Disease Treatment

What Is Cell Therapy?

Cell therapy involves using a patient’s own cells or donor cells to reset the immune system. Unlike current biologics, which often require long-term use and don’t always prevent disease flares, cell therapies aim to achieve remission—complete and lasting disease inactivity.

Two key approaches were presented at ACR 2024:

CAR-T Therapy: Resetting the Immune System

Presented by Bristol Myers Squibb , CAR-T therapy is a process where:

T-cells are extracted: A patient’s T-cells are drawn and sent to a lab.
Modified and reintroduced: These cells are modified and infused back into the body after mild chemotherapy depletes existing B-cells.
Resetting the immune system: The therapy provides a “reset,” drastically reducing or eliminating disease activity.

Impact for Patients:

Remission as the Goal: Nearly all patients treated in studies achieved remission, with some cases reporting sustained remission for over five years.
Cancer Inspiration: Originally developed for lymphoma, CAR-T therapy has been life-changing for cancer patients and is now bringing similar hope to those with autoimmune diseases.

Donor Cell Therapy: A Non-Hospitalized Approach

Developed by RTV, this therapy uses donor cells from umbilical cord blood. The approach differs in several ways:

No chemotherapy required: Unlike CAR-T therapy, there’s no need for chemotherapy to deplete existing cells.
Outpatient administration: This therapy can be performed without hospitalization, making it more accessible and less disruptive for patients.

Impact for Patients:

Simpler Treatment: The lack of hospitalization and chemotherapy means fewer risks and a faster recovery time.
Versatility: This therapy is being tested for lupus, both with and without nephritis (kidney involvement).

What Makes Cell Therapy Revolutionary?

Achieving Remission:

Patients who undergo cell therapy often experience complete remission, a term rarely used in autoimmune care.

A “One-Time” Treatment?

Unlike ongoing biologic therapies, cell therapy could potentially be a one-time or occasional treatment, reducing the need for continuous medication.

Long-Term Benefits:

Current data shows sustained remission in patients who received these therapies years ago, but longer-term studies are needed.

Challenges Ahead

While cell therapy brings immense promise, several hurdles must be addressed:

Cost and Accessibility:

These treatments are expected to be expensive, and questions remain about how healthcare systems will make them accessible.

Duration of Effectiveness:

It’s unclear how long remission will last—whether it’s one treatment in a lifetime or multiple treatments.

Equity in Access:

Ensuring patients worldwide, regardless of socioeconomic status, can benefit from these therapies is a priority for future research and policy.

What This Means for Patients

The development of cell therapy signals a shift in how autoimmune diseases are managed:

Hope for a Cure: For the first time, the word “cure” is entering discussions about autoimmune diseases.
Less Burden: A potential reduction in the need for daily or monthly medications could significantly improve the quality of life for patients.
A Bright Future: With ongoing clinical trials and a growing body of evidence, cell therapy is becoming a tangible reality for many.

Looking Ahead

While much remains to be studied, the advancements in cell therapy represent a beacon of hope for the autoimmune community. With continued research, collaboration, and advocacy, these therapies could redefine what it means to live with an autoimmune disease.

Stay tuned as researchers and organizations like AiArthritis work to bring these groundbreaking therapies closer to reality for patients everywhere.

Watch The Go With Us Video Debrief

Crushing Fatigue & Brain Fog: Must-Know Insights from Rheumatic Disease Experts | ACR 2024 with Deb

Tue, 08 Apr 2025 10:18:26 GMT

Crushing Fatigue & Brain Fog: Must-Know Insights from Rheumatic Disease Experts | ACR 2024 with Deb

Fatigue: The Overlooked Burden

What It Is: Fatigue is one of the most common and debilitating symptoms of rheumatic diseases, but it is often misunderstood or dismissed during medical consultations.

Expert Insights: The panel stressed that fatigue is not just “feeling tired”—it is a relentless, physical and mental exhaustion that is not relieved by rest. Many patients are told to simply "power through," but experts emphasized the importance of personalized management strategies. Addressing fatigue is not a one-size-fits-all approach—it requires understanding the underlying causes, like inflammation, sleep disturbances, or medication side effects.

Why It Matters: Better fatigue management could enable patients to improve their quality of life by restoring energy for work, family, and social engagements.

Cognitive Impairment (Brain Fog): The Invisible Challenge

What It Is: Brain fog affects countless patients with rheumatic diseases, making it difficult to concentrate, recall information, or make decisions.

Expert Insights: The panel noted that many clinicians overlook this symptom because it is less tangible than joint pain or swelling. However, it profoundly affects day-to-day life, from completing work tasks to managing household responsibilities. They advocated for raising awareness among healthcare professionals to recognize brain fog as a genuine and significant issue.

Why It Matters: By addressing brain fog, patients can regain confidence in their cognitive abilities and better manage the complexities of living with a chronic illness.

Discover More Of Our Resources

Mental Health: Prioritizing Emotional Well-Being

What It Is: Depression and anxiety are common in patients with rheumatic diseases due to the emotional toll of chronic pain and fatigue. Unfortunately, mental health concerns are often sidelined during brief medical appointments.

Expert Insights: Dr. Susan Bartlett underscored the importance of integrating mental health care into routine rheumatology visits. Stress management techniques, counseling, and open conversations about emotional health can make a significant difference. Multidisciplinary care involving psychologists and counselors could help patients develop coping strategies and improve resilience.

Why It Matters: Taking mental health seriously alongside physical health helps reduce the emotional burden of living with a chronic condition, fostering a better quality of life.

Sleep Disturbances: Breaking the Cycle

What It Is: Poor sleep is both a symptom and a driver of rheumatic diseases. Pain and inflammation often interfere with sleep quality, while lack of sleep exacerbates fatigue and emotional stress.

Expert Insights: Sleep is frequently overlooked in treatment plans, but addressing it can yield significant improvements. The panel discussed interventions like cognitive behavioral therapy for insomnia (CBT-I), sleep hygiene practices, and adjustments to medications that may be disrupting rest.

Why It Matters: Prioritizing sleep could reduce the overall symptom burden, including fatigue, pain, and mental health challenges.

Improving Communication in Healthcare

A significant theme of the session was the critical need for better communication between patients and providers:

Short Appointments, Missed Conversations: The panel acknowledged that limited appointment times often focus on managing visible symptoms like joint inflammation, leaving little room to address “hidden” symptoms like fatigue and brain fog.
Empowering Patients: Resources, such as the QR code shared during the session, empower patients to advocate for themselves. These tools encourage patients to bring up neglected symptoms and ensure they’re part of the conversation during medical visits.

Example of Empowerment: Patients could use tools like symptom-tracking apps to clearly communicate their experiences with fatigue or brain

Why This Matters for Patients

The symptoms highlighted—fatigue, brain fog, mental health issues, and sleep disturbances—often have a more significant impact on daily life than joint pain alone. Tackling these symptoms:

Enables Holistic Care: Patients can receive support that considers their entire well-being, not just physical pain.
Improves Quality of Life: Addressing these hidden challenges can empower patients to better manage their routines, relationships, and aspirations.

Next Steps for Patients and Providers

For Patients:

Speak Up: Don’t hesitate to bring up symptoms like fatigue, brain fog, and sleep disturbances during medical appointments.
Seek Support: Join patient communities or consult multidisciplinary experts who understand the complexities of rheumatic diseases.
Track Symptoms: Keeping a log of your experiences can help you clearly communicate your needs to your healthcare provider.

For Providers:

Dedicate Time: Make space during appointments to discuss symptoms beyond joint pain.
Refer to Specialists: Consider referrals to occupational therapists, dietitians, or psychologists to address symptoms holistically.
Educate Patients: Provide resources and tools that empower patients to better manage their conditions.

This session at ACR 2024 emphasized the urgent need to address the often-ignored symptoms of rheumatic diseases. By fostering open communication, integrating mental health into care, and prioritizing holistic symptom management, we can take meaningful steps toward improving patient outcomes.

Go With Us Video Debrief

New Biomarkers in Rheumatoid Arthritis: A Step Toward Better Care

Sat, 05 Apr 2025 13:47:41 GMT

New Biomarkers in Rheumatoid Arthritis: A Step Toward Better Care

New Biomarkers Offer Hope

The session unveiled three promising biomarkers for seronegative RA, with a focus on one called anti-RA 33 . Here’s why these discoveries matter:

Better Diagnostics: Biomarkers like anti-RA 33 were detected in 42% of patients who later developed seronegative RA.
Identifying these markers early could enable earlier and more accurate diagnoses, reducing the frustration and delays many patients face.
Tailored Treatments: Research revealed that patients with the anti-RA 33 biomarker respond better to methotrexate, a commonly prescribed RA medication. This finding could lead to more targeted treatments, sparing patients the trial-and-error approach often associated with RA therapy.
Disease Prediction and Prevention: Studies on “preclinical RA” are exploring whether the presence of certain biomarkers can predict the onset of RA before symptoms occur. Early identification could pave the way for preventive strategies, potentially stopping the disease in its tracks.

Discover More About Our Biomarkers Resources

What This Means for Patients

This research represents a paradigm shift in how seronegative RA is understood and managed:

Personalized Care: Biomarker tests could help match patients to the most effective treatments, improving outcomes and quality of life.
Empowered Patients: With better diagnostic tools, patients can advocate for earlier intervention and avoid being dismissed due to negative lab results.
Preventive Opportunities: Identifying at-risk individuals before symptoms arise could lead to proactive care that minimizes the disease’s impact.

Barriers to Access

Despite these exciting advances, challenges remain. Access to biomarker testing and treatments often hinges on policy and legislation. Organizations like AiArthritis are advocating to ensure these tools are available to all patients who need them.

Looking Ahead

The discovery of new biomarkers marks a significant step forward in the fight against seronegative RA. As this research evolves, patients can look forward to earlier diagnoses, more personalized care, and even the possibility of prevention. Stay informed and engaged with organizations that champion patient-centered advancements in arthritis care—because the future of RA treatment is brighter than ever.

Go With Us Video Debrief

Biosimilars: Advancing Treatment Options and Improving Patient Lives

Fri, 04 Apr 2025 21:36:24 GMT

Biosimilars: Advancing Treatment Options and Improving Patient Lives

What Are Biosimilars?

Biosimilars are near-identical alternatives to biologic drugs, designed to provide the same therapeutic benefits. They are often developed as lower-cost options, making treatments more accessible to patients. Despite their potential, the adoption of biosimilars in the United States lags behind other regions like Europe due to systemic challenges.

Why Biosimilars Matter to Patients?

Cost-Effective Treatment: Biosimilars promise to reduce the financial burden of biologic therapies, which are often prohibitively expensive. By introducing competition, they can lower overall healthcare costs and expand access.

Access to Advanced Therapies: Patients in need of biologic treatments may find biosimilars more readily available, especially in regions where cost is a barrier.

Challenges in the U.S.

While the benefits of biosimilars are evident, their rollout in the U.S. has faced roadblocks:

Insurance and PBM Dominance: Pharmacy Benefit Managers (PBMs) hold significant sway over drug availability, often favoring biosimilars manufactured by companies they own. This consolidation can limit patient options and raise ethical concerns.

Non-Medical Switching: Patients may be switched from one drug to another for reasons unrelated to medical necessity, disrupting continuity of care. This practice, known as non-medical switching, is a major concern for those with chronic conditions.

Discover More About Our Biosimilars Resources

The Global Perspective

In Europe, regulations ensure that biosimilars can only be substituted for biologics with a doctor’s approval. This safeguard, known as interchangeability, protects patients by keeping treatment decisions in the hands of healthcare professionals. The U.S. is set to introduce a similar model in 2025, but with a critical difference: pharmacy-level substitution may occur without doctor approval. This raises questions about patient safety and autonomy.

How Research and Advocacy Can Improve Patient Lives

Informed Decisions: Ongoing research into biosimilar safety and efficacy equips patients and providers with the knowledge needed to make informed treatment choices.

Advocacy for Patient-Centric Policies: Organizations and individuals must advocate for policies that preserve doctor-patient collaboration in treatment decisions. Patients should not face non-medical switching unless it’s deemed beneficial by their healthcare team.

How Patients Can Stay Empowered

Know Your Rights: Understand the implications of switching treatments and when it is or isn’t appropriate.
Share Your Experiences: Positive and negative patient stories can guide advocacy and improve practices.
Engage in Advocacy: Support efforts to maintain medical integrity and protect access to the most effective treatments.

A Collaborative Future

Biosimilars have the potential to transform healthcare, but their success hinges on prioritizing patient needs and collaboration. By staying informed, sharing experiences, and advocating for thoughtful integration, patients and providers can work together to unlock the full benefits of these groundbreaking treatments.

Go With Us Video Debrief

Breaking Ground: New Treatments for Sjogren’s and Psoriatic Arthritis from ACR 2024

Fri, 04 Apr 2025 20:27:13 GMT

Breaking Ground: New Treatments for Sjögren's Disease and Psoriatic Arthritis from ACR 2024

A Novel Treatment for Sjögren's Disease

One of the most discussed advancements was Nipocalimab , a treatment presented by Johnson & Johnson. As Sjogren’s disease currently has no approved therapies, this development marks a monumental step forward.

How It Works:

Nipocalimab targets IgG autoantibodies, preventing their recycling and effectively “starving” them.

This leads to reduced disease activity, as the chain reaction of inflammation is halted.

Clinical Trial Progress:

Nipocalimab is currently in phase two trials , showing promising safety and efficacy results. If these findings hold, the treatment will move to phase three trials and, potentially, to market.

Why It Matters: Patients with Sjogren’s disease have long waited for targeted therapies to address the underlying mechanisms of the disease. If successful, Nipocalimab could be the first approved treatment, offering hope for improved symptom management and quality of life.

Discover More Of Our Resources

Advances in Psoriatic Arthritis: TYK2 Inhibition

Takeda unveiled a new treatment targeting psoriatic arthritis: a TYK2 (Tyk2) inhibitor. This oral therapy builds on the success of JAK inhibitors while introducing more targeted inhibition.

How It Works:

Tyk2 inhibitors focus specifically on the Tyk2 pathway, which plays a crucial role in immune system regulation.

Unlike JAK inhibitors, which target multiple pathways, Tyk2 inhibition is more selective, potentially reducing side effects while maintaining effectiveness.

Clinical Trial Progress:

Trials evaluated various doses (5 mg, 15 mg, and 30 mg), with the 15 mg and 30 mg doses showing significant improvements.
By 12 weeks, many patients reported low disease activity or remission.

Why It Matters: Psoriatic arthritis can be difficult to manage, with patients often cycling through multiple therapies. The introduction of Tyk2 inhibitors offers an innovative option for those who may not respond well to existing treatments.

Find Out More Through These Resources

The Impact of These Advancements

Both therapies underscore the rapid pace of innovation in autoimmune disease treatment. Here’s how they could improve patient lives:

Targeted Relief:

Both Nipocalimab and Tyk2 inhibitors aim to address specific mechanisms of disease, offering more precise and effective treatment options.

Expanded Options:

For patients who haven’t found success with current therapies, these new treatments provide additional avenues for disease management.

Potential Remission:

Early data suggests that both treatments may lead to remission for some patients, a game-changing possibility for those living with chronic inflammation.

Looking Ahead

While these treatments are still in clinical trials, the progress is promising. With continued research, the hope is that these therapies will soon be accessible to patients, offering new hope for better disease management and quality of life.

Stay tuned for more updates from ACR 2024 as we continue to see breakthroughs that shape the future of autoimmune care.

Go With Us Video Debrief

April: Sjögren's Awareness Month

Thu, 03 Apr 2025 15:03:42 GMT

April: Sjögren's Disease Awareness Month

Origins of Sjögren's Disease

Sjögren's Disease is named after Dr. Henrik Sjögren, a Swedish ophthalmologist who, in 1933, conducted groundbreaking research to describe the condition. His work led to the recognition of Sjögren's as a distinct autoimmune disease, characterized by hallmark symptoms like dry eyes and dry mouth. Over time, understanding of the disease has evolved, with the term "Sjögren's disease" now reflecting its systemic nature. Beyond dryness, it can lead to serious complications, including organ involvement, emphasizing its complexity and impact on overall health.

History of Sjögren's Awareness Month

Sjögren's Awareness Month was established in 1998 when New York Congresswoman Louise Slaughter entered it into the Congressional Record. Since then, the Sjögren's Foundation has worked diligently each April to spread awareness. Their annual #ThisIsSjögrens campaign highlights patient stories and showcases the diverse experiences of those affected by the disease, helping to foster greater empathy and understanding.

Key Facts About Sjögren's Disease

Gender Prevalence: Approximately 90% of those diagnosed with Sjögren's are women, suggesting hormonal factors may play a role in its development.
Systemic Nature: Once seen as just a collection of symptoms, Sjögren's is now understood as a systemic autoimmune disease with far-reaching effects on the body.

Discover More Of Our Resources

What is Sjögren's Disease?

Sjögren’s disease primarily affects the body’s moisture-producing glands, leading to dryness in areas like the eyes, mouth, and skin. However, it can also impact major organs such as the lungs and kidneys, adding layers of complexity to the condition.

Symptoms of Sjögren's Disease

The symptoms of Sjögren's vary from person to person and may include:
Persistent dryness (eyes, mouth, nose, skin).
Swollen, painful salivary glands, particularly near the jaw.
Mouth sores and oral yeast infections.
Persistent dry cough or bronchitis.
Headaches and difficulty swallowing.
Lung issues like interstitial lung disease or pneumonia.
Peripheral neuropathy or Raynaud’s phenomenon (fingers/toes turning white or blue in cold or stress).

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

These symptoms can significantly affect quality of life. Early diagnosis and treatment are critical for managing the disease and preventing complications.

Learn more about Sjögren's Disease

How to Get Involved

Want to make a difference during Sjögren's Awareness Month? Here’s how:

Spread Awareness: Use hashtags like #SjögrensAwarenessMonth and #ThisIsSjögrens on social media to share stories and educational content.
Participate in Events: Attend virtual or in-person events like webinars, walk-a-thons, and fundraisers organized by the Sjögren's Foundation.
Wear Purple: Purple is the color of Sjögren's awareness. Show your support by wearing purple throughout April.
Donate: Consider contributing to organizations like the Sjögren's Foundation to fund research and patient resources.
Advocate: Contact policymakers to advocate for better healthcare access and increased research funding for Sjögren's Disease.

Moving Forward

Sjögren's Awareness Month is an opportunity to bring attention to this complex autoimmune disease, promote research, and build a supportive community for those affected. By sharing knowledge and showing solidarity, we can drive progress toward better outcomes for patients. This April, let’s work together to raise awareness and make a lasting impact in the lives of people living with Sjögren's disease.

Tune into the AiArthritis Voices 360 Talk Show, where patients, doctors, and advocates come together to discuss the latest in autoimmune and autoinflammatory arthritis. Join the conversation to learn, share, and make a difference in the world of arthritis care!

Raising Awareness for a Rare Autoinflammatory Disease: Sarcoidosis

Thu, 03 Apr 2025 13:47:33 GMT

Raising Awareness for a Rare Autoinflammatory Disease: Sarcoidosis

Sarcoidosis Awareness Events

World Sarcoidosis Day was first declared on April 13, 2019, by the Foundation for Sarcoidosis Research in conjunction with Sarcoidosis Awareness Month , which was established in April 2008.

World Sarcoidosis Day

Every year on April 13th, the world comes together to observe World Sarcoidosis Day, a day dedicated to raising awareness about sarcoidosis. This rare inflammatory disease affects thousands of people worldwide. This day encourages those living with sarcoidosis to support one another and educate others about the challenges of living with this condition.

Sarcoidosis Awareness Month

April is recognized as Sarcoidosis Awareness Month in the United States, a time dedicated to raising awareness about sarcoidosis, a rare inflammatory disease that affects thousands of individuals. This month-long observance aims to educate the public about the condition, promote research efforts, and provide support to those living with sarcoidosis. Organizations like the Foundation for Sarcoidosis Research (FSR) and the International Foundation of Autoimmune and Autoinflammatory Arthritis play a crucial role in spreading awareness and providing resources for patients and healthcare professionals.

The 2025 Theme Show how you Stand Up for Sarc!

Join the FSR community and show how you Stand Up for Sarc! Post a photo of yourself on social during the month of April wearing purple showing how you are a super hero for sarcoidosis awareness or write down how you are taking action for sarcoidosis. Make sure to tag @stopsarcoidosis and use #StandUpForSarc! Be sure to also tag us at AiArthritis!

Discover more ways to get involved on the Foundation for Sarcoidosis Research page.

Discover More Of Our Resources

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Understanding Sarcoidosis Symptoms

Symptoms of Sarcoidosis

The symptoms of sarcoidosis vary depending on which organs are affected. Common symptoms include:

Lung involvement: shortness of breath, wheezing, chronic cough
Night sweats
Irregular heartbeat
Swollen legs
Vision and eye issues (pain, redness, burning)
Discoloration and rash
Sensitivity to light
Enlarged lymph nodes
Erythema nodosum: raised, red, and tender bumps form on the skin, usually on the front of the legs

If the condition affects the eyes, symptoms may include dryness, redness, and pain. When granulomas grow in the lungs, they can cause shortness of breath or wheezing. In some cases, symptoms may go into remission without requiring treatment, while others may experience persistent and debilitating symptoms.

Discover The Early Symptoms of AiArthritis Study: This study has advanced understanding of key early indicators, helping researchers and healthcare providers improve timely diagnosis and care for autoimmune arthritis patients. Learn more.

Learn more about Sarcoidosis

Ways to Observe World Sarcoidosis Day

There are several ways to get involved and support World Sarcoidosis Day:

Wear Purple: Purple is the color associated with sarcoidosis awareness. Wearing purple clothing or accessories can help spread awareness and show support for those affected by the disease.
Share Your Story: Patients with sarcoidosis are encouraged to share their experiences on social media using hashtags like #WorldSarcDay and #StopSarcoidosis. Personal stories can help educate others and provide support to those going through similar challenges. Consider using #AiArthritis and tagging us on social media so we can support your content!
Participate in Events: Join or organize events such as patient conferences, walk-a-thons, and fundraisers to raise awareness and funds for sarcoidosis research.
Educate Others: Use this day to educate friends, family, and colleagues about sarcoidosis. Share information about the disease, its symptoms, and the importance of early diagnosis and treatment.

World Sarcoidosis Day is an important opportunity to shine a light on this rare inflammatory disease and support those affected by it. By raising awareness, promoting research, and building a supportive community, we can work towards better outcomes for patients with sarcoidosis. Let's come together on April 13th to make a difference and show our support for the sarcoidosis community.

Discover more ways to get involved on the Foundation for Sarcoidosis Research page.

Breaking the Silence: Celebrating IgG4-RD Awareness Day on April 4

Thu, 27 Mar 2025 11:23:00 GMT

Breaking the Silence: Celebrating IgG4-RD Awareness Day on April 4

What is IgG4-Related Disease (IgG4-RD)?

IgG4-related disease (IgG4-RD) is a chronic illness that causes swelling and damage in various parts of the body. It occurs when the immune system mistakenly attacks healthy organs. This disease can lead to lumps or swelling in different areas and may be confused with infections, cancer, Sjogren’s Disease or Sarcoidosis. Although IgG4-RD predominantly affects men aged 50-70, it can occur in anyone. The exact cause remains unknown, but early treatment can help prevent severe damage.

The Most Frequent Symptoms of IgG4-RD

Symptoms of IgG4-RD can vary among individuals and may fluctuate over time. Common symptoms include:

Pain in affected areas
Swelling of organs or glands
Fatigue and low energy
Digestive issues, such as nausea or stomach pain
Unexplained weight loss

What Organs Are Involved In IgG4-RD

Given its ability to impact multiple organs, diagnosing IgG4-RD can be challenging. Key organ systems that may be affected include:

Salivary and lacrimal glands : Swelling, dry mouth, and dry eyes
Pancreas : Autoimmune pancreatitis and digestive issues
Biliary tract : Sclerosing cholangitis leading to jaundice
Kidneys : Tubulointerstitial nephritis and impaired kidney function
Lungs : Inflammation causing breathing difficulties
Retroperitoneum : Fibrosis obstructing the urinary tract
Orbits (eyes) : Swelling, bulging eyes (proptosis), and vision issues
Lymph nodes : Swelling in multiple areas

Diagnosing IgG4-RD

Diagnosing IgG4-RD requires various tests, as the disease can mimic other conditions. These tests are also used to monitor the disease and detect flares, when symptoms worsen suddenly.:

Blood tests : Check for elevated IgG4 antibody levels, though not all patients exhibit high levels.
Scans (X-rays, CT scans, MRIs, PET scans) : Detect lumps or swelling inside the body.
Tissue biopsy : Examine affected tissue under a microscope for signs of IgG4-RD.

Treating IgG4-RD

IgG4-RD is an ongoing condition that needs to be closely watched. Without treatment, IgG4-RD can worsen and cause permanent organ damage. Adhering to the doctor's treatment plan is crucial. While there is no cure for IgG4-RD, treatment focuses on managing the disease. As of March 26th 2025, there are no FDA-approved treatments for IgG4-RD, so a doctor may prescribe other therapies:

Steroids (like prednisone) : Common first treatment to reduce swelling and pain. Long-term use may cause side effects like weight gain, weak bones, and high blood sugar.
Other immune system medications (like azathioprine or mycophenolate mofetil) : Some people need medicine that helps calm the immune system
Biologics (like rituximab) : Used for patients who don't respond to steroids or cannot take them long-term.
Clinical trials : Researchers are exploring new treatments to improve care for IgG4-RD patients.
*Update: As of April 3, 2025, there is now an FDA-approved treatment for IgG4-RD. To learn more about this new option, visit: uplizna.com/about-uplizna

Who Treats IgG4-RD?

Since IgG4-RD can affect many organs, multiple specialists may be involved or required to manage IgG4-RD, including:

Rheumatologists : Autoimmune disease experts
Gastroenterologists : Specialists for stomach, pancreas, or liver issues
Nephrologists : Kidney specialists
Ophthalmologists : Eye-related issue experts
Pulmonologists : Lung specialists
Hematologists : Blood disorder experts
Primary care doctors : Coordinate care and monitor overall health

Living with IgG4-RD

Managing IgG4-RD involves proactive measures:

Report new symptoms : Do not ignore pain, swelling, or other changes.
Track flares : Recording symptoms can help doctors identify patterns.
Communicate with loved ones : Informing family and friends about the condition can provide support.
Stay informed : Keep up with new treatments and research on IgG4-RD.

Is IgG4-Related Disease an Autoimmune or Autoinflammatory Arthritis Disease?

Right now, IgG4-related disease (IgG4-RD) is not officially classified as an autoimmune or autoinflammatory arthritis disease. Scientists are still learning how this disease works, and there isn’t enough evidence yet to say for sure if it’s an autoimmune condition. While arthritis (joint inflammation) can sometimes happen in people with IgG4-RD, it is usually not a main symptom. The disease more commonly affects organs like the pancreas, kidneys, salivary glands, and lungs.

Why is AiArthritis Raising Awareness About IgG4-RD?

At AiArthritis, we focus on helping people who live with autoimmune and autoinflammatory arthritis diseases — especially those who are still waiting for answers. That includes people who may have been misdiagnosed or not diagnosed at all.

IgG4-related disease (IgG4-RD) is not currently classified as an AiArthritis disease. However, some of its symptoms can look very similar to those in our community, like dry mouth, swollen glands, or even joint pain. Because of these similarities, IgG4-RD is often misdiagnosed as other conditions like Sjögren’s disease or sarcoidosis — two diseases we commonly hear about from patients in our community.

That’s why we’re working to bring more attention to IgG4-RD.

AUTO + Inflammatory Arthritis = X or YZ

One projects is called AUTO + Inflammatory Arthritis = X or YZ . It’s designed to help people and their doctors figure out what’s really going on when symptoms don’t quite add up. This project was also heavily based on findings from our AiArthritis Early Symptoms Study used to collect data on symptoms in early disease to educate health care professionals and encourage early detection and treatment.

In this project, “X” represents a known autoimmune or autoinflammatory arthritis disease (like rheumatoid arthritis or psoriatic arthritis).
But sometimes, symptoms don’t fit just one disease. So “Y” or “Z” could be something else, like IgG4-RD or fibromyalgia.

This project helps us look deeper at overlapping or similar conditions, so people get the right diagnosis faster — and feel better sooner.

Helping the Undiagnosed – Our “Mystery Patient” Mission

One of our biggest goals this year is to shine a light on undiagnosed or “mystery patients.” These are people who are clearly sick, but they don’t yet have a name for their disease. That can be a scary and frustrating place to be.

At AiArthritis, we’re working hard to create guidance and resources that help mystery patients expedite diagnosis and get the right treatment. By raising awareness about conditions like IgG4-RD, we hope to make it easier for people to find answers — even if their condition is rare or misunderstood.

You can learn more about our AUTO + Inflammatory Arthritis = X or YZ project and our efforts to support undiagnosed or “mystery patients” by visiting our website. Check out the page to dive deeper into the project, listen to related Talk Show episodes, and download the latest version of our Mystery Patient Guide: www.aiarthritis.org/Equation

Even though IgG4-related disease is rare and not always easy to recognize, raising awareness can lead to faster diagnoses and better care. By learning more and sharing this information, we can help support those still searching for answers — and make sure no one feels alone on their journey.

To continue learning about IgG4-RD, check out these helpful resources:

IGG4ward – A patient-focused organization with tools, stories, and information to support those living with IgG4-RD.
IgG4-RD Outloud – A medical resource offering in-depth information about symptoms, diagnosis, and treatment options.

Together, we can shine a light on this often-misunderstood condition and help more people get the answers they deserve.

Take a Deep Breath: Coping, Finding Support

Fri, 21 Mar 2025 11:12:47 GMT

Take a Deep Breath: Coping, Finding Support

Step 2: After ILD Diagnosis

By Denae Cedar, RDN and person living with Interstitial Lung Disease

After the medical beginning of diagnosis and discovering the correct treatments— what about our emotions, our personal lives, our future hopes and dreams?

Maybe the diagnosis was a relief. “Finally someone believes me! At last there is real proof that something is going on.”

Or it may have been terrifying. “Another serious condition! How will I cope with this additional burden and more losses?”

Sometimes friends and family do not understand. It is our right to take all the time we need before we share information with them. And it is also OK not to share with everyone – this is yet another medical diagnosis which is serious and very personal.

Some of us may be part of the “Invisible Disabilities” tribe. ILD is a restrictive lung disease, so it doesn’t sound like COPD or another thick, phlegm-producing condition. This means that people (including some healthcare providers) may not think we really have lung disease if we “only” have fatigue and a dry cough in the beginning. We may often hear people say “you don’t look disabled” and experience this in multiple ways:

1) They may trying to be kind but simply not understanding how that sounds to us.
2) It may seem that they are consciously or unconsciously disrespecting/denying that our disability challenges are real or significant.
3) It may feel that an employer, friend, or family member is expecting more from us than we are comfortable offering or capable of giving.

Others of us have visible disabilities and yet friends and family may not fully understand how it feels to have this additional diagnosis, full of uncertainty and new limits, to face.

Either way, we may feel hurt, unheard, scared, sad, or angry.

My pulmonologist very gently and kindly told me that the prognosis with ILD secondary to autoimmune disease can vary widely. People may live 5 years or even up to 20 years (depending upon our age and other health conditions we have) after an ILD diagnosis. If funding for research continues, the younger you are the more likely you are to see significant improvement in ILD treatment in your future.

When we receive a diagnosis with a serious prognosis, it is important have support. We need to reach out to people with whom we feel comfortable sharing our news and our feelings. We also need people we can rely upon to be emotionally present with us and sometimes available for physical assistance such as a ride to a doctor’s appointment, or a run to the grocery store. Just as we may already do for our other AiArthritis-related conditions.

In addition to your personal support network, I encourage everyone to consider working for some time with a good therapist who specializes in helping people with chronic diseases or serious diagnoses. Not all therapists have that very specific set of skills, but most therapists are experienced in helping people deal with losses.

Because whether we feel lonely, scared, sad or angry – all of those feelings are all related to grief. We have lost something.

Yes, we have likely adjusted to prior AiArthritis-related diagnoses, but this one is new and different. Breath is life itself. So therapy/counseling is helpful in facing the grief of losing more things that we may not be able to do anymore or facing the fact that perhaps our time may be somewhat shorter. Let yourself grieve this.

Grief ignored

harms us more

than grief explored.

Exploring/experiencing meaning in our lives is also vitally important. If we are part of a religious community our minister, priest, pastor, rabbi, imam, sheikh, or other spiritual leader likely has experience in how to help people face mortality as well. If we are atheist, agnostic, or not religious at all, or if we are independently spiritually oriented, our life purpose/ethics/morals/beliefs and how we manifest them are still the most essential part of who we are in this world. Good therapy helps us explore and define these values.

Therapy is also helpful in learning how to communicate with the other people in our lives. Good communication increases support and – just as important – deepens connections and nourishes love.

Journaling our thoughts and feelings is a great way to explore them. Compared to thinking the same thoughts over and over, writing spontaneously in a state of flow can reveal things that our conscious mind has been ignoring. Sometimes we surprise ourselves!

Group support, either in person or online, can be helpful as a way to find people who share our diagnosis and who may be able to offer coping tips and practical tips based on personal experience. Social media may also sometimes be a place where some people may overdo the “ranting” or express much fear and negativity, so pay attention to whether it is helpful for you or not.

In addition to support from other human beings, many of us find love and joy from our animal companions. Don’t they sometimes just know when we need some love? And they keep it simple, just loving us without a lot of questions.

We may also heal our feelings via time in nature: seeing/hearing/smelling/touching beautiful natural life. A stroll in the park. A lovely houseplant, a bouquet of scented flowers, the soothing sound of rain on a roof, or even some adaptive gardening if we can do it. There are few things as satisfying as growing something, even if it is just putting a few seeds in a pot.

As we deal with this new diagnosis, it’s helpful to purposefully seek out all the things which give us peace and make us happy. Perhaps listening to – or making-- music. Watching a great movie or following a good series. Practicing any creative arts or crafts you enjoy. Treat yourself—try something brand new! You can find free instruction on YouTube if you don’t feel up to going to classes. Even if we have stiff fingers, we can still create. Reading or listening to books can also help us explore other lives/places – an interesting escape within our own space.

These joys come to us, in my experience, after we have allowed ourselves to honestly feel our grief, accept our new diagnosis, and move forward into living NOW. Remember that even if our health journey feels like “two steps forward, one step back” at times, we are still moving forwards. As we live “one day at a time”, let us each discover our own unique sources of joy, companionship, wisdom, hope and beauty.

In our next conversation, we will explore practical lifestyle tips on managing our condition(s) and living healthfully. For now, Take a Deep Breath and move forward….life is here in each moment, ready to participate with us.

Nourishing Your Body: Healthy Eating Tips for People Living with AiArthritis Diseases

Sun, 09 Mar 2025 11:48:32 GMT

Nourishing Your Body: Healthy Eating Tips for People Living with Ai Arthritis Diseases

Foods to Order In:

Grilled Salmon with Vegetables: Salmon is rich in omega-3 fatty acids, which have anti-inflammatory properties. Pair it with a side of steamed or roasted vegetables for a nutritious meal.
Quinoa Salad with Mixed Greens: Quinoa is a great source of protein and fiber, and mixed greens provide essential vitamins and antioxidants. Look for salads with a variety of colorful vegetables.
Chicken and Vegetable Stir-Fry: Opt for a stir-fry with lean chicken and a mix of vegetables like broccoli, bell peppers, and snap peas. This dish is packed with nutrients and low in unhealthy fats.
Lentil Soup: Lentils are high in protein and fiber, making them a great choice for sustained energy. A hearty lentil soup with vegetables can be both comforting and nutritious.
Avocado and Tomato Sandwich: Avocados provide healthy fats, while tomatoes are rich in antioxidants. Choose whole grain bread for added fiber and nutrients.

Foods to Grab from Your Kitchen:

These foods are not only nutritious but also easy to prepare or order in, making them ideal choices when you're dealing with pain and fatigue.

Fresh Fruit: Berries, oranges, and apples are easy to grab and packed with vitamins and antioxidants that can help reduce inflammation.
Nuts and Seeds: Almonds, walnuts, and chia seeds are great sources of healthy fats and protein. They can provide a quick energy boost and help manage inflammation.
Greek Yogurt: Plain Greek yogurt is high in protein and probiotics. Add some fresh fruit or a drizzle of honey for a delicious and nutritious snack.
Vegetable Sticks with Hummus: Carrot and celery sticks paired with hummus make for a crunchy and satisfying snack that's rich in fiber and healthy fats.
Oatmeal: A bowl of oatmeal topped with nuts, seeds, and fresh fruit can provide sustained energy and help reduce inflammation.

Five Anti-Inflammatory Freezer Meals

Meal prepping can be a lifesaver on tough days. Here are five anti-inflammatory meals you can prepare in advance and store in your freezer:

Turkey and Vegetable Chili:

Ingredients: Ground turkey, bell peppers, onions, tomatoes, black beans, kidney beans, corn, chili powder, cumin, garlic, olive oil.
Instructions: Sauté the turkey with onions and garlic. Add the vegetables, beans, and seasonings. Simmer until fully cooked. Portion into freezer-safe containers and freeze. Reheat as needed.
Benefits: Packed with lean protein, fiber, and anti-inflammatory spices.

Lentil and Vegetable Stew:

Ingredients: Green or brown lentils, carrots, celery, tomatoes, spinach, garlic, vegetable broth, olive oil, thyme, bay leaves, turmeric.
Instructions: Sauté the garlic, carrots, and celery in olive oil. Add the lentils, tomatoes, vegetable broth, and seasonings. Simmer until lentils are tender. Stir in spinach. Portion into containers and freeze. Reheat as needed.
Benefits: High in fiber, protein, and anti-inflammatory nutrients.

Quinoa and Black Bean Stuffed Peppers:

Ingredients: Bell peppers, quinoa, black beans, corn, tomatoes, onions, garlic, cumin, chili powder, olive oil.
Instructions: Cook quinoa and mix with black beans, corn, tomatoes, onions, garlic, and seasonings. Stuff the mixture into halved bell peppers. Bake until peppers are tender. Cool and freeze in containers. Reheat as needed.
Benefits: Rich in plant-based protein, fiber, and antioxidants.

Baked Salmon with Sweet Potatoes and Broccoli:

Ingredients: Salmon fillets, sweet potatoes, broccoli, olive oil, lemon juice, garlic, thyme.
Instructions: Season salmon fillets with lemon juice, garlic, and thyme. Arrange on a baking sheet with sweet potato cubes and broccoli florets. Drizzle with olive oil. Bake until salmon is cooked and vegetables are tender. Cool and freeze in containers. Reheat as needed.
Benefits: High in omega-3 fatty acids, fiber, and vitamins.

Chickpea and Spinach Curry:

Ingredients: Chickpeas, spinach, tomatoes, onions, garlic, ginger, coconut milk, curry powder, turmeric, olive oil.
Instructions: Sauté onions, garlic, and ginger in olive oil. Add chickpeas, tomatoes, coconut milk, and spices. Simmer until flavors meld. Stir in spinach until wilted. Portion into containers and freeze. Reheat as needed.
Benefits: Rich in protein, fiber, and anti-inflammatory spices.

Tips for Freezer Meal Prep:

Label and Date: Clearly label each container with the meal name and date to keep track of freshness.
Portion Control: Divide meals into individual portions for easy reheating.
Storage: Use freezer-safe containers or bags to prevent freezer burn.
Reheating: Thaw meals in the fridge overnight or reheat directly from the freezer in the microwave or on the stovetop.

Stock Up On Healthy Ingredients:

Keeping your pantry stocked with healthy, quick, and easy-to-grab foods is a great way to ensure you always have nutritious options on hand. Here are some staples you might consider:

Whole Grains:

Oats: Perfect for a quick breakfast or snack, and you can easily add fruits, nuts, or seeds.
Quinoa: Cooks quickly and can be used in salads, as a side dish, or as a base for bowls.
Brown Rice: A versatile grain that can be paired with veggies, proteins, or used in stir-fries.
Whole Grain Pasta: A healthier alternative to regular pasta, it provides more fiber and nutrients.

Canned or Packaged Goods:

Canned Beans (e.g., black beans, chickpeas, kidney beans): Great sources of protein and fiber, perfect for salads, soups, or stews.
Canned Tuna or Salmon: High in protein and omega-3 fatty acids, can be used in salads, sandwiches, or casseroles.
Canned Tomatoes: Useful for making quick sauces, soups, or adding to stews.
Nut Butters (e.g., almond butter, peanut butter): Great for quick snacks on whole grain bread, fruits, or as a dip for veggies.

Nuts and Seeds:

Almonds, Walnuts, Chia Seeds, Flaxseeds: High in healthy fats and protein, perfect for adding to yogurt, oatmeal, or salads.

Snacks:

Whole Grain Crackers: Pair with cheese, hummus, or nut butter for a quick snack.
Dried Fruits (e.g., raisins, apricots, cranberries): Natural sources of sweetness and fiber, great for a quick energy boost.

Cooking Essentials:

Olive Oil or Coconut Oil: Healthy fats for cooking and dressing salads.
Spices and Herbs (e.g., turmeric, ginger, garlic, basil, rosemary): Enhance the flavor of your dishes while providing health benefits.

Beverages:

Green Tea: Packed with antioxidants and can be enjoyed hot or cold.
Herbal Teas: Offer a variety of flavors and health benefits without caffeine.

Cooking with autoimmune and autoinflammatory arthritis can be especially difficult due to the pain, fatigue, and cognitive dysfunction associated with these conditions. Preparing meals requires physical effort, which can be challenging when dealing with joint pain and stiffness. Fatigue can make it hard to find the energy to cook, and cognitive dysfunction, often referred to as "brain fog," can impact the ability to follow recipes and make decisions in the kitchen. Despite these challenges, making nutritious food choices is crucial for managing symptoms and improving quality of life. By focusing on easy-to-prepare meals and utilizing meal prep strategies, it is possible to maintain a healthy diet even on the toughest days.

Looking for more resources on diet? Download the AiArthritis Anti-Inflammatory Food takeaway sheet or check out the blog post about National Nutrition Month .

Check out blogs on different meal ideas:

Unveiling the Dynamics: Exploring the Connection Between Autoimmune and Autoinflammatory Arthritis and Dynamic Disabilities

Sun, 09 Mar 2025 11:34:21 GMT

Unveiling the Dynamics: Exploring the Connection Between Auto immune and Auto inflammatory Arthritis and Dynamic Disabilities

Patient Perspective

What is a Dynamic Disability

A dynamic disability refers to a condition or impairment that fluctuates in severity and impact over time. Unlike a static disability, such as amputation or paralysis, which remains constant, a dynamic disability may have periods of remission or exacerbation. This can make it challenging for individuals with dynamic disabilities to predict and manage their symptoms, as the level of impairment can change unexpectedly.

Consider this the next time you see someone with a mobility aid one day and then without it another time. They are not faking their disability, it just fluctuates. The same goes for someone with an invisible disability and their ability to do something one day and then struggle to do it the next.

Autoimmune and Autoinflammatory Arthritis as a Dynamic Disability

Autoimmune and autoinflammatory arthritis perfectly fit into the concept of dynamic disability, though the concept is confusing to many, even myself, though I live with multiple forms of arthritis. One moment I can be on a roll, getting stuff done, feeling alright, then boom, I need to lay down and I’m down for days. In simpler terms, I have good days, bad days and days sort of in between.

Dynamic disabilities can vary in severity and the extent to which they impact daily life. This unpredictability can significantly impact the quality of life for individuals with autoimmune and autoinflammatory arthritis, as it can affect their ability to perform tasks, participate in activities, and maintain independence. My triggers can be simple things like weather changes, physical exertion, or emotional stress, which can exacerbate how I am feeling, leading to increased disability at any given moment. I can also predict flares due to medication changes, big events like holidays or traveling, or changes in my routine.

Infections Can Have a Dynamic Impact on Our Health

While there are many forms of arthritis, autoimmune and autoinflammatory forms can put us at a greater risk for infections and often come with slower healing times than someone without an autoimmune disease. A simple cold can put me out for weeks, on top of what it does to my inflammatory arthritis. Infections are one of the main causes of our diseases flaring, our medications failing us, and even a main cause of death for some with autoimmune arthritis.

The Dynamics of Our Disability is Beyond Joint Pain. The Pain of Autoimmune and Autoinflammatory Arthritis is Not Just Physical

The pain of autoimmune and autoinflammatory arthritis is not just physical. These conditions can also have a significant impact on mental and emotional health. Living with a dynamic disability like autoimmune and autoinflammatory arthritis can lead to frustration, anxiety, and depression, especially when the symptoms worsen or limit participation in meaningful activities. Because dynamic disabilities like autoimmune and autoinflammatory arthritis can vary in severity from day to day or even throughout the day, this variability can make it challenging for individuals living with these conditions to plan and anticipate their needs accurately. I find myself having to cancel, postpone, or change plans all the time because of my arthritis, which can cause extreme feelings of guilt and impact my confidence. This has had an impact on my mental health and my social life. Loneliness and isolation can be very common for those living with a dynamic disability, leading to poorer outcomes.

Dynamic Disabilities Are Hard to Understand and Even Harder to Live With

What is even more difficult for someone to understand and at times show compassion for us if they do not live with a fluctuating condition themselves. Add in the often invisible nature of autoimmune and autoinflammatory arthritis and the misconceptions that it is only the elderly who are impacted, add more to the confusion of the impact of arthritis on someone at any given moment.

The unpredictable nature of dynamic disabilities can make them challenging to manage. Individuals with dynamic disabilities often face unique daily obstacles in terms of planning, accessibility, and adapting to changing needs. Arthritis sufferers may need to modify their daily routines, use assistive devices, or seek medical interventions during periods of increased disability. This highlights the importance of a multidisciplinary approach involving healthcare professionals, occupational therapists, and support networks to provide comprehensive care and support.

Why It’s Important to Understand and Show Support for Dynamic Disabilities

Public awareness about autoimmune and autoinflammatory arthritis and their dynamic nature can help reduce stigma, plus promote understanding and empathy towards individuals living with these conditions. We can work towards creating a more inclusive and supportive environment for those living with these conditions by understanding the dynamic nature of autoimmune and autoinflammatory arthritis, which allows for better management and support for individuals living with these diseases. Not only that, addressing the unique challenges associated with dynamic disabilities, we can empower those with autoimmune and autoinflammatory arthritis to lead fulfilling lives while managing their condition effectively.

5 Anti-Inflammatory Dinners To Fall In Love With This National Nutrition Month

Sun, 09 Mar 2025 11:20:25 GMT

5 Anti-Inflammatory Dinners To Fall In Love With This National Nutrition Month

Pro-Inflammatory Dinners to Avoid:

For individuals with autoimmune and autoinflammatory arthritis, it is important to limit dinners that can potentially trigger inflammation. Here are some dinners to limit:

Processed and Red Meats: Avoid processed meats like sausages and hot dogs, as well as red meats that are high in saturated fats.
Fried Foods: Steer clear of fried chicken, French fries, and other deep-fried items that contain unhealthy fats and can promote inflammation.
Refined Grains: Skip white rice, white pasta, and white bread. These can spike blood sugar levels and contribute to inflammation.
Sugary Desserts: Limit desserts high in refined sugars like cakes, cookies, and ice cream, which can increase inflammation.
High-Sodium Foods: Avoid canned soups, processed snacks, and frozen dinners that are high in sodium, which can exacerbate inflammation.

Simplifying Your Lunch: Tips for Easier Healthy Eating

Making eating a healthy dinner easier can be simple with a few helpful strategies. Here are some tips to consider:

Plan Ahead

Meal Prep: Spend some time each week preparing ingredients or entire meals in advance. This way, you have healthy options ready to go when you're short on time.
Create a Menu: Plan your dinners for the week, so you know exactly what you'll be eating and can avoid last-minute unhealthy choices.

Keep it Simple

One-Pot Meals: Opt for meals that can be made in one pot or pan, reducing both prep time and cleanup.
Quick Recipes: Choose recipes that require minimal ingredients and can be prepared in under 30 minutes.

Stock Up on Essentials

Healthy Staples: Keep your pantry and fridge stocked with healthy essentials like whole grains, lean proteins, frozen vegetables, and healthy fats. This ensures you always have nutritious ingredients on hand.
Pre-Washed Vegetables: Buy pre-washed and pre-cut vegetables to save time on meal prep.

Batch Cooking

Cook in Bulk: Prepare larger batches of meals and store leftovers in the fridge or freezer. This way, you have healthy dinners available for several days without having to cook every night.

Use Convenient Tools

Slow Cooker/Instant Pot: Utilize kitchen gadgets like a slow cooker or Instant Pot to make healthy meals with minimal effort. Simply add the ingredients and let the appliance do the work.

Make it Fun

Get Creative: Experiment with new recipes and flavors to keep your meals interesting and enjoyable. Eating healthy doesn't have to be boring!
Involve Family: If you have family or friends around, involve them in the cooking process. It can make the experience more enjoyable and help you stay motivated.

5 Anti-Inflammatory Dinners:

1. Grilled Salmon with Quinoa and Roasted Vegetables:

Season salmon with herbs and grill until cooked through. Serve with a side of quinoa and roasted vegetables like bell peppers, zucchini, and carrots. Salmon is rich in omega-3 fatty acids, and quinoa and vegetables provide fiber and antioxidants.

2. Lentil and Vegetable Stir-Fry:

Cook lentils and stir-fry with a mix of colorful vegetables such as bell peppers, broccoli, and snap peas. Season with turmeric, ginger, and garlic. Lentils are a great source of plant-based protein and fiber.

3. Turkey and Sweet Potato Shepherd's Pie:

Prepare a shepherd's pie using ground turkey, sautéed vegetables, and mashed sweet potatoes as a topping. Turkey is a lean protein, and sweet potatoes are high in beta-carotene and fiber.

4. Spinach and Chickpea Stuffed Bell Peppers:

Stuff bell peppers with a mixture of cooked chickpeas, spinach, quinoa, and diced tomatoes. Bake until the peppers are tender. This dish is packed with protein, fiber, and vitamins.

5. Baked Cod with Lemon and Asparagus:

Season cod fillets with lemon juice, olive oil, and herbs. Bake with a side of asparagus spears. Cod is a low-fat source of protein, and asparagus is rich in antioxidants and anti-inflammatory compounds.

These anti-inflammatory dinners are not only nutritious but also easy to prepare and affordable. Incorporating these meals into your routine can help manage inflammation and support overall health. Celebrate National Nutrition Month by prioritizing your well-being with these delicious and healthy dinner options!

Looking for more resources on diet? Download the AiArthritis Anti-Inflammatory Food takeaway sheet or check out the blog posts about National Nutrition Month and Tips for Eating Healthy .

Check out blogs on different meal ideas:

World Young Rheumatic Diseases Day: Raising Awareness and Promoting Early Diagnosis

Sat, 08 Mar 2025 14:18:33 GMT

World Young Rheumatic Diseases Day: Raising Awareness and Promoting Early Diagnosis

World Young Rheumatic Diseases Day (WORD Day) is an annual event held on March 18th to raise awareness about rheumatic diseases in children and young people. This day aims to educate parents, healthcare professionals, and the general public about the early signs and symptoms of these conditions, emphasizing the importance of early diagnosis and timely referral to pediatric rheumatology specialists.

More information about this awareness day

Types of Young Rheumatic Diseases that are Autoimmune and Autoinflammatory Arthritis ( Ai Arthritis) Diseases:

Juvenile Idiopathic Arthritis (JIA) : An autoimmune disease causing chronic joint inflammation in children.

Oligoarthritis (Persistent and Extended): A subtype of JIA affecting four or fewer joints, which can persist or extend to more joints over time.
Polyarthritis: A subtype of JIA that involves five or more joints, often including both large and small joints.
Systemic: A subtype of JIA affecting the entire body, causing fever, rash, and inflammation of internal organs.
Undifferentiated : A subtype of JIA that doesn't fit into any specific category but still involves chronic arthritis.
Enthesitis-Related Arthritis: A subtype of JIA that involves inflammation where tendons and ligaments attach to bones, often affecting the lower limbs and spine.
Juvenile Axial Spondyloarthritis : A form of JIA that primarily affects the spine and sacroiliac joints, causing pain and stiffness.
Juvenile Psoriatic Arthritis : A subtype of JIA associated with both arthritis and psoriasis, a skin condition characterized by red, scaly patches.

Systemic Lupus Erythematosus (SLE) : An autoimmune disease causing inflammation and damage to various organs, including the skin, joints, and kidneys.
Still's Disease (also known as Systemic Juvenile Idiopathic Arthritis or SJIA): A form of JIA causing systemic inflammation, fever, rash, and joint pain.
Systemic Juvenile Idiopathic Arthritis (SJIA): A subtype of JIA characterized by systemic inflammation, fever, rash, and joint involvement.
Familial Mediterranean Fever (FMF) : An inherited condition causing recurrent episodes of fever and inflammation, often starting in childhood.
Cryopyrin-Associated Periodic Syndromes (CAPS) : A group of rare genetic disorders causing recurrent episodes of inflammation.
Familial Cold Autoinflammatory Syndrome (FCAS): A type of CAPS triggered by cold exposure, leading to episodes of fever and inflammation.
Muckle-Wells Syndrome (MWS): A type of CAPS causing recurrent inflammation, hearing loss, and potential kidney damage.
Neonatal-Onset Multisystem Inflammatory Disease (NOMID): A severe form of CAPS presenting in infancy with chronic inflammation affecting multiple organs.
Hyper IgD Syndrome (HIDS): A genetic disorder causing recurrent episodes of fever and inflammation, often starting in infancy or early childhood.
Chronic Nonbacterial Osteomyelitis/Chronic Recurrent Multifocal Osteomyelitis (CNO/CRMO): A condition causing recurrent episodes of bone inflammation, often starting in childhood.

The Importance of Early Diagnosis

Early diagnosis of rheumatic diseases in children and young people is crucial for effective treatment and improved long-term outcomes. Rheumatic diseases, such as juvenile idiopathic arthritis (JIA), can cause significant pain, swelling, and stiffness in joints, leading to impaired physical function and quality of life. Early intervention can help manage symptoms, prevent joint damage, and enable children to lead a normal, active life.

Ai Arthritis Resources Relevant to WORD Day

WORD Day is celebrated through various activities and events organized by local committees in different countries. These events include:

How You Can Get Involved

There are many ways to support WORD Day and help raise awareness about rheumatic diseases in children and young people:

Share Your Story : Share your experiences and stories on social media using the hashtag #WORDDay to raise awareness and inspire others.
Support Organizations : Donate to or volunteer with organizations that work to improve the lives of children and young people with rheumatic diseases.
Advocate for Change : Advocate for better access to pediatric rheumatology services and support policies that promote early diagnosis and treatment.

World Young Rheumatic Diseases Day is a vital opportunity to raise awareness about rheumatic diseases in children and young people and promote early diagnosis and treatment. By coming together and supporting this cause, we can make a difference in the lives of those affected by these conditions and help them lead healthier, happier lives.

Living with Rheumatoid Arthritis: When Flares Strike

Sat, 08 Mar 2025 13:46:03 GMT

Living with Rheumatoid Arthritis: When Flares Strike

The views and opinions expressed in this post are those of the patient and do not necessarily reflect the official policy or position of AiArthritis.

What Does a Flare Feel Like?

When a flare hits, it's like your body's turned up the volume on everything. Your joints don't just ache – they scream. They swell up like balloon animals, and moving feels like you're wading through wet cement. The fatigue hits differently too. We're not talking about your average "I need a coffee" tired – this is the "I might need a nap after brushing my teeth" kind of exhaustion.

Common symptoms include:

Joint pain that makes you question every movement
Swelling that turns your fingers into mini sausages
Stiffness that feels like your joints have rusted overnight
Bone-deep fatigue that coffee can't touch
A general feeling of "everything's wrong" that's hard to explain
Sometimes even a low-grade fever
Unexplained weight loss
A mood that matches the weather during storm season

The Ripple Effect

Living with RA flares is like trying to plan your life around an unreliable weather forecast. Work deadlines don't care that your hands aren't cooperating. Friends don't always understand why you've canceled plans again. Even keeping up with basic household chores becomes a negotiation with your body.

The Usual Suspects: What Triggers Flares

While some flares seem to come out of nowhere, others have clear triggers:

Stress (both the mental and physical kinds)
That cold your kid brought home from school
Injuries (even minor ones)
Hormonal changes
Weather shifts (yes, your joints really can predict rain)
Poor sleep
Smoking
Some people even swear certain foods set them off

Surviving the Storm

Managing flares is part science, part art. Here's what helps:

Medication Adjustments : Consult with my healthcare provider to adjust medications during a flare. This may include increasing doses or adding short-term treatments to manage symptoms.
Rest and Self-Care : Prioritize rest to allow the body to recover. Gentle stretching and relaxation techniques can help alleviate stiffness and pain.
Heat and Cold Therapy : Applying heat or cold packs to affected joints can provide relief from pain and inflammation.
Healthy Diet : Eating a balanced diet rich in anti-inflammatory foods can support overall health and potentially reduce the severity of flares.
Support System : Leaning on friends, family, and support groups can provide emotional support and practical assistance during flares.
Lifestyle changes: Consider lifestyle changes such as stress management, regular exercise, avoidance of smoking, maintaining good oral hygiene and a healthy diet.

First, work with your doctor. Sometimes you'll need medication adjustments, other times you can ride it out with your current treatment plan. Learn to read your body's signals.

During a flare, become best friends with self-care. Heat packs become your constant companions. Rest isn't lazy – it's necessary. Gentle movement, when possible, keeps your joints from completely freezing up. And don't underestimate the power of a good support system.

The Communication Challenge

One of the trickiest parts of RA flares is explaining them to others. How do you tell your boss that yes, you were fine yesterday, but today your body's staging a revolt? Or help friends understand that you're not being flaky when you cancel plans – you're being realistic about what your body can handle?

The key is honesty. Help people understand that RA isn't just "a bit of arthritis." It's an unpredictable chronic condition that can change from day to day. Most people want to understand and support you – they just need to know how.

Living with RA means accepting uncertainty while staying prepared. It means being gentle with yourself during flares while remaining determined to live your life. Most importantly, it means remembering that while flares are part of your story, they don't have to be the whole story.

The Hidden Face of Discrimination: Living with AiArthritis in an Ableist World

Sat, 08 Mar 2025 13:33:55 GMT

The Hidden Face of Discrimination: Living with Ai Arthritis in an Ableist World

The views and opinions expressed in this post are those of the patient and do not necessarily reflect the official policy or position of AiArthritis.

Think about it: we live in a world built for able-bodied people. Buildings without ramps. Elevators missing braille buttons. Events planned in spaces some people can't access. These aren't just inconveniences – they're messages saying "you don't belong here."

Living with rheumatoid arthritis means navigating a maze of other people's assumptions. Some days are good, some days I can barely move, and that's what throws people off. They can't wrap their heads around a disability they can't see. "But you don't look sick," they say, or my personal favorite, "You're too young for arthritis!" As if chronic illness checks ID at the door.

The comments pile up like a greatest hits album of ignorance:

"Just push through it."
"It's all in your head."
"If you tried this miracle cure..."
"I know someone who has that, and they're fine!"

Each one stings a little more than the last.

Sometimes the ableism gets ugly. Like the "friend" who thought it was hilarious to yell "let the cripple through!" at a concert. Or the guy who deliberately licked his finger and touched my sweater during the pandemic after I asked for space. These weren't just moments of thoughtlessness – they were acts of cruelty dressed up as jokes.

The hardest part? The voice in my own head. That internalized ableism that whispers I'm somehow less worthy because my body works differently now. It's tough not to compare yourself to healthy people your age, not to feel guilty when you have to cancel plans again because your joints are screaming.

Arthritis is the leading cause of long-term disability worldwide, with over 200 different types affecting people of all ages. Yet the stereotypes persist. People assume it's just an old person's disease, a little joint pain that some ibuprofen will fix. They don't see the brain fog, the bone-deep fatigue, the daily calculations of energy expenditure that would put a mathematician to shame.

But here's the thing: staying quiet won't change anything. We need to talk about ableism – not just in whispered conversations among the disabled community, but out loud, in spaces where it matters. Because until we do, people will keep designing buildings without thinking about accessibility, planning events without considering inclusion, and making assumptions about what disability looks like.

I didn't choose to join the disabled community, but I can choose to speak up. To challenge the assumptions. To remind people that disability doesn't fit neatly into their preconceptions. Because the world isn't divided into "able" and "disabled" – it's a spectrum we all move along throughout our lives.

So next time you catch yourself making assumptions about someone's abilities, pause. Remember that disabilities don't always come with visible signs. Remember that your temporary convenience – like parking in a disabled spot "just for a minute" – could be making someone else's life unnecessarily harder.

Change starts with awareness. It grows with understanding. And it flourishes when we all decide to do better.

5 Anti-Inflammatory Lunches To Discover For National Nutrition Month

Sat, 08 Mar 2025 12:55:14 GMT

5 Anti-Inflammatory Lunches To Discover For National Nutrition Month

Pro-Inflammatory Lunches to Limit:

For individuals with autoimmune and autoinflammatory arthritis, it is important to limit lunches that can potentially trigger inflammation. Here are some lunches to limit:

Sugary Beverages and Desserts: Avoid sodas, sweetened teas, and desserts high in refined sugars, which can contribute to inflammation.
Processed Meats: Skip deli meats, sausages, and other processed meats that contain high levels of preservatives and unhealthy fats.
Fried Foods: Fried chicken, French fries, and other deep-fried items can increase inflammation due to their high fat content and harmful trans fats.
White Bread and Refined Grains: Steer clear of sandwiches made with white bread, pasta, and other refined grains that can spike blood sugar levels and promote inflammation.
Creamy Dressings and Sauces: Many store-bought dressings and sauces are high in unhealthy fats, sugars, and preservatives. Opt for homemade or low-sugar options instead.

Simplifying Your Lunch: Tips for Easier Healthy Eating

Meal Prep Ahead: Prepare ingredients or entire meals in advance to save time and effort during busy days. Portion out servings and store them in the fridge or freezer for quick access.
Opt for Quick and Nutritious Options: Keep healthy staples on hand, like whole grain wraps, pre-washed salad greens, canned beans, and lean proteins. These can be easily assembled into a nutritious meal without much hassle.
Batch Cooking: Make larger batches of soups, stews, and casseroles that can be portioned out for multiple lunches. This reduces daily cooking time and ensures you always have a healthy option ready to go.
Mindful Snacking: Choose nutrient-rich snacks like fruit, nuts, or yogurt that complement your lunch and keep you satisfied throughout the afternoon. Avoid processed snacks that can lead to energy crashes.

5 Anti-Inflammatory Lunches:

1. Quinoa Salad with Vegetables:

Mix cooked quinoa with chopped vegetables like bell peppers, cucumbers, cherry tomatoes, and spinach. Add a drizzle of olive oil and lemon juice. Quinoa is a great source of protein and fiber, while vegetables provide essential vitamins and antioxidants.

2. Grilled Salmon with Steamed Broccoli:

Season salmon with herbs and grill it until cooked through. Serve with steamed broccoli and a squeeze of lemon. Salmon is rich in omega-3 fatty acids, which have anti-inflammatory properties.

3. Chickpea and Avocado Wrap:

Mash chickpeas and avocado together, then spread the mixture onto a whole grain wrap. Add fresh spinach and sliced tomatoes. This wrap is packed with fiber, healthy fats, and plant-based protein.

4. Lentil Soup:

Cook lentils with diced vegetables like carrots, celery, and onions in a vegetable broth. Season with herbs and spices. Lentils are a good source of protein and fiber, and the vegetables add vitamins and minerals.

5. Greek Yogurt with Nuts and Berries:

Choose plain Greek yogurt and top it with a handful of nuts (such as almonds or walnuts) and fresh berries. Greek yogurt provides probiotics and protein, while nuts and berries offer healthy fats and antioxidants.

These anti-inflammatory lunches are not only nutritious but also easy to prepare and affordable. Incorporating these meals into your routine can help manage inflammation and support overall health. Celebrate National Nutrition Month by prioritizing your well-being with these delicious and healthy lunch options!

Looking for more resources on diet? Download the AiArthritis Anti-Inflammatory Food takeaway sheet or check out the blog posts about National Nutrition Month and Tips for Eating Healthy .

Check out blogs on different meal ideas:

Breakfast
D inner

A Single Mom's Guide to Parenting Through Chronic Illness

Fri, 07 Mar 2025 12:07:36 GMT

A Single Mom's Guide to Parenting Through Chronic Illness

Put Your Oxygen Mask On First

Remember those airline safety demonstrations? There's a reason they tell you to secure your own mask before helping others. You can't pour from an empty cup, and with chronic illness, that cup drains faster than most. Self-care isn't selfish—it's survival. This means keeping up with treatments, doctor's appointments, and whatever keeps you feeling human, even if that means saying no to other things.

Your Kids Are Always Watching

The silver lining of parenting with chronic illness? Your kids learn resilience by example. My son has become surprisingly health-conscious, even joining me for workouts because he's seen how movement helps manage my symptoms. He's developed empathy too, often volunteering alongside me at arthritis organizations. Though I'll admit, he's also learned to use "I'm tired" as his go-to excuse for avoiding chores—clearly taking after his mother's legitimate need for rest.

Embrace the Mess

Life got easier when I stopped expecting perfection and started accepting reality. Bad days will come—that's just part of the deal. But good days will too, and they're worth every moment of struggle. There's no rulebook for parenting with chronic illness, so write your own story.

Get Strategic About Everything

Organization isn't just helpful—it's essential. I keep a strict but flexible routine, limiting myself to 3-5 major tasks per day. Whether it's shopping, cleaning, or appointments, everything gets tracked. Using a fitness tracker and RA app has helped me understand my body's patterns and triggers, making it easier to plan around flares.

Simplify Your Life

Pre-RA, I was the mom who'd bake from scratch and hand-craft party decorations. Now? I've learned to embrace store-bought solutions and smaller gatherings. Energy is a precious resource—spend it wisely.

Make Food Work for You

Batch cooking has become my best friend. On good days, I cook extra and freeze portions for when standing at the stove feels impossible. And yes, sometimes dinner is just snacks or takeout. The world won't end if your kids don't get a home-cooked meal every night.

Lower Your Standards (Just a Bit)

Some days, the TV becomes an unofficial babysitter while you manage a flare. Other days, you might be late to school drop-off or let the dishes pile up. That's okay. Perfect parenting is a myth, even for those without chronic illness.

Build Your Village

I've learned to be open with my son's teachers about my condition, and their understanding has made a world of difference. Teaching kids to help with age-appropriate chores isn't just practical—it's preparing them for life while making yours a bit easier.

Ignore the Barbaras

You know the type—those parents who seem to do it all and still find time to judge others. Their opinion of your parenting matters exactly zero percent. Focus on what works for your family.

Drop the Guilt

My son often reminds me not to apologize for what my body can't do. Kids are surprisingly wise that way. While the guilt doesn't disappear completely, remember that you're doing your best with the cards you've been dealt.

Ask for Help

This might be the hardest lesson, but it's crucial: asking for help isn't weakness—it's wisdom. Whether it's hiring a cleaner, ordering grocery delivery, or seeking therapy, support comes in many forms. Use it.

This journey with chronic illness and parenting isn't one I would have chosen, but it's taught me more about strength, resilience, and adaptation than I ever imagined possible. The key isn't to be the perfect parent—it's to be the parent your kids need, even if that looks different from what you initially pictured.

What strategies have you found helpful in managing parenthood with chronic illness?

March Autoimmune Disease Awareness Month: Autoimmune Arthritis Focus

Fri, 07 Mar 2025 10:50:46 GMT

March is Autoimmune Disease Awareness Month: Autoimmune Arthritis Focus

Autoimmune Disease Awareness Month is observed every March to increase understanding and awareness of autoimmune diseases. The initiative is led by organizations like the Autoimmune Association and their National Coalition of Autoimmune Patient Groups (NCAPG) . The goal is to recognize the millions impacted by autoimmune diseases, amplify their voices, and advocate for greater research, support, and understanding. During this month, communities worldwide participate by issuing proclamations, illuminating landmarks, and sharing stories to promote awareness and support

What is an autoimmune disease?

An autoimmune disease occurs when the immune system mistakenly attacks the body's own healthy tissues. Instead of protecting against harmful invaders like bacteria and viruses, the immune system targets its cells and organs. This results in inflammation, tissue damage, and various symptoms depending on the specific disease and affected area.

Common Autoimmune Diseases

There are over 100 known autoimmune diseases, including well-known conditions such as rheumatoid arthritis, multiple sclerosis, and Type 1 diabetes, as well as less common diseases like myositis and antiphospholipid syndrome. Approximately 50 million Americans are living with autoimmune diseases, and the numbers are rising. Autoimmune diseases affect approximately one in ten people worldwide with autoimmune arthritis being the most common type of autoimmune disease. Other types of autoimmune diseases include:

Multiple Sclerosis
Type 1 Diabetes
Psoriasis
Hashimoto's Thyroiditis
Graves' Disease
Celiac Disease
Myasthenia Gravis
Addison's Disease
Autoimmune Hepatitis
Pemphigus Vulgaris
Vitiligo
Autoimmune Hemolytic Anemia
Dermatomyositis
Primary Biliary Cholangitis (PBC)

Why Autoimmune Disease Awareness Matters:

Approximately 300 million people worldwide are diagnosed with at least one Ai Arthritis disease. However, research suggests that over 50% of patients go undiagnosed or are diagnosed with a " undifferentiated" disease ", increasing this number to an estimated 450 million. Autoimmune diseases often take a long time to diagnose and are frequently missed for several reasons:

Symptom Overlap: Many autoimmune diseases share common symptoms , such as fatigue, joint pain, and inflammation, which can overlap with other conditions. This makes it challenging for healthcare providers to pinpoint the exact cause.

Non-Specific Symptoms: Symptoms of autoimmune diseases can be vague and non-specific, such as general malaise, muscle aches, and weakness. These symptoms can be attributed to a variety of other health issues, leading to misdiagnosis or delayed diagnosis.

Episodic Nature : Autoimmune diseases often have periods of remission and flare-up s. During remission, symptoms may subside, making it difficult for doctors to observe the full clinical picture.

Lack of Specific Tests: There is often no single test that can definitively diagnose an autoimmune disease. Diagnosis usually requires a combination of clinical evaluation, blood tests, imaging studies, and sometimes biopsies.

Rarity and Complexity: Some autoimmune diseases are rare or complex, and many healthcare providers may not have extensive experience with them. This can lead to missed or delayed diagnoses as doctors may not immediately recognize the signs.

Gender Bias: Autoimmune diseases are more common in women, and sometimes symptoms may be dismissed or attributed to stress or psychological factors. This can delay proper diagnosis and treatment.

Variability in Presentation: Autoimmune diseases can present differently in each individual. The variability in symptoms and severity can make it challenging to identify the disease early on.

Misdiagnosis: Due to the overlapping and non-specific nature of symptoms, autoimmune diseases are often misdiagnosed as other conditions. This can lead to inappropriate treatments and further delays in reaching the correct diagnosis.

Raising Autoimmune Disease Awareness Encourages:

Early Diagnosis : Many autoimmune diseases have symptoms that can be mistaken for other conditions, leading to delays in diagnosis. By raising awareness, we can encourage people to seek medical attention early, improving their prognosis and quality of life.
Advancing Research : Increased awareness can lead to more funding and interest in research, helping to develop better treatments and potentially finding a cure.
Reducing Stigma : Educating the public about autoimmune diseases can help reduce the stigma and misconceptions surrounding these conditions.
Building a Supportive Community : Awareness initiatives can help create a supportive community where individuals with autoimmune diseases can share their experiences and find support.

Understanding The Difference Between Autoimmune and Autoinflammatory Arthritis

There are over 100 autoimmune and autoinflammatory diseases, but only a couple dozen prominently feature inflammatory arthritis (referred to as Auto immune Arthritis and Auto inflammatory Arthritis, or Ai Arthritis). These diseases are caused by the immune system, which is a network of cells and tissues throughout the body that work to defend us from viruses, bacteria, and infection. In our diseases, immune cells target the body's own healthy tissues by mistake and signals the body to attack them. While there is no one cause for either autoimmune or autoinflammatory diseases, we do know each originates in a part of the immune system.

While arthritis unites these diseases, because they are autoimmune and autoinflammatory in nature they affect more than just the joints. The inflammation travels through the bloodstream, so these diseases affect the whole body, including tissues and organs.

Autoimmune Arthritis Diseases:

Autoimmune Disease. A group of over 80 diseases caused by reactions of the adaptive immune system, which develops over time. In most cases, these diseases result from a combination of genetic and environmental influences, such as viruses, bacteria, and hormonal triggers, especially in individuals with a genetic predisposition. Autoimmune Arthritis Diseases:

Rheumatoid Arthritis (RA)
Psoriatic Arthritis (PsA)
Palindromic Rheumatism
Systemic Lupus Erythematosus (SLE)
Sjögren's Disease
Systemic Sclerosis (Scleroderma)
Mixed Connective Tissue Disease (MCTD)
Crohn’s Disease
Antisynthetase Syndrome
Undifferentiated Disease (UD)
Relapsing Polychondritis (RP)
Axial Spondyloarthritis (axSpA)
Non-radiographic axSpA
Ankylosing Spondylitis (AS)
Juvenile Idiopathic Arthritis (JIA)
Oligoarthritis (Persistent and Extended)
Polyarthritis
Systemic
Undifferentiated
Enthesitis-Related Arthritis
Juvenile Axial Spondyloarthritis
Juvenile Psoriatic Arthritis

Autoinflammatory Arthritis Diseases:

Autoinflammatory Disease. A group of around 2 dozen rare diseases caused by Innate Immune System (inborn) reactions. While often there is no known cause, genetic mutations are often thought to be responsible.

Still's Disease
Adult-Onset Still's Disease (AOSD)
Systemic Juvenile Idiopathic Arthritis (sJIA)
Familial Mediterranean Fever (FMF)
Cryopyrin-Associated Periodic Syndromes (CAPS)
Familial Cold Autoinflammatory Syndrome (FCAS)
Muckle-Wells Syndrome (MWS)
Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
VEXAS Syndrome
Sarcoidosis
Behcet’s Disease
Hyper IgD Syndrome (HIDS)
Schnitzler syndrome
Chronic Nonbacterial Osteomyelitis/Chronic Recurrent Multifocal Osteomyelitis (CNO/CRMO)

Learn more about Autoimmune vs. Autoinflammatory: https://www.aiarthritis.org/whatisaiar thritis

Three Ways How You Can Get Involved

There are many ways to participate in Autoimmune Disease Awareness Month and support the cause:

Share Your Story : Share your experiences and stories on social media using the hashtag #AutoimmuneAwarenessMonth to raise awareness and inspire others.
Organize Events : Host events such as information sessions, workshops, or fundraisers to educate others about autoimmune diseases and raise funds for research and support services.
Support Organizations : Donate to or volunteer with organizations that provide support and resources for people with autoimmune diseases.

World Sleep Day: Improving Sleep Hygiene with AiArthritis

Fri, 07 Mar 2025 10:42:17 GMT

World Sleep Day: Improving Sleep Hygiene with Ai Arthritis Diseases

Every year the world comes together to celebrate World Sleep Day —a day dedicated to raising awareness about the importance of sleep and addressing sleep-related issues. Organized by the World Sleep Society, this global event aims to highlight the impact of sleep on overall health and well-being and encourage better sleep habits for people of all ages.

The 2026 Theme: Sleep Well, Live Better

World Sleep Day is an opportunity to promote sleep health alongside thousands of other sleep health professionals and advocates. When we all promote sleep health and #WorldSleepDay together, our combined effort is greater than the sum of its parts. Spread the word about sleep health on World Sleep Day, and help elevate the conversation around sleep!

The Importance of Sleep for Ai Arthritis Diseases

Sleep is a fundamental human need, essential for physical, mental, and emotional health. It plays a crucial role in various bodily functions, including memory consolidation, immune system support, and emotional regulation. Adequate sleep improves cognitive performance, enhances mood, and reduces the risk of chronic illnesses such as heart disease, diabetes, and obesity.

Proper sleep is essential for individuals with auto immune and auto inflammatory arthritis ( AI A rthritis) as it can significantly impact their overall health and well-being. Here are some ways in which proper sleep leads to a healthier future for AI arthritis patients:

Reduced Inflammation: Adequate sleep helps regulate the immune system and reduce inflammation. Poor sleep can lead to increased production of pro-inflammatory cytokines, exacerbating symptoms and disease activity.
Pain Management: Quality sleep can help manage pain by allowing the body to repair and regenerate tissues. During deep sleep, the body releases growth hormones that aid in the repair of minor muscle tears and reduce pain sensitivity.
Improved Mood and Mental Health: Proper sleep is crucial for mental health and emotional well-being. It helps regulate stress hormones and reduces the risk of depression and anxiety, which are common in individuals with chronic pain conditions.
Enhanced Cognitive Function: Good sleep improves cognitive function, including memory, concentration, and decision-making. This can help AI arthritis patients better manage their daily activities and treatment plans.
Increased Energy Levels: Adequate sleep helps restore energy levels, reducing fatigue and improving overall quality of life. This allows patients to engage in physical activities and maintain an active lifestyle.
Better Immune Function: Proper sleep supports the immune system, making it more effective in fighting infections and reducing the risk of flare-ups. This is particularly important for individuals with autoimmune conditions.
Weight Management: Quality sleep helps regulate appetite and metabolism, reducing the risk of weight gain and obesity. Maintaining a healthy weight is important for managing AI arthritis symptoms and reducing joint stress.

The Impact of Sleep on Auto immune and Auto inflammatory Arthritis Diseases

For individuals living with autoimmune and autoinflammatory diseases, such as rheumatoid arthritis , lupus , and psoriatic arthritis , sleep plays a crucial role in managing symptoms and improving quality of life. Poor sleep can exacerbate inflammation and fatigue, leading to a vicious cycle of worsening symptoms and decreased well-being.

Research has shown that sleep disruption can alter immune cell profiles, increasing the risk of inflammatory responses and chronic conditions. For those with autoimmune diseases, this means that inadequate sleep can lead to heightened disease activity, increased pain, and reduced ability to perform daily activities. Therefore, prioritizing good sleep hygiene is essential for managing these conditions and enhancing overall health.

Poor sleep is a common issue for patients with autoimmune and autoinflammatory arthritis ( Ai Arthritis). Here are some examples of sleep problems they may experience:

Difficulty Falling Asleep: Pain and discomfort from inflamed joints can make it hard to relax and fall asleep.
Frequent Nighttime Awakenings: Patients may wake up multiple times during the night due to pain, stiffness, or the need to change positions.
Non-Restorative Sleep: Even if they manage to sleep through the night, the sleep may not be restful, leaving them feeling tired and unrefreshed in the morning.
Excessive Daytime Sleepiness: Poor sleep quality can lead to excessive daytime sleepiness, making it difficult to stay awake and alert during the day.
Restless Legs Syndrome (RLS): Some patients with AI arthritis may experience RLS, a condition characterized by an uncontrollable urge to move the legs, especially at night, which can disrupt sleep.
Obstructive Sleep Apnea (OSA): OSA, a condition where breathing repeatedly stops and starts during sleep, is more common in people with arthritis and can significantly interfere with sleep.
Pain-Related Alertness: Increased joint pain can lead to heightened alertness and difficulty staying asleep, as the body remains on high alert due to discomfort.
Fatigue and Depression: Chronic pain and sleep disturbances can contribute to fatigue and depression, further impacting sleep quality.

Tips for Improving Sleep Hygiene

Sleep hygiene refers to practices that promote good sleep quality. Improving sleep quality involves adopting healthy sleep habits and addressing any underlying sleep disorders. Here are some tips to promote better sleep:

Maintain a Consistent Sleep Schedule: Go to bed and wake up at the same time every day, even on weekends. Consistency helps regulate your body's internal clock and improves sleep quality.
Create a Relaxing Bedtime Routine: Engage in calming activities before bed, such as reading, meditating, or taking a warm bath.
Optimize Your Sleep Environment: Ensure your bedroom is cool, dark, and quiet. Invest in a comfortable mattress and pillows. Use blackout curtains, earplugs, or white noise machines to minimize disruptions.
Limit Screen Time Before Bed: Avoid using electronic devices, such as smartphones and tablets, at least an hour before bedtime. The blue light emitted by these devices can interfere with the production of the sleep hormone melatonin.
Be Mindful of Your Diet : Avoid large meals, caffeine, and alcohol close to bedtime. These can disrupt sleep and make it harder to fall asleep or stay asleep.
Stay Active During the Day: Regular physical activity can promote better sleep. However, avoid vigorous exercise close to bedtime, as it may have the opposite effect.
Manage Stress and Anxiety: Practice stress-reducing techniques such as deep breathing exercises, yoga, or journaling. Managing stress can significantly improve sleep quality and overall well-being.

Do symptoms from your AiArthritis disease affect your ability to get consistent quality sleep? Are you frustrated about other aspects of your AiArthritis disease? Let us know what's bothering you by SUBMITTING YOUR RANT! Here at AiArthritis, we don't represent the patient voice, we ARE the patient voice and we want to hear YOUR story!

5 Anti-Inflammatory Breakfasts To Try During National Nutrition Month

Fri, 07 Mar 2025 09:55:37 GMT

5 Anti-Inflammatory Breakfasts To Try During National Nutrition Month

Pro-Inflammatory Breakfasts to Limit

For individuals with autoimmune and autoinflammatory arthritis, it is important to limit breakfasts that can potentially trigger inflammation. Here are some breakfasts to steer clear of:

Sugary Cereals and Pastries: These are high in refined sugars, which can contribute to inflammation and exacerbate symptoms.
Processed Meats: Bacon, sausages, and other processed meats contain high levels of saturated fats and additives that can promote inflammation.
High-Fat Fried Foods: Foods like hash browns, fried eggs, and fried breakfast meats can increase inflammation due to their high fat content.
White Bread and Pastries: Refined grains can cause blood sugar spikes and contribute to inflammation. Opt for whole grains instead.
Dairy Products: Some people with autoimmune conditions find that dairy can trigger inflammation or digestive issues. Consider alternatives like almond or soy milk.
Highly Processed Breakfast Bars: Many breakfast bars are packed with added sugars and artificial ingredients, which can promote inflammation.
Sweetened Yogurts: Yogurts with added sugars can contribute to inflammation. Choose plain yogurt and add your own fresh fruits.
Excessive Coffee: While moderate coffee consumption may have benefits, excessive amounts can lead to dehydration and increased inflammation in some individuals.

Simplifying Your Morning: Tips for Easier Healthy Eating

Making healthy eating easier in the morning can set a positive tone for the rest of your day but can be challenging when living with AiArthritis due to pain and fatigue. Here are some practical tips to help:

Plan Ahead: Prepare breakfast the night before. Overnight oats, chia seed pudding, or smoothie ingredients can be assembled in advance, saving you time in the morning.
Keep It Simple: Choose quick and easy recipes that require minimal preparation. Options like avocado toast, yogurt with berries, or a fruit and nut mix can be ready in minutes.
Batch Cooking: Make large batches of breakfast items, such as muffins, frittatas, or breakfast burritos, and freeze them. Simply reheat in the morning for a convenient and healthy meal.
Stock Your Pantry: Keep a variety of healthy staples on hand, such as whole grain cereals, nuts, seeds, fruits, and Greek yogurt. This ensures you have nutritious options readily available.
Prep Ingredients: Wash and chop fruits and vegetables in advance. Store them in the fridge for easy access when assembling your breakfast.
Set a Routine: Establish a consistent morning routine that includes time for a healthy breakfast. Prioritizing breakfast can help make it a daily habit.
Mix and Match: Combine different healthy ingredients to keep breakfast interesting. For example, mix berries into your oatmeal or add nuts and seeds to your yogurt.

Here are five easy-to-make, budget-friendly breakfasts packed with anti-inflammatory ingredients:

1. Chia Seed Pudding with Berries: Start your day with a nutrient-packed chia seed pudding. Combine chia seeds with almond milk and a touch of honey, and let it sit overnight in the fridge. In the morning, top it with fresh berries for a delicious and antioxidant-rich breakfast. Chia seeds are loaded with omega-3 fatty acids, fiber, and antioxidants, making them a perfect choice for reducing inflammation.

2. Avocado Toast with Tomato and Egg: Avocado toast is a classic and versatile breakfast option. Simply toast a slice of whole grain bread, spread mashed avocado on top, and add a slice of tomato and a fried egg. Avocados provide healthy fats and essential nutrients, while tomatoes offer antioxidants like lycopene. The egg adds protein to keep you full and energized throughout the morning.

3. Sweet Potato and Egg Breakfast Bowl: For a hearty and satisfying breakfast, try a sweet potato and egg bowl. Roast sweet potato cubes and mix them with sautéed spinach. Top the bowl with a poached or fried egg. Sweet potatoes are high in beta-carotene and fiber, which can help reduce inflammation, while spinach adds vitamins and minerals.

4. Green Smoothie: A green smoothie is an excellent way to pack in nutrients without spending much time in the kitchen. Blend together kale, spinach, banana, and almond milk. Add a tablespoon of chia seeds for extra fiber and omega-3s. This smoothie is packed with anti-inflammatory nutrients and is perfect for a quick, on-the-go breakfast.

5. Oatmeal with Nuts and Berries: Oatmeal is a timeless breakfast staple that can be customized to your liking. Cook oats with water or almond milk and top with a handful of nuts (like walnuts or almonds) and fresh berries. Oats are a great source of fiber, and nuts provide healthy fats, both of which can help reduce inflammation and keep you feeling full.

Looking for more resources on diet? Download the AiArthritis Anti-Inflammatory Food takeaway sheet or check out the blog posts about National Nutrition Month and Tips for Eating Healthy .

Check out blogs on different meal ideas:

Lunch
D inner

Harnessing Nutrition to Manage Autoimmune and Autoinflammatory Arthritis: National Nutrition Month Spotlight

Fri, 07 Mar 2025 09:46:46 GMT

Harnessing Nutrition to Manage Autoimmune and Autoinflammatory Arthritis: National Nutrition Month Spotlight

Nutrition plays a crucial role in managing autoimmune and autoinflammatory diseases for several reasons:

Reducing Inflammation: Certain foods have anti-inflammatory properties that can help reduce inflammation in the body. For example, omega-3 fatty acids found in fatty fish, flaxseeds, and walnuts can help modulate the immune response and reduce inflammation.
Supporting Immune Function: A balanced diet rich in vitamins, minerals, and antioxidants supports the immune system. Nutrients like vitamins C and E, beta-carotene, and selenium found in fruits and vegetables help neutralize free radicals and reduce oxidative stress.
Managing Symptoms: Proper nutrition can help manage symptoms of autoimmune and autoinflammatory diseases. For instance, avoiding trigger foods like gluten, dairy, and excessive sugar can alleviate symptoms and improve overall health.
Maintaining Energy Levels: A nutrient-dense diet provides the energy needed to cope with fatigue, a common symptom of autoimmune and autoinflammatory diseases. Whole grains, lean proteins, and healthy fats can help maintain steady energy levels throughout the day.
Preventing Nutrient Deficiencies: Individuals with autoimmune and autoinflammatory diseases may be at risk of nutrient deficiencies due to malabsorption or dietary restrictions. A well-balanced diet ensures adequate intake of essential nutrients to support overall health.
Improving Quality of Life: Adopting a balanced, anti-inflammatory diet can significantly improve the quality of life for individuals with autoimmune and autoinflammatory diseases. It can help reduce pain, improve mobility, and enhance overall well-being.

National Nutrition Month: A Time to Focus on Healthy Eating

National Nutrition Month , celebrated every March, is an annual campaign established by the Academy of Nutrition and Dietetics to promote healthy eating habits and raise awareness about the importance of nutrition. This year's theme, "Food Connects Us," highlights how food brings people together and its impact on health and well-being.

Proper nutrition is a powerful tool in managing autoimmune arthritis, helping to reduce inflammation and improve quality of life. National Nutrition Month provides an excellent opportunity to focus on healthy eating habits and make positive changes that can benefit both physical and mental health.

During National Nutrition Month, individuals are encouraged to focus on lifestyle to navigate inflammation:

Limit Pro-Inflammatory Foods: Reducing the intake of sugary drinks, fried foods, and refined carbohydrates can help manage symptoms and prevent flare-ups.
Focus on Hydration: Staying well-hydrated is essential for overall health and can help reduce joint stiffness and pain.
Learn About Healthy Eating: Educate yourself about making informed food choices and developing healthy eating habits.
Cook and Share Meals: Experiment with new recipes and share meals with family and friends to celebrate the connection between food and culture.
Engage in Physical Activity: Combine healthy eating with regular physical activity to maintain overall health and well-being.
Aim for Adequate Sleep: Ensure you get 7-9 hours of quality sleep each night. Poor sleep can increase inflammation.
Apply Stress Management: Practice stress-reducing techniques such as meditation, deep breathing exercises, or mindfulness. Chronic stress can contribute to inflammation.
Aim For Consistency: Maintain a consistent routine that includes regular meals, physical activity, and relaxation techniques. Consistency can help manage inflammation and improve overall well-being.
Listen to Your Body: Pay attention to how your body reacts to different foods and activities. Adjust your routine as needed to support your health and well-being.

Nutrition and Anti-Inflammatory Research Spotlight: The Mediterranean Diet

The Mediterranean diet is a heart-healthy eating plan inspired by the traditional dietary patterns of countries like Greece, Italy, and Spain. Research has shown that this diet offers numerous health benefits, including a reduced risk of cardiovascular diseases, cognitive decline, type 2 diabetes, certain cancers, and metabolic syndrome. Adherence to the Mediterranean diet is linked to lower rates of heart attacks, strokes, and overall cardiovascular mortality, as well as improved memory and executive function. Its emphasis on whole, minimally processed foods, healthy fats, and anti-inflammatory properties contributes to its protective effects.

The diet has been associated with increased longevity and reduced inflammation due to the inclusion of foods rich in omega-3 fatty acids, antioxidants, and polyphenols, making it a widely recognized healthy dietary pattern. The 2022 American College of Rheumatology (ACR) guidelines for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis (RA) recommend the Mediterranean diet for its anti-inflammatory properties. The guidelines highlight its emphasis on whole, minimally processed foods, healthy fats (such as those in olive oil and fatty fish), and a high intake of fruits, vegetables, and legumes, which can help reduce inflammation and improve overall health

Key Components of the Mediterranean Diet:

Fruits and Vegetables: Abundant consumption of a variety of fruits and vegetables, providing essential vitamins, minerals, and antioxidants.
Whole Grains: Preference for whole grains such as whole wheat, brown rice, quinoa, and oats over refined grains.
Healthy Fats: Emphasis on healthy fats, particularly extra virgin olive oil, which is rich in monounsaturated fats and antioxidants. Nuts and seeds are also included for their healthy fats and nutrients.
Lean Proteins: Moderate consumption of lean proteins, with a focus on fish and seafood (at least twice a week) for their omega-3 fatty acids. Poultry and eggs are also included, while red meat is limited.
Legumes: Regular inclusion of legumes like beans, lentils, and chickpeas as a source of plant-based protein and fiber.
Dairy: Moderate consumption of dairy products, primarily in the form of yogurt and cheese.
Herbs and Spices: Use of herbs and spices to flavor foods, reducing the need for salt and adding health benefits.
Red Wine: Optional moderate consumption of red wine, usually enjoyed with meals. (Note: This is not recommended for everyone, and individuals should consult their healthcare provider.)
Limited Processed Foods: Minimization of processed and sugary foods, refined grains, and unhealthy fats.
Social and Lifestyle Aspects: Emphasis on enjoying meals with family and friends, staying physically active, and savoring food.

Health Benefits:

Heart Health: The Mediterranean diet is known for its heart-protective benefits, reducing the risk of cardiovascular diseases.
Anti-Inflammatory: The diet's emphasis on healthy fats, fruits, vegetables, and whole grains helps reduce inflammation.
Weight Management: This diet promotes satiety and balanced nutrition, which can aid in weight management.
Chronic Disease Prevention: It may reduce the risk of chronic diseases such as type 2 diabetes, certain cancers, and neurodegenerative diseases.

Tips to Get Started

Start Small: Begin by making small changes to your diet. Swap sugary cereals for oatmeal or add a handful of berries to your morning yogurt.
Plan Your Meals: Plan your meals for the week to ensure you have healthy options available. Include a variety of fruits, vegetables, whole grains, lean proteins, and healthy fats.
Grocery Shopping: Create a shopping list based on your meal plan. Stick to the outer aisles of the grocery store where fresh produce, meats, and dairy are typically found.
Prep in Advance: Spend some time prepping ingredients in advance. Wash and chop vegetables, cook grains, and portion out snacks to make healthy eating more convenient.
Experiment with New Recipes: Try new recipes that incorporate anti-inflammatory ingredients. Cooking at home allows you to control what goes into your meals and experiment with flavors.
Be Mindful of Portions: Pay attention to portion sizes to avoid overeating. Use smaller plates and bowls to help control portions.
Listen to Your Body: Pay attention to how your body reacts to different foods. Keep a food journal to track what you eat and how it affects your symptoms.
Seek Professional Guidance: Consider consulting a registered dietitian nutritionist (RDN) for personalized advice and support. They can help you create a nutrition plan tailored to your needs.
Stay Consistent: Consistency is key to making lasting changes. Establish a routine that includes regular meals, physical activity, and relaxation techniques.

Looking for more resources on diet? Download the AiArthritis Anti-Inflammatory Food takeaway sheet or check out the blog post about healthy eating tips .

Check out blogs on different meal ideas:

March 1st: Honoring the Impact of Wheelchairs on International Wheelchair Day

Thu, 27 Feb 2025 14:45:52 GMT

March 1st: Honoring the Impact of Wheelchairs on International Wheelchair Day

The Importance of Wheelchairs

Wheelchairs have been essential for providing individuals with mobility challenges access to the world. From ancient times to modern technology, wheelchairs have evolved significantly. The self-propelled wheelchair was invented in the mid-17th century, and power wheelchairs became available by the mid-20th century, enhancing mobility for users.

Types of Wheelchairs

There are several types of wheelchairs designed to meet different needs:

Manual Wheelchairs: Propelled by the user or an attendant, suitable for those with upper body strength.
Power Wheelchairs: Electrically powered, ideal for users with limited upper body strength or severe mobility issues.
Sports Wheelchairs: Specialized for sports activities, providing greater maneuverability and speed.
Standing Wheelchairs: Allow users to switch between sitting and standing positions.
Pediatric Wheelchairs: Designed specifically for children, accommodating their growth and development needs.

Celebrating International Wheelchair Day

International Wheelchair Day celebrates advancements in wheelchair technology and the independence it provides users. It also raises awareness about the challenges faced by wheelchair users and promotes understanding of mobility solutions and disability rights. Events include wheelchair sports demonstrations, educational workshops, and community outreach programs.

Relevant Hashtags:  #InternationalWheelChairDay 

Why People with Autoimmune and Autoinflammatory Conditions Might Use a Wheelchair

People living with autoimmune and autoinflammatory conditions, such as rheumatoid arthritis, lupus, and idiopathic inflammatory myopathies, might use a wheelchair due to severe joint pain, muscle weakness, and fatigue. These conditions can cause significant mobility impairments, making it difficult for individuals to walk or stand for extended periods.

Part-time Use of Wheelchairs

Patients with these conditions might not always use a wheelchair. There can be periods of remission where symptoms are less severe, allowing for greater mobility. Additionally, some individuals might use a wheelchair only for longer distances or when fatigue sets in. Adaptive tools and treatments can also help manage symptoms, reducing the need for a wheelchair at times

The Impact of Wheelchairs with Autoimmune and Autoinflammatory Arthritis

Wheelchairs can have a significant impact on the lives of patients with autoimmune and autoinflammatory conditions. Here are some key impacts:

Enhanced Mobility: Wheelchairs provide increased mobility for patients who experience severe joint pain, muscle weakness, and fatigue, allowing them to move around more freely and participate in daily activities.
Independence: By enabling patients to move independently, wheelchairs can reduce reliance on caregivers and improve the overall quality of life.
Pain Management: For patients with conditions like rheumatoid arthritis, wheelchairs can help reduce the strain on painful joints, minimizing discomfort and preventing further damage.
Social Participation: Wheelchairs can facilitate social interactions and participation in community activities, helping patients maintain a sense of normalcy and connection with others.
Mental Well-being: The increased independence and mobility provided by wheelchairs can positively impact mental health, reducing feelings of isolation and depression.
Adaptability: Modern wheelchairs come with various features and customizations, allowing patients to choose options that best suit their needs, such as power wheelchairs for those with limited upper body strength.
Invisible Disabilities: Wheelchairs can also support individuals with invisible disabilities, such as chronic pain or neurological conditions, by providing a means to manage their symptoms and maintain mobility.

Supporting wheelchair users involves fostering inclusivity, understanding, and empathy. Here are some ways others can help:

Promote Accessibility

Advocate for accessible public spaces, including ramps, elevators, and accessible restrooms.
Support policies and initiatives that improve accessibility in your community.

Ensure Clear Pathways

Keep sidewalks, ramps, and entrances clear of snow and ice to prevent slips and falls.
Use salt or sand to provide better traction on icy surfaces.

Educate Yourself and Others

Learn about the challenges and needs of wheelchair users.
Share this knowledge with friends, family, and colleagues to raise awareness.

Be Respectful and Considerate

Always ask before offering help, and respect the person's response.
Be mindful of personal space and avoid leaning on or touching a person's wheelchair without permission.

Support Mobility Rights

Stand up for the rights of wheelchair users and advocate for their inclusion in all aspects of life.
Encourage the use of inclusive language and challenge stereotypes or misconceptions.

Enhance Social Inclusion

Include wheelchair users in social activities and events, ensuring venues are accessible.
Listen to their experiences and perspectives to understand their needs better.

What AiArthritis Diseases Are Considered Rare?

Thu, 27 Feb 2025 12:52:43 GMT

Which Ai Arthritis Diseases Can Be Considered Rare?

Classification of Rare Diseases: A Global Perspective

Rare diseases are health conditions that affect a small percentage of the population. However, the definition of what constitutes a "rare disease" can vary significantly from one country to another.

Generally, a rare disease is defined based on its prevalence within a population. For instance, in the United States, a rare disease is one that affects fewer than 200,000 people. In the European Union, a disease is considered rare if it affects fewer than 1 in 2,000 people. In India, rare diseases are defined as those that affect fewer than 1 in 2,500 people. Also there may be some diseases that are more prevalent in specific ethnicities so for those diseases, that can affect prevalence as well.

How Rare are Auto immune and Auto inflammatory Arthritis Diseases?

Autoimmune and autoinflammatory arthritis diseases encompass a spectrum of conditions with varying prevalence. While individually some of these diseases are rare, collectively they affect millions worldwide, underscoring the importance of awareness, research, and support for those living with these chronic conditions.

Considered Rare Globally

The World Health Organization defines a rare disease as one that impacts fewer than 65 per 100,000 people. Here is a breakdown of how common Ai Arthritis Diseases are.

Cryopyrin-Associated Periodic Syndromes (CAPS):

Cryopyrin-Associated Periodic Syndromes (CAPS) are a group of rare autoinflammatory disorders with an estimated prevalence of less than 1 in 1,000,000 caused by mutations in the NLRP3 gene. They all share common features such as recurrent episodes of fever, rash, joint pain, and systemic inflammation, but they vary in severity and specific symptoms.

Familial Cold Autoinflammatory Syndrome (FCAS)- FCAS is extremely rare, with an estimated prevalence of less than 1 in 1,000,000. It is primarily reported in families of North American and European descent and affects both males and females equally.
Muckle-Wells Syndrome (MWS) - MWS is also a rare condition, with an estimated prevalence of around 1 in 360,000 people. This number may vary globally due to underdiagnosis or misdiagnosis.
Neonatal-Onset Multisystem Inflammatory Disease (NOMID) - NOMID is the rarest and most severe form of CAPS, with an estimated prevalence of less than 1 in 1,000,000. It is characterized by chronic inflammation affecting multiple systems in the body from birth or early infancy.

Schnitzler Syndrome (SS):

Very rare, with an estimated prevalence of fewer than 1 in 1,000,000 people. Schnitzler Syndrome is a rare autoinflammatory disorder characterized by chronic urticaria (hives) and recurrent fever, along with bone pain, joint pain, and other systemic symptoms. Diagnosis is often challenging due to the rarity and variability of symptoms.

Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO):

The prevalence of CNO is not well-documented, but it is considered a rare condition, with fewer than 1 in 1,000,000 individuals affected. Chronic Nonbacterial Osteomyelitis (CNO) is a rare autoinflammatory bone disorder that primarily affects children and adolescents.

Familial Mediterranean Fever (FMF):

Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disorder primarily affecting individuals of Turkish, Armenian, Middle Eastern, North African Jewish, and Arab descent. The prevalence of FMF varies significantly by region, with the highest rates observed in Turkey (1 in 150 to 1 in 10,000) and Armenia (1 in 500). FMF is less common in other regions but still notable among populations with Mediterranean ancestry.

VEXAS Syndrome

VEXAS Syndrome is a rare condition, with an estimated prevalence of about 1 in every 13,591 adults. It is more common in middle-aged to older men.

Hyperimmunoglobulinemia D Syndrome (HIDS):

Rare, with several hundred cases reported globally. Hyperimmunoglobulinemia D Syndrome (HIDS) is a rare autosomal recessive genetic disorder. The syndrome typically presents in early childhood, with most patients experiencing their first attack within the first year of life. HIDS is more prevalent among individuals of Dutch and French ancestry, but cases have been reported worldwide. The exact prevalence is unknown, but it is estimated to affect several hundred people globally.

Relapsing Polychondritis (RP):

Relapsing Polychondritis (RP) is a chronic autoimmune disorder characterized by recurrent inflammation of cartilage and other tissues throughout the body. The prevalence of RP is estimated to be around 1 in 285,000 people, making it quite rare

Undifferentiated Disease (UD):

Undifferentiated Disease (UD) , is a term used to describe a condition where a person exhibits symptoms and lab test results indicative of a systemic autoimmune disorder or connective tissue disease, but these features are not specific or extensive enough to meet the criteria for a definitive diagnosis. UD is relatively common in rheumatology clinics, accounting for about 10% to 20% of referrals to rheumatology specialists

Common types of undifferentiated disease include:

Undifferentiated Connective Tissue Disease (UCTD) is relatively common among patients seen by rheumatologists, with estimates suggesting that up to 25% of patients may have UCTD.
Undifferentiated Spondyloarthritis (USpA) prevalence varies, but it is generally low, with estimates ranging from 0.0% to 0.7%.
Unclassified Seronegative Spondyloarthritis is a condition that is part of the broader category of spondyloarthritis, which has a prevalence of about 0.5% to 1% globally.
Undifferentiated Inflammatory Arthritis/Polyarthritis affects approximately 41 to 149 per 100,000 adults.

Sarcoidosis (Sarc):

Sarcoidosis and Juvenile Systemic Granulomatosis (also called Blau Syndrome or Early Onset Sarcoidosis) are rare inflammatory diseases. They are very uncommon, occurring in less than 1 person per 1.5 million people each year.

Sarcoidosis is an inflammatory disease that causes small clusters of immune cells called granulomas to form in various organs, most commonly the lungs and lymph nodes. The exact cause is unknown, but it is believed to be a combination of genetic and environmental factors. Symptoms can vary widely depending on the organs affected and may include fatigue, fever, swollen lymph nodes, and lung issues like a persistent cough and shortness of breath. In many cases, sarcoidosis resolves on its own, but some people may require treatment to manage symptoms and prevent complications.
Juvenile Systemic Granulomatosis (Blau Syndrome) and Early Onset Sarcoidosis are rare inflammatory diseases that start in early childhood. Both involve the formation of clusters of immune cells in various organs. Blau Syndrome is caused by mutations in the NOD2 gene and leads to joint, eye, and skin inflammation. Early Onset Sarcoidosis affects children and shares similar symptoms due to the same gene mutations.

Behcet's Disease (BD):

The prevalence of Behcet's Disease varies by region, being more common in the Middle East, Asia, and the Mediterranean basin, and less common in the United States and Europe. The disease typically begins in the 20s to 40s age range and affects both men and women equally

Still's Disease

Both Adult Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (sJIA) share similar systemic symptoms and are part of the Still's disease spectrum, but they differ in the age of onset and specific clinical manifestations.

Adult Onset Still's Disease (AOSD) is a rare type of arthritis that shows up unexpectedly in early adulthood. It causes symptoms like high fevers, joint pain, and a unique salmon-colored rash. AOSD is very rare, affecting about 0.22 to 0.34 people per 100,000 each year, and around 0.73 to 1.47 people per 100,000 overall. The disease mostly occurs in two age groups: 15-25 years old and 36-46 years old.
Systemic Juvenile Idiopathic Arthritis (sJIA) is a rare subtype of juvenile idiopathic arthritis that causes body-wide inflammation. It is the only subtype of JIA considered an autoinflammatory disease rather than autoimmune.sJIA accounts for approximately 10% to 20% of all cases of juvenile idiopathic arthritis. It affects both boys and girls equally and can occur at any age during childhood, most commonly starting around two years of age.

Palindromic Rheumatism (PR):

Palindromic Rheumatism (PR) is a rare type of inflammatory arthritis PR typically affects people between the ages of 20 and 50. It's estimated to affect about 1 in 20,000 people.

Antisynthetase Syndrome (ASS):

Antisynthetase Syndrome is a rare autoimmune disorder that causes inflammation in various parts of the body, including muscles, joints, lungs, and skin. Antisynthetase Syndrome is quite rare. It affects approximately 1 to 3 people per 100,000 worldwide. It's more common in women, with about 1 in 25,000 to 33,000 people being affected.

Mixed Connective Tissue Disease (MCTD):

Mixed Connective Tissue Disease (MCTD) is a rare autoimmune disorder that exhibits features of three different connective tissue diseases: systemic lupus erythematosus (SLE), scleroderma, and polymyositis. The prevalence and incidence rates vary, but it's estimated to affect about 2 to 3.8 persons per 100,000 in the general population. MCTD is more commonly diagnosed in females, with a female-to-male ratio ranging from 3:1 to 16:1.

Systemic Sclerosis (Scleroderma):

Systemic Sclerosis (Scleroderma) is a rare autoimmune disorder characterized by the hardening and tightening of the skin and connective tissues, potentially affecting internal organs like the lungs, heart, kidneys, and digestive system. There are two main types:

Limited Cutaneous Systemic Sclerosis (formerly known as CREST syndrome), which primarily affects the skin of the hands, arms, and face, progresses more slowly, and generally has a better prognosis
Diffuse Cutaneous Systemic Sclerosis, which affects larger areas of the skin including the torso, upper arms, and legs, is more likely to involve internal organs, and can lead to significant organ damage.

Considered Less Rare Globally

Sjögren's Disease (SD):

Sjögren's Disease (SD ) is a chronic autoimmune disorder that primarily affects the body's moisture-producing glands, leading to symptoms like dry eyes and dry mouth. It's more common in women, particularly those over the age of 40. The prevalence of SD varies widely, but it is estimated to affect between 0.3 to 180 per 10,000 people globally. In the United States, it is estimated that there are between 499,950 to 1,433,190 cases.
Juvenile Sjögren's Disease (juvenile SD) is much rarer and often presents differently than in adults. Children with juvenile SD may not exhibit the classic symptoms of dry eyes and dry mouth as prominently. Instead, they might experience recurrent parotitis (inflammation of the salivary glands), joint pain, and other systemic symptoms. There have been 145 recorded cases of primary juvenile SD in international pediatric literature.

Crohn's Disease

Arthritis is a common extraintestinal manifestation of Crohn's disease , affecting up to 30% of individuals with the condition. The number of people diagnosed with Crohn's disease is increasing, and it is considered one of the highest prevalence rates of IBD in the world.

Juvenile Idiopathic Arthritis (JIA):

The most common type of arthritis in children , with several subgroups including oligoarticular JIA, polyarticular JIA, and enthesitis-related arthritis (ERA).

Oligoarticular JIA: This is the most common form, affecting about 50% of children with juvenile idiopathic arthritis (JIA). It involves fewer than five joints, often the knees and ankles.
Polyarticular JIA: This type affects 5 or more joints and is less common than oligoarticular JIA. It can be more severe and persistent.
Enthesitis-related arthritis (ERA): This form is less common but still significant, involving inflammation where tendons and ligaments attach to bones.

Psoriatic Arthritis (PsA) and Juvenile Psoriatic Arthritis (JPsA):

Psoriatic Arthritis (PsA ) is a chronic inflammatory arthritis that often occurs in association with psoriasis. The global prevalence of PsA is estimated to be around 112 per 100,000 adults. It's more common in Europe and North America compared to Asia and South America.
Juvenile Psoriatic Arthritis (JPsA) is a subtype of juvenile idiopathic arthritis (JIA) and constitutes about 5% of JIA cases making it relatively rare. Girls are slightly more likely to develop JPsA than boys.

Systemic Lupus Erythematosus (SLE) and Juvenile Systemic Lupus Erythematosus (JSLE):

Systemic Lupus Erythematosus (SLE) , commonly known as lupus, is more common in women, particularly those of childbearing age, and its prevalence varies globally, being more prevalent among certain racial and ethnic groups.
Juvenile Systemic Lupus Erythematosus (JSLE) , or childhood-onset SLE, occurs in children and adolescents. While it shares many similarities with adult SLE, JSLE tends to be more severe and can lead to earlier organ damage. It affects approximately 1.1 to 9.7 per 100,000 children and adolescents worldwide.

Lupus is generally considered a rare disease in many countries, though classifications vary based on prevalence thresholds:

In Europe, lupus is considered rare, with an estimated prevalence of fewer than 5 in 10,000 people.
In the United States, it's classified as rare if it affects fewer than 200,000 people.
In India, lupus is deemed rare when it affects fewer than 1 in 2,500 people.

Despite these classifications, lupus affects over 5 million people worldwide. It's a complex autoimmune disease that can impact multiple organs and presents with a wide range of symptoms

Rheumatoid Arthritis (RA):

Thought to be the most common autoimmune arthritis, though axial spondyloarthritis may be taking the lead now. RA affects millions of people worldwide. Rheumatoid arthritis (RA ) is not extremely rare, but it's not incredibly common either. Approximately 1% of the worldwide population is affected by RA. In the United States, over 1.3 million Americans are living with RA. The prevalence tends to be higher in industrialized countries, and women are about two to three times more likely to develop RA than men.

Axial Spondyloarthritis (AxSpA):

Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA) are subtypes of Axial Spondyloarthritis (AxSpA), a chronic inflammatory condition affecting the spine and sacroiliac joints. AxSpA is significant, affecting about 0.9% to 1.4% of the U.S. population.

Ankylosing Spondylitis (AS) is diagnosed when there is radiographic evidence of sacroiliitis (inflammation of the sacroiliac joints) seen on X-rays. It's relatively rare globally, with a prevalence ranging from 0.1% to 1.4%. Higher rates are observed in Northern Arctic communities, while lower rates are seen in Sub-Saharan Africa. AS typically presents with chronic back pain and stiffness and can lead to the fusion of vertebrae, resulting in reduced flexibility and mobility.
Non-Radiographic Axial Spondyloarthritis (nr-axSpA) presents similar symptoms to AS, such as persistent pain and stiffness in the lower back and buttocks, but lacks definitive radiographic evidence of sacroiliitis. Its prevalence is less well-documented but is believed to be more common than AS. Studies show that 5% to 30% of individuals with nr-axSpA may progress to AS over a period of 2 to 30 years.
Juvenile Axial Spondyloarthritis refers to AxSpA occurring in children and adolescents. It is rare and can present similarly to adult AxSpA but may involve other joints and cause symptoms like enthesitis (inflammation of tendons and ligaments) and uveitis (eye inflammation).

Staying Productive with Brain Fog: Strategies for Success

Wed, 12 Feb 2025 23:17:18 GMT

Staying Productive with Brain Fog: Strategies for Success

Strategies for Staying Productive with Cognitive Dysfunction

1. Use External Memory Aids

If brain fog makes it difficult to remember important details, structure and organization can help:

Use planners, apps, or sticky notes to keep track of tasks and appointments.
Break larger tasks into smaller, manageable steps.
Set reminders or alarms for important activities.
Prioritize tasks based on urgency and importance.
Create to-do lists and develop daily routines to enhance consistency.

Lived-Experience Tips from Fellow Patients:

"I rely on voice-to-text and Google Calendar to keep track of everything with reminders."
"I use alarms and post-it notes, and my sister and I share tips for managing fatigue and brain fog."
"Writing things down where I can see them—whiteboards, post-its, and calendar reminders—keeps me on track."
"When I’m overwhelmed, I stop, make a list, and prioritize tasks based on urgency."

2. Manage Your Energy, Not Just Your Time

Instead of focusing solely on time management, consider energy management:

Schedule tasks for when you feel most alert and focused.
Alternate between high-focus tasks and less demanding activities.
Take short breaks between tasks to reset your brain.
Reduce sensory stimuli when tired by working in a quiet space or using noise-canceling headphones.
Spend time outdoors and stay physically active to enhance cognitive function.

Lived-Experience Tips from Fellow Patients:

"My brain fog is worst when my fatigue is at its peak. A short 20-minute nap can help."
"Instead of a to-do list, I track what I’ve accomplished—it helps keep me motivated."

3. Create a Structured Routine

A predictable routine can help reduce mental strain:

Start your day with a consistent morning routine.
Group similar tasks together to minimize mental transitions.
Set designated times for work, rest, and self-care.
Develop routines that incorporate occupational therapy techniques, such as memory aids and task organization strategies.

4. Use Simplified Decision-Making Techniques

Making decisions can feel overwhelming when dealing with brain fog. Try:

Limiting choices to reduce decision fatigue.
Using checklists to streamline tasks.
Pre-planning meals, outfits, and routines to conserve mental energy.
Engaging in humor and maintaining perspective to reduce cognitive strain.

5. Reduce Mental Clutter

Decluttering your physical and digital spaces can improve focus:

Keep your workspace tidy and organized.
Minimize unnecessary digital notifications.
Store frequently used items in designated places to avoid searching for them.

6. Communicate Your Needs

Cognitive dysfunction can be invisible to others, making it important to advocate for yourself:

Explain your symptoms to family, friends, or coworkers.
Ask for accommodations at work if needed, such as flexible deadlines or note-taking assistance.
Seek support from patient communities or support groups.
Educate yourself about cognitive dysfunction—psychoeducation can empower you to manage symptoms better.

7. Consider Natural Supplements

In addition to maintaining a healthy diet, some natural supplements may aid cognitive function:

Lion’s Mane mushrooms – Known for its neuroprotective properties and potential to enhance memory and focus.
Omega-3 fatty acids – Found in fish oil and flaxseeds, which support brain health.
Vitamin B12 – Essential for nerve function and cognitive clarity.
Magnesium – Plays a role in brain function and relaxation.
Ginseng – May help with energy levels and mental alertness.

Before trying any supplement, consult with your healthcare provider to ensure it’s safe for you.

Additional Insights from EULAR 2024

Cognitive dysfunction is influenced by fatigue, pain, physical inactivity, psychological distress, and sleep problems. Managing these factors is crucial.
Occupational therapy can help individuals with cognitive dysfunction by teaching strategies like memory aids and structured routines.
Research highlights the need to address cognitive dysfunction as part of overall disease management, as symptoms often peak during flares or before infusions.
Screening tools like the Montreal Cognitive Assessment (MoCA) and the Multidimensional Inventory of Subjective Cognitive Impairment (MISCI) can help assess cognitive function and challenges like task-switching and word retrieval.
Emphasis is placed on managing the impact of cognitive dysfunction rather than solely treating symptoms, with hope for future research leading to better treatments.

Cognitive dysfunction can make productivity feel like an uphill battle, but implementing these strategies can help you stay on track. By using external memory aids, managing energy levels, and structuring your day effectively, you can work through brain fog and accomplish what matters most. Remember, what works for one person may not work for another, so be patient with yourself as you experiment with different approaches.

Shining a Light on the Unseen: Understanding Rare Disease Month

Sat, 08 Feb 2025 16:22:03 GMT

Shining a Light on the Unseen: Understanding Rare Disease Month

The Origin of Rare Disease Month

Rare Disease Month began in 2008 when EURORDIS (the European Organization for Rare Diseases) launched the first Rare Disease Day on February 29th —a rare date that occurs only once every four years. This symbolic choice highlighted the uniqueness of rare diseases and the challenges faced by those living with them. The initiative aimed to raise awareness among the general public and decision-makers about the profound impact these conditions have on patients' lives. Since then, Rare Disease Day has been observed annually on the last day of February, expanding into a month-long campaign in many countries. This global movement unites patients, families, caregivers, and healthcare professionals to shine a light on rare diseases, promote research, and advocate for improved access to treatments and support.

Why Rare Disease Month?

Rare Disease Month is all about bringing attention to diseases that affect a small percentage of the population. A disease is typically classified as rare when it impacts fewer than 200,000 people in the United States or fewer than 1 in 2,000 people in Europe. There are over 7,000 known rare diseases , many of which are genetic and manifest early in life.

The expansion from a single day to an entire month allows for a greater range of activities and events, maximizing awareness and fostering a stronger sense of community. Rare Disease Month has become a catalyst for change, driving policy improvements and encouraging collaborations that benefit the rare disease community. If you're inspired to get involved, there are numerous ways to participate—from attending local events and sharing stories on social media to supporting organizations dedicated to rare disease research and advocacy.

Why Is Rare Disease Month So Important?

Amplifying Voices : Many rare disease patients feel isolated due to the lack of understanding and resources. This month gives them a platform to share their stories and connect with others.
Promoting Research : Rare diseases often receive less funding and attention. Awareness campaigns encourage investments in research, leading to better treatments and hope for cures.
Educating the Public : Increasing knowledge about rare diseases reduces misconceptions and promotes empathy within communities.
Early Diagnosis : Increased knowledge among healthcare professionals and the public can lead to earlier detection and intervention.
Influencing Policy : Advocacy efforts can lead to policy changes that improve access to healthcare, support services, and patient rights.
Support Networks : Connecting patients and families facing similar challenges fosters a community of support and shared resources.

How You Can Get Involved

Share Stories : Use social media to spread awareness. Personal experiences can be powerful tools for education.
Participate in Events : Many organizations host walks, seminars, and virtual events. Joining in shows solidarity and helps raise funds.
Support Organizations : Donating time or money to nonprofits dedicated to rare diseases can make a tangible difference.
Advocate : Reach out to local representatives to support legislation that benefits rare disease research and patient care.

Why the Zebra is a Symbol for Rare Diseases

The zebra has become the emblem for rare diseases due to a medical adage: "When you hear hoofbeats, think horses, not zebras." This saying encourages doctors to consider common diagnoses before rare ones. However, for those of us with rare diseases—the "zebras"—this mindset can lead to misdiagnosis or delayed treatment.

Rare Disease Organizations To Follow

These organizations are vital for those affected by rare diseases. They engage in advocacy and policy change to improve access to diagnosis and treatment, provide research funding for new treatments and cures, offer patient support and education through resources and support groups, and run awareness campaigns like Rare Disease Day to raise public consciousness.

Rare diseases impact over 300 million people worldwide but are often misunderstood or overlooked. These organizations work to connect patients and families, reducing isolation, accelerate research by fostering collaboration, and improve quality of life

National Organization for Rare Disorders (NORD)

NORD is a U.S.-based patient advocacy organization dedicated to individuals with rare diseases and the groups that serve them. Founded in 1983, NORD provides support programs, educational resources, and advocates for policy changes to advance care and research.

Global Genes

Global Genes is a global non-profit advocating for the rare disease community. They focus on eliminating challenges faced by people with rare diseases through advocacy, awareness, and education. They host events like the Rare Patient Advocacy Summit, bringing together patients, caregivers, and experts.

Rare Diseases International (RDI)

RDI is the global alliance of people living with a rare disease, uniting national and regional patient organizations from around the world. They advocate for rare diseases as an international public health priority and collaborate with international agencies like the World Health Organization.

EURORDIS - Rare Diseases Europe

EURORDIS is a non-profit alliance of over 900 patient organizations from more than 70 countries. They work to improve the lives of people living with rare diseases in Europe through advocacy, support for research, and facilitating patient engagement.

Genetic and Rare Diseases Information Center (GARD)

GARD, a program of the National Center for Advancing Translational Sciences (NCATS), provides the public with access to current, reliable information about rare and genetic diseases in understandable language.

EveryLife Foundation for Rare Diseases

This foundation works to accelerate biotech innovation for rare disease treatments through science-driven public policy. They focus on removing barriers that prevent the development of life-saving treatments.

Rare Disease Foundation

Based in Canada, they focus on transforming the lives of children living with rare diseases through community-connected research and care. They fund Microgrant Programs to support innovative research projects.

Rare Voices Australia

As Australia’s national alliance representing people living with a rare disease, they advocate for policy reform, raise awareness, and support the implementation of the National Strategic Action Plan for Rare Diseases.

Canadian Organization for Rare Disorders (CORD)

CORD is Canada’s national network for organizations representing all those with rare disorders. They work with governments, researchers, and industry to promote research, diagnosis, treatment, and services for all rare disorders in Canada.

Rare Disease UK

The national alliance for people with rare diseases and those who support them in the UK. They campaign for health and social care policies that work for people with rare diseases.

Asia-Pacific Alliance of Rare Disease Organizations (APARDO)

APARDO brings together rare disease patient organizations from across the Asia-Pacific region to collaborate on advocacy, awareness, and patient support initiatives.

International Rare Diseases Research Consortium (IRDiRC)

IRDiRC unites national and international organizations investing in rare disease research to achieve common goals, like accelerating medical breakthroughs for people with rare diseases.

What Is Rheumatoid Arthritis Awareness Day and Why Does It Matter?

Sun, 02 Feb 2025 13:11:00 GMT

What Is Rheumatoid Arthritis Awareness Day and Why Does It Matter?

February 2nd Annually

Rheumatoid Arthritis Awareness Day, observed annually on February 2nd, is a vital initiative aimed at spreading awareness about rheumatoid arthritis (RA), an autoimmune disease that affects millions of people worldwide.

Origin of Rheumatoid Arthritis Day

Established by the Rheumatoid Patient Foundation (RPF) in 2013, this day seeks to educate the public about the challenges faced by those living with RA and to dispel common myths surrounding the condition. Unfortunately it appears as this organization is no longer active, stating on their facebook last year that their domain no longer belongs to them either. It’s unfortunate to see no activity on this day, which is why I am making content and raising my voice as someone living with rheumatoid arthritis.

Why is Rheumatoid Arthritis Awareness Day Important?

Rheumatoid Arthritis Awareness Day is important because it educates the public about RA, encouraging early diagnosis and treatment. It promotes advocacy and support, dispels myths, highlights the challenges faced by individuals with RA, and encourages research and innovation. The day also builds support networks, helping people with RA manage the disease more effectively and fostering a sense of community and understanding.

What Is Rheumatoid Arthritis?

RA is a chronic inflammatory disorder that primarily affects the joints, causing pain, swelling, stiffness, and loss of function. However, its impact extends beyond the joints, potentially affecting other organs such as the heart and lungs. Some individuals experience flare-ups with increased joint soreness, followed by periods of few symptoms, while others may have gradually worsening symptoms over time. Despite its prevalence, RA is often misunderstood, leading to delayed diagnosis and treatment.

Symptoms of Rheumatoid Arthritis

Joint pain and stiffness : Especially in the morning or after periods of inactivity.
Swelling : Persistent swelling in multiple joints, particularly in the hands, wrists, and feet.
Fatigue : Feeling unusually tired.
Fever and loss of appetite : Sometimes present.
Symmetrical symptoms : Affecting the same joints on both sides of the body.

How To Ask Your Doctor About Rheumatoid Arthritis

The first step to a rheumatoid arthritis test is to bring up your symptoms to your family physician, ask for the appropriate blood work and referral to see a rheumatologist. The sooner the better because wait times to see rheumatologists are often long as there is a lack of them in many communities.

Describe your symptoms : Be specific about the pain, stiffness, and swelling you're experiencing. Don’t forget to mention fatigue, malaise, or cognitive dysfunction if you are experiencing these. Discuss how they are impacting your everyday life and how long they have been happening. Be sure to mention if anything makes your symptoms worse or feel better. I highly suggest writing them out, be precise and do not skip any details.

Ask about diagnostic tests and referral to a rheumatologist : Inquire about blood tests (like rheumatoid factor and anti-CCP antibodies) and imaging tests (like X-rays or MRIs). Rheumatologists are the ones who diagnose patients with rheumatoid arthritis or similar conditions.

Diagnosing Rheumatoid Arthritis

Physical examination : Checking for joint swelling, redness, and warmth.
Blood tests : Elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), rheumatoid factor, and anti-CCP antibodies.
Imaging tests : X-rays, MRI, or ultrasound to assess joint damage.

Not All Rheumatoid Arthritis Is The Same

Seropositive rheumatoid arthritis (RA) is characterized by the presence of specific antibodies, such as rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies, in the blood. These antibodies are typically absent in seronegative RA. While both forms involve similar symptoms, such as joint pain, swelling, and stiffness, seropositive RA may be associated with more severe disease progression and a higher risk of extra-articular manifestations (involving organs other than the joints), compared to seronegative RA.

Not everyone’s rheumatoid arthritis is the same, there are mild, moderate and severe which are similar but have a different impact on someone’s life and are treated differently.

Mild Rheumatoid Arthritis

Symptoms : Joint pain, stiffness, and slight swelling, primarily affecting smaller joints like fingers and toes.
Impact : Symptoms are manageable with over-the-counter medications and regular activity. Minimal effect on daily activities and quality of life.
Treatment : Non-steroidal anti-inflammatory drugs (NSAIDs) and physical therapy.

Moderate Rheumatoid Arthritis

Symptoms : More noticeable joint pain, swelling, and stiffness, often in larger joints such as the wrists, elbows, and knees. Symptoms may last longer and be more persistent.
Impact : Daily activities become more challenging, and there may be occasional flare-ups. Reduced range of motion and increased fatigue.
Treatment : Disease-modifying antirheumatic drugs (DMARDs), biologics, physical therapy, and lifestyle changes.

Severe Rheumatoid Arthritis

Symptoms : Intense pain, severe swelling, significant joint deformity, and loss of function. Symptoms may affect multiple joints and other body parts, including the skin, eyes, lungs, heart, and kidneys.
Impact : Major limitations in daily activities and mobility, requiring assistance for routine tasks. High risk of complications and other health issues.
Treatment : Advanced DMARDs, biologics, corticosteroids, and potentially surgery to repair or replace damaged joints.

There Are Over 100+ Forms Of Arthritis

If it's not rheumatoid arthritis (RA), several other conditions could present similar symptoms:

Osteoarthritis (OA) : A degenerative joint disease often called "wear-and-tear" arthritis.
Lupus : An autoimmune disease affecting multiple organs, including joints.
Sjögren's Disease : Another autoimmune disorder causing dry eyes and mouth, along with joint inflammation.
Psoriatic Arthritis : Associated with psoriasis, causing joint pain and swelling.
Lyme Disease : Caused by a tick bite, leading to joint pain and swelling.
Gout : Caused by uric acid crystals in the joints, leading to severe pain and swelling.
Fibromyalgia : Characterized by widespread pain and tenderness in the muscles and soft tissues.

Each of these conditions has distinct features and requires different treatments, so it's important to get an accurate diagnosis from a rheumatologist.

Creating Awareness For Rheumatoid Arthritis Awareness Day

The colors indigo and gold symbolize Rheumatoid Arthritis Awareness Day. Indigo represents wisdom, knowledge, and infinity, highlighting the importance of understanding and awareness. Gold symbolizes hope and triumph, offering optimism to those affected by RA and the hope for a cure.

Other Rheumatoid Arthritis awareness ribbon colors include purple and blue. Purple represents courage and strength, highlighting the resilience of those living with rheumatoid arthritis and their determination to manage the condition. Blue symbolizes hope and support, evoking feelings of optimism for those affected by RA and emphasizing the importance of support networks in managing the disease.

Here are some ways to create awareness for Rheumatoid Arthritis Awareness Day:

Social Media Campaigns : Share information and personal stories with relevant hashtags. Encourage other people with RA to share their experiences. - #RheumDay, #TheRealRD #RheumAwarenessDay #RheumatoidArthritisAwareness #RheumatoidArthritisAwarenessDay
Wear the Ribbon, Colors or Merchandise :Proudly display the purple and blue or purple and indigo awareness ribbon, wear the colors in your clothing, or use related merchandise to show support and spark conversations.
Educational Content and Share Resources : Create and share informative videos, blogs, and articles. Distribute educational materials in community spaces.
Fundraising: Organize events to support RA research and patient fronted organizations.

Other awareness dates for Rheumatoid Arthritis

February 2 – Rheumatoid Arthritis Awareness Day – #RheumatoidArthritisAwarenessDay
May – Arthritis Awareness Month in the US – #ArthritisAwarenessMonth
September – Arthritis Awareness Month in Canada – #ArthritisAwarenessMonth
September – Pain Awareness Month in the US – #PainAwarenessMonth
September – Rheumatic Disease Awareness Month in the US – #RDAM
September 12-17 – Rheumatoid Arthritis Awareness Week in the UK
October 7-13 – National Arthritis Week UK- Arthritis Research UK
October 12 – World Arthritis Awareness Day – #WorldArthritisAwarenessDay
October 15-21- Invisible Disabilities Week #InvisibleDisabilitiesWeek
December 3 – International Day of People With Disabilities – #InternationalDayOfPeopleWithDisabilities

An Unexpected Detour: Life With Mixed Connective Tissue Disease

Sun, 02 Feb 2025 12:45:59 GMT

An Unexpected Detour: Life With Mixed Connective Tissue Disease

No one expects their life to change dramatically over a short period of time.

No one expects their life to change dramatically over a short period of time. This story highlights the most stressful period of my life in my mid-twenties. Traveling through the unfamiliar terrain of a new job, new city, and new relationships, I was trying to establish my career and a new, “normal” life away from college and all that was familiar. Crashing through was a diagnosis that changed my life. forcing me to plan differently, give up plans, and make new ones, to live as fully as possible with a rare, chronic disease. With no cure, and 40 years ago, limited effective treatments I share here my experiences as a young person who went from devastated to coping, to dare I say it, living well and thriving. I am not a medical professional. All opinions and medicals comments are from my personal experience and are my own.

Born and raised in Philadelphia, upon college graduation, with my degree and teaching certificate in hand I followed my passion for teaching to the Washington, DC area, where I went to work in a private Christian school as a second-grade teacher. Teaching was hard, the pay was low, but I loved it and poured myself into it. For the next few years, I taught thoroughly enjoying all of it.

During my fifth (and as it turns out, last) year of teaching I began getting sick. I had recently ended a long-term relationship that had been caring but unexceptional. Unfortunately, my boyfriend had mental health issues surrounding rejection that proved toxic, appearing suddenly after a seemingly amicable break-up. I didn’t understand how toxic until he began appearing unexpectedly outside of places I frequented, showing up and making threats at my workplace, and even vaguely threatening a police officer. The officer later said to me “Unfortunately since you two are not married, I can’t arrest him, but I’ll be telling my colleagues to keep an eye out for him.” This frightened me even more. A Psychologist advised me to leave the state. Being the 1980s, stalking laws were not in place, at least in my state, so I bore this burden with the help of friends, prayer, and a nervous system on constant high alert. This continued for nearly a year, although it felt much longer, with the stalking finally tapering off.

With fear and anxiety running high and 4 years of being sick with every infection and illness my little second graders could share with me I knew this level of intensity could not continue. Symptoms of what I simply called stress emerged. Walking up my apartment steps I became out of breath and needed to rest on the landing before continuing. In the shower, I would reach over my shoulders to wash my back and could not keep my arms up due to muscle fatigue. This was odd to me, since I took aerobics classes, but soon the classes became too hard for me

to do. I ran fevers but didn’t have an infection I could pinpoint. Then one day, I woke up in the morning and my hands felt funny. Lying in bed, I looked down to see hands I didn’t recognize. Puffy, swollen to twice their normal size and painful. This alarmed me, having just finished reading a book about a woman who had liver failure whose symptoms included just that! At 25 years old, I had been raised by depression-era parents who took us to medical appointments only infrequently, and only when “absolutely necessary”. With no habit of routine medical care

or an established doctor to call on, I randomly picked one and made an appointment.

To say the appointment was disappointing is an understatement. My blood work was “unremarkable.” The physical examination did not seem of interest. I told him about joint pain in many joints. He laughed when I said my elbows hurt. I held up my hands and said, “But what about my hands?” The response? “Some people’s hands just do that.” At that, I left the office deeply discouraged and unsure what to do next. As a shy and unassertive person at the time, I would have typically accepted that and soldiered on. But this time I said to myself “I know my hands don’t swell like this, and I also know I have been feeling bad for a while.” With courage I didn’t typically have, I called his office back for a referral. Any referral. Surprisingly, he agreed and referred me to a Cardiologist. I was scared but was never happier to go to a doctor’s appointment.

A kinder man I could not have encountered at the Cardiology office. Dr. Shah, a Sigmund Freud look-alike, did a very thorough physical examination, questioned me about all aspects of my life and health, then brought me back to his office. He looked at me intently for a few moments, thinking, and then took my temperature. He pulled a book off his shelf, shuffled through it then said, “Late-afternoon fevers……Lupus.” He looked at me with compassion, and said “Young woman, I don’t know what you do have, but I know you do not have a disease in my specialty. I’d like you to see a Rheumatologist.” He referred me to the Rheumatologist who would go on to diagnose me and manage my care for the next 35 years.

Meanwhile, I felt completely drained with no energy upon waking nor throughout the day. I was fortunate to have the only student teacher utilized in our school that year and she got quite an education. I had so many doctor appointments and felt so unwell during the January term that perhaps slightly before she may have been ready, I allowed her to take on most of the teaching, sparing me walking, standing, and doing things I was increasingly unable to do. I called a nurse-friend one morning on the day of a field trip, and said “I can’t do it.” I’m so stiff I can’t

move much less walk all day around a botanical garden.” She listened then recommended I get up, take a warm bath and aspirin, and see if that helped. It helped enough that I did go on that field trip. This was a significant first lesson in coping with chronic illness. Calling on others when needed and pushing myself gently to do things when it was important enough for me to do. I felt proud that I had shown up for “my kids” that day amidst days of sadness and unwellness.

But I was very eager for my appointments with the Rheumatologist, Dr. Oliver Lawless. Sitting in his office after an examination and more bloodwork, he pointed to a whiteboard, upon which he had written unfamiliar words. Rheumatoid Arthritis. Systemic Lupus Erythematosus. Mixed Connective Tissue Disease. Scleroderma. “It’s not clear yet, but I believe you have one of these diseases.” The words were all unknown to me, so scared and fearful for the future did not even begin to convey my feelings. What I remember well is that he took the time to briefly explain each of these diseases and say “I will help you. We’ll get through it.” He also added that he hesitated to diagnose me with anything at my young age as it would affect my future ability to get life insurance and would saddle me with a “pre-existing condition label,” should I change jobs in the future. Lack of health care coverage for an illness deemed “pre-existing” (and thus excluded from coverage in the US) was a serious concern in the 1980’s. These concerns were too “adult” for me at the time, but I was grateful with my limited resources and support, that he was “on it.”

My symptoms became more pronounced: rashes, fevers, joint pain, and swelling, continued hand-swelling, Raynaud’s, increasingly abnormal bloodwork. This led to routine changes to medications. After another round of lab work, I received a message at work one day to call his office for the results. Upon doing so he asked me to come in but would not convey why over the phone. Alarmed, I asked him if I could bring a friend with me, and he said it would be a good idea. Upon seeing him my friend and I were told, based upon blood test results and my symptoms over time, I had MCTD. With the anti-RNP positive, the ANA very high positive and speckled, the rest of the blood work and clinical signs were sufficient for a diagnosis.

The sense of relief I felt was palpable. Since my initial presentation looked like Lupus and it was easier to say than “Mixed Connective Tissue Disease” I often said, “I have Lupus.” As the years went by, I began working for a technology company, and different features of MCTD emerged. After endoscopies and esophageal motility studies prompted my gastroenterologist to say, “That’s a Scleroderma gut;” after a physical therapist said, “Those are Rheumatoid arthritis hands,” and after a consulting Rheumatologist said, “Well don’t you just have your very own

unique disease,” I determined it was best to simply state “I have Mixed Connective Tissue Disease” and then define it at the audience’s level of need and interest.

After flareups were repeatedly tamped down with medications and having made determined efforts to reduce unnecessary stress, I went into a sustained remission. Over time, I felt fortunate to be able to take my concerns to a faith community who prayed for and with me, and with whom I enjoyed a deep level of practical support and emotional and spiritual care. At menopause, my bloodwork went a little crazy, but with no obvious clinical issues, my dear Rheumatologist’s response was to simply monitor me, which in that case was the best course. I remain in clinical remission at this point in life in my mid-sixties. The Scleroderma-like features that appeared early remain but are managed; aging has not improved decades of joint, muscle and tendon problems, so I find myself addressing issues as they come. It has been interesting to realize I am now dealing with problems of aging, being of an age I was not sure I would ever reach.

With nearly 40 years of chronic illness “under my belt” I’m reminded of one of the first books I read about chronic illness, highlighting the life of Henrietta Aladjem, a founder of the Lupus Foundation of America, Inc. She lived a good long life with periods of life-threatening Lupus activity. Reading her biography early on convinced me there is life after diagnosis with chronic illness. I continue to try to make the most of mine and hope this article has encouraged you to do the same.

Community Chat Takeaway: Anti-Inflammatory Foods & Recipes

Fri, 03 Jan 2025 13:09:27 GMT

Community Chat Takeaway: Anti-Inflammatory Foods & Recipes

Why an Anti-Inflammatory Diet? For individuals with AiArthritis diseases, an anti-inflammatory diet can be a powerful tool in preventing or delaying the onset of co-morbidities such as cardiovascular disease and lupus nephritis. This dietary approach focuses on incorporating foods that reduce inflammation, offering a holistic way to manage health.

What Foods Are Considered Anti-Inflammatory?

Increase fish intake for protein, rich in omega-3 fatty acids.
Consume 1-2 cups of fruit and 2-3 cups of vegetables daily.
Opt for vegan or plant-based options when possible.
Limit cooking oils high in omega-6 fatty acids (e.g., vegetable and canola oil) and choose oils rich in monounsaturated fats (e.g., olive and avocado oil).
Nuts are an excellent source of monounsaturated fats.
Choose whole grains over refined grains.
Don’t view white rice and potatoes as "bad." These foods, when heated, cooled, and reheated, can introduce beneficial bacteria to the digestive tract.
Remember that dietary tips are not "one-size-fits-all"; each person has unique triggers. An elimination diet can help identify these triggers (e.g., gluten, dairy).

Additional Diet Tips for Reducing Inflammation and Promoting Overall Healthy Eating:

Eat a Variety of Colors: Incorporate a range of colorful fruits and vegetables into your meals. Each color provides different antioxidants and nutrients that can help reduce inflammation.
Include Healthy Fats: Integrate healthy fats like those found in avocados, olive oil, and fatty fish. These fats contain anti-inflammatory properties that can help manage symptoms and improve heart health.
Spice It Up: Add anti-inflammatory spices like turmeric, ginger, and cinnamon to your dishes. These spices not only enhance flavor but also provide powerful anti-inflammatory benefits.
Stay Hydrated: Drink plenty of water throughout the day to help flush out toxins and keep your body functioning optimally. Staying hydrated is crucial for overall health and can aid in reducing inflammation.
Eat Lean Protein: Include sources of lean protein such as chicken, turkey, tofu, and legumes. Protein is essential for maintaining muscle mass and overall health.
Avoid Processed Foods: Limit your intake of processed foods, sugary snacks, and beverages. These foods can increase inflammation and contribute to various health issues.
Opt for Fermented Foods: Incorporate fermented foods like yogurt, kefir, sauerkraut, and kimchi into your diet. These foods are rich in probiotics that support gut health and can help reduce inflammation.
Balance Your Meals: Ensure each meal contains a balance of carbohydrates, proteins, and fats. This balance can help maintain stable blood sugar levels and reduce inflammation.
Limit Red Meat: Reduce your consumption of red and processed meats, which can contribute to inflammation. Instead, focus on plant-based proteins and lean meats.
Mindful Eating: Practice mindful eating by paying attention to your hunger and fullness cues, and savoring each bite. This can help you make healthier choices and improve your relationship with food.

Diet Tips:

Success in changing one’s diet depends on individual needs, budget, and lifestyle. Realistic, small changes are more sustainable than drastic overhauls.
Avoid disordered eating by incorporating foods you enjoy and that meet your nutritional needs.
Save money by gardening or buying in bulk; frozen fruits and vegetables are nutritious options.
Make healthy adjustments to the food you already have, like adding vegetables to canned soup or macaroni and cheese.
Small swaps, such as choosing whole grain noodles, can make a significant impact.
Changing one meal at a time, like starting with a nutritious breakfast, can lead to positive long-term habits.
Recognize your limitations and find replacements for foods you don’t like within the same food group.

Resources from Our Special Guests:

Cristina Montoya (@ArthritisDietitian): Website
Deb Constien (@debconstien): Anti-inflammatory Diet Tips Handout

We hope these tips and resources help you on your journey towards a healthier, more anti-inflammatory lifestyle!

A Guide To Antisynthetase Syndrome

Fri, 27 Dec 2024 14:12:38 GMT

Understanding Antisynthetase Syndrome

Antisynthetase Syndrome (ASS) is a rare autoimmune disorder characterized by inflammation in various parts of the body, including muscles, joints, lungs, and skin. This condition is associated with the presence of specific autoantibodies called antisynthetases, which target aminoacyl-tRNA synthetases, enzymes crucial for protein synthesis.

Antisynthetase Syndrome (ASS) is a relatively recent addition to the spectrum of autoimmune diseases, first described in the late 20th century. The syndrome is characterized by the presence of antisynthetase antibodies, which target aminoacyl-tRNA synthetases, enzymes crucial for protein synthesis.

Key Milestones in the History of Antisynthetase Syndrome (ASS)

Late 1980s : The first cases of ASS were identified, with patients presenting symptoms such as myositis, interstitial lung disease (ILD), and mechanic's hands.
1990s : Researchers began to recognize the association between antisynthetase antibodies and ASS, leading to a better understanding of the disease.
Early 2000s : The anti-Jo-1 antibody was identified as the most common antisynthetase antibody in ASS patients. This discovery helped in the diagnosis and differentiation of ASS from other myositis-related conditions.
Recent Years : Advances in diagnostic techniques, such as more sensitive antibody tests and imaging studies, have improved the detection and management of ASS.
Ongoing Research : Current research continues to explore the pathogenesis of ASS, the role of genetic and environmental factors, and the development of targeted therapies.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog , making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Antisynthetase Syndrome (ASS)

The symptoms of ASS can vary widely but often include:

Myositis : Chronic inflammation of the muscles, leading to muscle pain, weakness, and fatigue.
Mechanic's Hands : Thickened, cracked skin on the palms and fingers.
Interstitial Lung Disease (ILD) : Inflammation and scarring of the lung tissue, causing shortness of breath, dry cough, and chest discomfort.
Polyarthritis : Arthritis affecting five or more joints simultaneously, resulting in joint pain, stiffness, and swelling.
Raynaud's Phenomenon : Color changes and numbness in the fingers and toes in response to cold or stress.
Fever : Unexplained fevers that are not related to infections.

Causes of Antisynthetase Syndrome (ASS)

The exact cause of ASS is unknown, but it is believed to involve a combination of genetic and environmental factors. The presence of antisynthetase antibodies suggests an autoimmune response where the immune system mistakenly attacks the body's own tissues.

Diagnosis of Antisynthetase Syndrome (ASS)

Medical History and Physical Examination : Detailed medical history and physical examination to identify characteristic symptoms.
Laboratory Tests : Blood tests to detect antisynthetase antibodies and other markers of inflammation , such as elevated levels of creatine kinase (CK) and aldolase.
Imaging Studies : Chest X-rays, CT scans, or MRIs to assess lung involvement and other affected areas.
Pulmonary Function Tests : To evaluate lung function and detect ILD.

Treatment of Antisynthetase Syndrome (ASS)

While there is no cure for ASS, treatment focuses on managing symptoms and preventing complications:

Glucocorticosteroids : Medications like prednisone to reduce inflammation and suppress the immune system.
Immunosuppressive Medications : Drugs such as methotrexate, azathioprine, or mycophenolate mofetil to control the autoimmune response.
Physical Therapy : To improve muscle strength and function.
Pulmonary Rehabilitation : To manage ILD and improve lung function.
Lifestyle Modifications : Including a balanced diet, regular exercise, and avoiding smoking to support overall health.

Antisynthetase Syndrome (ASS) is typically managed by a multidisciplinary team of healthcare providers, including:

Rheumatologists : Specialists in autoimmune and inflammatory diseases, they play a central role in diagnosing and managing ASS.
Pulmonologists : For managing interstitial lung disease (ILD) and other respiratory issues associated with ASS.
Physical Therapists : To help improve muscle strength and function.
Occupational Therapists : To assist with daily activities and adaptive techniques.
Dermatologists : For treating skin manifestations like "mechanic's hands."
Primary Care Physicians : For initial evaluation and ongoing care coordination.

Collaboration among these specialists ensures comprehensive care and management of the various symptoms and complications associated with ASS.

Antisynthetase Syndrome is a complex and rare autoimmune disorder that requires a multidisciplinary approach to diagnosis and treatment. Understanding the symptoms, causes, and treatment options can help individuals with ASS and their healthcare providers develop an effective management plan.

Looking to provide input or get involved? Fill out the Ai Arthritis Feedback Form to share your thoughts and contribute to improving resources for autoimmune and autoinflammatory arthritis patients. Your voice matters!

Learn More About Antisynthetase Syndrome

Precision Medicine, Ageism, Fatigue, and More - Public Debrief #EULAR2022

Fri, 27 Dec 2024 13:51:28 GMT

Precision Medicine, Ageism, Fatigue, and More - Public Debrief #EULAR2022

For this public and patient-led debrief, we gathered together again to hold a conversation with our "Go With Us" team about the new advancements from #EULAR2022 , one of the largest rheumatological conferences in the world.

Conference Overview

Our final public debrief from EULAR 2022 (European Alliance of Associations for Rheumatology) was hosted by AI Arthritis, focusing on cutting-edge research, education, and both pharma and non-pharma approaches. Topics discussed included precision medicine, aging, comorbidities, detection and diagnosis, and personalized treatment matching.

Panelist Introductions

Tiffany Westrich-Robertson : CEO of AI Arthritis, living with undifferentiated connective tissue disease, rheumatoid arthritis, non-radiographic axial spondyloarthritis, and Behçet's disease.
Deb Constien : Living with RA for 40+ years, retired dietician, AI Arthritis volunteer.
Katie Simons : Senior Programs Manager at AI Arthritis, living with RA for 20 years.
Eileen Davidson : Living with RA for 7 years, involved in various patient research and advocacy groups.
Lisa Chandler : Living with seronegative arthritis for 20 years, long-time AI Arthritis volunteer.
Kerry Wong : Living with sarcoidosis, RA, Sjögren's, and other conditions, active in various patient advocacy roles.
Cristina Montoya : Registered dietitian, living with RA and Sjögren's since childhood, known as the Arthritis Dietitian.

Personalized vs. Precision Medicine

Personalized Therapies : Non-pharma approaches tailored to individual needs.
Precision Medicine : Pharma-based, science-driven approaches using patient-specific data (e.g., DNA, biomarkers) to match treatments, improve diagnosis, and predict adverse reactions.

Beyond Medication: Self-Management Workshop

Structure : Five-week group session led by two professionals and a patient, focusing on patient participation.
Goals : Help patients accept their new reality, manage fatigue, sleep, and pain, and foster a sense of community.

Key Points:

Encourage patients to take baby steps and problem-solve together.
Implement a “grace period” of three days to process flare-ups before moving forward.
Promote shared decision-making with healthcare providers.
Create a safe environment for patients to express fears, challenges, and successes.

Discussion Points

Mental and Emotional Support : Addressing these early in diagnosis is crucial.
Initial Grief Period : Recognizing the varied duration for patients.
Validation : Patients often face dismissal of their symptoms before proper diagnosis, making validation crucial both internally and externally.

Conference Themes

Validation was a recurring theme throughout the conference. Research presented at the conference emphasized holistic patient care, incorporating both pharmaceutical and non-pharmaceutical approaches.

Aging and Rheumatic Diseases

Aging research in rheumatic diseases is becoming increasingly relevant, focusing on both current elderly patients and those who will age into these diseases. The current generation may be treated with biologics from childhood to old age, leading to new research into long-term effects.

Ethical and Cost Considerations

Ethical concerns arise around treating elderly patients with medications like steroids, which are typically avoided in younger populations due to long-term side effects. The cost-effectiveness of treating elderly patients with expensive biologics is also under scrutiny, with considerations of quality-adjusted life years (QALYs).

Treatment Evolution

Treatment protocols have evolved over the decades, moving from lifestyle changes to aggressive early treatment (Treat-to-Target) aimed at remission. The potential need to taper or stop biologic treatments as patients age ties into broader discussions about aging and treatment sustainability.

Fatigue in Rheumatic Diseases

Fatigue is a significant issue for patients with rheumatic diseases, with biological and immunological factors contributing to it. Energy reserves in the body are primarily stored in the liver (glycogen) and adipose tissue (fat), with the brain and immune system being major energy consumers.

Impact of Smoking : Smoking exacerbates fatigue and decreases quality of life.
Muscle Fatigue : Feels like lifting a heavy weight, making simple tasks difficult.

Fatigue Types

Physical Fatigue : Persistent tiredness, sometimes requiring multiple naps throughout the day.
Brain Fatigue : Caused by anxiety or stress, leading to an initial energy surge followed by a crash.

Impact of Traumatic Events

Traumatic events can exacerbate muscle fatigue due to the adrenaline rush and subsequent crash. Positive events can also lead to fatigue and flares.

DAS 28 and Fatigue

Disease Activity Score 28 (DAS 28) incorporates joint counts and patient global assessment. Fatigue is heavily tied to pain, which is a significant part of the DAS 28 score.

CRP Levels and Fatigue

C-reactive protein (CRP) levels, a marker of inflammation, explain about 35% of fatigue. Pain accounts for over 55% of fatigue.

Inflammation and Brain

Research indicates a disconnect between controlling inflammation and pain relief in RA patients. Studies using MRIs and fibromyalgia as a control group are ongoing to understand how inflammation and pain interact in the brain.

Vagus Nerve and Brain

Stimulation of the vagus nerve might affect how the brain processes pain and inflammation, with potential implications for RA and fibromyalgia treatment.

Precision Medicine

Focuses on identifying individual biomarkers for tailored treatment approaches. Psoriatic arthritis and Still's disease studies are examples where precision medicine is being applied. DNA sequencing is essential to match patients to effective treatments.

RA Research and Other Diseases

RA is frequently studied because it’s easier to diagnose and enroll patients, benefiting research that can be applied to other diseases.

Pain and Non-Pharma Approaches

Due to concerns with opioids, there is a significant movement toward natural pain therapies and mental stimulation to address pain.

Sarcoidosis

Diagnosed through a process of exclusion with a combination of lab results, biopsies, and clinical criteria. The diagnosis is often “highly suggestive” rather than definitive, and treatment options are limited.

For more insights from EULAR 2022 and discussions on these important topics, be sure to check out the full debrief on our YouTube channel here . Let's continue advancing our understanding and care for rheumatic diseases together!

What Is Palindromic Rheumatism?

Thu, 26 Dec 2024 14:24:53 GMT

Understanding Rare Autoinflammatory Disease Palindromic Rheumatism (PR)

Ai Arthritis Disease Symptoms

Symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Palindromic Rheumatism (PR)

PR typically presents with:

Sudden Joint Pain and Swelling : Attacks usually affect one or a few joints, often the hands, feet, or knees. The affected joints become painful, stiff, and swollen.
Short Duration of Attacks : Each episode can last from a few hours to several days. The frequency of attacks varies widely, from once a year to several times a week.
Absence of Symptoms Between Attacks : Joints return to normal between attacks, and there is no permanent joint damage.
Other Symptoms : Some individuals may experience fatigue, fever, or the development of nodules under the skin near affected joints.

Learn more about Palindromic Rheumatism (PR)

Diagnosis of Palindromic Rheumatism (PR)

Diagnosing Palindromic Rheumatism (PR) can be challenging due to its episodic nature and the similarity of its symptoms to other forms of arthritis. Here's an overview of the diagnostic process:

Medical History and Physical Examination : The diagnosis begins with a detailed medical history and physical examination. The doctor will look for characteristic symptoms such as sudden joint pain, swelling, and stiffness.
Diagnostic Criteria : There are no specific diagnostic criteria for PR, but doctors often use the presence of recurrent, self-resolving inflammatory attacks in and around the joints as a key indicator.
Laboratory Tests : Blood tests may be ordered to rule out other conditions, such as rheumatoid arthritis (RA) and lupus. These tests can include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and antinuclear antibody (ANA) tests.
Imaging Studies : X-rays, ultrasound, or MRI scans may be used to assess joint involvement and rule out other conditions. Imaging can help identify inflammation in and around the joints.
Exclusion of Other Diseases : Since PR is a diagnosis of exclusion, doctors will rule out other well-defined connective tissue diseases such as RA, lupus, and Sjögren's syndrome.
Monitoring Over Time : Regular follow-up and monitoring are essential to track the progression of symptoms and adjust treatment as needed.

Discover More Of Our Resources

Treatment of Palindromic Rheumatism (PR)

The treatment of Palindromic Rheumatism (PR) typically involves medications to manage pain, reduce inflammation, and address the underlying condition. Here are some commonly used medications:

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) : Medications like ibuprofen, naproxen, and diclofenac are used to reduce pain and inflammation during attacks.
Corticosteroids : Prednisone and other corticosteroids may be prescribed for acute attacks to quickly reduce inflammation. Steroid injections can also be used for fast relief in severely inflamed joints1.
Disease-Modifying Antirheumatic Drugs (DMARDs) : Medications such as hydroxychloroquine and sulfasalazine are used to reduce the frequency and severity of attacks. Methotrexate may be used in more severe cases1.
Biologic Agents : Anti-TNF drugs like infliximab, etanercept, and adalimumab may be prescribed if DMARDs are ineffective. These medications target specific parts of the immune system to reduce inflammation1.
Antimalarial Drugs : Hydroxychloroquine and chloroquine, which are also used to treat malaria, have been shown to reduce the duration of PR attacks and the likelihood of progression to rheumatoid arthritis (RA).
Supportive Medications : Depending on symptoms, additional medications may be prescribed to manage specific issues, such as antibiotics for infections or medications for heartburn and reflux.
Lifestyle Modifications : Balancing activity and rest, maintaining a nutritious diet, and managing stress to help reduce the frequency of attacks.
Supportive Care : Physical therapy, counseling, and support groups to help manage the emotional and physical impact of PR.

It's important to work closely with a healthcare provider to determine the most appropriate treatment plan based on individual needs and the severity of the condition.

Who Treats Palindromic Rheumatism (PR)

Palindromic Rheumatism (PR) is typically treated by a rheumatologist , a specialist in autoimmune and inflammatory diseases. Rheumatologists have the expertise to diagnose and manage complex conditions like PR, which involve episodic joint pain and inflammation.

In some cases, a multidisciplinary team may be involved in the treatment, including:

Primary Care Physicians : For initial evaluation and ongoing care.
Physical Therapists : To help manage symptoms and improve joint function.
Occupational Therapists : To assist with daily activities and adaptive techniques.
Pain Management Specialists : For additional support in managing chronic pain.

Collaboration among these specialists ensures comprehensive care and management of the various symptoms and complications associated with PR.

News on Exercise and Fatigue Management in RA | EULAR 2024 Highlights with Leila

Wed, 25 Dec 2024 16:44:17 GMT

News on Exercise and Fatigue Management in RA | EULAR 2024 Highlights with Leila

Exercise and Physical Activity

Insufficient Evidence : Current studies on Rheumatoid Arthritis (RA) and exercise show insufficient evidence to conclude a direct effect on inflammation. However, exercise remains a vital part of RA management.
Delayed Onset Muscle Soreness (DOMS) : New exercisers may mistake DOMS for disease activity, but it's a normal reaction to exercise and usually subsides within a few days.
Recommended Exercise : Combining strength training with cardiovascular training, such as high-intensity interval training (HIIT), is most effective for managing RA.

Study on Exercise in RA Patients

A recent study highlighted the benefits of a 16-week program combining interval-based aerobic training with resistance training and dietary changes. The results showed improved cardiometabolic risk profiles and decreased disease activity in RA patients. Additionally, exercise positively affects the innate immune system and T cells, which are crucial in RA management.

Exercise and Pain Management

A meta-analysis reviewing 381 studies found that regular exercise decreases pain and improves the quality of life in RA patients without exacerbating disease activity. The release of endorphins and serotonin during exercise also contributes to enhanced well-being.

Cardiac Output Measurement

The Cardiopulmonary Exercise Test (CPET) measures cardiovascular health during exercise, helping tailor exercise prescriptions to individual needs in rheumatology. This personalized approach ensures optimal benefits while minimizing risks.

Leila’s Personal Experience

After undergoing weight loss surgery, Leila began exercising regularly in February and noticed significant reductions in joint pain and fatigue, except in her hands. Her experience underscores the importance of incorporating exercise into RA management.

Fatigue and New EULAR Recommendations

Despite ongoing research, few new insights or treatments for fatigue have emerged, and it remains an under-discussed issue in rheumatology. The complexity and varying causes of fatigue make it difficult to study and treat effectively. Leila encourages healthcare professionals to discuss fatigue with their patients, even though pharmacological options are limited.

Breaking Down Relapsing Polychondritis (RP)

Wed, 25 Dec 2024 16:16:53 GMT

Breaking Down Relapsing Polychondritis (RP)

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

What Are The Symptoms of Relapsing Polychondritis (RP)?

The condition can range from mild to severe, with symptoms varying widely between patients:

Ear Problems - The earliest sign is often ear pain and inflammation. In severe cases, cartilage breakdown can lead to floppy or "cauliflower" ears.
Facial Changes - Cartilage deterioration can cause the bridge of the nose to collapse, creating what's known as a "saddle nose" deformity.
Joint and Body Pain - Many patients experience arthritis-like pain throughout their body, particularly in their hands, knees, and other joints. Some also report discomfort near their breastbone and ribs.
Eye Issues - Eye inflammation ranges from mild irritation to severe conditions like scleritis or uveitis, which can threaten vision if left untreated.
Respiratory Complications - When RP affects the airways, patients may struggle with breathing or swallowing. In severe cases, this can become life-threatening.

Additional Symptoms

Hearing problems and balance issues
Nasal congestion
Skin rashes
Fatigue and fever
In rare cases, heart, kidney, or nervous system involvement

The severity of RP determines its impact. Mild cases may feature brief flare-ups with manageable symptoms that respond well to over-the-counter medications. Severe cases often require aggressive treatment and careful monitoring by specialists, as they can lead to serious complications and organ damage.

Even with mild symptoms, early medical attention is crucial for preventing the condition from worsening. Regular monitoring helps catch and address complications before they become severe.

Learn More About Relapsing Polychondritis (RP)

Diagnosis of Relapsing Polychondritis (RP)

Diagnosing RP can be challenging due to its nonspecific symptoms and rarity. There is no definitive test for RP, and diagnosis is typically based on clinical evaluation and the presence of at least three associated symptoms over time. Imaging studies and blood tests may be used to rule out other conditions. Here's an overview of the diagnostic process:

Clinical Evaluation: The diagnosis begins with a thorough clinical evaluation, including a detailed medical history and physical examination. The doctor will look for characteristic symptoms such as ear pain, nasal changes, joint pain, and eye inflammation.
Diagnostic Criteria: Two sets of criteria are commonly used to diagnose RP: the McAdam criteria and the Damiani criteria. Both require the presence of specific clinical features over time. For example, the McAdam criteria require at least three of the following features: recurrent episodes of auricular chondritis, nasal chondritis, respiratory tract chondritis, ocular inflammation, and arthritis.
Laboratory Tests: While there is no specific blood test for RP, certain tests can help rule out other conditions and support the diagnosis. These may include:
Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP): To measure inflammation levels.
Antinuclear Antibody (ANA) Test: To check for autoimmune markers.
Comprehensive Metabolic Panel (CMP): To assess organ function.
Imaging Studies: Imaging studies such as X-rays, CT scans, or MRIs may be used to assess the extent of cartilage involvement and rule out other conditions.
Biopsy: In some cases, a biopsy of affected cartilage may be performed to confirm the diagnosis and rule out other conditions.
Exclusion of Other Diseases : Since RP is a diagnosis of exclusion, doctors will rule out other well-defined connective tissue diseases such as lupus, rheumatoid arthritis, and scleroderma.
Monitoring Over Time: Regular follow-up and monitoring are essential to track the progression of symptoms and adjust treatment as needed.

Discover More Of Our Resources

Treatment for Relapsing Polychondritis (RP)

Treatment for RP focuses on managing symptoms and preventing complications. This may include:

Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids: To reduce inflammation.
Immunosuppressive Drugs : Medications like methotrexate, azathioprine, and mycophenolate mofetil may be used to suppress the immune system and reduce inflammation.
Biologic Agents : In severe cases, biologic agents such as rituximab or infliximab may be considered to target specific parts of the immune system.
Lifestyle Modifications : Avoiding triggers, maintaining a healthy lifestyle, and regular monitoring by a healthcare professional.
Supportive Care: Physical therapy, counseling, and support groups to help manage the condition and improve quality of life.

Who Treats Relapsing Polychondritis (RP)

Relapsing Polychondritis (RP) is typically treated by a rheumatologist , a specialist in autoimmune and inflammatory diseases. Rheumatologists have the expertise to diagnose and manage complex conditions like RP, which involve inflammation of cartilage and other connective tissues.

In some cases, a multidisciplinary team may be involved in the treatment, including:

Otolaryngologists (ENT specialists) : For ear and nasal symptoms.
Ophthalmologists : For eye inflammation and related issues.
Pulmonologists : For respiratory tract involvement.
Cardiologists : If there are heart-related complications.

Collaboration among these specialists ensures comprehensive care and management of the various symptoms and complications associated with RP.

Prognosis of Relapsing Polychondritis (RP)

The prognosis for RP varies. Some individuals may experience mild symptoms that respond well to treatment, while others may have more severe and persistent symptoms. Regular follow-up with a healthcare provider is essential to monitor the condition and adjust treatment as needed.

Relapsing Polychondritis (RP) is a complex and rare condition that requires careful management and monitoring. Understanding the symptoms, causes, and treatment options can help individuals with RP and their healthcare providers develop an effective management plan.

The Evolving Landscape of Pain and Fatigue Management in Rheumatology: Insights from EULAR 2024

Tue, 24 Dec 2024 12:13:08 GMT

The Evolving Landscape of Pain and Fatigue Management in Rheumatology: Insights from EULAR 2024

The opioid story in rheumatology is complex. While these medications have long been a go-to solution, recent data suggests we might need to rethink this approach. A striking study from the UK found that musculoskeletal conditions account for over 70% of opioid prescriptions among nearly 3 million people, excluding cancer patients. But here's the catch: research increasingly shows that opioids might not offer any special advantage over non-opioid alternatives, especially for chronic conditions.

Interestingly, the COVID-19 pandemic didn't drive up opioid prescriptions for musculoskeletal conditions as many feared. In fact, prescribing rates have dropped since 2021 for rheumatic and musculoskeletal diseases (RMDs). This trend reflects a growing awareness of the distinction between short-term use for acute issues and the risks associated with long-term use.

The medical community isn't standing still. Artificial intelligence is emerging as a promising tool to identify patients who might be at higher risk from opioid therapy. But the challenge remains: many RMD patients rely on long-term opioid prescriptions simply because their therapeutic options are limited. This reality demands careful, individualized treatment plans and close monitoring.

But medication is just one piece of the puzzle. The real story of managing rheumatic diseases plays out in patients' daily lives – all 9,000 hours per year when they're not in a doctor's office. This is where self-management becomes crucial.

Effective self-management goes beyond taking pills on schedule. It's about empowering patients to take control of their health through lifestyle changes, better health behaviors, and maintaining social connections. The emotional aspect is particularly crucial – helping patients maintain their sense of identity and purpose while living with a chronic condition.

What works? The basics matter more than ever: good sleep habits, regular physical activity, balanced daily routines, and dedicated relaxation time. But technology is opening new doors too. Virtual reality, while primarily used for acute pain like phantom limb syndrome, shows promise for broader applications in rheumatic conditions. While VR hasn't been studied specifically for fatigue management, other digital tools are stepping up to fill the gap.

A new generation of apps is emerging, designed specifically for RMD patients. These focus on the full spectrum of challenges: pain, fatigue, mood, physical activity, coping strategies, and medication adherence. Perhaps most exciting is the development of what's being called "compassionate technology" – systems that adapt to users' needs rather than forcing users to adapt to them.

As we move forward, the key seems to lie in balance – between medication and lifestyle changes, between technology and human touch, between managing symptoms and maintaining quality of life. For rheumatology patients, this holistic approach might just be the path to better days ahead.

Key Points

Global Concern : The opioid epidemic is a global issue, with significant impact in the U.S., Europe, and other regions.
UK Study : A UK study found that over 70% of nearly 3 million people prescribed opioids were for musculoskeletal conditions, excluding cancer.
Questionable Effectiveness : Research suggests that opioids may not be more effective than non-opioid methods for musculoskeletal pain, particularly chronic issues.
Pandemic Impact : The pandemic did not increase opioid prescribing for musculoskeletal conditions; in fact, prescribing has decreased since 2021 for RMDs.
Short-Term vs. Long-Term Use : Short-term opioid use for acute issues is less concerning than long-term use, which poses significant risks.
AI in Opioid Prescribing : AI is being explored to identify patients at higher risk of harm from opioid therapy.
Challenges in Rheumatology : RMD patients often have long-term opioid prescriptions due to limited therapeutic options, making individualized plans and close monitoring essential.
Non-Opioid Treatments : Even when opioids are prescribed, non-opioid treatments should be included in the management plan.

Self-Management of Pain and Fatigue in RMDs :

Importance of Quality of Life : The overall goal is to improve the quality of life for patients, who manage their disease primarily on their own (9,000 hours a year).
Empowerment and Self-Management : Patients should be empowered to manage their disease, focusing on more than just medical management, but also lifestyle changes, health behaviors, and social participation.
Emotional Self-Management : Emphasizes the importance of emotional well-being, refinding identity, and maintaining a sense of purpose despite chronic disease.
Key Strategies : Sleep hygiene, physical activity, balanced daily activities, relaxation phases, and emotional management are vital for pain and fatigue management.

Technology in Pain and Fatigue Management :

Virtual Reality (VR) : VR techniques are currently used for acute pain (like phantom pain) and hold promise for broader applications in RMDs.
No VR Studies on Fatigue : There are no VR studies specifically for fatigue, but other methods like nature, breathing techniques, yoga, and virtual social interactions are beneficial.
Innovative Apps : Studies are exploring the effectiveness of apps designed for RMD conditions, focusing on pain, fatigue, mood, physical activity, coping mechanisms, and medication adherence.
Compassionate Technology : The concept of technology that adapts to the user’s needs, rather than the user adapting to the technology, is a promising area of development.

What Is Undifferentiated Disease (UD)?

Mon, 23 Dec 2024 14:58:30 GMT

What Is Undifferentiated Disease (UD)?

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms Associated with Undifferentiated Disease

Undifferentiated disease can display symptoms associated with any autoimmune or autoinflammatory arthritis condition. These symptoms highlight the diverse and overlapping nature of undifferentiated diseases, making diagnosis a complex process. Examples of symptoms could include

Fatigue
Skin rashes
Dry eyes and mouth (also called “sicca symptoms”)
Hair loss
Mouth ulcers
Weight loss
Inflammation around the lungs (pleuritis) or heart (pericarditis)
Raynaud’s phenomenon: extremities turning white or blue in cold temperatures
Thyroid disease
Arthritis

In saying this, UD can include any symptom from any of the 100+ autoimmune or autoinflammatory diseases, which is more than only the diseases we focus on - which narrows the group down to the couple dozen that also usually involve inflammatory arthritis as a major clinical component.

Learn more about Undifferentiated Disease

Common Types of Undifferentiated Disease:

Undifferentiated Connective Tissue Disease (UCTD)

Undifferentiated Connective Tissue Disease (UCTD) is a condition where patients exhibit symptoms and laboratory findings suggestive of a systemic autoimmune disorder or connective tissue disease, but not enough to meet the criteria for a specific diagnosis like lupus or rheumatoid arthritis. Common symptoms include joint pain, swelling, skin rashes, fatigue. Undifferentiated Connective Tissue Disease might later on be diagnosed as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, sjogren’s disease or myositis.

Often UCTD is a go to diagnosis under the UD umbrella, possibly because it’s studied in research more often or maybe because the diseases it may evolve into conditions diagnosed more often.

Years ago it was thought about 15% of patients initially diagnosed with UCTD evolve into a different diagnosis, but more recent studies suggest that number is closer to 35%. AiArthritis believes the number of patients who actually have UCTD - or a similar UD subgroup - is 50%, but many meet the criteria for diagnosis and go undiagnosed altogether, staying a “mystery patient” for months or years. We proved this theory to be true in 2013 during our Early Symptoms of AiArthritis Diseases , where 15% of patients initially diagnosed with UD evolved into a different disease and an additional 39% had no diagnosis but could have qualified for UD. They all evolved to an AiArthritis disease, making the prevalence 54%.

Undifferentiated Spondyloarthritis (USpA)

Undifferentiated Spondyloarthritis (USpA) refers to a condition where individuals show signs and symptoms of spondylitis, such as inflammatory back pain or heel pain and pain in other joints, but do not meet the criteria for a definitive diagnosis of specific spondyloarthritis types like axial spondyloarthritis (which includes diagnoses of non-radiographic axial spondyloarthritis and ankylosing spondylitis), reactive arthritis, psoriatic arthritis, or enteropathic arthritis (associated with inflammatory bowel diseases). Conditions, like ankylosing spondyloarthritis - but not as often with non-radiographic axial spondyloarthritis, are often associated with the HLA-B27 gene. Over time, some patients with USpA may develop a more well-defined form of spondylitis, while others may continue to experience chronic but generally mild symptoms.

Unclassified Seronegative Spondyloarthritis

Similar to USpA, Unclassified Seronegative Spondyloarthritis is characterized by inflammatory back pain, uveitis, gastrointestinal symptoms, and rashes, but without the presence of rheumatoid factor or other inflammatory blood markers often associated with AiArthritis diseases. (Negative blood markers means “seronegative”.).Like USpA, Unclassified Seronegative Spondyloarthritis can evolve into a diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis.

Undifferentiated Inflammatory Arthritis/Polyarthritis

Undifferentiated Inflammatory Arthritis/Polyarthritis is a term used when patients exhibit signs of inflammatory arthritis affecting one joint for 6 weeks or longer (inflammatory arthritis) or multiple joints (polyarthritis) but do not fulfill the criteria for a specific type of inflammatory arthritis like rheumatoid arthritis or psoriatic arthritis. Undifferentiated Inflammatory Arthritis/Polyarthritis may turn into a diagnosis of rheumatoid arthritis (RA) or psoriatic arthritis.

Get Involved with AiArthritis’ Work to Improve Lives of Those Living with UD

Diagnosing Undifferentiated Disease (UD)

Undifferentiated Disease (UD) presents a significant challenge in the medical field. The absence of diagnostic criteria for many forms of UD makes the process difficult. Rheuma tologists typically rely on a combination of physical examinations, blood tests (such as ESR, WBC, RBC), and imaging studies, along with a family history of autoimmune or autoinflammatory diseases. Note: for most AiArthritis diseases, blood tests do not need to be positive, which, unfortunately, is not well known - even by health professionals.

Doctors assess common symptoms of autoimmune and autoinflammatory conditions, including fatigue, fevers, and muscle pain (myalgia). They then evaluate more specific features such as skin or organ involvement. The presence of arthritis or joint pain can help narrow down the diagnosis to an autoimmune or autoinflammatory arthritis, but the condition may still remain undifferentiated if the clinical features are not definitive.

Given that symptoms can be intermittent, it is essential to conduct tests and imaging during flare-ups to capture signs of inflammation. If this is not feasible, documenting symptoms through photos and symptom logs can be crucial in aiding diagnosis.

The Role of Rheumatologists and Undifferentiated Disease (UD)

A rheumatologist plays a crucial role in diagnosing and managing Undifferentiated Connective Tissue Disease (UCTD), Undifferentiated Spondyloarthritis (USpA), Unclassified Seronegative Spondyloarthritis, and Undifferentiated Inflammatory Arthritis/Polyarthritis. Here's how they contribute:

Diagnosis: Rheumatologists are specialists in identifying and diagnosing various rheumatic diseases. They use a combination of medical history, physical examinations, lab tests, and imaging studies to differentiate between these complex conditions and provide an accurate diagnosis.
Treatment Plans: They develop personalized treatment plans tailored to the specific needs and symptoms of the patient. This can include medications (such as NSAIDs, DMARDs, or biologics), physical therapy, and lifestyle modifications.
Monitoring Progress: Rheumatologists regularly monitor patients' progress to ensure that the treatment is effective and to adjust the plan as needed. They track disease activity and watch for potential side effects of medications.
Patient Education: They provide valuable education and support, helping patients understand their conditions, the importance of adherence to treatment, and strategies for managing symptoms and maintaining quality of life.
Collaboration with Other Specialists: Rheumatologists often work with other healthcare professionals, such as physical therapists, occupational therapists, and primary care physicians, to provide comprehensive care for patients with rheumatic diseases

Treatment for Undifferentiated Disease (UD)

Identifying a subtype of UD can help guide treatment decisions, but even if the disease remains undifferentiated treatments should be considered. Treatment for Undifferentiated Disease (UD) focuses on managing symptoms and preventing disease progression. Here are some common approaches:

Medications: Nonsteroidal anti-inflammatory drugs (NSAIDs) can help reduce pain and inflammation. Corticosteroids may be prescribed for more severe inflammation. Other medications may include hydroxychloroquine, or steroids. Pending severity, immunosuppressive drugs might be used to control the immune system's activity.
Lifestyle Changes: Regular exercise, a balanced diet, and adequate rest can help manage symptoms and improve overall health. Avoiding triggers, such as stress and extreme temperatures, is also important. However, lifestyle changes alone have not been proven to treat UD and subgroups - with the exception of very mild disease.
Physical Therapy: Physical therapy can help maintain joint flexibility and muscle strength, reducing pain and improving mobility.
Regular Monitoring: Regular follow-up appointments with a rheumatologist are essential to monitor the condition and adjust treatment as needed.
Supportive Care: Counseling or support groups can provide emotional support and help patients cope with the challenges of living with a chronic condition.

Each treatment plan is tailored to the individual's specific symptoms and needs. It's important to work closely with a healthcare provider to develop a comprehensive management plan.

Unlocking the Secrets of Fatigue, Pain, and Opioids in RA | Becky Hosey's Insights

Sun, 22 Dec 2024 14:13:54 GMT

Unlocking the Secrets of Fatigue, Pain, and Opioids in RA | Becky Hosey's Insights

Watch the YouTube Go With Us Debrief

Key Statistics :

82% of U.S. RA patients report fatigue as a major symptom; 76% report pain.
Only 26% are satisfied with their RA treatment.

Fatigue and Pain as Unmet Needs :

Fatigue and pain are more disabling than other symptoms, regardless of whether the condition is inflammatory or non-inflammatory.
Providers struggle to assess these symptoms because they are not visible like joint swelling.
Potential underreporting by patients due to various reasons.

Complexity of Fatigue :

No clear medical consensus on defining fatigue; it's subjective with various subtypes.
Physical fatigue (low energy, muscle weakness) vs. psychological fatigue (brain fog, cognitive weariness).
Disease control doesn't necessarily improve fatigue; 60% of patients report fatigue despite low disease activity.

Understanding Pain :

Pain is a personalized sensory and emotional experience influenced by biological, psychological, and social factors.
Pain doesn't always correlate with inflammation; residual pain can persist even with optimal treatment.
Challenges in treating pain despite advancements in controlling inflammation.

Types of Pain :

Nociceptive Pain : Arises from actual or threatened tissue damage (e.g., joint inflammation).
Neuropathic Pain : Results from nerve damage, often responding to locally targeted treatments.
Nociplastic Pain : Pain without clear tissue damage, often widespread and associated with sensitivity to light, sound, etc.

Recent Research :

A study found certain gene modules in RA patients' joint fluid that grew new nerve endings in lab cultures.
JAK inhibitors may improve pain better than some other biologics.

Fibromyalgia and Rheumatic Diseases :

High prevalence of fibromyalgia in RMD patients (about 20%).
Primary vs. secondary fibromyalgia: Different nerve pathways involved, which may influence treatment effectiveness.

Societal Factors :

Patients in wealthier countries report higher pain and fatigue, potentially due to higher health expectations.

Consequences of Underappreciating Fatigue and Pain :

Delayed diagnoses, negative impacts on quality of life, mental health issues, reduced productivity, and burden on healthcare systems.

Call to Action :

Need for increased awareness among patients and providers.
Importance of open communication and comprehensive assessments (PROMs).
Tailored treatment plans should incorporate both medical and non-medical interventions.

Staying Active with Autoimmune and Autoinflammatory Arthritis

Sun, 22 Dec 2024 13:35:56 GMT

Staying Active with Auto immune and Auto inflammatory Arthritis

Why Exercise? Exercise helps in many ways:

Reduces pain and stiffness: Moving your body regularly helps keep your joints flexible and reduces pain.
Boosts mood: Exercise releases chemicals like endorphins that make you feel happier and more energized.
Builds strength: Strength exercises help muscles support your joints better, which can reduce joint pain.
Improves heart health : Regular physical activity keeps your heart strong and healthy.
Helps with weight management: Maintaining a healthy weight reduces pressure on your joints, improving your overall well-being.

Exercise for Adults with Autoimmune and Autoinflammatory Arthritis

Adults with autoimmune or autoinflammatory arthritis, like rheumatoid arthritis (RA) or axial spondyloarthritis , often wonder how to stay active when they’re dealing with pain or stiffness. Here are some safe exercises that can help manage symptoms while keeping your body strong and healthy.

Appropriate Exercises for Adults:

Walking: Walking is a low-impact exercise that helps improve circulation and flexibility. Start with short walks and build up to 20-30 minutes a day.
Swimming or Water Aerobics: Exercising in water reduces stress on your joints while still giving you a full-body workout. Swimming or water aerobics are great for improving strength and flexibility.
Stretching: Gentle stretches help keep your muscles and joints flexible. Try to stretch every day, especially in the morning, to ease stiffness.
Strength Training: Light weights or resistance bands can help strengthen the muscles around your joints. Even bodyweight exercises, like wall push-ups or chair squats, can build strength safely.
Yoga or Tai Chi: These gentle movements combine stretching, balance, and breathing exercises, helping reduce stiffness while calming your mind. They can even be done in bed or on a chair.

Tips for Getting Started:

Start slow: Begin with short, gentle exercises and gradually increase the intensity as you feel stronger.
Listen to your body: If something hurts, stop and rest. It's important to avoid pushing through severe pain.
Include Rest: Rest is as important as physical activity.
Group activities can help: Group exercises, like yoga or fitness classes, provide extra motivation and can be more fun than working out alone.
Consult your doctor: Before starting a new exercise routine, talk to your doctor or physical therapist to make sure it’s safe for you.

Exercise for Kids with Autoimmune and Autoinflammatory Arthritis

Kids with conditions like Juvenile Idiopathic Arthritis (JIA) and other juvenile forms of autoimmune and autoinflammatory arthritis can also benefit from regular exercise. Staying active helps children manage pain, stay flexible, and improve their overall health—just like adults! Exercise even improves medication efficacy. The key is to make exercise fun and enjoyable while being mindful of their symptoms.

According to the Canadian 24-hour movement guidelines, children should aim for at least 60 minutes of moderate to vigorous activity every day.

Fun Exercises for Kids:

Bike Riding: Riding a bike is a great way to stay active without putting too much pressure on the joints. It's fun and helps improve endurance and strength.
Swimming: Just like for adults, swimming is perfect for kids with arthritis. The water supports their body weight, making it easier to move around without joint pain.
Dancing: Turn on some music and let your child dance! Dancing is a fun way to get their heart rate up while moving their body in a gentle way.
Playground Time: Climbing, sliding, and swinging at the playground can be great exercise for kids. Let them play and move at their own pace.
Stretching Games: Incorporating stretches into games like "Simon Says" or "Twister" can help kids stay flexible and have fun while doing it.

Tips for Helping Kids Stay Active:

Adapt to their needs: If your child is having a flare-up, they might need to rest or try gentler activities, like stretching or light walking.
Encourage rest when needed: It’s okay for kids to take breaks if they’re in pain. Let them rest and pick up the activity when they’re feeling better.
Work with teachers and coaches: If your child is involved in physical activities at school, talk to their teachers or coaches about ways to support them and adapt activities when needed.

Whether you’re an adult or a child with autoimmune and autoinflammatory arthritis, staying active is one of the best ways to manage symptoms, improve strength, and feel better overall. Remember to start slow, listen to your body, and make exercise a regular part of your routine. And don’t forget to have fun with it—find activities that you enjoy, and it won’t feel like work!

Always check with your healthcare provider before starting a new exercise routine, especially if you’re dealing with chronic pain or other health conditions. Your body will thank you for staying active!

Discover More

This resource post was made in conjunction with several videos from our Go With Us! To Conferences program.

Click the titles below to view the videos:

Tapering Medications: A Careful Approach to Maintaining Remission

Sat, 21 Dec 2024 11:44:52 GMT

Tapering Medications: A Careful Approach to Maintaining Remission

What is Tapering?

Tapering involves slowly and carefully reducing the dosage of medication under the guidance of a healthcare provider. This process is generally considered when a patient has been in remission or has had controlled disease activity for an extended period.

There are two key approaches to tapering:

Step-Down Tapering : Medications are reduced gradually over time, typically one at a time, with close monitoring to watch for any signs of disease flare-ups.

Combination Tapering: Multiple medications may be tapered simultaneously, often when a patient has been on a combination of drugs for a long period and wants to minimize overall medication use.

Benefits and Risks of Tapering

Tapering medications can have significant advantages:

Reduced Side Effects: Many medications used to manage chronic diseases can have serious side effects. Tapering can help minimize the long-term risks associated with these drugs, such as organ damage or infections.
Cost Savings: Reducing the dosage or discontinuing certain medications can help lower healthcare costs, especially for expensive biologics or long-term treatments.
Decreased Medication Burden: Taking fewer medications can simplify a patient’s daily routine, reduce stress, and improve overall well-being.

However, there are also potential risks:

Risk of Flare-Ups: One of the primary concerns with tapering is the possibility of disease flare-ups. Patients who stop medications too quickly may experience a resurgence of symptoms that can be difficult to control.
Difficulty Returning to Remission: In some cases, once a patient stops a medication and experiences a flare, it may be harder to return to the previous state of remission or low disease activity. Rarely medications are completely stopped during remission but dosage may be reduced.

Tapering: A Shared Decision-Making Process

Shared decision making (SDM) in rheumatology is a collaborative process where patients and healthcare providers work together to make informed treatment decisions. This approach respects the patient's preferences, values, and needs while considering the best available medical evidence.

Tapering should always be a shared decision between the patient and their healthcare provider. It’s important to have an honest conversation about the potential benefits and risks, and to make sure that the patient is monitored closely during the tapering process.

The decision to taper medications is highly individualized, based on factors such as:

• How long the patient has been in remission

• Biomarker levels and other laboratory results

• The severity of the disease prior to treatment

• The patient’s overall health and lifestyle factors

Tapering can be a successful strategy for many patients, but it requires careful planning and close monitoring. If you are considering tapering your medications, talk to your healthcare provider about whether it’s the right choice for you and how to approach it safely.

Just Diagnosed with an AiArthritis Disease? Here's What Our Community Wants You to Know

Thu, 19 Dec 2024 14:30:44 GMT

Just Diagnosed with an AiArthritis Disease? Here's What Our Community Wants You to Know

Find a Great Doctor

The number one tip from our community is to find a good doctor called a rheumatologist. This is a special doctor who knows all about arthritis. Laura Mae says it's worth traveling to find the right doctor. Another member, Johanna, drives 92 miles just to see her doctor! She says she feels lucky to have found such a good one.

Laura Torchinsky tells us it's super important to find a doctor you trust. You'll see this doctor a lot, so you should feel comfortable asking them any questions - even the ones you think might sound silly!

Learn About Your Condition

Cynthia shared some really smart advice about learning more about AiArthritis. She says you should:

Read about your type of arthritis
Learn about different treatments
Know what signs to watch for
Join AiArthritis and other support groups
Find groups that focus on your specific type of arthritis

The more you know about your condition, the better you can take care of yourself.

Connect with other patients who understand

Everyone agrees that having support from others is super important. You don't have to deal with this alone! There are lots of people who know exactly what you're going through. They can share tips and tricks that helped them feel better.

What to Remember

Here are the main things our community wants you to know:

Take time to find a good doctor, even if they're far away
Make sure you trust your doctor
Learn everything you can about your condition
Join groups where you can meet others with AiArthritis
Take your time getting used to everything

Remember that lots of people with AiArthritis live happy, active lives. Yes, some days might be hard, but you'll learn what works best for you. With good doctors, helpful information, and friendly support, you can handle this!

You're joining a big family of strong people who understand what you're going through. We're here to help you every step of the way. You might feel alone right now, but trust us - you're not. There are lots of us here to support you!

Thanks to our community members Laura Mae, Laura Torchinsky, Joanna Derrick, and Cynthia Hart for your insight.

Clinical Research: Real Stories From Real Patients

Fri, 13 Dec 2024 13:18:38 GMT

Clinical Research: Real Stories From Real Patients

We asked people in our community about their experiences with clinical research, and their answers were super interesting!

Different Ways to Help

Some people, like Carrie, have seen medical research from two different sides. She's helped as both a nurse (the person giving care) and as a patient (the person getting care). That's pretty cool, right? It's like being both a teacher and a student!

Making a Big Difference

Cynthia shared an amazing story about joining a study in 2008 when she first found out she had a condition called rheumatoid arthritis. She tested a medicine called Orencia, and guess what? She did so well that the study went on longer than planned! Instead of three years, it lasted five years. They even paid her to do a special DNA test that helped her learn more about her health.

Why People Join Studies

Jennifer and others said they're excited about new discoveries in medicine, especially for conditions like rheumatoid arthritis. Judith, who has rheumatoid arthritis, explained that even though she hasn't been in a study yet, she'd love to help if she got the chance. Why? Because it could help other people who might get sick in the future.

Different Types of Studies

Some people, like Ma Rel, are super busy with research - they're in three studies at the same time! Others, like Karen, are just thinking about trying it for the first time. Both ways are totally fine!

What's Cool About Being in a Study?

Here's what makes being in a medical study awesome:

You might get to try new medicines before anyone else
You help doctors learn important things about treating sick people
Sometimes you learn cool stuff about yourself (like Cynthia with her DNA test!)
You become part of making medicine better for everyone

Want to Know More?

If you're interested in being part of medical research, you can:

Talk to your doctor about studies they know about

Look for research hospitals in your area

Ask people with your same health condition if they know of any studies

Remember that it's okay to just think about it, like Karen!

Being part of medical research is helping doctors find better ways to make people feel better. And just like our community members shared, there are lots of different ways to help out. Whether you're ready to jump in like Cynthia or just thinking about it like Karen, every person who helps with medical research makes a difference!

Thanks to Carrie Bransom Shepperson, Jennifer Weaver, Cynthia Cole Hart, Judith Flanagan and, Ma Rel

Remember: Always talk to your doctor before joining any medical study. They'll help you figure out if it's right for you!

Understanding Familial Cold Autoinflammatory Syndrome (FCAS)

Wed, 11 Dec 2024 14:56:27 GMT

Understanding Familial Cold Autoinflammatory Syndrome (FCAS)

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Familial Cold Autoinflammatory Syndrome (FCAS)

Symptoms of FCAS typically appear within the first few months of life, with the average age of onset being around 47 days. Common symptoms include:

Rash: Episodes of urticar ia (hives) that appear within hours of cold exposure.
Fever: Episodes of fever that usually last less than 24 hours.
Joint Pain: Arthralgias (joint pain) and swelling.
Fatigue: Generalized fatigue and malaise during episodes.
Other Symptoms: Headache, conjunctivitis, and eye pain.

Discover More Of Our Resources

Diagnosing Familial Cold Autoinflammatory Syndrome (FCAS)

Familial Cold Autoinflammatory Syndrome (FCAS) typically presents in infancy or early childhood, often within the first few months of life. However, in very rare cases, it might be diagnosed later in life if symptoms are mild or if the disease is not recognized initially. Late-onset cases can present diagnostic challenges, as symptoms might be less pronounced or resemble other conditions. Despite this, it is unusual for FCAS to first appear in adulthood.

Diagnosis is based on clinical features and confirmed by genetic testing for mutations in the NLRP3 gene. A detailed medical history and physical examination are essential for identifying the characteristic symptoms and triggers.

Treatment of Familial Cold Autoinflammatory Syndrome (FCAS)

The primary treatment for FCAS involves anti-IL-1 therapy, such as anakinra, which blocks the activity of IL-1β and helps reduce inflammation.

Other treatments include:

Canakinumab: Another IL-1β inhibitor used for patients who do not respond to anakinra.
Rilonacept: A fusion protein that inhibits IL-1β.
Lifestyle Modifications: Avoiding cold exposure and wearing protective clothing to minimize symptoms.
Supportive Care: Use of nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids to manage symptoms during acute episodes.

Who Treats Familial Cold Autoinflammatory Syndrome (FCAS)

Familial Cold Autoinflammatory Syndrome (FCAS) is typically managed by a multidisciplinary team of specialists, including rheumatologists, dermatologists, immunologists, and geneticists. These healthcare providers work together to diagnose, treat, and monitor the condition, ensuring comprehensive care for affected individuals.

With early diagnosis and appropriate treatment, individuals with FCAS can lead relatively normal lives. Regular monitoring and management of symptoms are essential to prevent complications and improve quality of life.

Familial Cold Autoinflammatory Syndrome (FCAS) is a rare but manageable condition that requires a multidisciplinary approach for effective treatment. Advances in understanding the genetic basis and treatment options have significantly improved outcomes for affected individuals. Continued research and awareness are crucial for further enhancing the care and quality of life for patients with FCAS.

Understanding Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

Wed, 11 Dec 2024 14:28:10 GMT

Understanding Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

Causes and Genetic Basis of Chronic Infantile Neurological/Cutaneous, Articular Syndrome (CINCA), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

CINCA/NOMID is caused by mutations in the NLRP3 gene (also known as CIAS1). These mutations lead to the overproduction of interleukin-1β (IL-1β), a key cytokine involved in inflammation. The disease is typically inherited in an autosomal dominant manner, meaning only one copy of the mutated gene is necessary to cause the disorder.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms and Clinical Features of Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

The symptoms of CINCA/NOMID usually appear within the first few months of life and can include:

Skin Rash: Persistent urticarial rash that often appears at birth.
Arthritis: Severe joint inflammation leading to pain, swelling, and potential joint deformities.
Neurological Involvement: Chronic aseptic meningitis causing headaches, vomiting, and cognitive delays. Sensorineural hearing loss and seizures may also occur.
Other Symptoms: Growth delays, hepatosplenomegaly (enlargement of the liver and spleen), and elevated inflammatory markers in blood tests.

Discover More Of Our Resources

Diagnosing Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

CINCA/NOMID typically manifests within the first few months of life, often presenting symptoms at or shortly after birth. In some cases, signs can even be detected prenatally through ultrasound. However, in rare cases, it might be diagnosed later in childhood or even in adulthood due to milder symptoms or delayed recognition of the disease. These late-onset cases can present diagnostic challenges, as symptoms might be less severe or resemble other conditions.

Diagnosis is primarily clinical, based on the characteristic triad of skin rash, arthritis, and central nervous system involvement. Genetic testing for mutations in the NLRP3 gene can confirm the diagnosis in many cases, although some patients may have somatic mosaicism and not show the mutation in their germline DNA.

Treatment of Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

Medications: The mainstay of treatment for CINCA/NOMID is anti-IL-1 therapy, particularly the use of anakinra, which blocks the activity of IL-1β. Early initiation of this trea tment can significantly improve outcomes, reducing inflammation and preventing complications such as intellectual disability and hearing loss.
Supportive Care: This includes managing symptoms such as pain, fever, and joint swelling with medications like nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and physical therapy.
Monitoring and Management of Complications: Regular monitoring for complications such as hearing loss, vision problems, and neurological issues is essential. Early intervention can help mitigate these complications.

Who Treats Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

CINCA/NOMID is typically treated by a multidisciplinary team of specialists, including rheumatologists, immunologists, neurologists, dermatologists, and geneticists. Early diagnosis and treatment by these experts are crucial for managing the disease effectively and improving patient outcomes.

With early diagnosis and appropriate treatment, the prognosis for children with CINCA/NOMID has improved significantly. Many patients can lead relatively normal lives, although ongoing management of symptoms and monitoring for complications is necessary.

CINCA/NOMID is a challenging condition that requires a multidisciplinary approach for effective management. Advances in understanding the genetic basis and treatment options have greatly improved the quality of life for affected individuals. Continued research and awareness are essential for further improving outcomes for patients with this rare disorder.

Sarcoidosis Abstracts at ACR24

Wed, 11 Dec 2024 13:54:09 GMT

Sarcoidosis Abstracts at ACR24

The latest research on Sarcoidosis presented at The 2024 American College of Rheumatology conference

Sarcoidosis is an inflammatory disease that can affect various organs in the body, most commonly the lungs and lymph glands. It is characterized by the formation of tiny clumps of inflammatory cells known as granulomas. These granulomas can interfere with how an organ functions, leading to symptoms that vary depending on which organs are involved. In the lungs, for instance, sarcoidosis can cause coughing, shortness of breath, and chest pain. While the exact cause of sarcoidosis remains unknown, it is thought to result from the body's immune system responding to an unknown substance. Treatment often involves managing symptoms with medications like corticosteroids to reduce inflammation and prevent further organ damage. Though sarcoidosis can resolve on its own in some cases, chronic or severe forms of the disease may require long-term treatment.

View all Sarcoidosis Abstracts from previous years

2024 American College of Rheumatology Conference abstracts on Sarcoidosis

The Incidence and Prevalence of Sarcoidosis in England

This study examines the occurrence of sarcoidosis in England using data from primary care electronic health records. The research found that the prevalence of sarcoidosis increased from 40 per 100,000 people in 2003 to 168 per 100,000 people in 2023. The incidence, or the rate of new cases, also rose by 21% from 6.81 per 100,000 person-years in 2003 to 8.22 in 2022. The study highlights that sarcoidosis is more commonly diagnosed in males and people aged 40-60 years, with a notable increase in diagnoses among males over 60 years old.

Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis

This study evaluates the effectiveness of mycophenolate mofetil (MMF), a medication that modifies the immune system, in treating patients with isolated cardiac sarcoidosis (iCS). iCS is a form of sarcoidosis where only the heart is affected, leading to symptoms like heart failure, arrhythmias, and atrioventricular block. The researchers conducted a retrospective chart review of patients diagnosed with iCS and treated with MMF. They assessed clinical outcomes such as worsening heart failure, new arrhythmias, and the need for devices like left ventricular assist devices (LVAD) or heart transplants. Radiologic outcomes were also evaluated based on changes in myocardial uptake on PET scans and left ventricular ejection fraction on echocardiograms. The study aims to provide insights into the clinical and radiologic outcomes of MMF treatment in iCS patients.

Investigation of Sarcoidosis-associated Neuropathy: Challenges with Diagnosis of Small Fiber Neuropathy

This study explores the difficulties in diagnosing small fiber neuropathy (SFN) in patients with sarcoidosis. SFN is a condition where nerve damage affects the small fibers, leading to symptoms like pain and numbness. The researchers evaluated 20 patients with biopsy-confirmed sarcoidosis using various diagnostic tools, including the Utah Early Neuropathy Scale (UENS), Toronto Consensus Criteria (TCC), electromyography (EMG), and skin biopsy. They found that while the TCC was more likely to identify SFN in patients with suspected neuropathy, skin biopsy and EMG did not show significant differences between those with and without neuropathy. The study suggests that skin biopsy may not be a reliable diagnostic tool for SFN in sarcoidosis patients and highlights the need for better screening methods.

The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy

This study evaluates whether EMG, a test that measures muscle response to nerve stimulation, is effective in diagnosing neuropathy (nerve damage) in patients with sarcoidosis. The researchers compared EMG results with other diagnostic tests, such as skin biopsies and clinical evaluations, in a group of patients with biopsy-confirmed sarcoidosis. They found that EMG may not be a reliable screening tool for sarcoidosis-associated neuropathy, as some patients with normal EMG results still had neuropathy confirmed by other tests. The study suggests that EMG alone may not be sufficient for diagnosing this condition.

Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida

This study conducted at Mayo Clinic Florida examines the mortality rates among patients with cardiac sarcoidosis, a condition where inflammation causes clusters of cells (granulomas) in the heart. The retrospective analysis included patients diagnosed with cardiac sarcoidosis and found that the condition is associated with a high mortality rate. Out of the patients studied, several passed away due to complications such as cardiogenic shock, cardiopulmonary arrest, and side effects of immunosuppressive therapy. The study highlights the need for better management and treatment strategies for cardiac sarcoidosis to improve patient outcomes.

Comparative Effectiveness of Disease Modifying Antirheumatic Drugs for Cardiac Sarcoidosis

This study compares the effectiveness of different DMARDs (medications that modify the immune system) in treating cardiac sarcoidosis. Researchers looked at three drugs: methotrexate, mycophenolate mofetil, and azathioprine. They analyzed data from patients with and without cardiac sarcoidosis to see how well these drugs worked in preventing serious heart outcomes, such as needing a pacemaker or experiencing cardiac arrest. The study found that all three drugs had similar effectiveness in preventing severe heart issues. However, mycophenolate mofetil was associated with a higher risk of serious infections compared to the other two drugs.

Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study

This nationwide retrospective cohort study investigates the effects of TNF inhibitors (a type of medication) on patients with cardiac sarcoidosis. The study aims to understand how these medications impact heart failure, overall survival, and arrhythmias in these patients. By analyzing data from a large healthcare database, researchers compared patients who used TNF inhibitors with those who did not, looking at factors like age, gender, and other health conditions. The findings will help determine the safety and effectiveness of TNF inhibitors in treating cardiac sarcoidosis.

Comparing the Prevalence of Sarcoidosis in Canadian Rural, Urban, and Farming Populations

This study compares the occurrence of sarcoidosis among people living in rural, urban, and farming areas in Alberta, Canada. Researchers used health data to identify cases of sarcoidosis and found that the prevalence was slightly higher in farming populations compared to rural and urban areas. However, there were no significant differences between the groups. The study helps understand how environmental factors might influence the development of sarcoidosis in different settings.

Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registr y

This study compares the rates of in-hospital mortality and readmission between patients with pulmonary sarcoidosis (affects the lungs) and cardiac sarcoidosis (affects the heart). Using data from a nationwide registry, researchers found that while cardiac sarcoidosis patients had more severe health conditions and higher medical costs, the in-hospital mortality rates were similar between the two groups. Both groups also had comparable rates of readmission within 30 days. The most common reasons for readmission included heart failure exacerbation and sepsis.

Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

This study examines the effectiveness of TNF-α inhibitors, a type of medication, in treating cardiac sarcoidosis. Cardiac sarcoidosis involves inflammation in the heart, which can lead to serious health problems. The researchers analyzed data to understand how well these inhibitors work in reducing heart inflammation and improving heart function in affected patients. The findings provide valuable insights into the potential benefits and limitations of using TNF-α inhibitors for managing cardiac sarcoidosis.

FoxP3Hi CTLA4+ ICOS+ Regulatory T Cells Are Expanded in Patients with Sarcoidosis but Not Systemic Sclerosis or IgG4-Related Disease

This study investigates the presence of a specific type of immune cell, known as FOXP3hi CTLA4+ ICOS+ regulatory T cells, in patients with sarcoidosis. The researchers found that these cells are expanded in sarcoidosis patients compared to those with systemic sclerosis or IgG4-related disease. This discovery could provide insights into the immune mechanisms involved in sarcoidosis and help develop targeted therapies for better management of the condition.

Healthcare Disparities and Clinical Outcomes in Cardiac Sarcoidosis. a Retrospective Cohort Study

This study examines the differences in healthcare access and treatment outcomes among patients with cardiac sarcoidosis. By analyzing data from a diverse group of patients, the researchers aim to identify disparities in diagnosis, treatment, and clinical outcomes. Understanding these disparities can help improve healthcare delivery and outcomes for all patients with cardiac sarcoidosis, ensuring equitable care and better management of the disease.

Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients

This study investigates the use of a new cardiac MRI parameter called hemodynamic forces to evaluate heart involvement in patients with sarcoidosis. Hemodynamic forces are the physical forces exerted by blood flow within the heart. By using cardiac MRI to measure these forces, the researchers aim to improve the detection and assessment of heart problems in sarcoidosis patients. This novel approach could lead to better diagnosis and management of cardiac involvement in sarcoidosis.

Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center

This study provides an overview of how sarcoidosis affects the lungs and the different treatment options available at a university center. Sarcoidosis causes inflammation and the formation of lumps called granulomas in the lungs, leading to symptoms like shortness of breath, cough, and fatigue. The study discusses various treatment approaches, including medications and therapies used to manage these lung manifestations.

Key Take Aways for Patients

Incidence and Prevalence of Sarcoidosis in England: S arcoidosis prevalence increased significantly from 2003 to 2023, especially among older males.
Mycophenolate Mofetil for Isolated Cardiac Sarcoidosis: MMF treatment outcomes in isolated cardiac sarcoidosis were assessed, highlighting clinical and radiologic results.
Diagnosis Challenges of Small Fiber Neuropathy in Sarcoidosis: Diagnosing small fiber neuropathy in sarcoidosis patients is difficult; skin biopsy and EMG are not reliable.
EMG as a Screening Tool in Sarcoidosis Neuropathy: EMG may not be sufficient alone for diagnosing sarcoidosis-associated neuropathy.
High Mortality in Cardiac Sarcoidosis: Cardiac sarcoidosis has high mortality, underscoring the need for improved treatment strategies.
Effectiveness of DMARDs in Cardiac Sarcoidosis: Methotrexate, mycophenolate mofetil, and azathioprine show similar effectiveness with varied infection risks.
Clinical Outcomes with TNF Inhibitors in Cardiac Sarcoidosis: TNF inhibitors' effects on cardiac sarcoidosis patients' heart failure, survival, and arrhythmias were studied.
Sarcoidosis Prevalence in Canadian Populations: Slightly higher sarcoidosis prevalence in farming populations compared to rural and urban areas.
Mortality and Readmission in Pulmonary vs Cardiac Sarcoidosis: Cardiac and pulmonary sarcoidosis have similar in-hospital mortality rates but higher medical costs for cardiac patients.
TNF-α Inhibitors in Cardiac Sarcoidosis: TNF-α inhibitors reduce heart inflammation and improve heart function in cardiac sarcoidosis.
Expansion of Regulatory T Cells in Sarcoidosis: Specific regulatory T cells are expanded in sarcoidosis patients, aiding in immune mechanism understanding.
Healthcare Disparities in Cardiac Sarcoidosis: Identifies disparities in healthcare access and outcomes for cardiac sarcoidosis patients, aiming to improve care.
Hemodynamic Forces in Cardiac MRI for Sarcoidosis : Investigates a novel cardiac MRI parameter to better detect and manage heart involvement in sarcoidosis patients.
Lung Manifestations in Sarcoidosis and Treatments: Provides an overview of lung sarcoidosis symptoms and various treatment approaches at a university center.

Understanding Muckle-Wells Syndrome (MWS)

Wed, 11 Dec 2024 10:06:23 GMT

Understanding Muckle-Wells Syndrome (M SW)

CAPS Encompasses Three Main Conditions:

These conditions share common features such as recurrent episodes of fever, rash, joint pain, and systemic inflammation, but vary in severity and specific symptoms. Early diagnosis and treatment with IL-1 inhibitors can significantly improve patient outcomes and quality of life.

Causes of Muckle-Wells Syndrome (MWS)

MWS is caused by a mutation in the NLRP3 gene, which leads to increased activity of the protein cryopyrin. This protein plays a role in the body's immune response, and its overactivity results in excessive production of interleukin-1 beta (IL-1β), a cytokine that causes inflammation.

Since it is inherited in an autosomal dominant manner, it means that only one copy of the mutated gene is necessary to cause the disorder. This means that if one parent has the condition, there is a 50% chance that their child will inherit it. The prevalence of MWS is estimated to be around 1 in 360,000 people, based on a French survey. However, this number may vary globally due to underdiagnosis or misdiagnosis.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Muckle-Wells Syndrome (MWS)

Muckle-Wells Syndrome (MWS) significantly impacts the quality of life for those affected by its persistent and debilitating symptoms. The symptoms of MWS typically begin in early childhood and can include:

Recurrent fevers and chills
Urticaria (hives) or skin rashes
Arthralgia (joint pain)
Conjunctivitis (pinkeye)
Sensorineural hearing loss
Amyloidosis, leading to kidney dysfunction

Learn more about Cryopyrin-Associated Periodic Syndromes (CAPS)

Diagnosis of Muckle-Wells Syndrome (MWS)

Muckle-Wells Syndrome (MWS) typically presents in childhood or adolescence, but it can sometimes be diagnosed later in life if symptoms are mild or not initially recognized. While it's uncommon for MWS to first appear in adulthood, it's not impossible. Early diagnosis and treatment are crucial for managing the condition and preventing complications.

Diagnosis of MWS involves a combination of clinical evaluation, family history, and genetic testing to identify mutations in the NLRP3 gene. Blood tests may also be conducted to measure levels of inflammatory markers and to detect amyloid deposits.

Treatment of Muckle-Wells Syndrome (MWS)

With appropriate treatment, individuals with MWS can lead relatively normal lives. Early intervention and ongoing management are crucial to prevent long-term complications, particularly amyloidosis. Patients need to adhere to a strict treatment regimen to manage symptoms effectively, which requires significant time and effort.

Treatment for MWS focuses on managing symptoms and preventing complications. Medications that block the action of IL-1β, such as anakinra, canakinumab, and rilonacept, have been effective in reducing inflammation and improving quality of life. Hearing aids or cochlear implants may be recommended for those with significant hearing loss.

Learning to adapt to limitations and finding ways to manage daily life with MWS is essential. This might include lifestyle adjustments, such as modifying work hours or utilizing assistive technologies.

Who Treats Muckle-Wells Syndrome?

Living with MWS requires a multidisciplinary approach involving rheumatologists, immunologists, and audiologists. Patients and their families may benefit from support groups an d resources that provide education and emotional support.

Muckle-Wells Syndrome (MWS) is typically managed by a rheumatologist, a specialist in autoimmune and inflammatory disorders. Rheumatologists are trained to diagnose and treat conditions like MWS that involve chronic inflammation and immune system dysfunction.

In addition to a rheumatologist, other healthcare providers may be involved in the care of someone with MWS, including:

Immunologists: Specialists in the immune system who can help manage the inflammatory aspects of the disease.
Geneticists: Experts in genetic disorders who can provide genetic counseling and testing.
Nephrologists: Specialists in kidney health, especially important if amyloidosis affects kidney function.
Audiologists: Specialists in hearing who can help manage hearing loss associated with MWS.

A multidisciplinary approach ensures comprehensive care and better management of the various symptoms and complications of MWS.

Patient Perspectives at ACR24

Wed, 04 Dec 2024 12:03:02 GMT

Patient Perspectives at ACR24

Highlighting the patient perspective abstracts at the 2024 American College of Rheumatology convergence.

An OCEAN of Change: The Impact of an RA Diagnosis on My Big Five Personality Traits

Laura Sambursky shares their personal experience of being diagnosed with rheumatoid arthritis (RA) and how it has affected their personality. Before the diagnosis, Laura was healthy, confident, and outgoing. However, after developing painful symptoms and receiving an RA diagnosis, they had to make significant lifestyle changes and start various medications. This experience has led to changes in their personality traits, such as becoming more cautious, less outgoing, and more prone to anxiety. Laura] reflects on how accepting these changes has helped them improve their quality of life.

Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS

Robert Fearon shares their journey of living with Sjögren’s syndrome and Postural Orthostatic Tachycardia Syndrome (POTS). Robert describes the challenges of getting a diagnosis, which took nearly 13 years, and the difficulties of managing symptoms like severe pain, fatigue, and deconditioning. Robert emphasizes the importance of finding a knowledgeable physical therapist who helped them create an individualized exercise routine. Over time, they have been able to regain strength and improve their quality of life, although they still face challenges like pain, fatigue, and the need to carefully balance their exercise routine.

Healing Together: The Role of Black, Indigenous and People of Color (BIPOC) -Only Chronic Illness Spaces in Comprehensive Care

The abstract explores the significance of BIPOC-only chronic illness support spaces in providing comprehensive care for patients. It emphasizes the unique challenges faced by BIPOC individuals with chronic illnesses, including systemic racism, health disparities, and cultural stigma. These exclusive spaces offer a sense of community, cultural understanding, and tailored support that traditional healthcare settings often lack. The abstract highlights how these spaces can improve mental and physical health outcomes by fostering a supportive environment that addresses the specific needs of BIPOC patients.

How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities

Shelly Fritz discusses their experience of conducting a systematic literature review on rheumatoid arthritis (RA) and its comorbidities. This rigorous process enhanced their ability to find and analyze relevant research, leading to a deeper understanding of their condition. The author highlights how the skills gained from the review process, such as identifying high-quality studies and synthesizing findings, have empowered Shelly to make informed decisions about their healthcare and better manage their RA and related health issues.

Involving Pediatric Patients in Their Own Care

In this abstract by Whitney LaBar they discuss the importance and benefits of involving pediatric patients in their own healthcare. It emphasizes that engaging children in their treatment plans can improve adherence to medical advice, enhance their understanding of their health conditions, and foster a sense of responsibility and independence. The abstract highlights various strategies to achieve this, including age-appropriate education, shared decision-making, and the use of digital tools to facilitate communication and monitoring. By empowering young patients, healthcare providers can improve outcomes and support the long-term well-being of pediatric patients.

Living Well with a Rare Rheumatic Disease – Becoming a “Precision” Patient on the Horizon of Precision Medicine

Ida shares her personal journey with a rare, chronic rheumatic disease, Granulomatosis with Polyangiitis (GPA), which began with symptoms like joint pain, night sweats, and sinus congestion. After a series of hospitalizations and treatments, including Rituximab (RTX), she has learned to manage her condition proactively by staying informed about the latest medical information and working closely with her healthcare team. Ida emphasizes the importance of patient advocacy, communication, and trust in the patient-physician relationship. She also highlights how precision medicine is becoming a promising approach for managing autoimmune diseases, allowing patients to take a more active role in their care.

Living Well with Chronic Illness: Decades with MCTD

Carol Kaminski, shares her journey of living with Mixed Connective Tissue Disease (MCTD) for nearly 40 years. Initially experiencing symptoms like fatigue, joint pain, and swollen fingers, she was eventually diagnosed with MCTD after several medical consultations. Over the years, she learned to manage her condition through various therapies and lifestyle adjustments, such as using leather gloves for racquet sports to protect her hands and requesting work accommodations to avoid sunlight. Despite ongoing challenges like swallowing issues, Carol has found ways to live well with her chronic illness, and her disease has been in remission for the last 15 years.

My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective

Joseph Washington, shares his personal experience of living with diffuse scleroderma and interstitial lung disease (ILD). He describes how his symptoms began in high school with Raynaud's phenomenon and progressed over time. After being diagnosed with systemic sclerosis (SSc) based on blood tests revealing positive anti-SCL70, he started treatment with amlodipine for Raynaud's symptoms and later transitioned to other medications like mycophenolate mofetil (MMF), nintedanib, and tocilizumab. Washington highlights the challenges of managing a rare disease, including navigating insurance and accessing specialty drugs. His background as a pharmacist helped him advocate for himself, enroll in manufacturer-sponsored assistance programs, and reduce out-of-pocket costs. He emphasizes the importance of collaborative specialist care and patient advocacy in managing his condition and maintaining a high quality of life.

Reunion with Forgotten Relationships and Memories

Noriko Okochi reflects on how living with a chronic illness impacted their personal relationships and memories. Over time, the demands of managing the illness led to the neglect of certain friendships and connections. The abstract highlights the emotional journey of reconnecting with these forgotten relationships and the joy and challenges that come with rekindling old bonds. It emphasizes the importance of support networks and the therapeutic value of remembering and cherishing past experiences as part of comprehensive care for chronic illness.

Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis

Eileen Davidson, shares her personal experience of using sauna therapy to manage her rheumatoid arthritis (RA) symptoms. Since her diagnosis in 2015, she has found that regular sauna sessions help alleviate muscle pain, stiffness, and chronic fatigue associated with RA flares. The sauna has also improved her joint mobility, making it easier to return to physical activities after periods of inactivity. Beyond physical benefits, the sauna has positively impacted her mental health by providing a sense of relaxation and escape, especially during harsh Canadian winters. Eileen emphasizes the importance of incorporating non-pharmacological strategies like sauna therapy into RA management routines for better overall well-being.

Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally

The author, Bridget Kelly, shares her journey of managing sarcoidosis and osteoarthritis through exercise. Initially experiencing severe joint pain and neuropathy, she was diagnosed with sarcoidosis after a series of tests. Despite the challenges, Bridget committed to a daily walking routine, which helped her manage her symptoms both physically and emotionally. Over the years, she faced additional health issues, including osteopenia and osteoporosis, and underwent surgeries for tendon tears and spinal issues. However, her dedication to walking and strength training allowed her to regain strength and maintain her health. Bridget emphasizes the importance of staying active and committed to self-care to manage chronic conditions effectively.

Whispers of Resilience: Navigating Life with Rheumatism

The author, Vinchelle Hardison, shares her childhood experience of living with a rheumatic condition, which included Mixed Connective Tissue Disease (MCTD) with components like arthritis, scleroderma, dermatomyositis, and lupus. She describes the emotional challenges of growing up with a chronic illness, such as feeling different from other children and dealing with numerous medical tests and treatments. Vinchelle emphasizes the importance of providing age-appropriate resources and support to help children understand and cope with their diagnosis. She also highlights the role of resilience and the impact of supportive physicians in helping patients navigate their new reality with confidence and strength.

Understanding Cryopyrin-Associated Periodic Syndromes (CAPS)

Tue, 03 Dec 2024 20:47:00 GMT

Understanding Cryopyrin-Associated Periodic Syndromes (CAPS)

CAPS Encompasses Three Main Syndromes:

Familial Cold Autoinflammatory Syndrome (FCAS) is a rare genetic condition where exposure to cold temperatures triggers episodes of fever, rash, and joint pain. Symptoms typica lly begin in infancy or early childhood and include chills, muscle pain, and fatigue. The episodes usually last for a few hours to a day and resolve on their own once the person warms up. Other symptoms may include conjunctivitis (red, irritated eyes) and headache. FCAS is caused by mutations in the NLRP3 gene, leading to the overproduction of interleukin-1β (IL-1β), a protein involved in inflammation. Learn more about Familial Cold Autoinflammatory Syndrome (FCAS)

Muckle-Wells Syndrome (MWS) is a rare genetic disorder characterized by episodes of fever, rash, joint pain, and progressive hearing loss, often triggered by cold or stress. Additional symptoms may include abdominal pain, fatigue, red eyes, and amyloidosis—a condition where protein builds up in organs like the kidneys, potentially leading to organ failure. MWS is caused by mutations in the NLRP3 gene, resulting in excessive production of interleukin-1β (IL-1β), which triggers widespread inflammation. Without proper treatment, MWS can lead to serious complications, including chronic kidney disease and hearing loss. Learn more about Muckle-Wells Syndrome.

Neonatal-Onset Multisystem Inflammatory Disease (NOMID) , also known as Chronic Infantile Neurologic Cutaneous and Articular (CINCA) syndrome , is a rare genetic disorder characterized by persistent inflammation affecting multiple body systems, including the skin, joints, and central nervous system, starting in early infancy. Symptoms include a persistent rash, fever, joint deformities, chronic aseptic meningitis, and developmental delays. NOMID can also cause hearing loss, vision problems, and severe headaches. It is caused by mutations in the NLRP3 gene, leading to an overactive inflammatory response driven by interleukin-1β (IL-1β). Early and aggressive treatment with IL-1 inhibitors is crucial to manage symptoms and prevent long-term damage. Learn more about Neonatal-Onset Multisystem Inflammatory Disease (NOMID), also known as Chronic Infantile Neurologic Cutaneous and Articular (CINCA) syndrome .

How Common Are Cryopyrin-Associated Periodic Syndromes (CAPS)?

Cryopyrin-Associated Periodic Syndromes (CAPS) are quite rare. The estimated prevalence is 2 to 5 per million individuals. However, this number might be higher due to underdiagnosis and misdiagnosis, as CAPS symptoms can be similar to other more common conditions. Cryopyrin-Associated Periodic Syndromes (CAPS) affect both men and women, but there isn't a significant gender difference in prevalence. Both genders are equally likely to develop CAPS due to the genetic nature of the condition

CAPS are caused by changes in a gene called NLRP3, which makes a protein called cryopyrin. This change causes the body to make too much of a chemical called interleukin-1β (IL-1β), which causes inflammation. The NLRP3 gene is found on chromosome 1.

Learn More About CAPS

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Clinical Features of Cryopyrin-Associated Periodic Syndromes (CAPS)

The syndromes within CAPS share overlapping clinical features but vary in severity

Fever: Often accompanied by fatigue, malaise, and mood disorders.
Skin Rash: Urticarial or maculopapular rash, especially after cold exposure.
Musculoskeletal Involvement: Myalgia, arthralgia, arthritis, and joint deformities.
Ophthalmological Involvement: Conjunctivitis, uveitis, optic nerve atrophy, cataract, and glaucoma.
Neurological Involvement: Headaches, papilloedema, meningitis, seizures, and intellectual disability.
Hearing Loss: Sensorineural hearing loss is common in FCAS.

Discover More Of Our Resources

How is Cryopyrin-Associated Periodic Syndromes (CAPS) Diagnosed?

Diagnosis of CAPS is based on clinical features, family history, and genetic testing to identify mutations in the NLRP3 gene. Laboratory tests may show elevated levels of inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

What Are The Treatments For Cryopyrin-Associated Periodic Syndromes (CAPS)?

Management of CAPS focuses on controlling inflammation and preventing complications - Treatment options include:

Anti-IL-1 Therapy: Drugs like anakinra, canakinumab, and rilonacept target IL-1β to reduce inflammation
NSAIDs and Corticosteroids: Used to manage acute inflammatory episodes
Supportive Care: Addressing specific symptoms such as pain management and hearing aids for hearing loss

What is The Prognosis of Cryopyrin-Associated Periodic Syndromes (CAPS)?

Cryopyrin-Associated Periodic Syndromes (CAPS) can significantly impact the quality of life due to their chronic and systemic nature. Some key ways CAPS affects quality of life:

Chronic Pain and Discomfort: Persistent pain and discomfort from symptoms like joint pain, headaches, and skin rashes can limit daily activities and reduce overall well-being.
Fatigue and Malaise : Frequent fevers and systemic inflammation can lead to ongoing fatigue, making it difficult to maintain regular routines and participate in social activities.
Neurological and Sensory Issues: Neurological complications such as headaches, hearing loss, and vision problems can affect communication, mobility, and independence.
Emotional and Psychological Impact: Living with a chronic condition can lead to emotional distress, anxiety, and depression, impacting mental health and overall quality of life
Social and Professional Challenges: Absenteeism from work or school due to flare-ups and medical appointments can affect career progression and educational opportunities.
Caregiver Burden: Family members and caregivers may experience emotional and financial stress due to the demands of providing care and support.

CAPS are complex autoinflammatory disorders requiring a multidisciplinary approach for effective management. Ongoing research continues to enhance our understanding of these syndromes and improve treatment strategies. Early diagnosis and treatment are crucial for improving outcomes. With appropriate management, many patients can lead a relatively normal life, although chronic symptoms may persist.

Rare AiArthritis Disease Abstracts at ACR24

Sun, 01 Dec 2024 12:36:54 GMT

Rare Ai Arthritis Disease Abstracts at ACR24

Latest research on rare AiArthritis Disease presented at the ACR24 conference.

Mixed Connective Tissue Disease

Mixed Connective Tissue Disease (MCTD) is a rare autoimmune disorder that combines features of several other connective tissue diseases, such as systemic lupus erythematosus (SLE), scleroderma, and polymyositis. It is sometimes referred to as an "overlap" disease because it shares characteristics with these conditions. Symptoms can include Raynaud's phenomenon (where fingers or toes turn white or blue in response to cold or stress), joint pain and swelling, muscle weakness, and skin changes. MCTD can also affect internal organs, such as the lungs, heart, and kidneys

Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort

This multicenter retrospective study evaluates therapeutic strategies for patients with Mixed Connective Tissue Disease (MCTD) within the French MCTD cohort. By analyzing treatment outcomes across multiple centers, researchers aim to identify the most effective approaches for managing MCTD, considering the variability in patient responses and the potential for adverse events. The study underscores the importance of personalized treatment plans and aims to enhance the overall management of MCTD through evidence-based practices.

All Mixed Connective Tissue Disease Abstracts

Antisynthetase Syndrome

Antisynthetase Syndrome (ASS) is a rare autoimmune disorder characterized by inflammation in various parts of the body due to the immune system mistakenly attacking its own tissues. It often involves muscle inflammation (myositis), polyarthritis (inflammation of multiple joints), interstitial lung disease (ILD), mechanic's hands (thickened, cracked skin on the palms and fingers), and Raynaud's phenomenon (color changes and numbness in fingers and toes in response to cold). The exact cause of ASS is unknown, but it is associated with antibodies against aminoacyl-tRNA synthetases, with anti-Jo-1 being the most common.

The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome

This study investigates the association between the rs35705950 promoter variant of the MUC5B gene and the development of usual interstitial pneumonia (UIP) in patients with antisynthetase syndrome (ASSD). The research found that carrying this genetic variant significantly increases the risk of UIP in ASSD patients, highlighting the importance of genetic factors in the progression of lung involvement in this autoimmune condition.

View all ACR abstracts on Antisynthetase Syndrome

Enteropathic Arthritis

Enteropathic Arthritis (EnA), also known as enteropathic arthropathy, is a type of chronic inflammatory arthritis associated with inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. It causes joint inflammation and tenderness, primarily affecting the arms, legs, and sometimes the spine

Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype

This study explores the coexistence of Raynaud's phenomenon, morphea, or scleroderma in patients with spondyloarthritis (SpA). By analyzing data from a retrospective cohort at Houston Methodist Hospital, researchers identified a unique phenotype characterized by the overlap of these conditions. The majority of affected patients were Caucasian females with a negative HLA-B27 status, suggesting distinct clinical features compared to typical SpA cases.

All Enteropathic Arthritis Abstracts

Chronic Nonbacterial Osteomyelitis

Chronic Nonbacterial Osteomyelitis (CNO) is a rare, inflammatory bone disorder that primarily affects children and adolescents, but can also be seen in adults. Unlike bacterial osteomyelitis, CNO is not caused by an infection, but rather an abnormal immune response leading to bone inflammation. The condition is characterized by recurrent episodes of bone pain and swelling, often involving the long bones of the legs, pelvis, and spine. The exact cause of CNO remains unknown, but it's believed to involve genetic, immunological, and environmental factors.

All Chronic Nonbacterial Osteomyelitis Abstracts

Absolute Agreement and Inter-rater Reliability of a Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO) Amongst Radiologists

This study evaluates the absolute agreement and inter-rater reliability of a web-based standardized scoring tool called CROMRIS (ChRonic nonbacterial Osteomyelitis Magnetic Resonance Imaging Scoring) for assessing MRI images from children with Chronic Nonbacterial Osteomyelitis (CNO). The tool aims to provide a user-friendly interface for radiologists to consistently score specific features of bone and soft tissue inflammation. The study involved three pediatric radiologists independently scoring MRI scans, and the results showed substantial agreement among the raters

Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data

This study focuses on the validation of the Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric measures for children with Chronic Nonbacterial Osteomyelitis (CNO), using data from the Chronic Nonbacterial Osteomyelitis International Registry (CHOIR). The PROMIS measures, which have been validated in other pediatric rheumatic diseases, were administered to children with CNO to assess their effectiveness in capturing patient-reported outcomes.

Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children

This study investigates osteoclastogenesis (the formation of osteoclasts, which are cells that break down bone tissue) from peripheral blood mononuclear cells (PBMCs) in children with Chronic Nonbacterial Osteomyelitis (CNO) and compares it to healthy children. The research aims to understand whether there are differences in the osteoclast formation process between these two groups. The findings suggest that osteoclastogenesis in children with CNO is similar to that in healthy children, indicating that other factors might be contributing to the disease's pathology

Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis

This study explores the relationship between culture-negative infectious osteomyelitis (IO) and chronic nonbacterial osteomyelitis (CNO). It aims to understand the similarities and differences between patients initially diagnosed with culture-negative IO who later develop CNO. The research involves a retrospective chart review of patients diagnosed with culture-negative IO, comparing their clinical features, laboratory results, and responses to treatment with those who were later diagnosed with CNO. The findings could help improve early identification and treatment of CNO

To Biopsy or Not to Biopsy: Imaging Features of Chronic Nonbacterial Osteomyelitis of the Clavicle

This study, titled "To Biopsy or Not to Biopsy: Imaging Features of Chronic Nonbacterial Osteomyelitis of the Clavicle", investigates whether biopsy is necessary for diagnosing Chronic Nonbacterial Osteomyelitis (CNO) of the clavicle. The researchers conducted a retrospective chart review of patients with unifocal clavicular lesions, comparing clinical and imaging features between those diagnosed with CNO and other conditions. They found that certain imaging features, such as multifocal lesions and specific MRI findings, could help distinguish CNO from other conditions, potentially reducing the need for biopsy

Factors Associated with Health-related Quality of Life in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – a Cross Sectional Analysis from the SAPHO-CNO Study

This study examines the factors associated with health-related quality of life (HRQOL) in adults with SAPHO syndrome and Chronic Nonbacterial Osteomyelitis (CNO). Using the EuroQol-5 Dimension instrument (EQ-5D-5L), researchers assessed HRQOL across five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The study found that disease features like inflammatory arthritis, spine involvement, skin rash, and total musculoskeletal symptom score significantly impacted HRQOL. The findings highlight the importance of addressing these factors to improve the quality of life for adults with SAPHO-CNO.

Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis

This study focuses on the development and validation of a novel score system designed to guide diagnostic procedures in children suspected of having Chronic Nonbacterial Osteomyelitis (CNO). The goal is to identify subsets of patients with either a very low or very high probability of CNO before deciding whether to perform a bone biopsy. This scoring system aims to improve diagnostic accuracy and reduce the need for invasive procedures.

Systemic Scleritis

Systemic Scleritis is a severe, chronic inflammatory disease that affects the sclera, the white outer layer of the eye. It often causes intense pain, redness, and swelling, and can lead to serious complications, including vision loss if left untreated. Systemic Scleritis is frequently associated with underlying autoimmune conditions, such as rheumatoid arthritis, granulomatosis with polyangiitis, and systemic lupus erythematosus.

View all Systemic Scleritis Abstracts

Scleritis and the Rheumatologist. Does the Type of Scleritis Help to Distinguish an Infectious Cause from an Immune Cause? Among the Immune Causes, Does It Help Differentiate Between Systemic Causes and Those Limited to the Eye?

The abstract discusses the role of rheumatologists in evaluating and treating scleritis, an inflammation of the white outer layer of the eye. It highlights the challenge of distinguishing between infectious and immune causes of scleritis, as well as differentiating between systemic immune causes and those limited to the eye. The study evaluated patients diagnosed with various types of scleritis and categorized them based on immune or infectious etiology. The findings suggest that understanding the type of scleritis can help in identifying its cause and guiding appropriate treatment.

Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)

This abstract discusses the demographic and ocular characteristics of scleritis patients with systemic rheumatologic diseases, based on data from the IRIS Registry (Intelligent Research in Sight). The study found that 30-40% of scleritis cases are associated with systemic autoimmune diseases, and these patients often have worse visual outcomes. The most common associated condition was rheumatoid arthritis. The study also noted that anterior scleritis was the most frequent subtype among these patients, and there were high rates of comorbid conditions like uveitis and macular edema.

Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study

This abstract discusses a retrospective cross-sectional study that examined racial disparities in ocular complications among patients with systemic rheumatic diseases. The study found that Black and Asian patients were disproportionately affected by ocular complications such as keratitis, scleritis, retinopathy, and optic neuropathy compared to other racial groups. These complications were associated with poorer in-hospital outcomes, including longer hospital stays, higher healthcare costs, and increased rates of non-home discharge

Sjögren's Disease

Sjögren's Disease is an autoimmune disorder in which the body's immune system mistakenly attacks its own moisture-producing glands. This primarily affects the salivary and lacrimal glands, leading to symptoms like dry mouth and dry eyes. People with Sjögren's can also experience fatigue, joint pain, and swollen glands. While the exact cause is unknown, it is believed to involve a combination of genetic and environmental factors.

View All Sjögren's Disease Abstracts

Mortality and Its Predictor Variables in Patients with Sjögren Disease: Data from SjögrenSER-Pros Prospective Registry

The study investigates the risk of mortality in patients with Sjögren's Disease compared to the general population. It identifies predictive factors of mortality, such as advanced age, male sex, and certain disease manifestations like parotid enlargement and vasculitis2. The study aims to provide insights into the causes of death and help improve patient management and outcomes

The Problem of Pain in Rheumatology: Sociodemographic and Disease-related Correlates of Agreement Between Structured Data Elements and Clinical Notes in Chronic Pain Documentation Practices in EHR

The study investigates the risk of mortality in patients with Sjögren's Disease compared to the general population. It identifies predictive factors of mortality, such as advanced age, male sex, and certain disease manifestations like parotid enlargement and vasculitis. The study aims to provide insights into the causes of death and help improve patient management and outcomes.

Rheumatic Disease Patients: Assessment of Hydroxychloroquine’s Effects on QTc Intervals with Weight Based Dosing (RAISE-QT) Study

The study investigates the effects of hydroxychloroquine (HCQ) on QTc intervals in patients with rheumatic diseases such as Systemic Lupus Erythematosus (SLE), Sjögren's Disease, and Rheumatoid Arthritis (RA). After 12 weeks of treatment, there was a statistically significant increase in QTc intervals among patients, even without the use of other QT-prolonging medications or chronic kidney disease. However, no significant correlation was found between HCQ blood levels and QTc interval changes.

Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren’s Disease

The study explores how social media can provide insights into the daily struggles of people living with Sjögren's Disease. By analyzing 84,034 posts/comments from the Reddit community r/sjogrens over 11 years, researchers identified frequent activities of daily living (ADLs) such as eating, sleeping, and professional activities. They linked these ADLs to clinical concepts like dryness of mouth, pain, and fatigue, as well as emotions like fear. This study aims to better understand the real-world impact of Sjögren's Disease on patients' lives through their own words and experiences.

VEXAS Syndrome Abstracts at ACR24

Sat, 30 Nov 2024 14:51:53 GMT

VEXAS Syndrome Abstracts at ACR24

Latest research on VEXAS Syndrome

VEXAS syndrome is a rare, adult-onset autoinflammatory disease primarily affecting males, discovered in December 2020 and first reported in The New England Journal of Medicine. The name VEXAS is an acronym for its key features: Vacuoles, E1 enzyme, X-linked, Autoinflammatory, and Somatic. It is caused by somatic mutations in the UBA1 gene in hematopoietic progenitor cells. Patients with VEXAS syndrome experience symptoms such as fever, skin rashes, joint pain, and hematologic abnormalities like macrocytic anemia and bone marrow failure.

View all VEXAS Syndrome Abstracts from previous years

2024 American College of Rheumatology Conference abstracts on VEXAS Syndrome

Clinical and Biological Features of VEXAS Syndrome in Women: Study of 9 French Cases Compared with 263 Men

The study examines the clinical and biological features of VEXAS syndrome in women, comparing them to 263 men with the condition. VEXAS syndrome is an autoinflammatory disease caused by somatic mutations in the UBA1 gene, which is located on the X chromosome. The study found that while the syndrome is more common in men, it can also occur in women, often due to constitutional or acquired X monosomy.. In the small cohort of women studied, common symptoms included fever, altered general condition, neutrophilic dermatosis, chondritis, pulmonary infiltrate, and thromboembolic events.

Neutrophil Transcriptomics in VEXAS Syndrome

This study investigates how changes in gene expression in neutrophils (a type of white blood cell) might contribute to VEXAS syndrome, a rare inflammatory condition caused by mutations in the UBA1 gene. By analyzing neutrophils from patients with VEXAS, researchers hope to better understand the disease and potentially identify new targets for treatment.

Pervasive Inflammation Poisons Hematopoiesis and Drives Clonal Dominance in VEXAS Syndrome

This study explores how widespread inflammation in VEXAS syndrome can harm normal blood cell production (hematopoiesis) and lead to the dominance of abnormal blood cell clones. The findings suggest that inflammation plays a key role in the disease's progression and highlights potential targets for treatment.

Clinical and Biological Features of VEXAS Syndrome in Women: Study of 9 French Cases Compared with 263 Men

This study compares the clinical and biological features of VEXAS syndrome in women to those in men. It aims to understand how the disease manifests differently based on gender, providing insights into potential differences in symptoms, disease progression, and treatment responses between women and men with VEXAS syndrome.

Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome

This study investigates how VEXAS syndrome affects natural killer (NK) cells, revealing that these cells show impaired function and signs of exhaustion. By deeply analyzing the characteristics of peripheral NK cells, researchers aim to better understand the disease mechanisms and identify potential targets for treatment.

Heterogeneity of VEXAS Syndrome: A Multicenter Case-series of 299 Cases from the French VEXAS Study Group (FRENVEX)

This study examines the diverse clinical presentations and characteristics of VEXAS syndrome through a multicenter case series of 299 patients from the French VEXAS Study Group (FRENVEX). By analyzing a large cohort, researchers aim to better understand the variability in symptoms, laboratory findings, treatments, and outcomes, providing a comprehensive overview of this complex autoinflammatory condition.

Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment

This study from Spain focuses on finding more specific and effective treatments for VEXAS syndrome, a rare inflammatory disease. By analyzing data from multiple centers, researchers aim to improve understanding of the disease and develop better therapeutic strategies. The study highlights the importance of personalized treatment approaches and aims to identify more targeted and effective therapies to improve patient outcomes.

A Systematic Review of Treatment Strategies in VEXAS Syndrome

This systematic review evaluates the effectiveness and safety of current treatment strategies for VEXAS syndrome, a rare inflammatory condition caused by mutations in the UBA1 gene. By analyzing data from multiple studies, the review aims to identify the most promising treatments and highlight the need for individualized treatment plans due to the variability in patient responses and the potential for adverse events

Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients

This study examines the phenotypical differences in VEXAS syndrome, focusing on a national cohort of rheumatological patients. By comparing clinical and biological features between women and men, the research aims to uncover gender-specific manifestations, disease progression, and treatment responses, providing a deeper understanding of this complex autoinflammatory condition.

Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study

This study compares polyarteritis nodosa (PAN) associated with VEXAS syndrome and chronic myelomonocytic leukemia (CMML) to primary forms of PAN. Researchers aim to evaluate differences in presentation, management, and prognosis, providing insights into how these secondary forms of PAN might require different treatment approaches compared to primary PAN.

Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency

This study investigates the relationship between bone marrow failure in VEXAS syndrome and the degree of UBA1b deficiency. Researchers found that patients with more severe UBA1b deficiency experienced more frequent and severe bone marrow failure, including anemia and thrombocytopenia, compared to those with partial deficiency1. The study highlights the importance of UBA1b in maintaining healthy blood cell production and suggests that targeting this pathway could be a potential therapeutic strategy for VEXAS syndrome

V asculitis Associated with VEXAS Syndrome

This study examines the prevalence, distribution, and characteristics of vasculitis in patients with VEXAS syndrome, a rare inflammatory condition caused by mutations in the UBA1 gene. Researchers found that a significant proportion of patients with VEXAS syndrome develop vasculitis, with small vessel vasculitis being the most common type. The study highlights the importance of recognizing vasculitis as a potential manifestation of VEXAS syndrome and suggests that it may require different treatment approaches compared to primary forms of vasculitis.

A Comprehensive Approach Utilizing a Combination of Genetics, Cytological Analysis, and Imaging Techniques to Speed up the Diagnostic Process in VEXAS Patients

This study presents a comprehensive approach to diagnosing VEXAS syndrome by combining genetics, cytological analysis, and imaging techniques. By integrating these methods, researchers aim to speed up the diagnostic process and better characterize VEXAS patients from the outset. The study includes genetic analysis to identify UBA1 mutations, cytological evaluation of blood cells to observe cellular abnormalities, and imaging techniques like PET-CT scans to assess inflammation and other abnormalities. This multi-faceted approach helps provide a more accurate and timely diagnosis for patients with VEXAS syndrome.

Developing Predictive Models for the Diagnosis of VEXAS Syndrome

This study aims to develop predictive models to improve the diagnosis of VEXAS syndrome, a rare autoinflammatory disorder caused by mutations in the UBA1 gene. By analyzing clinical and laboratory features from patients who underwent UBA1 testing, researchers created models to help clinicians identify which patients should be tested for VEXAS syndrome. The models were designed using advanced statistical methods and evaluated for their accuracy in distinguishing between positive and negative cases.

Key Patient Take Aways

VEXAS syndrome is a rare inflammatory condition caused by mutations in the UBA1 gene, which is located on the X chromosome. It is more common in men but can also occur in women.
Common symptoms of VEXAS syndrome include fever, altered general condition, neutrophilic dermatosis, chondritis, pulmonary infiltrate, and thromboembolic events.
The disease can cause widespread inflammation that harms normal blood cell production and leads to the dominance of abnormal blood cell clones.
Natural killer cells, a type of immune cell, may show impaired function and signs of exhaustion in patients with VEXAS syndrome.
VEXAS syndrome can present differently in different people, with a range of clinical features and severity.
Treatment strategies for VEXAS syndrome are still being developed and may need to be individualized due to the variability in patient responses.
Some patients with VEXAS syndrome may develop vasculitis, a condition where the blood vessels become inflamed.
Bone marrow failure is a potential complication of VEXAS syndrome, and the risk may be associated with the degree of UBA1b deficiency.
A comprehensive diagnostic approach using genetics, cytological analysis, and imaging techniques may help speed up the diagnosis of VEXAS syndrome.
Predictive models are being developed to help clinicians determine which patients should be tested for VEXAS syndrome based on their clinical and laboratory features.

Familial Mediterranean Fever Abstracts at ACR24

Sat, 30 Nov 2024 14:27:49 GMT

Familial Mediterranean Fever Abstracts at ACR24

Latest research on Familial Mediterranean Fever.

Familial Mediterranean Fever (FMF) is an inherited disorder that primarily affects people of Mediterranean descent, such as those from Turkey, Armenia, and the Arab countries. The condition is characterized by recurring episodes of fever and inflammation, particularly in the abdomen, chest, and joints. These attacks can last from a few hours to several days and vary in intensity. FMF is caused by mutations in the MEFV gene, which encodes a protein involved in inflammation regulation. While there's no cure for FMF, treatments like colchicine can help manage symptoms and prevent long-term complications.

Discover all Familial Mediterranean Fever abstracts from previous years

The 2024 American College of Rheumatology conference abstracts on Familial Mediterranean Fever

Liver Disease Complicating Familial Mediterranean Fever: A Study on 57 Patients from the French Adult JIR Cohort

This study investigates liver disease in patients with Familial Mediterranean Fever (FMF), a genetic autoinflammatory disorder. Researchers examined 57 patients from the French Adult JIR Cohort and found that 10.7% had chronic liver abnormalities, with 30% developing cirrhosis. The study highlights the delayed diagnosis of liver disease in FMF patients and suggests that inflammation plays a significant role in liver complications. The findings emphasize the need for regular monitoring and early intervention to manage liver involvement in FMF patients effectively.

Path to Diagnosis in Familial Mediterranean Fever (FMF)

This study investigates the diagnostic journey for Familial Mediterranean Fever (FMF), focusing on the time from symptom onset to diagnosis and the various medical specialties involved. By surveying patients at an autoinflammatory clinic, researchers aim to understand the pathways to an FMF diagnosis and identify potential delays or barriers in the diagnostic process1. The findings will help improve early detection and management of FMF.

Role of Mutual Information Profile Shifts in Assessing the Pathogenicity of Mutations on Protein Functions: The Case of Pyrin Mutations in Familial Mediterranean Fever

This study explores a novel method to assess the pathogenicity of mutations in the Pyrin protein, which is associated with Familial Mediterranean Fever (FMF). By using mutual information (MI) to quantify the correlation between residue motions or fluctuations, researchers aim to predict how mutations affect protein function and disease severity. The study demonstrates that shifts in MI profiles can reveal insights into the molecular mechanisms underlying disease progression and help identify potential therapeutic targets.

The Needed Daily Dose of Colchicine in Patients with Familial Mediterranean Fever May Be Higher in Women, a Study on Behalf of the JIR Cohort

This study investigates whether the required daily dose of colchicine for managing Familial Mediterranean Fever (FMF) might be higher in women compared to men. By analyzing data from the French Adult JIR Cohort, researchers aim to determine if gender differences influence the effectiveness and dosage requirements of colchicine in FMF patients.

Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever

This study aims to develop machine learning algorithms to predict colchicine resistance in patients with Familial Mediterranean Fever (FMF). By analyzing clinical and genetic data from FMF patients, researchers hope to create models that can accurately identify patients who are likely to be resistant to colchicine, allowing for more personalized and effective treatment strategies.

Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort

This study investigates the prevalence of iron deficiency in 211 adult patients with Familial Mediterranean Fever (FMF) from the JIR cohort. Researchers found that 31.8% of the patients were iron deficient, with a significant majority being women. Iron-deficient patients had lower hemoglobin levels, body mass index, and were generally younger compared to those without iron deficiency. The study suggests that iron deficiency in FMF patients, particularly in women, may contribute to increased fatigue and potentially more frequent disease attacks.

Canakinumab Treatment in Patients with Familial Mediterranean Fever: A Tertiary Center Experience

This study evaluates the effectiveness and safety of canakinumab, a medication that targets interleukin-1 beta (IL-1β), in treating Familial Mediterranean Fever (FMF) patients. By analyzing data from a tertiary center, researchers aim to provide insights into how well canakinumab works for FMF patients, especially those who do not respond to traditional treatments like colchicine. The study highlights the potential of canakinumab as a valuable treatment option for managing FMF symptoms and preventing complications.

Increased Risk of Psoriatic Arthritis in Patients with Familial Mediterranean Fever: A Population-Based Cohort Study

This population-based cohort study investigates the association between Familial Mediterranean Fever (FMF) and an increased risk of developing psoriatic arthritis (PsA). Researchers analyzed data from a large healthcare database, including around 4.9 million members, to compare the incidence of PsA in patients with FMF to those without FMF. The study found that FMF patients had a significantly higher risk of developing PsA, even after adjusting for demographic factors and comorbidities. This suggests that the chronic inflammation and immune dysregulation in FMF may contribute to the development of PsA.

Key Patient Take Aways

FMF is a genetic autoinflammatory disorder that can cause chronic liver abnormalities and potentially lead to cirrhosis in some patients.
The diagnostic process for FMF can be complex and may involve multiple medical specialties. There may be delays in diagnosis, highlighting the need for improved early detection strategies.
Researchers are exploring new methods to assess the pathogenicity of mutations in the Pyrin protein, which is associated with FMF. These approaches could provide insights into disease mechanisms and help identify potential therapeutic targets.
The required daily dose of colchicine, a common treatment for FMF, may be higher in women compared to men. This suggests that gender differences could influence treatment approaches for FMF.
Machine learning algorithms are being developed to predict which FMF patients may be resistant to colchicine. These models could help personalize treatment plans and improve outcomes for patients who do not respond well to colchicine.
Iron deficiency is common in FMF patients, particularly women, and may contribute to increased fatigue and more frequent disease attacks.
Canakinumab, a medication that targets interleukin-1 beta (IL-1β), may be an effective treatment option for FMF patients who do not respond well to traditional therapies like colchicine.
FMF patients may have an increased risk of developing psoriatic arthritis (PsA), suggesting that the chronic inflammation and immune dysregulation in FMF could contribute to the development of PsA.

A Matter of Life and Breath: Living with Interstitial Lung Disease

Wed, 27 Nov 2024 02:16:36 GMT

A Matter of Life and Breath: Living with Interstitial Lung Diseas e

“Dr. C, please can you refer me to a pulmonologist? I am still feeling short of breath when I do anything physical, I have this dry cough, and I’m just exhausted all the time.”

Dr. C is my PCP. She takes her stethoscope and places it on my back and then my chest, having me take deep breaths while she listens. I can’t breathe nearly as deeply as I used to, but she shakes her head and says, “Sorry, but I don’t hear anything, so I can’t refer you to a pulmonologist. There has to be a reason.”

This is the third time we have had this discussion in the past year. I know I must find a way around this. So….I wait until I know she will be gone for a couple of weeks and I make an appointment to see Dr. A, who covers for her.

When I ask Dr. A the same question, she uses the stethoscope but then uses a spirometer and also tests my O2 with oximeter. She says the reason nothing is heard with the stethoscope is because I have restrictive lung disease, not congestive. And that the dry cough is a sign of this, as well as “it is not good that you cough after exhaling. And your lung capacity on the spirometer is only 75-77% of normal. I am making a stat referral to Dr. J in pulmonology.”

Dr. J saw me the next week. He ordered high-resolution lung CT scans and did further in-depth spirometry testing and took a very extensive medical history. When I came back for the results, he showed me the CT scans on the screen and explained the white parts of my lower lungs were “ground glass opacities” where the lung cells are dead.

You may have heard of ground glass opacities in the lungs as resulting from serious COVID infections but this may also occur as a result of …. you guessed it: an AiArthritis Disease co-condition. And the combination – getting COVID when you have an AiArthritis Disease -- will up your lung risks severely.

There are actually hundreds of types of ILD, but the autoimmune type is our focus here. Autoimmune Interstitial Lung Disease or Autoimmune ILD is usually associated with RA, Sjogren’s, Lupus, or Scleroderma but it may also be seen with some other AiArthritis Diseases.

Dr. J began to work with me on treatment. He explained he was not going to do a lung biopsy because it wouldn’t change the treatment and the risk of a lung infection from the procedure would be too high in someone on immune-suppression.

Why do I share this story with so much detail? Because you may run into what I did: a PCP not willing to refer you because they have no knowledge of restrictive lung disorders or ILD.

So…..if you have the symptoms of difficulty breathing, a chronic dry cough, and chronic

fatigue, start by telling your rheumatologist. Don’t wait too long! We can never bring those dead cells back to life, but we can slow down (not stop, but definitely slow) the death of more cells in our lungs.

Your rheumatologist will know that these symptoms could be ILD. They may refer you directly to a pulmonologist or they may recommend that your PCP do this, depending upon how your health plan works.

Autoimmune ILD severity depends on how advanced it is when you are diagnosed, the quality of healthcare you receive, how old you are, and how many other health conditions you have. Also, sadly, in the U.S. and some other healthcare systems, a huge factor in your prognosis is how much access you have to quality healthcare. Sometimes a medical social worker can assist you.

Treatment:

After diagnosis, it takes a while to discover which medications are best for you. First your pulmonologist may have you try some oral medications, then progress to inhalers and/or a nebulizer. The diagnosis of ILD may even influence which immune- suppression treatments your rheumatologist prefers for you.

If we have multiple conditions ALL our providers will need to know of our new diagnosis and our pulmonologist may need to consult with our other specialists.

Medications are not the only treatment:

When the lungs weaken, the heart has to work harder, so we need to take care of our heart as well as our lungs.
ILD eventually may lead to heart failure, so controlling blood pressure and following a heart-healthy eating style are also very important. You may request to receive a referral to a Registered Dietitian Nutritionist for help designing a personal plan.
Breathing exercises and cardio exercises such as walking, cycling or swimming help keep our lungs working well and our heart strong. You can ask to be referred to a
Physical Therapist or even a brief cardiac rehab program to build up your exercise tolerance.
Many pulmonologists are also “sleep doctors” and can test you for sleep apnea (cessation of breathing while sleeping). Untreated sleep apnea will greatly stress your heart and lungs, so if your doctors suggest this testing/treatment, it is essential. Breathing is fundamental!

Diagnosis and Treatment is the beginning of our path….yet at the same time, we are faced with the emotional impact of yet another diagnosis, one which is serious. How to cope?

Let’s talk about that in Part Two of this series...stay tuned for A Matter of Life and Breath: Coping with the Diagnosis of Autoimmune Interstitial Lung Disease

(author: Denae Cedar, RDN)

Celebrating International Day of Persons with Disabilities on December 3rd

Wed, 27 Nov 2024 00:37:09 GMT

Celebrating International Day of Persons with Disabilities on December 3rd rd

Observed globally on December 3rd, the International Day of Persons with Disabilities (IDPD) rallies support for the crucial issues surrounding disability inclusion, raises awareness about disability-related challenges, and highlights the advantages of creating an inclusive and accessible society for everyone.

The History and Significance of the Day

Instituted by the United Nations in 1992, IDPD aims to foster an inclusive, accessible world where everyone can participate fully, regardless of their abilities. The significance of this day goes beyond mere acknowledgment; it’s about action and inclusion. By recognizing the challenges and achievements of people with disabilities, we encourage a more empathetic, supportive society. This day reminds us that disability is part of the human condition; anyone can experience it at any point in life, through illness, accident, or aging.

The United Nations proclaimed December 3rd as IDPD to increase awareness and understanding of disability issues and to mobilize support for the dignity, rights, and well-being of persons with disabilities. Over the years, this day has grown into a platform for people with disabilities and their allies to raise their voices and call for more equitable practices in all areas of society.

Why is Disability Awareness Important?

Disability awareness is crucial for many reasons:

Promoting Inclusion and Equity: Awareness fosters inclusive societies, ensuring equal opportunities for all .
Reducing Stigma and Discrimination: It helps break down stereotypes, fostering respect and understanding.
Improving Accessibility: Awareness leads to support for making environments more accessible.
Enhancing Empathy and Support : It builds a supportive community environment.
Encouraging Diverse Perspectives: Recognizing the contributions of people with disabilities enriches society.
Legal and Policy Advocacy: Awareness drives policy changes to protect disability rights.
Empowering Individuals: Representation and value foster a sense of belonging.

Understanding and addressing these challenges creates a more just, inclusive, and compassionate society, benefiting everyone.

Theme 2025: Fostering disability-inclusive societies to advance social progress

Across every region, persons with disabilities and their families continue to encounter major barriers to achieving core social development goals. They face a higher risk of poverty; persistent discrimination in employment, including lower wages and concentration in the informal sector; and uneven or inadequate social protection systems that rarely account for disability-related costs and often exclude informal workers. Many also navigate care and support structures that disregard their dignity, autonomy, and agency.

The three pillars of social development, eradicating poverty, promoting full and productive employment and decent work for all, and strengthening social integration , are inseparable and reinforce one another. Achieving them requires environments that remove structural barriers and uphold equal participation. Including persons with disabilities as both contributors to and beneficiaries of development is essential, making disability inclusion across social, economic, cultural, and political life a non-negotiable priority.

The 2025 International Day of Persons with Disabilities theme, “Fostering disability-inclusive societies for advancing social progress,” reflects the renewed global commitment voiced at the Second World Summit for Social Development. Leaders affirmed the need for a more just, inclusive, equitable, and sustainable world, and recognized that real progress in social development is only possible when all members of society are fully included.

Learn more about these events

Together, these efforts and events highlight the vital role of persons with disabilities in shaping a more inclusive and sustainable future.

How You Can Participate

Raise Awareness: Share information about IDPD on social media using hashtags like #IDPD2024, #DisabilityInclusion, and #AccessibilityMatters.
Educate Yourself: Read articles, watch documentaries, and learn more about the challenges faced by people with disabilities.
Support Organizations: Donate to or volunteer with organizations that work towards disability rights and inclusion. Consider making a donation to The International Foundation for Autoimmune and Autoinflammatory Arthritis to continue making resources and tools for with disabilities from AiArthritis diseases.
Promote Accessibility: Advocate for accessible environments in your community, whether it's improving physical infrastructure or supporting inclusive digital experiences.

International Day of Persons with Disabilities is not just about celebrating the contributions of people with disabilities, but also about recognizing the barriers they face and committing to removing these barriers. By working together, we can create a world where everyone has the opportunity to thrive.

Mark your calendar for December 3rd, and join the global movement toward a more inclusive and equitable world. Remember, each small step we take towards understanding and inclusion makes a big difference.

Hyper-IgD Syndrome (HIDS): A Comprehensive Overview

Tue, 26 Nov 2024 23:07:05 GMT

Hyper-IgD Syndrome (HIDS): A Comprehensive Overview

Causes and Genetics

HIDS is caused by mutations in the mevalonate kinase (MVK) gene, which is responsible for producing an enzyme involved in cholesterol and isoprenoid biosynthesis. The disorder is inherited in an autosomal recessive manner, meaning that a child must receive a mutated gene from both parents to develop the condition. Most patients have two mutations on the MVK gene, one from each parent. HIDS is more common in certain populations, particularly those of Dutch or French ancestry. However, cases have been reported worldwide. The condition affects both males and females equally.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms of Hyper-IgD Syndrome (HIDS)

The primary symptom of HIDS is recurrent fever, which typically begins in infancy. Symptoms can vary greatly among individuals and even from one episode to another in the same person. The frequency of fever episodes can range from every 1 to 12 weeks, and each episode usually lasts 3 to 7 days . Fevers are often accompanied by:

Rash
Abdominal pain
Swollen lymph nodes
Mouth sores
Nausea
Diarrhea
Vomiting
Headache
Enlarged liver and spleen
Cough/inflammation of back of throat
Seizures
Conjunctivitis & uveitis
Colitis
Cutaneous vasculitis

Learn more about Hyper-IgD Syndrome (HIDS)

Diagnosing Hyper-IgD Syndrome (HIDS)

Diagnosing HIDS involves a combination of clinical evaluation, laboratory tests, and genetic testing. Elevated levels of immunoglobulin D (IgD) and immunoglobulin A (IgA) in the blood are often indicative of the condition. Genetic testing can confirm mutations in the MVK gene.

Management and Treatment

There is no cure for HIDS, but treatment focuses on managing symptoms and preventing complications. This may include:

Nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce fever and inflammation
Corticosteroids for severe inflammation
Biologic agents such as interleukin-1 (IL-1) inhibitors for more severe cases
Supportive care to manage symptoms like pain and dehydration

Supportive care includes pain management, maintaining hydration and nutrition, and appropriate physical activity levels. Lifestyle support through stress management techniques, support groups, and education for patients, families, and caregivers is also crucial. As research advances, new therapies may become available, offering hope for improved management of HIDS.

Discover More Of Our Resources

Impact On Quality of Life

Hyper-IgD Syndrome (HIDS) can significantly impact the quality of life due to its recurrent and unpredictable nature. Here are some ways it can affect individuals:

Frequent Fever Episodes: The recurrent fevers, which can reach high temperatures, often lead to discomfort, fatigue, and missed school or work days.
Chronic Pain: Joint pain, abdominal pain, and headaches are common during fever episodes, causing ongoing discomfort and affecting daily activities.
Social and Emotional Impact: The unpredictability of fever episodes can lead to social isolation, anxiety, and stress for both the affected individual and their family.
Physical Limitations: During episodes, individuals may experience reduced physical activity due to pain and fatigue, impacting their overall fitness and well-being.
Healthcare Burden: Frequent medical appointments, hospital visits, and treatments can be time-consuming and financially burdensome.

Despite these challenges, many individuals with HIDS can lead relatively normal lives with proper management and support. Early diagnosis and tailored treatment plans can help mitigate some of these impacts and improve the overall quality of life.

Prognosis

The prognosis for individuals with HIDS varies. While some may experience a reduction in the frequency and severity of symptoms as they get older, others may continue to have s ignificant symptoms throughout their lives. Early diagnosis and appropriate management can help improve the quality of life for those with HIDS.

Hyper-IgD Syndrome is a complex and challenging condition that requires a multidisciplinary approach for effective management. Ongoing research and advances in genetic testing continue to improve our understanding of HIDS and may lead to more targeted therapies in the future. Effective management of HIDS is highly individualized, and working closely with healthcare providers is crucial to developing a comprehensive care plan that meets the specific needs of each patient.

Familial Mediterranean Fever (FMF): A Comprehensive Overview

Tue, 26 Nov 2024 21:52:40 GMT

Familial Mediterranean Fever (FMF): A Comprehensive Overview

How Common is Familial Mediterranean Fever (FMF)?

Familial Mediterranean Fever (FMF) is most prevalent among individuals of Turkish, Armenian, Middle Eastern, North African Jewish, and Arab descent. In some places like Armenia, about 1 in 5 people carry a mutation related to FMF. Here are some key points ab out its prevalence:

Turkey: FMF is highly prevalent, with estimates ranging from 1 in 150 to 1 in 10,000 people, depending on the region.
Armenia: The prevalence is about 1 in 500 people, with a carrier rate of 1 in 7.
Israel: Among non-Ashkenazi Jews, the prevalence ranges from 1 in 500 to 1 in 1,000, while among Ashkenazi Jews, it is much lower at 1 in 73,000.
Other Regions: FMF has also been reported in Greece, Italy, Japan, and China, but at lower prevalence rates.
The carrier rates for MEFV gene mutations vary among different ethnic groups , with 1 in 5 among Iraqi Jews, 1 in 3.5 among Moroccan Jews, and 1 in 4.3 among Muslim Arabs

Causes and Genetic Basis of Familial Mediterranean Fever

FMF is caused by mutations in the MEFV gene, which encodes a protein called pyrin. Pyrin plays a crucial role in regulating inflammation in the body. When mutations occur in the MEFV gene, it disrupts the function of pyrin, leading to uncontrolled inflammation. The disorder follows an autosomal recessive inheritance pattern, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop FMF.

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms and Attacks of Familial Mediterranean Fever (FMF)

Symptoms of FMF typically begin during childhood and manifest as sudden episodes or "attacks" that last from 1 to 3 days. These attacks can vary in intensity and frequency. Common symptoms include:

Fever: High fever is a hallmark of FMF attacks.
Abdominal Pain: Severe abdominal pain resembling peritonitis (inflammation of the abdominal lining).
Chest Pain: Pain in the chest, often due to inflammation of the pleura (pleuritis) or pericardium (pericarditis).
Joint Pain: Painful, swollen joints, usually in the knees, ankles, and hips.
Rash: A red rash on the legs, particularly below the knees.
Muscle Aches: Generalized muscle aches.
Scrotal Pain: In males, inflammation of the tunica vaginalis can cause a swollen, tender scrotum.

Learn More About Familial Mediterranean Fever (FMF)

Quality of Life with FMF

One of the most serious complications of FMF is amyloidosis, a condition where abnormal proteins (amyloid) accumulate in organs, particularly the kidneys, leading to organ dysfunction. Early diagnosis and treatment are crucial to prevent this complication.

Familial Mediterranean Fever (FMF) can significantly impact the quality of life (QoL) of affected individuals. Here are some key ways it affects daily life:

Physical Impact: Recurrent fever episodes and chronic pain can lead to physical limitations, affecting mobility and the ability to perform daily activities. This can result in missed work or school days and reduced overall physical functioning.
Psychological Impact: The unpredictability of FMF attacks can cause anxiety and stress. Chronic pain and frequent hospital visits can also lead to depression and emotional distress.
Social and Recreational Impact: FMF can interfere with social interactions and recreational activities. The need for frequent medical care and the fear of sudden attacks can make it difficult for individuals to participate in social events and maintain relationships.
Sleep Disturbances: Pain and discomfort during attacks can disrupt sleep patterns, leading to fatigue and decreased energy levels. Poor sleep quality can further exacerbate the physical and psychological burden of the disease.
Impact on Work and Education: The physical and emotional toll of FMF can affect performance at work or school. Frequent absences and reduced productivity can hinder career advancement and educational progress.
Healthcare Burden: Managing FMF requires regular medical appointments, medication, and sometimes hospitalizations, which can be financially and logistically challenging.

Despite these challenges, effective management and treatment can help improve the quality of life for individuals with FMF. Regular follow-up with healthcare providers, adherence to treatment plans, and psychological support are crucial in mitigating the impact of the disease.

Discover More Of Our Resources

Diagnosing Familial Mediterranean Fever

There’s no single test that can confirm a Familial Mediterranean Fever (FMF) diagnosis, so rheumatologists rely on a combination of physical exams, genetic testing for mutations in the MEFV gene, and family history of autoimmune or autoinflammatory diseases, as well as ethnicity, since FMF is more common in certain populations. While genetic testing for the MEFV mutation is important, the absence of mutations does not completely rule out FMF. In some cases, doctors may start patients on Colchicine to see if symptoms improve, as a positive response can strongly suggest an FMF diagnosis.

The Tel-Hashomer criteria are also used to aid in diagnosis. Patients must meet more than one major criteria or more than two minor criteria:

Major criteria:

Attacks of generalized peritonitis
Pleuritis (unilateral) or pericarditis
Monoarticular arthritis of the hip, knee, or ankle
Fever as the only symptom
Incomplete abdominal attacks

Minor criteria:

Incomplete attacks involving joints, chest, or both
Leg pain with exertion
Favorable response to Colchicine treatment
Typical attacks are recurrent (at least three episodes of the same type), febrile (rectal temperature ≥ 38° C), and short in duration (12 hours to 3 days)

Complete attacks are painful, recurrent, and usually follow a predictable pattern, but they may differ in some features, such as lower temperatures (< 38° C), variation in attack length (6 hours to 1 week), or atypical symptoms like localized abdominal attacks or arthritis in joints other than the hip, knee, or ankle.

Though there are no specific ACR or EULAR guidelines for FMF, these organizations emphasize comprehensive evaluation, including genetic testing and clinical response to treatments like Colchicine, to ensure an accurate diagnosis and proper management of the disease.

Treatment and Management of Familial Mediterranean Fever

While there is no cure for FMF, treatment focuses on managing symptoms and preventing complications. The primary medication used is colchicine, which helps reduce inflammation and prevent attacks. For those who do not respond to colchicine, other medications that block interleukin-1, such as canakinumab, rilonacept, and anakinra, may be prescribed. Regular monitoring and follow-up with a healthcare provider are essential to manage the condition effectively.

Familial Mediterranean Fever is a complex genetic disorder that requires careful management and treatment to prevent recurrent attacks and complications. Understanding the genetic basis, recognizing the symptoms, and adhering to a treatment plan can significantly improve the quality of life for individuals with FMF.

#ACR24 Abstracts: Diagnosing, Imaging and Clinical Trials

Tue, 26 Nov 2024 06:53:42 GMT

#ACR24 Abstracts: Diagnosing, Imaging and Clinical Trials

Empowering Patients Through Innovation in Rheumatology

Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort

The study found that anti-RA33 autoantibodies were present in a significant number of seronegative RA patients. This suggests that these autoantibodies could be useful biomarkers for identifying RA in patients who do not have the typical antibodies.

Conclusion: Anti-RA33 autoantibodies show promise as a sensitive and specific tool for diagnosing seronegative RA, potentially improving the accuracy of RA diagnosis and helping to tailor treatments for these patients.

A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation

Researchers have developed a machine learning model to help identify rheumatoid arthritis (RA) earlier. This model analyzes data to find patterns that might indicate a person is at risk of developing RA before they show clear symptoms. Early identification is crucial because it can lead to earlier treatment, which can improve outcomes for patients

Active Hand Inflammation: Differing Clinical and Ultrasound Patterns in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. A Cross-Sectional and Multicenter Study

Researchers conducted a study to compare active hand inflammation in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). They used both clinical assessments and ultrasound imaging to identify differences in inflammation patterns between the two groups. The goal was to better understand how these patterns vary, which could help improve diagnosis and treatment for patients with these conditions.

Accurate Detection of Arthritis Using Hand-held Thermal Imaging and Machine Learning

The article discusses a study on using hand-held thermal imaging and machine learning to detect arthritis. Thermal imaging captures heat patterns from the body, which can indicate inflammation. By combining this imaging with machine learning algorithms, researchers aim to create a non-invasive, easy-to-use tool for detecting arthritis. This method could be a cost-effective and radiation-free alternative to traditional diagnostic techniques.

The article discusses using Similarity Network Fusion (SNF) to identify patient clusters for people with systemic inflammatory diseases. SNF is a method that combines different types of data (like genetic, clinical, and demographic information) to find patterns and group patients with similar characteristics. This can help doctors better understand the disease and tailor treatments to individual patients.

Appointment Adherence: Impact of Health Portal Access, Letters, Phone Calls and Text Message Reminders in Underserved Population

The article explores how different methods of appointment reminders (like health portal access, letters, phone calls, and text messages) impact appointment adherence in an underserved population. The study found that these reminders did not significantly improve the rate at which patients attended their appointments. This was especially challenging during the peak of the COVID-19 pandemic.

Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study

This UK-based study explores the factors influencing patient participation in rheumatology clinical trials. It surveyed 2,024 patients with rheumatic conditions, categorizing them based on their willingness to participate in future research. Results showed that 6% preferred remote participation (phone/video), 23% were willing to participate but not for additional hospital visits, and 69% were open to participating regardless of additional visits. Ethnicity also played a role: Caucasian patients were most likely to participate even with extra hospital visits, while East Asian patients were least likely. The study underscores the importance of offering flexible participation options to increase engagement in clinical trials.

Key Patient Takeaways

The 2024 American College of Rheumatology conference highlighted groundbreaking research that could revolutionize the diagnosis and management of rheumatic diseases. These findings underscore the importance of patient-centered care and the need for continued innovation:

Novel biomarkers for accurate diagnoses: The discovery of anti-RA33 autoantibodies in seronegative RA patients could lead to more precise diagnoses and personalized treatment plans. Patients must advocate for access to these emerging biomarkers.
Early detection through machine learning: A machine learning model that identifies high-risk individuals before symptoms arise could transform the management of rheumatoid arthritis. Patients must push for further research into these predictive tools.
Non-invasive diagnostics: Hand-held thermal imaging offers a potential alternative to invasive or radiation-based diagnostic methods. Patients should advocate for access to these innovative, patient-friendly technologies.
Personalized medicine through data-driven approaches: Similarity Network Fusion highlights the power of integrating diverse data to tailor care to individual patients. Patients must demand a seat at the table in the development of these personalized strategies.

As research continues to push boundaries, patients must remain at the forefront, advocating for access to emerging tools and innovations. By empowering patients and putting them at the center of care, we can create a future where rheumatic diseases are managed with precision and compassion.

#ACR24 Abstracts: Cognitive Dysfunction

Tue, 26 Nov 2024 06:39:45 GMT

#ACR24 Abstracts: Cognitive Dysfunction

New Research Sheds Light on Cognitive Dysfunction in Rheumatic Diseases

Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes

Cognitive dysfunction affects up to 87% of individuals with systemic sclerosis (SSc), impairing daily activities and exacerbating symptoms like pain, fatigue, and depression.

An 8-week online cognitive rehabilitation intervention was tested to improve cognitive function and self-management in people with SSc. It showed promise but needs a larger trial to confirm its effectiveness. More research like this is needed for chronic conditions.I see this is such a huge gap in Rheumatology research and I hope to see more like this in the near future for all RMDs!

Cognitive Impairment Prevalence and Most Affected Domains in Patients with SLE by the ACR Comprehensive Neuropsychological Battery

The study investigates the prevalence and domains of cognitive impairment in patients with Systemic Lupus Erythematosus (SLE) using the American College of Rheumatology (ACR) Comprehensive Neuropsychological Battery. It found that cognitive impairment is common among SLE patients, affecting multiple cognitive domains such as memory, attention, and executive function. The study highlights the importance of early cognitive assessment and intervention in SLE patients to improve their quality of life.

Biobehavioral Basis and Outcomes of Cognitive Dysfunction in Childhood Systemic Lupus Erythematosus

The study investigates the biobehavioral basis and outcomes of cognitive dysfunction in childhood-onset systemic lupus erythematosus (SLE). It examines how neuroinflammatory processes, reflected by choroid plexus (CP) volume and brain metabolites, contribute to cognitive dysfunction in these patients. The study found that patients with childhood-onset SLE (cSLE) demonstrated impaired performance on cognitive tasks and altered prefrontal cortex functionality compared to healthy controls. These findings highlight the importance of addressing cognitive dysfunction in cSLE to improve health-related quality of life.

Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care

The study explores cognitive bias in lupus diagnosis within primary care settings. Researchers conducted a factorial survey experiment to evaluate how primary care providers' (PCPs) diagnoses of systemic lupus erythematosus (SLE) varied when all aspects of a clinical case were held constant, except for the patient's race and sex. The findings revealed that correct SLE diagnoses were influenced by the patient's race and sex, with Black females being most likely to receive a correct diagnosis.

Self-Reported Cognitive Function Among Older Adults with Systemic Lupus Erythematosus (SLE) Compared to Older Adults with Other Rheumatic and Musculoskeletal Conditions

This study compares self-reported cognitive function among older adults with systemic lupus erythematosus (SLE) to those with other rheumatic and musculoskeletal conditions like rheumatoid arthritis (RA), osteoarthritis (OA), and fibromyalgia (FM). Key findings include that older adults with SLE reported significantly worse cognitive function compared to those with other conditions. Additionally, worse cognitive function in SLE patients was associated with poorer self-reported disease status.

Key Patient Takeaways

The 2024 American College of Rheumatology conference highlighted several studies investigating cognitive dysfunction in patients with rheumatic diseases. These findings underscore the importance of addressing cognitive health in this population

Cognitive rehabilitation for systemic sclerosis: An 8-week online cognitive rehabilitation intervention showed promise in improving cognitive function and self-management in systemic sclerosis patients. Larger trials are needed to confirm its effectiveness.
Cognitive impairment in systemic lupus erythematosus (SLE): A study using the ACR Comprehensive Neuropsychological Battery found cognitive impairment is common in SLE patients, affecting multiple cognitive domains. Early cognitive assessment and intervention are crucial.
Cognitive dysfunction in childhood-onset lupus: Researchers found patients with childhood-onset SLE demonstrated impaired cognitive performance and altered brain functionality compared to healthy controls. Early intervention is vital.
Cognitive bias in lupus diagnosis: A study found that correct diagnoses of SLE in primary care were influenced by patient race and sex, highlighting the need for awareness and training to combat bias in diagnosis.
Self-reported cognitive function in older SLE patients:Research found older adults with SLE reported significantly worse cognitive function compared to those with other rheumatic conditions. Providers should proactively assess cognitive function in older SLE patients.

These studies underscore the importance of a comprehensive approach to managing rheumatic diseases that includes cognitive assessment and intervention. By working closely with their healthcare teams, patients can address cognitive dysfunction and improve their overall well-being.

#ACR24 Abstracts: Social Determinants, Patient Outcomes, Women's Health, and Risk Assessments

Tue, 26 Nov 2024 06:29:54 GMT

#ACR24 Abstracts: Social Determinants, Patient Outcomes, Women's Health, and Risk Assessments

The American College of Rheumatology (ACR) Conference 2024 highlighted the profound impact of social determinants of health, patient outcomes, women's health, and risk assessment on rheumatic disease management.

Social Determinants of Health

Addressing Economic Insecurities Could Improve Patient-Reported Outcomes in Lupus

The study explores how economic insecurities (like food, housing, healthcare, and financial insecurity) impact patient-reported outcomes in people with Systemic Lupus Erythematosus (SLE). It found that those with any economic insecurity had significantly worse outcomes across various measures, including physical function, quality of life, and mental health. Addressing these insecurities could potentially improve the health and well-being of SLE patients

Changes in Social Determinants of Health Needs Uncovered by a Rheumatology-Based Screening and Assistance Program

This program implemented social determinants of health (SDoH) screening in rheumatology clinics. It revealed persistent needs such as food insecurity, difficulty paying for utilities, and medication access issues. The program provided community resources and assistance to address these needs

Associations Between Social Determinants of Health and Acute Care Use Among Individuals with Lupus, Rheumatoid Arthritis and Osteoarthritis in the All of Us Research Program

The study explores the associations between social determinants of health (SDoH) and acute care use (hospitalizations and emergency department visits) among individuals with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and osteoarthritis (OA) in the All of Us Research Program. The findings indicate that adverse SDoH, such as economic insecurities, healthcare access challenges, and neighborhood vulnerabilities, are significantly associated with higher rates of acute care use. Additionally, repeated experiences of discrimination were linked to significantly higher rates of acute care use compared to those with less frequent experiences

Patient-reported Social Risk Factor Screening Among Rheumatology Outpatients

This study implemented a patient-reported social risk factor (SRF) screening tool among 148 rheumatology outpatients (79% of 187 patients) to identify social determinants impacting their care. The tool assessed four core SRF domains (financial strain, housing instability, food insecurity, transportation needs) and four supplemental domains (physical inactivity, social isolation, stress, depression). The screening revealed significant social risk factors with potential to influence health outcomes. The research underscores the importance of SRF screening in rheumatology to enhance patient care and outcomes.

Rural-dwelling Patients with Rheumatoid Arthritis or Those with Lower Income Are More Likely to Be Admitted for Myocardial Infarction in the U.S. and Have Worse Outcomes

This study investigated whether rural residence and lower income increase the likelihood of myocardial infarction (MI) hospitalization and worsen outcomes in patients with rheumatoid arthritis (RA), compared to urban-dwelling patients. Key findings included that rural RA patients were nearly twice as likely to be hospitalized for MI as urban patients (adjusted odds ratio [aOR] of 1.70), and lower income was also linked to higher MI hospitalization odds. The research revealed worse outcomes for rural and lower-income patients, underscoring substantial healthcare access and outcome disparities.

Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App

This study investigated predictors of patient engagement and usability of POCOS, a chronic musculoskeletal pain management app. The research explored how clinical and demographic factors impacted patient interaction with the app. Key findings included that 64% of participants agreed to use the app, with 55% actually downloading it, and 50% of downloaders actively using it. Significant correlations were found between app use and opiate medication (r = 0.57) and PTSD (r = 0.55), while depression was negatively correlated with use (r = -0.47). A strong correlation existed between completed health forms and app use (r = 0.84), indicating high compliance in documenting patient-reported outcomes.

Patient Outcomes

30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database

Study identifies factors associated with hospital readmissions within 30 days for rheumatoid arthritis patients: women, younger age, government insurance, additional health issues, smoking, hypertension, prednisone use, alcohol consumption, liver problems, atypical RA, and adult-onset Still's disease.

Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD

The study found that obesity, use of prednisone, and patient-reported outcomes (like fatigue and overall activity) are predictors of becoming difficult-to-treat in patients with rheumatoid arthritis (RA) who are on their first biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD).. On the other hand, taking methotrexate concurrently was associated with a lower risk of becoming difficult-to-treat

Development and Validation of a Brief Measure of Uncertainty Among Patients with Vasculitis and Other Rheumatic Diseases

The study focuses on developing and validating a brief measure of uncertainty among patients with vasculitis and other rheumatic diseases. The researchers aimed to create a shorter version of the existing Mishel Uncertainty in Illness Scale to make it more practical for routine clinical use. The new measure was tested for internal consistency and convergent validity, and it was found to effectively capture the key aspects of uncertainty related to rheumatic illnesses. Additionally, the study explored the primary sources of uncertainty in patients with systemic vasculitis through qualitative analysis.

Risk Assessments

Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database

Researchers used a large database of hospital patients to analyze data from 2016 to 2019 to study the risk of skin cancer in people with autoimmune diseases. They found that certain autoimmune diseases, like rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, are linked to a higher risk of a type of skin cancer called cutaneous squamous cell carcinoma.Those with dermatomyositis have a higher risk of melanoma, another type of skin cancer. Regular skin checks are important for people with these autoimmune conditions!

Native Americans Experience Profound Premature Mortality from Rheumatoid Arthritis

This study emphasizes the substantial premature mortality that Native Americans experience due to rheumatoid arthritis (RA). The research analyzed Centers for Disease Control and Prevention national mortality database data from 1999 to 2020. Key findings included that Native Americans had the highest age-standardized RA mortality rate (5.14 per 100,000 persons), which was 10.8 times greater than non-Hispanic whites aged 44 and younger. While the disparity lessened with age, it remained significant. Importantly, RA mortality rates decreased for most racial/ethnic groups over time except for Native Americans. The study underscores the urgent need for targeted interventions to address the elevated RA mortality among Native Americans.

More Than a Monolith: Disaggregating Rheumatoid Arthritis Prevalence Among Asian American Subgroups

This study investigated rheumatoid arthritis (RA) prevalence among different Asian American subgroups to highlight diagnosis and treatment disparities. The research analyzed data from 303,340 women aged 65-85 years in Kaiser Permanente Northern California. RA prevalence varied among subgroups, ranging from 1.0% in Filipinas to 2.8% in South Asians. Compared to non-Hispanic White women, RA prevalence was similar for Filipinas (0.9) but higher for South Asians (2.5). The study emphasizes the importance of disaggregating data among Asian American subgroups to better understand and address RA disparities.

Specific Causes for Hospitalization in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review

This systematic review sought to determine the primary reasons for hospitalization among individuals with inflammatory arthritis (IA) conditions, such as rheumatoid arthritis and gout. The study found that the most common causes for hospitalization were arthritis flares (sudden worsening of symptoms), infections (attributed to a weakened immune system), cardiac issues, and ambulatory care-sensitive conditions (those manageable with proper outpatient care)..

Women’s Health

Anti-CCP Generation in the Female Genital Tract Is Increased During the Postpartum Period in Women Without RA

The study found that anti-cyclic citrullinated peptide (anti-CCP) antibodies are increased in the female genital tract mucosa during the postpartum period in women without rheumatoid arthritis (RA). This suggests that local inflammation in the genital tract may contribute to the generation of these antibodies, which are typically associated with RA.. The study included women who had given birth within the past 12 months and found higher levels of anti-CCP antibodies compared to non-postpartum women.

Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

This study examined how sex influences medication adherence in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE). The research included 31,033 patients, with 27.3% identifying as male. Key findings showed that male patients had higher medication adherence than female patients (80.3% vs. 77.2%). Factors such as age, medication type, geographic location, and social determinants of health also impacted adherence. Overall, the study suggests that male RA, SLE, and PsA patients had better medication adherence than female patients, underscoring the need for targeted interventions to enhance adherence among women.

Rheumatology on Reddit: A Descriptive Analysis

This study conducted a descriptive analysis of rheumatology-related communities on Reddit. The research aimed to identify rheumatology-specific subreddits, describe characteristics such as subscribers and activity, and perform sentiment analyses to understand user interactions. Key findings included that 20 active subreddits met inclusion criteria, with the oldest being r/Fibromyalgia; subscribers ranged from 2,000 (r/Behcets) to 70,000 (r/Fibromyalgia); peak activity was between 16:00 and 23:00, with most in the year's second half; and common concerns were patient age and the COVID-19 vaccine's impact on rheumatic and musculoskeletal disease patients.

Key Takeaways for Patients

Economic insecurities significantly impact patient-reported outcomes in SLE, highlighting the importance of addressing basic needs.
Socioeconomic status substantially influences OA prevalence and risk factors, necessitating targeted interventions.
Rural-dwelling RA patients and those with lower income face increased cardiovascular risks, emphasizing the need for equitable access to care.
Patient engagement with digital health tools is influenced by factors like medication use and mental health status.
The postpartum period may be associated with increased autoantibody production in women without RA.
Medication adherence varies by sex in rheumatic disease patients, with males tending to have higher adherence.
Native Americans experience significantly higher premature RA mortality, necessitating urgent, culturally tailored interventions.
Rheumatoid arthritis prevalence varies substantially among Asian American subgroups, highlighting the importance of data disaggregation.

The ACR Conference 2024 abstracts underscore the complex interplay of social determinants, patient outcomes, women's health, and risk assessment in rheumatic disease management. By acknowledging and addressing these factors, healthcare providers can deliver more holistic, equitable care, ultimately improving the lives of patients with rheumatic diseases.

#ACR24 Abstracts: Covid-19

Tue, 26 Nov 2024 06:09:17 GMT

#ACR24 Abstracts: Covid-19

COVID-19 Vaccination and Rheumatic Diseases: Key Findings from the American College of Rheumatology Conference 2024

The American College of Rheumatology (ACR) Conference 2024 featured several abstracts shedding light on the complex relationship between COVID-19 vaccination, immune-mediated inflammatory diseases, and patient outcomes. These findings offer critical insights for patients with rheumatic conditions navigating the ongoing pandemic.

Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients

The article explores the presence of anti-spike antibodies in patients with systemic lupus erythematosus (SLE) who have been vaccinated against SARS-CoV-2 (the virus that causes COVID-19). Anti-spike antibodies are produced in response to the vaccine and help protect against the virus. The study examines how well these antibodies are generated in SLE patients, who often have weakened immune systems due to their condition or the medications they take. The findings can help understand the effectiveness of COVID-19 vaccination in this vulnerable group.

Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study

The article discusses findings from the SUCCEED study, which looked at how anti-spike antibodies (produced in response to the COVID-19 vaccine) protect against COVID-19 infection in patients with immune-mediated inflammatory diseases (IMIDs). The study found that these antibodies can help protect IMID patients from getting COVID-19, which is important because these patients often have weakened immune systems

Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital

The study compares COVID-19 infection and mortality rates between vaccinated and unvaccinated patients with autoimmune inflammatory rheumatic disease (AIRD), who are treated with conventional and biologic DMARDs. The findings indicate that vaccinated patients had lower infection and mortality rates compared to unvaccinated patients, highlighting the importance of vaccination in reducing COVID-19-related risks for individuals with AIRD.

Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients

The study conducts a comparative analysis of COVID-19 infection and outcomes between patients with rheumatological diseases and those with non-rheumatological diseases. Using data from five hospitals in Southeast Michigan, the researchers matched rheumatologic patients with controls based on age, sex, and race. The findings indicate that rheumatologic patients had similar infection rates but higher rates of ICU admission, ventilation, and mortality compared to non-rheumatologic patients. This highlights the increased vulnerability of rheumatologic patients to severe COVID-19 outcomes.

People Living with Autoimmune Disease Are at Higher Risk of Suffering from Post-Acute Sequelae of SARS-CoV-2 but Immunization Is Protective

This study investigates the risk of post-acute sequelae of SARS-CoV-2 (PASC) in people with autoimmune diseases and the protective effects of immunization. It involved a large cohort of individuals with autoimmune diseases and found that they are at a higher risk of developing PASC. Importantly, immunization was shown to be protective against PASC. Overall, the study highlights the critical importance of vaccination for people with autoimmune diseases to reduce their risk of post-COVID complications.

The Impact of COVID-19 and ‘Long COVID’ on Self-Reported Disease Activity, Disability, and Quality of Life in Patients with Inflammatory Arthritis

This study explores the impact of COVID-19 and long COVID on self-reported disease activity, disability, and quality of life in patients with inflammatory arthritis. It found that patients who contracted COVID-19 reported higher disease activity and worsened disability, especially with long COVID symptoms. Both COVID-19 and long COVID negatively affected quality of life, increasing fatigue, pain, and discomfort. Even patients without long COVID had worse disease control compared to those who never had COVID-19. These findings highlight the need for careful monitoring and management of COVID-19 and long COVID in inflammatory arthritis patients to mitigate their impact.

Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study

This study explores the association between COVID-19 vaccination and the risk of developing parenchymal lung disease in patients with rheumatoid arthritis (RA) after recovering from COVID-19. It found that vaccination was associated with a lower risk of developing this lung condition. The prospective study included RA patients who had recovered from COVID-19, and their pulmonary health was assessed through high-resolution computed tomography (HRCT) chest imaging and pulmonary function tests. These findings suggest that vaccination may provide protective benefits against lung complications in RA patients post-COVID-19.

Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study

The study "Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study" investigates the vaccination choices and outcomes for rheumatoid arthritis (RA) patients during the COVID-19 pandemic. It explores factors influencing their decisions, such as concerns about vaccine efficacy and safety, and assesses the impact on disease activity, flare rates, and overall health outcomes. The study offers valuable insights into how RA patients and healthcare providers navigate vaccination decisions, aiming to enhance vaccination strategies and patient education.

Key Takeaways for Patients

COVID-19 vaccines are effective in stimulating protective antibodies in immunocompromised patients with rheumatic diseases.
Vaccination significantly reduces COVID-19 infection and mortality rates in patients with autoimmune inflammatory rheumatic diseases.
Rheumatologic patients are more vulnerable to severe COVID-19 outcomes, making vaccination crucial.
COVID-19 and 'long COVID' can substantially impact disease activity and quality of life in patients with inflammatory arthritis.
Vaccination may protect against pulmonary complications in rheumatoid arthritis patients who have had COVID-19.
Open communication with healthcare providers is essential for navigating personalized COVID-19 vaccination decisions.

The ACR Conference 2024 abstracts underscore the vital role of COVID-19 vaccination in protecting patients with rheumatic diseases. While these conditions confer increased vulnerability to severe COVID-19 outcomes, the data affirm that vaccines are effective and potentially lifesaving in these populations. As the pandemic continues to evolve, ongoing research and open patient-provider communication will remain essential for optimizing COVID-19 vaccination strategies and improving outcomes in patients with rheumatic diseases.

#ACR24 Abstracts: Medications & Treatments

Tue, 26 Nov 2024 05:59:57 GMT

#ACR24 Abstracts: Medications & Treatments

ACR 2024 Conference Showcases Advances in Rheumatic Disease Treatments.

A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis

The study presents a novel blood-based assay that uses active chromatin cell-free DNA (cfDNA) signals to predict clinical response to TNFα inhibitors (TNFi) or Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA). The assay leverages machine learning classifiers to differentiate responders from non-responders with high sensitivity and specificity. This could help personalize treatment plans and improve outcomes for RA patients.

A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers

The study explores oral healthcare needs among Canadian patients with rheumatic diseases and their healthcare providers. Using qualitative methods, it examines how patients perceive their oral health, how they and their providers approach oral care, and the challenges they face. Key themes include oral health perception, strategies for optimizing oral health, communication barriers, and the need for improved models of care

A Patient-Focused Program for Using Steroids Wisely

The study introduces the "Steroids and Me" (SAM) program, a patient-focused initiative designed to help patients use steroids wisely. Developed through collaboration between academic physicians, patients, patient advocacy groups, and industry leaders, SAM provides educational resources and practical support to optimize steroid use. The program includes a web-based platform with resources on managing steroid side effects and tracking patient health, aiming to facilitate shared decision-making between patients and healthcare providers

Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs

The study presents a machine learning-based smart web application designed to predict steroid-induced hyperglycemia in patients with rheumatoid arthritis (RA) and other autoimmune rheumatic diseases. The application uses a random forest classifier trained on real-world data, achieving 88% accuracy in predicting hyperglycemia. The goal is to provide a personalized medicine approach, helping clinicians tailor glucocorticoid therapy to individual patients and minimize side effects

Annual Cost of Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis

The study examines the annual cost of biologic disease-modifying antirheumatic drugs (DMARDs) for treating rheumatoid arthritis (RA). It highlights that biologics are expensive, with annual costs ranging from $10,000 to $30,000 per patient. These high costs can pose a significant financial burden on patients, even with insurance coverage.

Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry

The study investigates infusion-related reactions (IRRs) in patients with rheumatoid arthritis (RA) treated with biologic disease-modifying antirheumatic drugs (bDMARDs), using data from the Korean College of Rheumatology Biologics (KOBIO) registry. Among 1,831 RA patients, 177 (9.7%) experienced IRRs. Factors such as younger age, higher CRP levels, and prior use of specific conventional DMARDs were associated with a higher risk of IRRs. The study suggests that abatacept or tocilizumab may be preferred options for patients with these risk factors.

Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis

The study presents a post hoc analysis of the Phase 3 FINCH 1 and FINCH 2 trials, evaluating sustained patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) treated with filgotinib (FIL). The analysis found that FIL (both 100 mg and 200 mg) provided early and sustained improvements in pain, fatigue, and physical functioning compared to placebo. These improvements were maintained over time, indicating that FIL could be a promising treatment option for RA patients seeking long-term relief

Effects of Anti-Obesity Medications in RA Patients

The study investigates the effects of anti-obesity medications (AOM), specifically semaglutide and tirzepatide, on patients with rheumatoid arthritis (RA). The findings indicate that treatment with AOM led to significant weight loss and improvements in acute phase reactants (ESR and CRP), pain visual analogue scale (VAS), and lipid levels. However, gastrointestinal side effects and insurance issues were common reasons for discontinuation.

Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves

The study evaluates meaningful within-person change thresholds in PROMIS-Fatigue scores from three Phase 3 clinical trials of sarilumab for rheumatoid arthritis. Using empirical cumulative distribution function (eCDF) curves, the researchers assessed changes in fatigue over time. The results showed that RA patients reported high baseline fatigue, and those receiving sarilumab had significant improvements in fatigue scores compared to placebo and adalimumab. The eCDF curves demonstrated clear separation between active treatment and placebo groups, indicating substantial patient-level improvements

Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy

This study explores the development of next-generation CAR-T cell therapy for treating autoimmune diseases without the need for conditioning chemotherapy. The objective is to create a safer and more effective therapy by engineering T cells to target and eliminate pathogenic cells causing autoimmune responses. Early results are promising, showing a reduction in autoimmune symptoms without the harsh side effects of traditional treatments. Overall, the study suggests that this new approach could potentially transform the treatment of autoimmune diseases.

Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study

This study evaluates the safety and preliminary efficacy of CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with rheumatic diseases as part of the CASTLE (CAR-T cells in systemic B cell-mediated autoimmune disease) phase I/II basket trial. It includes patients with systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The key findings reveal that the treatment was generally well-tolerated, with cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) being the most common adverse events. Additionally, the therapy led to deep depletion of B cells and showed promising clinical responses in some patients.

Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease

This study evaluates the safety and long-term efficacy of CD19 CAR T-cell therapy in 30 patients with autoimmune diseases, including systemic lupus erythematosus (SLE), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). Key findings indicate that the therapy was highly tolerable with no higher-grade toxicities. Patients with SLE and IIM achieved long-standing drug-free remission, while those with SSc showed no disease progression. Additionally, there was minimal recurrence of the disease even years after the intervention.

Key Takeaways for Patients

Novel blood-based assays and machine learning applications can help personalize treatment plans and minimize side effects in rheumatoid arthritis patients.
Patient-focused initiatives like the "Steroids and Me" program provide valuable resources to support optimal medication use.
Integrated care models addressing oral health are crucial for patients with rheumatic diseases.
Filgotinib may offer sustained benefits for rheumatoid arthritis patients seeking long-term symptom relief.
Anti-obesity medications may have a role in managing rheumatoid arthritis, although side effects and access issues need to be addressed.
Next-generation CAR-T cell therapy shows promise as a potentially transformative treatment for autoimmune diseases, offering improved safety and efficacy.

The ACR Conference 2024 abstracts underscore the rapid advancements in medications and therapies for rheumatic diseases. These innovations hold promise for improving treatment outcomes, patient safety, and quality of life for individuals with rheumatic diseases.

#ACR24 Abstracts: Mental Health

Sun, 24 Nov 2024 20:35:25 GMT

#ACR24 Abstracts: Mental Health

The ACR Conference 2024 abstracts highlight the connection between mental health and rheumatic diseases. By recognizing this link and offering holistic, patient-centered care, healthcare providers can enhance both physical and mental health outcomes for these individuals.

A Cross-sectional Study of the Association Between Anxiety State and Various Factors in Patients with Rheumatoid Arthritis

High anxiety in RA patients is associated with increased disease activity, pain, and depression. Managing disease activity from a bio-psycho-social perspective may help reduce anxiety in these patients.

Adverse Childhood Experiences Are Associated with Patient-Reported Outcomes in Adolescents and Young Adults with Systemic Lupus

Study highlights a crucial link between adverse childhood experiences (ACEs) and worse patient-reported outcomes in adolescents and young adults with systemic lupus erythematosus (SLE). This aligns with existing research indicating that ACEs are associated with higher disease activity, depression, and poorer overall health in adults with lupus

Association Between a History of Mental Illness and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-based Case-control Study

The study investigates the potential association between a history of mental illnesses and the risk of systemic autoimmune rheumatic diseases (SARD), utilizing data from the Taiwanese National Health Insurance Research Database. It included 77,848 SARD patients and 311,392 control subjects. Mental illness was defined based on specific diagnostic codes. The study found that individuals with a history of mental illnesses had a significantly higher risk of developing SARD, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), systemic sclerosis (SSc), and dermatomyositis/polymyositis (DM/PM). The association was strongest for SS and persisted across various definitions of mental illness and exposure periods. The findings suggest that a history of mental illness is a significant risk factor for these autoimmune conditions.

Associations Between Rheumatic Diseases and Mental Health Disorders

The study explores the associations between rheumatic diseases (such as rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and ankylosing spondylitis) and mental health disorders (anxiety and depression). Using a retrospective case-control design, the study found that patients with these rheumatic diseases had significantly higher odds of experiencing anxiety, depression, and both conditions compared to those without rheumatic diseases. The odds ratios ranged from 6.15 to 9.02 after adjusting for age and sex.

Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

This study examined how stable rheumatologic therapy affects depression outcomes in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). The research included 3,355 members with RA, PsA, or SLE. Members with stable therapy (no changes) were compared to those with therapy modifications. Key findings showed that patients with stable therapy had lower depression-related care utilization and fewer changes in antidepressant medications. The study concludes that well-controlled RA, PsA, or SLE appear to improve depression outcomes. Overall, the research suggests that maintaining stable rheumatologic therapy can positively impact depression outcomes in these patients.

Key Takeaways for Patients

High anxiety in rheumatoid arthritis patients is associated with increased disease activity, pain, and depression, highlighting the need for biopsychosocial management.
Adverse childhood experiences are linked to worse outcomes in young systemic lupus erythematosus patients, necessitating trauma-informed care and ACE screening.
A history of mental illness significantly increases the risk of developing systemic autoimmune rheumatic diseases.
Patients with rheumatic diseases have a higher risk of anxiety and depression, emphasizing the need for routine mental health screenings.
Maintaining stable rheumatologic therapy improves depression outcomes in patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.

The ACR Conference 2024 abstracts underscore the complex interplay between mental health and rheumatic diseases. By acknowledging this interplay and providing holistic, patient-centered care, healthcare providers can improve both physical and mental health outcomes for individuals with rheumatic diseases.

#ACR24 Abstracts: Diet, Supplements & Cannabis

Sun, 24 Nov 2024 20:02:02 GMT

#ACR24 Abstracts: Diet, Supplements & Cannabis

The 2024 American College of Rheumatology conference brought together researchers from around the world to share the latest findings on managing rheumatic diseases.

Nutrition

Assessing the Feasibility of a Mediterranean-Style Diet for Patients with Rheumatoid Arthritis in a Racially and Culturally Diverse Population Across the United States

The study assesses the feasibility of adopting a Mediterranean-style diet among patients with rheumatoid arthritis (RA) in a racially and culturally diverse population across the United States. The findings indicate that while many patients showed interest in the diet, barriers such as food insecurity, time constraints, and food aversions were common. The study highlights the need for tailored dietary interventions and support to help diverse RA populations adopt healthier eating habits.

Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity

This study examined how dietary modifications and intermittent fasting (IF) impact inflammatory activity in patients with axial spondylarthritis (axSpA). The research included 466 axSpA patients. Key findings showed that 55% of patients reported following a specific diet, with the Mediterranean diet being the most common (51%); 31% were currently practicing IF, and 48% had tried it previously. Importantly, both dietary changes and IF were associated with reduced inflammatory activity in patients. The study suggests that dietary modifications and intermittent fasting may help decrease inflammation in axSpA patients.

Dietary Exposures Associated with Incident Spondyloarthritis

This study examined the association between dietary factors and the risk of developing spondyloarthritis (SpA). The research identified 106 incident SpA patients and matched them with 530 controls. Non-diet soda and certain supplements (folate, other B-vitamins, and fish oil) were linked to an increased SpA risk, while moderate alcohol use was associated with lower risk. Greater fruit and vegetable intake showed a trend towards reduced risk, but this was not statistically significant; similarly, milk/dairy intake trended towards higher risk, but was also not significant. The study suggests that specific dietary factors and supplements may impact SpA risk, but further research is needed to confirm these findings.

Association Between Gut Microbiota, Inflammation, and Epigenetics in Rheumatoid Arthritis Patients

The study explores the association between gut microbiota, inflammation, and epigenetic modifications in patients with rheumatoid arthritis (RA). It found that RA patients had dysbiosis (altered gut microbiota) and lower microbiota diversity compared to healthy controls. Specific epigenetic changes were associated with RA diagnosis, suggesting that gut microbiota and inflammation may play a role in the development and progression of RA.

Characterizing Diet and Neighborhood Resources in Patients with Systemic Lupus Erythematosus

The study explores the diet and neighborhood resources available to patients with Systemic Lupus Erythematosus (SLE). It aims to understand how these factors influence dietary habits and overall health outcomes. The study involves 150 participants from the Lupus Intervention Fatigue Trial (LIFT) and examines the relationship between neighborhood resources (measured by the Areas of Deprivation Index) and dietary intake (assessed using the Healthy Eating Index). Preliminary findings suggest that neighborhood resources play a significant role in shaping dietary habits among SLE patients

Effects of Butyrate Supplementation in Modulation of Gut Microbiome and Its Metabolites in New Onset Rheumatoid Arthritis

This study examined the effects of butyrate supplementation on the gut microbiome and its metabolites in patients with new-onset rheumatoid arthritis (RA). The research included patients with newly diagnosed RA who received butyrate supplements for a specified period. Findings showed that butyrate supplementation led to changes in the gut microbiome and its metabolites. Importantly, there was a reduction in inflammation markers, suggesting potential benefits for managing RA. The study suggests that butyrate supplementation may positively impact the gut microbiome and reduce inflammation in RA patients.

Patients’ Behaviors and Beliefs Around Dietary Changes Among a Cohort of Patients with Rheumatic Disease

This study examined patients' behaviors and beliefs about dietary changes related to their rheumatic diseases. The research included 181 adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). Nearly three-quarters of participants considered improving their diet to manage symptoms, but only 40% were currently following a modified diet. The primary motivations for dietary changes were symptom improvement and preventing other autoimmune diseases. Common barriers included giving up favorite foods, lack of willpower, and cost. Notably, only 25% of participants had discussed dietary changes with their healthcare providers. The study suggests that while patients are interested in dietary changes, they face several barriers and need more support from their providers.

Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol

The PASCOD study evaluated the safety and tolerability of a combination of curcumin, omega-3, and vitamin D in healthy volunteers. The study found that most side effects were mild, with the most common being heartburn, fishy taste, and abdominal bloating. No significant laboratory abnormalities were detected, and adherence to the supplement regimen was high

Cannabis

A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity

The article discusses a study on circulating endocannabinoid levels in patients with rheumatoid arthritis (RA) and fibromyalgia syndrome (FMS). Endocannabinoids are chemicals naturally produced in the body that are similar to compounds found in cannabis. The researchers found significant changes in these levels in patients with RA and FMS and explored how these changes correlate with the severity of the diseases.

Key Take Aways For Patients

The 2024 American College of Rheumatology conference brought together researchers from around the world to share the latest findings on managing rheumatic diseases. Several studies focused on the role of diet, supplements, and cannabis in alleviating symptoms and potentially preventing disease progression. Here's what patients need to know:

Mediterranean diet shows promise, but barriers remain: A study found interest in a Mediterranean-style diet among rheumatoid arthritis patients, but food insecurity and other issues hindered adoption. This highlights the need for personalized dietary advice and support.
Dietary modifications and fasting may reduce inflammation: Patients with axial spondylarthritis who made dietary changes or practiced intermittent fasting had lower inflammatory activity. While promising, more research is needed to confirm the benefits.
Certain foods and supplements may impact disease risk: Consuming non-diet soda and certain supplements increased the risk of developing spondyloarthritis, while moderate alcohol use lowered it, according to a study on dietary exposures. These findings suggest that dietary choices may play a role in preventing disease.
Gut health matters: Research highlighted the link between the gut microbiome, inflammation, and rheumatoid arthritis. Supplementing with butyrate, a compound produced by gut bacteria, reduced inflammation in new-onset RA patients.
Patients are interested in diet, but need guidance: A survey found that most patients with rheumatic diseases want to improve their diet, but only a minority had discussed this with their doctors. This underscores the need for healthcare providers to proactively address nutrition with patients.

While these studies offer valuable insights, it's essential for patients to consult with their healthcare team before making any significant changes to their diet or supplement routine. With personalized guidance and support, patients can harness the potential of nutrition and lifestyle modifications to better manage their conditions.

#ACR24 Abstracts: Sleep & Exercise

Sun, 24 Nov 2024 19:40:42 GMT

#ACR24 Abstracts: Sleep & Exercise

These ACR Conference 2024 abstracts underscore the pivotal roles of sleep and exercise in managing rheumatic diseases. By prioritizing these lifestyle factors and providing patients with the necessary support and resources, healthcare providers can enhance patient outcomes and improve quality of life for individuals with rheumatic diseases.

Sleep and AiArthritis Diseases

Challenges and Opportunities in Integrating Sleep Recommendations into Counseling Patients with Arthritis: A Survey of Physical Therapists and Physical Therapy Students

The study investigates the challenges and opportunities in integrating sleep recommendations into the counseling of patients with arthritis. It surveyed physical therapists and physical therapy students to identify barriers and facilitators to incorporating sleep advice into practice. Key facilitators included the belief in the importance of sleep for health outcomes and the scope of practice for physical therapists. However, barriers such as lack of education on sleep counseling and time constraints were also noted.

Direct Comparison of Sleep Quality and Risk Factors for Poor Sleep Across Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis

This study compared sleep quality and poor sleep risk factors among patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). The research included 319 adult patients with these conditions. Poor sleep was reported by 53.8% of PsA patients, 56% of RA patients, and 66% of axSpA patients. Higher BMI and elevated CRP levels were associated with poor sleep in RA patients. Nighttime back pain was a significant factor for axSpA and PsA patients. Female gender and older age were additional risk factors for axSpA and PsA, respectively. The study underscores the varying risk factors for poor sleep across these conditions.

Exercise and AiArthritis Diseases

Association Between a Self-Report Screening Tool for Sarcopenia (SARC-F) and Disease Activity, Muscle Strength and Muscle Power Measures, Patient-Reported Outcomes and Body Composition in Patients with Spondyloarthritides

The study examines the association between the SARC-F screening tool (which assesses sarcopenia risk) and disease activity, muscle strength, muscle power, patient-reported outcomes, and body composition in patients with spondyloarthritis. The findings suggest that a higher SARC-F score is linked to greater disease activity, lower muscle strength and power, and worse patient-reported outcomes. This highlights the importance of early screening and intervention for sarcopenia in patients with spondyloarthritis to improve their overall health and functional status

Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis

The study investigates the effect of physical activity on mortality in patients with rheumatoid arthritis (RA) using a dose-response analysis. The research evaluated self-reported physical activity data from 520 participants over a median follow-up of 11.1 years. Participants were categorized into highly active (\>25 MET-h/week), low-active (0.1 to ≤25 MET-h/week), or inactive (0 MET-h/week) groups. The findings indicate that highly active RA patients had a significantly lower risk of all-cause mortality compared to inactive patients. The study suggests that physical activity of \>25 MET-h/week should be integrated into RA management strategies to reduce mortality risk.

Key Takeaways for Patients

Sleep is a critical factor in arthritis care, and healthcare providers should address sleep as part of comprehensive management.
Different rheumatic conditions have distinct risk factors for poor sleep, necessitating condition-specific sleep assessments and interventions.
Early screening and intervention for sarcopenia, including targeted exercise, is crucial in spondyloarthritis to preserve muscle mass and function.
Regular physical activity (>25 MET-h/week) significantly reduces mortality risk in rheumatoid arthritis, making it an essential component of disease management.

Understanding Mixed Connective Tissue Disease (MCTD)

Thu, 07 Nov 2024 01:06:12 GMT

Understanding Mixed Connective Tissue Disease (MCTD)

Ai Arthritis Disease Symptoms

Key symptoms include:

Severe fatigue that persists despite rest or stimulants
Brain fog, making concentration difficult
Flu-like sensations like nausea and muscle weakness
Low-grade fevers (higher in autoinflammatory diseases)
Joint stiffness, especially in the morning or after long periods of inactivity
Sudden, shifting joint pain that starts and stops abruptly

Symptoms Specific To Mixed Connective Tissue Disease

Raynaud’s Phenomenon
Difficulty swallowing
Hair loss
Lung involvement (shortness of breath)
Lupus-like skin inflammation in areas exposed to the sun
Associated with Lupus, Scleroderma and Sjögren’s disease

MCTD is marked by a range of symptoms that may vary widely among individuals. Common indicators include Raynaud's phenomenon, where fingers and toes turn white or blue in response to cold or stress, swollen fingers, muscle and joint pain, and skin rashes. The joint symptoms in MCTD can mimic those of rheumatoid arthritis, including pain, swelling, and stiffness. However, unlike rheumatoid arthritis, MCTD may also present with features of other connective tissue diseases, such as skin thickening (scleroderma) or muscle inflammation (polymyositis).

Because of its overlapping nature, diagnosing MCTD can be challenging. Healthcare providers often rely on a combination of clinical evaluation, laboratory tests (including specific antibodies like anti-U1 RNP), and the presence of characteristic symptoms to confirm the diagnosis.

Learn more about Mixed Connective Tissue Disease

Causes and Risk Factors

The exact cause of MCTD remains unknown, but it is believed to involve a combination of genetic predisposition and environmental triggers that lead to an abnormal immune response. Women are more frequently affected than men, and the disease typically manifests in individuals between the ages of 20 and 40. Understanding the genetic and immunological factors at play is crucial for developing targeted treatments and improving patient outcomes.

Treatment and Management

While there is no cure for MCTD, treatment aims to manage symptoms, reduce inflammation, and prevent complications. Commonly used medications include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive agents. Depending on the severity and organs involved, other treatments may include antimalarials, calcium channel blockers, and lifestyle modifications such as stress management and physical therapy. Regular monitoring and a multidisciplinary approach are essential for addressing the diverse challenges posed by MCTD.

Discover More Of Our Resources

Diagnosing Mixed Connective Tissue Disease

There’s no single test that can confirm a mixed connective tissue disease (MCTD) diagnosis, so rheumatologists rely on a combination of physical exams, blood tests, and family history of autoimmune diseases. Blood tests specifically focus on detecting anti-U1-ribonucleoprotein (anti-U1-RNP) antibodies, which is a hallmark finding in MCTD, as well as antinuclear antibodies (ANA), which are common in many autoimmune and autoinflammatory diseases. These criteria help to differentiate MCTD from other similar autoimmune conditions.

The Alarcón-Segovia diagnostic criteria may also be used to aid in diagnosis. This requires a high titer of anti-U1-RNP antibodies (greater than 1:1600) and the presence of three or more of the following clinical manifestations:
Raynaud phenomenon
Hand edema
Synovitis
Histologically proven myositis
Acrosclerosis

Living with MCTD

Living with MCTD requires a multidisciplinary approach, involving rheumatologists, pulmonologists, and other specialists. Regular monitoring and early intervention are crucial to managing the disease effectively. Patients are encouraged to adopt a healthy lifestyle, including a balanced diet, regular exercise, and stress management techniques.

Mixed Connective Tissue Disease is a complex condition that highlights the intricate interplay of the immune system and connective tissues. While it poses significant challenges, advancements in medical research and treatment options offer hope for improved quality of life for those affected.

NERVEmber: Nerve Pain Awareness Month

Wed, 30 Oct 2024 20:41:02 GMT

NERVEmber: Nerve Pain Awareness Month

Did you know that orange represents chronic pain awareness on a global scale? Among more than 150 conditions associated with nerve pain, RSD stands out as one of the most excruciating. Unfortunately, this condition is frequently misunderstood, mistreated, and often misdiagnosed.

#NERVEmber is recognized as International Nerve Pain Awareness Month, encompassing conditions such as RSD, CRPS, Diabetes, Neuropathy, and AiArthritis Diseases. Throughout #NERVEmber, you can show your support by going orange each day to raise awareness for these conditions that feature neurological symptoms.

By posting daily with #NERVEmber #iPain #GoOrange, you can help raise awareness for nerve pain. Utilizing these hashtags will highlight a condition relevant to your community.

Understanding Neuropathic Pain

Neuropathic pain, commonly referred to as nerve pain, arises when nerves in the body are damaged or malfunctioning. Unlike other types of pain that stem from injury or inflammation, neuropathic pain originates from the nervous system itself. This can result in chronic pain characterized by burning, stabbing, or shooting sensations, which can significantly impact a person's quality of life.

Nerve Pain and Autoimmune and Autoinflammatory Arthritis

Individuals living with autoimmune and autoinflammatory arthritis often experience neuropathic pain as a significant and debilitating symptom. Conditions such as rheumatoid arthritis (RA) and lupus can cause nerve damage, leading to chronic pain that exacerbates existing joint and tissue pain

Managing nerve pain in these patients can be particularly challenging, as it requires a multifaceted approach that often includes medication, physical therapy, and lifestyle modifications.

Medications: Anti-inflammatory drugs, anticonvulsants, and antidepressants are commonly used to manage neuropathic pain. These medications help reduce inflammation, modulate nerve signals, and alleviate pain.

Physical Therapy: Engaging in physical therapy can help maintain joint function, reduce stiffness, and improve overall mobility Physical therapists can provide tailored exercises and techniques to manage pain and improve quality of life.

Lifestyle Adjustments: I ncorporating stress management techniques, maintaining a balanced diet, and ensuring adequate rest are crucial for managing chronic pain . Support groups and counseling can also provide emotional support and practical strategies for coping with the daily challenges of living with chronic pain

The Importance of Awareness and Research

Raising awareness about neuropathic pain is essential for several reasons. First, it helps to reduce stigma and misunderstanding surrounding the condition, making it easier for individuals to seek and receive appropriate care. Second, increased awareness can drive funding and support for research initiatives aimed at developing new and more effective treatments. Organizations like the International Pain Foundation play a crucial role in advocating for patients, supporting research, and providing resources to those affected by neuropathic pain.

Future Directions

Ongoing research is vital for unraveling the complexities of neuropathic pain and finding innovative solutions. Scientists are exploring the genetic, molecular, and environmental factors that contribute to nerve damage and pain. Advances in neuroimaging and biotechnology are opening new avenues for understanding how nerve pain develops and how it can be effectively treated. With continued support and advocacy, there is hope for more effective therapies and improved quality of life for those living with neuropathic pain.

NERVEmber serves as a crucial platform to bring attention to the challenges faced by those living with neuropathic pain. By fostering greater understanding and supporting research, we can make significant strides in improving treatments and enhancing the lives of those affected..

For more information and resources, visit the International Pain Foundation's Nerve Pain Awareness Month page . Together, we can make a difference in the lives of those suffering from neuropathic pain.

Autoimmune Community Summit: Day Two Summary

Sat, 26 Oct 2024 10:12:41 GMT

Autoimmune Community Summit: Day Two Summary

Hot Topics in Autoimmune: What’s New and Exciting Day two Recap

Sustainable Anti-Inflammatory Diets for Autoimmune Disease and Planetary Health

A plant based diet can improve disease symptoms and decrease the risks of others.
The Standard American Diet (SAD) is high in processed foods, high in animal products and highly inflammatory.
Inflammatory foods, can contribute to systemic chronic inflammation which can lead to chronic diseases.
Ultra-processed foods can upset the microbiome and cause leaky gut syndrome.
You can decrease your greenhouse gas footprint by 85% if you eat a vegan diet.

Resources:

Dr. Andrew Weil’s Anti-Inflammatory Diet Pyramid
REACT Rheum

Our Warming Planet

Dr. Iazsmin Ventura, faculty physician at the University of Chicago talked to us about how Our Warming Planet is leading to an increase in autoimmune disease.

Autoimmune disease has been on the rise for over 40 years. Because of the quick changes and rates in autoimmune diseases occurring it is more likely that environmental exposures and daily life habits are more likely the cause of these changes than genetics. For example, air pollution has decreased the protective stratospheric ozone layer increasing exposure to UV B which increases the risks of Lupus, dermatomyositis and Sjorgens.

So what can we do about it? More education, more research and more sustainable healthcare.

Resources:

REACT Rheum

The Role of Trauma in Autoimmune Disease

In this session, Dr. Veronique tells us that genes aren't everything when it comes to determining autoimmune disease. In fact research is showing that the environment plays a much heavier role, 70-90%. Environment means things like infections, stress, trauma and toxins are often triggers to activate autoimmune disease. Technically the disease is always there but the development of the disease can sometimes take years before you see symptoms. Even adverse events that happen before birth can impact disease development like preeclampsia. Throughout your childhood, Many of us have Adverse Childhood Experiences or ACEs, which are tied to your risk of developing autoimmune disease. The more ACEs you have the higher your risk is but even 2 ACEs puts you at risk.

Resources

Health Ai

Dr. Bryan Anderson, CEO at Coalition for Health AI (CHAI), brought us up to speed on how a coalition is coming together to help AI and Health come together in a reliable way. They have created an Assurance Standards Guide 1 and Assurance Reporting Checklists to provide guidelines for deploying and evaluating AI technology. You can get involved by reviewing the Assurance Standards Guide 1 and Assurance Reporting Checklists and submit feedback.

Resources:

ASSURANCE STANDARDS GUIDE AND REPORTING CHECKLIST

Simplifying Autoimmune Nutrition and Cooking

In the session, Simplifying Autoimmune Nutrition and Cooking, registered dietician and founder of the Arthritis Dietitian, Christina Montoya breaks down the complicated world of nutrition and how we can cook with autoimmune disease.

Understanding the packaging

There are many components of a nutrition label from the ingredient list to calories, fats, and even macronutrients like Vitamin D, calcium and iron. Each component has its own purpose and importance.
Some ingredients to pay attention to with autoimmune disease are saturated fats, trans fats added sugars.
Look for warnings like made in a facility that contains gluten or nuts. This indicates a risk of contamination even if the product has a label that is gluten or nut free.
If you are eating gluten free products watch out for high fodmap ingredients that could also lead to IBS symptoms.

What is anti-inflammatory and how do I choose a diet?

Anti-inflammatory foods means that they tend to have more anti-inflammatory properties like selenium, turmeric, ginger than other foods.
Everyone will respond to foods differently, so pay attention to what impacts you and be mindful of that when planning your meals.

Tips & Tricks for cooking with Arthritis

Use kitchen gadgets like electric can opener, utensils with large holders and thumb rest slots, multi-tools like bottle, can, and jar openers
Get comfortable by bringing a chair into the kitchen
Prep foods that can be used in multiple meals and multiple ways

Resources:

Ways to Reduce Autoimmune Pain

In this session, Clinical Psychologist Afton Hassett teaches us about what pain is, how to build resiliency, and how to reduce pain.

Many things impact how you physically feel pain like memory, thought, feeling, habit, sleep and more. Pain is not an isolated experience, there are five symptoms that go together, in what is called SPACE, and pain is only one of them. Those five symptoms are S leep, P ain, A ffect, C ognitions, and E nergy.

Your ability to cope with these five symptoms, depends on your level of resilience. The more resilient you are, the faster you adapt to change and the less likely you are to have chronic pain, sleep impairment and poor mental health. Building resiliency is something that everyone can do and Afton recommends trying positive activity interventions(PAIs) like keeping a gratitude journal or performing random acts of kindness.

Resources:

Afton Hasset Website

Fatigue Science & Tips for Reducing Fatigue

Chronic fatigue is a real problem in our community. It seems like no matter what we do fatigue is there. At the recent Autoimmune Community Summit, Christine Stamatos, Nurse Practitioner at Northwell Health explained how fatigue works and how to get better sleep.

When you feel tired, it’s a warning sign to listen to your body and slow down. Our bodies can respond to stress and other triggers in the same way it responds to the fight or flight response. With autoimmune diseases, sometimes something that seems so small can send our body into fight mode by activating the defense system and causing systemic inflammation.

Once the defense system is activated it works quickly to signal throughout the body that it’s under attack. One of the ways it does this is by increasing cortisol (the stress hormone) which can impact sleep, making you tired.

So what can you do about it? Pay attention to these signs and build in periods of rest. Manage your stress, treat depression, move more, and manage your sleep, you can balance your energy and decrease fatigue.

Realistic Wellness and Stress Management for Difficult Days

The body runs on stress, it's the natural way our body uses to know when and how to respond to a situation. While stress is necessary, too much of it can wreak havoc on your body. Daily practice and integration of self-management practices to release stress are necessary to cope on difficult days.

To cope with and get ahead of stress, you need a good routine. Here are components of a good routine:

Have a daily activity plan that includes 5+ hours of activity like walks or yoga. Get up and move if you sit for long periods of time.
Get your 8 hours of sleep.
Practice meditation and mindfulness.

Now that you have your routine set, what should you do on a difficult day?

Reframe wellness. Acknowledge that rest is part of your wellness plan and is required to heal.
Acknowledge the emotions you are feeling. It is ok to be frustrated or accept.
Have a kit of things that energize you or boost your mood at the ready.

Autoimmune Community Summit: Day One Summary

Tue, 22 Oct 2024 22:47:04 GMT

Autoimmune Community Summit: Day One Summary

The Autoimmune Association hosted the Autoimmune Community Summit. Here’s a recap of Day One.

This two day virtual summit brought patients, caregivers, clinicians, researchers and entrepreneurs from many industries, disease communities and regions of the world together to build connections,share information and get inspired! We are excited to bring you the highlights from the perspective of one of our volunteers, Brittany Murray, a patient living with Psoriatic Arthritis and creator of ChronicDiseaseDiary .

In this post, we will give you the highlights of each session of day one, an option to read more, and links to resources.

Raising Awareness with Your Story: Why, Where and How!

In this session we heard from Nitika Chopra , Founder and CEO at Chronicon and the Chronicon Foundation. Nitika shares her story of Psoriasis and Psoriatic Arthritis, how she was diagnosed, what life was like after diagnosis and how to share your story.

Tips when sharing your story:

Know why you want to share it
Who you want to share it with
How you want to tell it

Resources:

Shared Decision Making

Shared Decision Making is something that I think we all can agree as AiArthritis patients is important. We want to feel heard, we want to understand our options, and we want to partner on what the right decision is for us and what the doctor recommends. In this session, Eileen Davidson, also known as Chronic Eileen, and Dr. Jennifer Barton, a Rheumatologist at Oregon Health & Science University and the Portland VA, show us just how important shared decision making is from both a patient and clinician perspective.

Here are the key takeaways:

Shared decision making requires engagement from both the patient and the clinician
Prepare for your appointment, know why you are there and what you need
Talk to other patients about what they have experienced and what questions they have asked their clinicians
Find a doctor that will listen or set expectations with your clinician so they listen
Do your research, learn about your disease, the treatment options and alternative resources that can help you
Most importantly, advocate for yourself
Read more.

Resources:

Understanding Complex Research

In this session, Dr. Carla Greenbaum, MD talks about how research studies work and what to pay attention to to know if it was a good study or not. She also covered some studies around Type 1 diabetes and shared that researchers are studying not only patients showing symptoms but also those in the preclinical phase before they develop symptoms.

What to pay attention to when looking at research studies:
Is the study rigorous, robust and reproducible?
Does the original design match the results?

Resources:

Benaroya Research

What Autoimmune Patients Should Know About Clinical Trials

As autoimmune patients we have all benefited from clinical trials. Every medication we have ever taken went through one of these trials. Shalome Sine at CISCRPA explains to us what clinical trials are and what patients should know about them.

Here is what you need to know:

A clinical trial is a study used to answer a specific health question like if a new treatment works.1
Clinical trials go through 4 phases to test the safety, dosing and efficacy of treatment.
Trials are reviewed by volunteer protections to ensure that trials are ethical, safe and follow the rules.
Volunteers go through an informed consent process so that they understand the details of the study.
You have the right to understand the study and can quit at any time.

Resources:

CISCRPA

Advocacy Update: Highlighting Community Health Centers and the Importance of the 340B Program

The Autoimmune Association and Basim Khan, CEO of Neighborhood Health , provided an Advocacy Update that is near and dear to AiArthritis's hearts. This session was centered around access to community health centers and reform of the 340B program.

Community Health Centers are non-profit organizations that help anyone in the community receive affordable primary care.

340B is a pharmacy program that allows qualified health centers like community health centers to purchase prescription drugs at discounted prices.

Community Health Centers and other organizations that qualify for 340B have the opportunity to provide all of their patients with discounted pricing, but some of them are not passing that discount to the patients. This is motivating many to advocate for 340B reform. The 340B bills hitting legislatures now require that these organizations pass these discounts onto their patients.

Resources:

Knowing Your Rights

For those of us with AiArthritis diseases, knowing our health care plan is super important. With open enrollment right around the corner, this is the perfect time to get up to speed on what our plans entail and how to choose the right one.

There are many ways we pay for health insurance throughout the year: premiums, deductibles, copays, coinsurance, and out-of-pocket maximums. In the session, Knowing your rights Joanna Doran, CEO at Triage Cancer , breaks down the key components of health insurance and how to get the care we need.

There are many ways we pay for health insurance throughout the year: premiums, deductibles, copays, coinsurance, and out-of-pocket maximums.
Not all healthcare plans are created equal.
Do the math to compare plans.
(Monthly Premium *12) + Out-of-Pocket Maximum = Total Cost for the Year
50% of the time patients are successful in getting the decisions overturned during appeal.
Don’t pay your medical bills until insurance has sent the Explanation of Benefits for that visit.
Know what laws and employee benefits are available to protect you when taking time off for treatments or a flare.

Resources:

Embracing Joy: Coping with AiArthritis Through Hobbies

Sat, 19 Oct 2024 12:49:20 GMT

Embracing Joy: Coping with Ai Arthritis Through Hobbies

Dancing, Reading, and Cooking Cheryl finds joy in dancing, reading, spending time with her puppy, and cooking. These activities not only keep her active but also provide a sense of normalcy and happiness.

Writing and Creativity Dedra loves writing, which she finds particularly comforting when she's relaxing on the couch. It's a great way for her to express herself and stay mentally engaged.

Artistic Pursuits Rheum2cre8art enjoys watercolor painting, a soothing and expressive outlet for creativity. Meanwhile, mtnkat79 finds solace in listening to books or news while working on decoupage, knitting, crochet, upcycling, and restoring furniture.

Physical Activities For gatorgirrrl, cross stitch and pool exercise are the go-to activities, while bionicquilter prefers reading on an e-reader to avoid straining her hands and wrists. Theerincoleman stays active by walking daily with her dog and doing weight training twice a week with a personal trainer who tailors the program to her needs.

Yearning for Water Sbriesh wishes for access to a pool, recognizing that water exercises make movement much easier and less painful.

Crafting and Gardening Noraandediebooks enjoys reading, needle felting, and making miniatures, while w.koski13 finds peace in gardening. These hobbies help them stay connected to their passions despite the challenges of arthritis.

Cooking, Baking, and Outdoor Activities Many find solace in cooking, baking, gardening, and simply being outside. Brittany Murray enjoys puzzles and volunteering for AI arthritis, which is fulfilling even during flares.

Staying Mentally Active Kerry Goldsworthy highlights the importance of mental engagement, noting that even when physical hobbies are impossible, writing remains a powerful outlet. Similarly, Becky Rodriguez finds joy in disability-related movies and soundtracks.

Low-Impact Hobbies Stephanie Schmid-Falcon balances physically demanding hobbies like gardening with low-impact activities such as reading, documentaries, and podcasts.

Swimming and Meditation Amy Millios emphasizes the benefits of swimming, reading, mindfulness meditation, and caring for her cats. Fiona Mann finds horseback riding a great way to stay active and socialize.

Tech and Gaming Autumn Despotis enjoys playing mindless games on her phone, which helps distract from pain. Sarah Price finds happiness in crochet, while Kathleen Lane enjoys quizzing, singing, and swimming.

Social and Outdoor Activities Ashley Lanclos loves spending time outside and practicing yoga, and Cynthia Cole Hart volunteers, bakes, and scrapbooks. Dennis Chamberlin enjoys low-impact frisbee tossing, and Rachel Herford practices yoga.

Crafts and Learning Mary Wright quilts and embroiders, while Lisa Hawkes has started highland dancing. Jessica Bowman Boles finds peace in yoga and meditation.

Reading and Exploring Laura Wohl Torchinsky enjoys reading, arts and crafts, trivia nights, and swimming. Peta Gourlay loves reading, and Michele Alexander is still searching for the perfect hobby. Gina Mastroantonio relies on music and podcasts when her body doesn't cooperate.

Shedding Light on Invisible Disabilities: Why This Week Matters

Sat, 19 Oct 2024 12:23:16 GMT

Shedding Light on Invisible Disabilities: Why This Week Matters

The Importance of Invisible Disabilities Week

Invisible Disabilities Week is a time to foster understanding, compassion, and support. It helps bridge the gap between those who live with these hidden conditions and those who might not be aware of their prevalence or impact. This week encourages education about the realities of living with an invisible disability, which can lead to greater empathy and advocacy.

History of Invisible Disabilities Week

Invisible Disabilities Week was founded by the Invisible Disabilities Association (IDA) in 2014. Since then, it has been celebrated annually in October, with the goal of bringing awareness, education, and support to individuals and communities about unseen disabilities. The week aims to highlight the challenges faced by those with invisible disabilities and to promote understanding and acceptance.

Sharing Your Story

Your story is powerful. Sharing your experiences can help others see the reality of living with an invisible disease and foster a sense of community and support. Here are some tips to share your story effectively:

Be Authentic: Speak honestly about your experiences. Share the ups and downs, and how your condition affects your daily life.

Educate: Provide information about your specific condition. Many people might not understand what autoimmune or autoinflammatory arthritis entails.

Highlight the Invisible: Emphasize the challenges of having an invisible illness—the fatigue, the pain, the mental and emotional impact.

Connect: Engage with others who have similar experiences. Joining support groups or online communities can provide a platform for sharing and receiving support.

Advocate: Use your story to advocate for better understanding and accommodations in workplaces, schools, and public spaces.

Use Hashtags: #InvisibleNoMore #InvisibleDisabilitiesWeek

Invisible Disabilities Week is a reminder that while some battles are invisible, they are no less significant. By sharing your story, you contribute to a culture of empathy and support, making the world a more understanding place for everyone.

World Arthritis Day: Raising Awareness and Empowering Lives Through Reliable Information

Thu, 10 Oct 2024 11:59:40 GMT

World Arthritis Day: Raising Awareness and Empowering Lives Through Reliable Information

Understanding Arthritis and Ai Arthritis Diseases

Arthritis is not a single disease but a term that encompasses over 200 different conditions affecting the joints, tissues around the joints, and other connective tissues. These conditions can cause pain, stiffness, swelling, and decreased range of motion, significantly impacting the quality of life. Rheumatic and musculoskeletal diseases (RMDs) are among the most common, disabling, and costly non-communicable diseases.

Of the 200 plus conditions under the umbrella of arthritis are 22 autoimmune and autoinflammatory arthritis diseases or known as AiArthritis Diseases.

Core Diseases

Rheumatoid Arthritis (RA)
Psoriatic Arthritis (PsA)
Systemic Lupus Erythematosus (SLE)
Sjögren's Disease (SD)
Axial Spondyloarthritis (AxSpA)
Still's Disease
Juvenile Idiopathic Arthritis (JIA)
Undifferentiated Disease (UD)

Additional diseases that may have more differentiating symptoms

These diseases are also under the AiArthritis umbrella. We separated them because there are disease features that could differentiate them easier from the conditions in the first group.

Crohn's Disease
Sarcoidosis
Relapsing Polychondritis (RP)
VEXAS Syndrome
Systemic Sclerosis/Scleroderma (SSc)
Behcet's Disease (BD)
Palindromic Rheumatism (PR)
Antisynthetase Syndrome (ASS)
Mixed Connective Tissue Disease (MCTD)

Very Rare Diseases

There are also some very rare autoinflammatory diseases that often include inflammatory arthritis as a major clinical component. These include:

Familial Mediterranean Fever (FMF)
HIDS
Cryopyrin-Associated Periodic Syndromes (CAPS)
Schnitzler Syndrome
Chronic Nonbacterial Osteomyelitis (CNO)

The Importance of Early Diagnosis and Treatment

One of the key messages of World Arthritis Day is the importance of early diagnosis and treatment. Early intervention can help manage symptoms more effectively, prevent further joint damage, and improve overall outcomes. Unfortunately, many people with RMDs remain undiagnosed or receive a diagnosis only after significant damage has occurred.

This Year’s Theme: “Informed Choices, Better Outcomes”

The theme for World Arthritis Day 2024 is "Informed Choices, Better Outcomes". In today’s digital age, access to information is both a blessing and a challenge. While there is a wealth of information available, it can be overwhelming and sometimes misleading. This year’s campaign focuses on empowering people with accurate, evidence-based information to make informed decisions about their health in partnership with healthcare professionals.

Why is it important to you to have reliable information about your disease?

Having reliable information about a disease is crucial for several reasons:

Informed Decision-Making: Accurate information helps you make better decisions about your treatment options, lifestyle changes, and overall health management.

Understanding the Condition: Knowing the details about your disease can reduce anxiety and help you understand what to expect, which can be empowering.

Effective Communication: It allows you to have more productive conversations with your healthcare providers, ensuring you can ask the right questions and understand their advice.

Support and Resources: Reliable information can guide you to appropriate support groups, resources, and services that can aid in managing your condition.

Preventing Misinformation: It helps you avoid the pitfalls of misinformation, which can lead to ineffective or harmful treatments.

At AiArthritis we are always striving to provide reliable resources. We have downloadable resources to help you better understand your AiArthritis Disease. We are also excited to announce our new Patient Journey pages to help guide patients along their AiArthritis Disease journey.

How You Can Get Involved

There are many ways to participate in World Arthritis Day and support the cause:

Spread Awareness: Use social media to share facts about arthritis and RMDs. Use hashtags like #WorldArthritisDay and #WAD2024 to join the conversation.

Educate Yourself and Others: Learn more about arthritis and RMDs. Share this knowledge with friends, family, and colleagues to help dispel myths and misconceptions.

Support Research: Consider donating to AiArthritis to fund arthritis reliable resources.

Join Events: Participate in local or virtual events such as webinars, walks, or support groups. These events can provide valuable information and a sense of community.

World Arthritis Day is a vital opportunity to shine a light on the challenges faced by those living with arthritis and RMDs. By raising awareness, promoting early diagnosis and treatment, and empowering individuals with accurate information, we can make a significant difference in the lives of millions. Let’s come together this October 12th to support and advocate for those affected by these conditions.

Navigating the Challenges of Autoimmune Symptoms: What We Wish We Could Control More Effectively

Sun, 22 Sep 2024 11:40:53 GMT

Navigating the Challenges of Autoimmune Symptoms: What We Wish We Could Control More Effectively

By Kelly Conway

Another common symptom voiced by community members was fatigue . This symptom often feels like a relentless shadow, draining energy and motivation. Many shared that fatigue not only affects their physical capabilities but also exacerbates other symptoms, making it harder to manage pain and inflammation. The sheer exhaustion can become a barrier to self-care, impacting everything from exercise to cooking nutritious meals.

Inflammation , particularly in the context of rheumatoid arthritis (RA), was also a significant concern. Members highlighted how the pain associated with inflammation can be debilitating, leading to joint damage over time. The inflammatory processes of autoimmune diseases can wreak havoc on daily life, leaving individuals feeling trapped in a cycle of discomfort and frustration.

Additionally, the issue of sleep disturbances , such as insomnia, emerged as a critical factor. Many noted that lack of sleep magnifies existing symptoms, including pain and fatigue, and can lead to cognitive challenges like brain fog. The connection between sleep and overall health is well-documented; when restorative sleep is elusive, the ability to cope with other symptoms diminishes.

Brain fog itself was another major topic of discussion. Many professionals, including those who had to shift from their desired careers due to their conditions, shared the emotional toll that cognitive difficulties can take. The sadness of not being able to pursue their professions, combined with the challenges of everyday tasks, was palpable in their responses.

This discussion reflects a broader reality for many living with autoimmune diseases: a constant battle against symptoms that often feel uncontrollable. While some members have found success with therapies that target inflammation and pain, fatigue remains a persistent issue for many, sometimes even as a side effect of the very medications that help alleviate other symptoms.

The emotional weight of these experiences is significant. Community members shared feelings of isolation, sadness, and frustration, revealing how these chronic conditions can impact mental health and quality of life. For many, the longing for control over their symptoms is tied to a desire for a more fulfilling, active life.

Ultimately, this conversation serves as a reminder of the need for ongoing research and innovation in the field of autoimmune disease treatment. The voices of those in the AiArthritis community echo a collective hope for better management strategies that address the multifaceted nature of these conditions.

As we continue to share our stories and support one another, it’s vital to advocate for awareness and advancements in treatment options. Together, we can work toward a future where living with autoimmune diseases becomes more manageable, allowing individuals to reclaim their lives from the grip of uncontrolled symptoms.

Navigating My 20s as a Newly Disabled Woman

Sat, 21 Sep 2024 16:08:11 GMT

Navigating My 20's as a Newly Disabled Woman

By Kailey Grant

Eventually doing dishes was becoming an increasingly painful task. I kept ignoring the pain thinking that I was weak for struggling so much with such a small task. I wanted so badly to pull my weight in my household and take some of the burden off of Keiran. When I brought this up to my doctor she looked at my hands and saw no noticeable swelling but, ordered a blood test to see if I had a Rheumatoid Arthritis marker. When my blood test came back, the marker wasn’t there however, my CRP (inflammation in my body) was on the high side. While this validated my feeling of something being wrong, it unfortunately didn’t indicate where the inflammation was coming from.

After many different tests including a MRI, Scope, Eye Exams, ECGs, X-Rays of numerous body parts, a 24-hour blood pressure monitor and regular blood tests, the only thing that remained consistent was the high CRP and no real other abnormalities. At this point, my pain was getting worse especially during flare ups and so sharp that I was struggling to hold objects and wash my hair. Walking, although possible, was becoming extremely difficult due to the pain in my ankles and toe joints. I began to lose sleep as the pain in my joints continued overnight which was only slightly dulled by numerous CBD creams and ibuprofen. I spent many different nights sobbing at the prospect of having to live with this pain forever and expressing to my partner that I simply couldn’t.

After 2 years of tests and. advocating for myself with a great health team, I was able to be seen by a rheumatologist who diagnosed me with seronegative inflammatory arthritis. The diagnosis was written on a document for my eye doctor and probably would appear so insignificant to another person but, the moment I read it, I felt hope again.

Becoming disabled in my 20s was not something I ever expected. I cannot express how frustrating and painful it is to mourn the body and life I once had that lived and laughed without a chronic illness. As someone who has always loved to lead and have control, I have felt extremely vulnerable asking for help doing mundane tasks. While I have modified a lot of my daily activities to suit my new disabled lifestyle, there are still many things I struggle with. But, I have learned that the most important thing for my body right now is to be patient with myself as we get reintroduced to each other.

One of the major things I have had to adapt to is relying on my partner for support. We have had to modify the way we do household chores to ensure that they are accessible for myself. For me, this means very rarely washing dishes as it causes a flare up in my hands. I have also had to rely on him for heavy lifting when carrying in groceries, opening jars or drinks and help with washing my hair when I can’t do it myself.

My partner has also been a great support for navigating disappointment due to my disability with our daughter. Being a young, newly disabled parent has been extremely hard to navigate on my own. Some times I have to miss out on activities in the sun due to my heat intolerance and also now being on NSAIDs. I cannot express how frustrating it is when I want nothing more than to show up for the people I care about but, my body is unable to allow me to. I have a tough time with the guilt of not being a “present” parent when I miss out on doing fun and adventurous things with my daughter. But, my partner and I consistently work together to try to recreate an experience and make it accessible for me.

While this is just the beginning of what will be a life long journey, I feel very fortunate for the support I have received. Although often I still feel guilty when I’m unable to participate in outings with friends and family, I try to remind my people pleasing self that it is time to show up for myself now. I think I’ll listen to myself this time around.

By Kailey Grant

Getting Burned by Medical Gaslighting

Sat, 21 Sep 2024 16:05:15 GMT

Getting Burned by Medical Gaslighting

By Rebecca Hosey

Most dictionaries define gaslighting as cognitive manipulation and misleading. These actions can even cause the unsuspecting person to question the authenticity of their own thoughts, feelings, and perceptions.

This buzzword originated from the 1938 play, Gas Light by British screen writer Patrick Hamilton. In this dark, psychological thriller set in the 1880’s, a husband attempts to convince his wife that she is going mad. He must prove her instability by committing her to a psychiatric hospital in order to control her inheritance money.

His elaborate strategy to persuade his wife of her lost sanity included tricking her through maneuvering the lights inside their home. By turning the lights on and off, he effectively dimmed the gas light to advance his scheming efforts.

I’m sure the writer did not expect that his play, which debuted in cinema in the 1940’s would spark such a powerful catchphrase so many years later.

So, why is such abusive behavior appalled on stage and screen, but essentially allowed to persist in the medical realm? Truthfully, medical providers are rarely disciplined for not listening to their patients.

Gaslighting can trigger a multitude of devastating consequences. The rather obvious physical impacts of a missed or delayed diagnosis, can lead to unnecessary poor outcomes and even death. However, it’s often the overlooked emotional distress which has the potential to generate just as much destruction. Gaslit individuals understandably grow to mistrust healthcare providers, and might eventually avoid seeking medical care all together.

Being in the unique position of both healthcare provider, as well as dismissed patient, I assure you that the burns from medical gaslighting can result in deep, penetrating wounds and extensive scarring. The inner turmoil of knowing that you are sick, but being betrayed by your trusted medical professional, is a hard pill to swallow.

But you are NOT a powerless patient! You have every right to demand better healthcare! Medicine is a consumer based industry and there is no service more important than your health and well-being!

Think of yourself as a powerful consumer! I doubt that you would accept a landscaper only cutting half of your front lawn, so why should you accept poor healthcare?

Never settle for substandard medical care! If you are unhappy with the care you’re receiving then make an attempt to alter it. It’s perfectly okay to challenge provider dismissiveness. As empowered patrons, we should and must demand better medicine.

Many of us have been wrongly taught that in order to be “good” patients we must be passive. That is, allow the provider to be in charge, with little to no say from us. This isn’t how good medicine should be. We need to be teamed up with our health professional, with mutual respect from both parties.

As a patient, you know your body best as you live with it every minute of every day. If the provider doesn’t listen to you after your intervention, then fire them. Keep in mind there are plenty of great health professionals out there who are ready and willing to give you the attention you deserve.

Being heard, then receiving competent and compassionate care is a fundamental human right, so never settle for anything less than the best!

Here are some tips if your provider isn’t listening or even dismissing you:

1. Reiterate the importance of your concern.

2. Politely comment that they seem distracted.

3. Ask them to focus on you (including to stop staring at their computer screen).

4. Make a few attempts to change the behavior.

5. Find a new provider if necessary.

Here are some tips for finding the right health provider:

1. Talk to friends and family.

2. Read reviews.

3. Use social media.

4. Join a support group.

5. Ask a nurse or another trusted person in medicine.

Thank you so much for reading! Please be well and visit: www.rebeccahosey.com if you

want to learn more!

Rebecca Hosey

Interstitial Lung Disease: An Overview

Fri, 13 Sep 2024 16:14:44 GMT

Interstitial Lung Disease: An Overview

September 18 is Interstitial Lung Disease Day.

Symptoms and Diagnosis

The primary symptoms of ILD are dyspnea (shortness of breath) and cough. As the disease advances, patients may experience fatigue, weight loss, and chest pain. In severe cases, blue discoloration of the skin and lips (cyanosis) can occur due to inadequate oxygenation of the blood. Diagnosis of ILD involves a combination of medical history, physical examination, lung function tests, imaging studies, and sometimes biopsy. High-resolution computed tomography (HRCT) scans are particularly useful in visualizing the interstitial scarring. Lung function tests, such as spirometry and diffusion capacity, quantify the degree of lung impairment.

Treatment and Outcomes

Treatment of ILD depends on the underlying cause. For idiopathic pulmonary fibrosis (IPF), the most common type of ILD, there is no cure, and treatment focuses on slowing disease progression and managing symptoms. Medications such as nintedanib and pirfenidone can slow the rate of forced vital capacity decline. Oxygen therapy is often necessary to combat hypoxia. Pulmonary rehabilitation programs, which include exercise training, education, and support, can improve quality of life. Lung transplantation may be considered for advanced cases. The prognosis for ILD varies widely depending on the specific type and rate of progression.

Known Causes of ILD

Patients with some inflammatory and connective tissue diseases are at a higher risk for ILD. These conditions include many AiArthritis diseases like rheumatoid arthritis, systemic scleroderma, myositis, including dermatomyositis and polymyositis (DM and PM), sarcoidosis, and Sjögren's.

By Kelly Conway

AiArthritis Blog

AiArthritis Advocacy Field Trip: 2026 BMS Policy Forum

Ai Arthritis Advocacy Field Trip: 2026 BMS Policy Forum

Where the Healthcare System is Missing the Mark

Keeping Patients at the Center of Policy

Why Patient Advocacy Matters

Drive Change Through Advocacy

How to Describe Pain Caused by Autoimmune and Autoinflammatory Arthritis Diseases

How to Describe Pain Caused by Auto immune and Auto inflammatory Arthritis Diseases

Potential Causes of Pain in Auto i mmune and Auto inflammatory Arthritis

Types of Pain in Auto immune and Auto inflammatory Arthritis

How to Describe Pain to a Doctor

Managing and Communicating Pain Effectively

Why Rheumatologists Must Prioritize Heart Health

Why Rheumatologists Must Prioritize Heart Health for Ai Arthritis Patients

Ai Arthritis Diseases and the Heart Are Deeply Connected

Understanding Cardiac Inflammation

What Science Is Teaching Us About Treatment

Why This Should Change Everyday Care

Brain Fog and Sleep in AiArthritis Diseases

Brain Fog and Sleep Issues in Ai Arthritis Diseases

What Brain Fog Actually Feels Like for Patients

What Cognitive Testing Is Showing in Fibromyalgia

The Gap in Rheumatoid Arthritis Research

Sleep Is a Common Thread Across Conditions

What This Means for Patients

Looking Ahead

Understanding Enthesitis: Why Tendon and Ligament Pain Matters in Spondyloarthritis

Understanding Enthesitis: Why Tendon and Ligament Pain Matters in Spondyloarthritis ﻿

What exactly is enthesitis?

How enthesitis can drive joint and bone damage

The gut, the skin, and inflammation pathways

Why this matters for diagnosis and treatment

A growing focus in spondyloarthritis research

Navigating the Emotional Rollercoaster of Being Undiagnosed

Navigating the Emotional Rollercoaster of Being Undiagnosed

Understanding the Emotional Impact of Being Undiagnosed

Coping Strategies for Managing Frustration and Fear

Self-Care Strategies for Navigating Uncertainty

Advocating for Yourself in Healthcare

Mystery Patient Guide by Ai Arthritis

What’s New in Lupus and Lupus Nephritis: Key Updates Patients Should Know

What’s New in Lupus and Lupus Nephritis: Key Updates Patients Should Know

Why lupus nephritis education matters so much

Monitoring and prevention are ongoing, not one-time conversations

Shared decision making is essential in lupus nephritis care

Mental and emotional health cannot be separated from physical care

Key takeaways for providers and patients

Looking ahead with hope

Related Blog Posts

What the Psoriatic Arthritis EULAR Abstracts Tell Us

What the Psoriatic Arthritis EULAR Abstracts Tell Us

Early Psoriatic Arthritis and the Step-Up Question

Why Disease Severity Changes the Picture

Focus on Enthesitis and Dactylitis

Long-Term Effectiveness Still Matters

What Patients Can Take From This

Nutrition, Exercise, and Stress: Holistic Management for Co-Existing Conditions with Autoimmune and Autoinflammatory Arthritis Diseases

Nutrition, Exercise, and Stress: Holistic Management for Co-Existing Conditions with Autoimmune and Autoinflammatory Arthritis Diseases

Nutrition: Reducing Inflammation Through Diet

Anti-Inflammatory Foods

Foods to Avoid

Hydration and Gut Health

Exercise: Maintaining Mobility and Strength

Low-Impact Exercises

Strength Training

Stretching and Recovery

Stress Reduction: Supporting Mental and Emotional Well-Being

Mindfulness and Relaxation

Sleep Optimization

Emotional Well-Being

What’s New in Still’s Disease: Key Takeaways from EULAR 2025

What’s New in Still’s Disease: Key Takeaways from EULAR 2025

Juvenile and adult Still’s are now understood as the same disease

Still’s is increasingly seen as both autoinflammatory and autoimmune

IL-18 is emerging as a key biomarker

A new area of concern: Still’s lung disease

Why this session mattered so much

The big picture for patients

Growing Up With AiArthritis: Supporting the Transition From Pediatric to Adult Care

Understanding Enthesitis: Why Tendon and Ligament Pain Matters in Spondyloarthritis

Why the votes shifted, and what that might mean